


PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION 2006 ANNUAL MEETING



TORONTO, CANADA ♦ MAY 20-25, 2006

APA 159th ANNUAL MEETING

Toronto, Canada, May 20-25, 2006

KEY LOCATIONS

TORONTO METRO CONVENTION CENTRE

<i>American Journal of Psychiatry and Psychiatric Services</i>	APPI Bookstore, Halls D-G, South, Level 800
Annual Meetings Office	Room 204, North, Level 200
APA Communications Office	Room 101, North, Level 100
APA Member Center	Halls D-G, South, Level 800
A/V Preview Room	Room 203B, North, Level 200
CME Course Enrollment	Hall C, North, Level 300
Computerized Evaluation	South Building, Level 600
<i>Daily Bulletin</i>	Room 103A, North, Level 100
Exhibit Office	Halls D-G, South, Level 800
Exhibits/Publishers' Bookfair	Halls D-G, South, Level 800
Information Center	North Foyer, Level 200
Internet Village	South Building, Level 600
Lost & Found	Room 204, North, Level 200
Message Center	North Foyer, Level 200
On-Site Job Bank and Placement Center	APA Member Center, Halls D-G, South, Level 800
Registration	Hall C, North, Level 300

FIRST AID

There are two first aid offices in the Toronto Convention Centre. The *North Building location* is on Level 100, directly across from Room 106 and Constitution Hall. The *South Building location* is on Level 800, directly across from Hall D. Hours of operation: Tuesday, May 16, through Thursday, May 25, and opens one hour prior to show opening and closes one hour after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 20, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Thursday, May 25, at 6:00 p.m. The Toronto Metro Convention Centre will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city map on page XIII for the location of hotels in relation to the Convention Centre.

EXHIBITS

Commercial and educational exhibits will be located in Exhibit Halls D-G, South, Level 800, Toronto Metro Convention Centre, along with the Publishers' Bookfair and the APA Member Center. For your convenience, the Publishers' Bookfair and APA Member Center will be open Saturday, May 20, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 21, 10:00 a.m.-4:30 p.m.; Monday, May 22, 10:00 a.m.-5:30 p.m.; Tuesday, May 23, 10:00 a.m.-6:00 p.m.; and the final day, Wednesday, May 24, 10:00 a.m.-3:00 p.m.

INFORMATION CENTER

Located in the North Foyer, Level 200, Toronto Metro Convention Centre and staffed during registration hours (with the exception of Thursday, May 25, when the Center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained at the Information Center.

MESSAGE CENTER

Located in the North Foyer, Level 200, Toronto Metro Convention Centre and staffed during registration hours (with the exception of Thursday, May 25, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Ancillary message centers will also be located on Level 600 and Level 800 in the South Building in the Toronto Metro Convention Centre. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA MEMBER CENTER

Located in Exhibit Halls D-G, South, Level 800, Toronto Metro Convention Centre. Hours of operation will be: Saturday, May 20, 10:00 a.m.-5:00 p.m.; Sunday, May 21, 10:00 a.m.-4:30 p.m.; Monday, May 22, 10:00 a.m.-5:30 p.m.; Tuesday, May 23, 10:00 a.m.-6:00 p.m.; and Wednesday, May 24, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, practice management, and APA periodicals.

APA JOB BANK

Visit the APA on-site Job Bank at APA 2006! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE & PRESS ROOM

Located in Room 101, North, Level 100, Toronto Metro Convention Centre. Hours of operation: Saturday, May 20, 11:00 a.m.-5:00 p.m.; Sunday-Wednesday, May 21-24, 8:00 a.m.-6:00 p.m.; and Thursday, May 25, 8:00 a.m.-12 noon. **This room is for the use of registered press and credentialed public relations representatives only.**

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 103A, North Level 100, by 12 noon prior to the date of publication.

RESIDENTS' RESOURCE CENTER

Located in the Niagara Room, Lower Level, Intercontinental Hotel. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 21, through Wednesday, May 24. Daily activities are scheduled for residents (such as the orientation, Residents Only Discussion Groups, and Resident Summits) and medical students. Meet and network with your colleagues and leaders in psychiatry. Resources specifically for residents and medical students are available here.

BUSINESS CENTERS

Toronto Metro Convention Centre: North Building, Exhibitor Services Centre, Street Level (across from Room 206F). South Building, Business Services Centre, 800 Level (outside entrance to Hall D). Hours of operation: Monday-Friday (North Building: 8:00 a.m.-5:00 p.m.; South Building: 8:30 a.m.-4:30 p.m.)

Royal York: East Lobby (outside of Epic Restaurant)
Hours of operation: Saturday: 9:00 a.m.-6:00 p.m.; Closed Sunday; Monday-Friday: 7:00 a.m.-10:00 p.m.

Sheraton Centre Toronto: Main Lobby
Hours of operation: Saturday: 10:00 a.m.-2:00 p.m.; Closed Sunday; Monday-Friday: 8:00 a.m.-8:00 p.m.

REGISTRATION

Admission to all sessions by registration badge

Located in Exhibit Hall C, North Level 300, Toronto Metro Convention Centre. Hours of operation: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APAMEMBERS

Full-Time Registration (<i>North American Members</i>)	\$295
Full-Time Registration (<i>International Members</i>)	\$295-\$520*
Members-in-Training (<i>Member Class MT</i>)	\$ 85
Daily Registration (<i>North American Members</i>)	\$150
Daily Registration (<i>International Members</i>)	\$275
Medical Students	no charge

*Fee determined by country's gross national income according to the World Bank.

NONMEMBERS

Full-Time Registration	\$860
Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains	\$100
Daily Registration (<i>all Nonmember categories</i>)	\$450
Medical Students	no charge

GUEST REGISTRATION

One only per full-time registrant

Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member. ID may be required.*

One-Day Exhibit Hall Only Pass (18 and older) 10.00
(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived **only** for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present, except for industry-supported symposium presenters who must pay the fee).

Nonmember psychiatric residents and other full-time students must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your

instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book*, *APA Member Center Guide*, and *New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

REGISTRATION BADGES

Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.

Registered exhibitors will receive red badges, which allow access only to his or her exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

Ticket purchase required for CME Courses

Located in Exhibit Hall C, North, Level 300, Toronto Metro Convention Centre. Hours of operation are the same as registration. Tickets for Courses not sold by April 22 will be on sale beginning at 12 noon on Friday, May 19. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION

Located in the South Building, Level 600, Toronto Metro Convention Centre and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH

Located in the North Foyer, Level 200, Toronto Metro Convention Centre. Hours of operation: Saturday, May 20, through Wednesday, May 24, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS

Editorial staff of *The American Journal of Psychiatry*, *Psychiatric Services*, *Academic Psychiatry*, *Journal of Neuropsychiatry and Clinical Neuroscience*, *Psychosomatics*, and APA's CME journal, *Focus* will be on hand to demonstrate online access for subscribers, answer questions regarding submissions, and show the new state-of-the-art website, www.psychiatryonline.com. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of *Psychiatric News* will be available at stands located throughout the Convention Centre. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program formats are designated as category 1: Advances in... Series, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Young Investigators' Oral/Slide Sessions, Presidential Symposia, Research Advances in Medicine, Review of Psychiatry, Roundtable Discussion, Scientific and Clinical Reports, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultation). Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* log sheet found in the front of the 2006 *Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. Before you leave the meeting, please complete your form and drop it in one of the evaluation boxes located throughout the meeting sites or consider the options below.

You can receive a parchment **Certificate of Attendance** at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information Center, or APA Member Center, all located in Toronto Metro Convention Centre). A **personalized Certificate of Attendance** will be available by completing the computerized general evaluation in the South Building, Level 600, Toronto Metro Convention Centre. Attendees may also access the web-based evaluation from their own computer during or after the meeting, and the program automatically generates a CME certificate. Please complete the general evaluation one time only.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the North Foyer, Level 200, Toronto Metro Convention Centre.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in **designated areas**.



TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Master Educator Clinical Consultations, the Clinical Case Conferences, and the Continuous Clinical Case Conferences, or unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2007 May 19-24	San Diego, CA
2008 May 3-8	Washington, DC
2009 May 16-21	San Francisco, CA
2010 May 22-27	New Orleans, LA
2011 May 14-19	Honolulu, HI

INSTITUTES ON PSYCHIATRIC SERVICES

2006 October 6-10	New York, NY
2007 October 11-14	New Orleans, LA
2008 October 2-5	Chicago, IL

Preliminary Programs for the 2006 Institute on Psychiatric Services are available at the Information Center, located in the North Foyer, Level 200, Toronto Metro Convention Centre.

GUIDE TO THE PROGRAM BOOK

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet. You can also create your own personal schedule by using the online itinerary planner. Visit APA's homepage www.psych.org and click on the 2006 Annual Meeting link. Then click on the link under the scientific session information heading and follow the instructions.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Toronto Metro Convention Centre, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

Floor Plans for Toronto Metro Convention Centre, Intercontinental Toronto Centre, Royal York, Sheraton Centre Toronto, Westin Harbour Castle	VI-XII
City Map	XIII
Local Information	XIV
Special Acknowledgments	XV-XVII
Format Descriptions	XVIII-XIX
Disclosure Information	XX-XXCVII
Benefits Concern	XXCVIII
APA's Online Library of 2006 Annual Meeting Sessions	XXCIX
Saturday Sessions	1-4
Sunday Sessions	5-15
Audiotape and CD Sales Information	16
Monday Sessions	17-42
Tuesday Sessions	43-66
Wednesday Sessions	67-95
Thursday Sessions	91-107
Topic Index	103-118
Join the APA Today	119
Participant Index	120-128
2006 Institute on Psychiatric Services	129
American Psychiatric Publishing, Inc.	130-131
American Psychiatric Foundation Special Events	132
Call for 2007 Annual Meeting Papers	133
Industry-Supported Symposia	134-156
APA Member Center	Back Cover


News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the *APA Exhibits Guide* for information on Exhibits, Publishers' Bookfair, and Dining Facilities in the Toronto Metro Convention Centre.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.


Toronto Convention Centre

255 Front Street West, Toronto, Ontario, Canada M5V 2W6
416-585-8000




Toronto Convention Centre


North Building



NORTH BUILDING | LEVEL 100




NORTH BUILDING | LEVEL 200




NORTH BUILDING | LEVEL 300

Toronto Convention Centre


South Building



SOUTH BUILDING | LEVEL 600



SOUTH BUILDING | LEVEL 700




SOUTH BUILDING | LEVEL 800


Intercontinental Hotel

225 Front Street West, Toronto, Ontario, Canada M5V 2W6
416-597-1400

Main Level




Lower Level




Royal York

100 Front Street West, Toronto, Ontario, Canada M5J 1E3
416-368-2511

Mezzanine Floor




Convention Floor




Sheraton Centre Toronto

123 Queen Street West, Toronto, Ontario, Canada M5H 2M9
416-361-1000


Lower Concourse



Mezzanine




Second Floor




Westin Harbour Castle

One Harbour Square, Toronto, Ontario, Canada M5J 1A6
416-869-1600



TORONTO CITY MAP



- 1 Bond Place Hotel
- 2 Best Western Primrose Hotel
- 3 Cambridge Suites
- 4 Courtyard by Marriott
- 5 Days Hotel and Conference Centre
- 6 Delta Chelsea
- 7 Four Seasons
- 8 Hilton Toronto
- 9 Holiday Inn on King
- 10 InterContinental Toronto
- 11 Intercontinental Toronto Centre
- 12 Le Royal Meridien King Edward

- 13 Marriott Eaton Centre
- 14 Metropolitan Hotel
- 15 Novotel Toronto Centre
- 16 Park Hyatt Toronto
- 17 Renaissance Toronto Hotel Downtown
- 18 Radisson Plaza Hotel Admiral Toronto
- 19 The Fairmont Royal York Toronto
- 20 Sheraton Centre Toronto
- 21 Strathcona Hotel
- 22 Sutton Place
- 23 Toronto Marriott Bloor-Yorkville
- 24 Westin Harbour Castle

LOCAL INFORMATION

Situated 566 feet above sea level on the northern shore of Lake Ontario, Toronto is one of the southernmost cities in Canada. In fact, it has nearly the same latitude as northern California. Toronto is home to more than 100 cultures with a population of 4.7 million; it's the fifth-largest city in North America, after Mexico City, New York, Los Angeles, and Chicago. Toronto isn't just diverse -- it's the most diverse city in the world -- and that leads Torontonians to look at things a little differently, from the perspective of a hundred cultures. Two transit tokens can take you from one country to another, passing along the way through the quaint neighborhoods that make up their intimate metropolis. It's a place of energy exchange. It's Unlimited!

Airport

When entering Canada you will be asked to fill out a customs form to present to customs officials. When returning to the U.S., you will go through U.S. Customs & Immigration in Toronto, as well as a security check where you will possibly be asked to open your baggage for searching. Once outside the Canadian Terminal there is a small kiosk where you can purchase a round trip bus ticket for \$27, which goes between downtown hotels and the airport.

Entering Canada

American visitors to Canada DO NOT need a passport to cross in either direction, **however it is still highly recommended.** Visitors who do not carry a passport will be asked to verify their citizenship and should therefore carry any one of the following documents: original birth certificate with raised seal, naturalization certificate, Green Card, or passport. Photo identification is also required so visitors should carry their driver's license or other photo ID. Individuals traveling from a country other than the U.S. may require a Visa. Please check with your Consulate or Embassy.

Languages Spoken

There are two official languages in Canada -- English and French. In addition to these official languages, the top five languages spoken in Toronto are Chinese, Italian, Tamil, Portuguese, and Spanish.

Weather

Springtime in Toronto is a sight to behold as the bulbs and buds begin to bloom. This seems to energize the population -- the first time the temperature rises into warm spring temperatures. **What to pack:** A light jacket and umbrella for those cool, rainy days.

Transit Safety -- Public Transit

Explore Toronto on one of North America's finest transportation systems -- the TTC. When using the TTC (public transit), a single fare will take you anywhere in the city on a one-way trip. You can freely transfer between subway, streetcar, and bus, but make sure you obtain a transfer (a slip of

paper) when and where you pay your fare. On buses and streetcars, exact change is required. TTC day passes are also available. Buses offer a "request-stop" program between 9:00 p.m. and 5:00 a.m., which allows a female to exit the bus between regular TTC stops.

Driving Around Town

Toronto's streets follow a basic grid pattern and are fairly easy to navigate, although some of the one-way streets can be confusing. The city's rush hour is more than an hour long -- count on heavy traffic from 7:00 a.m.-9:00 a.m. and again from 4:00 p.m.-6:00 p.m.

Parking

Parking on most downtown streets is limited to specific times of day and often requires you to purchase and display a ticket from one of the parking machines located along the street.

The Underground City

PATH is downtown Toronto's underground walkway linking 27 kms (16 miles) of subterranean shopping, services, and entertainment. Follow the brightly colored PATH signs and you'll reach your downtown destination easily in weather-proof comfort.

Currency

Here's what you need to know to spend money in Toronto: Toronto's currency is the Canadian Dollar. For denominations under five dollars, coins, including the "Loonie" (one dollar coin) and "Two-nie" (two dollar coin) are used. U.S. dollars are accepted in most Toronto establishments; although change from your transactions will be given in Canadian currency and exchange rates will differ with each merchant.

Taxes

The **Goods and Services Tax (GST)** is a 7% tax that is charged on all goods and services sold or provided in Canada. Toronto is part of the Province of Ontario, so purchases made in Toronto are also subject to the 8% **Provincial Sales Tax**

(PST). **Tax Rebates:** The good news is, foreign visitors to Canada can apply for a rebate on the GST that is paid on accommodations (up to 30 nights per visit), and on goods purchased in Canada and exported within 60 days of the purchase. Be sure to keep your receipts -- you'll need to have them validated by Canada Customs at the airport or border crossing when you leave. For more information about the visitors' tax refund and to obtain an application, visit www.cra.gc.ca/visitors or call 1-800-668-4748 (within Canada) or 1-902-432-5608 (from outside Canada).

Emergencies

Toronto's universal emergency number is **911**. Use it for police, fire, and medical emergencies. Each hotel has its own procedures for handling medical emergencies. If you experience a medical emergency, call the front desk at your hotel and they will assist in getting an ambulance or necessary medical help. Toronto Police Services has over 5,000 uniformed officers on patrol in the city and can be reached at 416-808-2222.

What to See

Tours? Visitor Information

Attendees are encouraged to use their hotel's concierge services to assist them with local information and dinner reservations. Please refer to pages 21-23 in this booklet for tours offered during the Annual Meeting. For local information, you may refer to www.mytorontomeeting.com.

Harbourfront Centre

Toronto's one-of-a-kind waterfront setting offers the arts, culture, and recreation. The outdoor patio bar, Splash, and indoor cafe, Lakeside EATS, offer a great place to meet friends and enjoy great snacks, meals, and drinks. Annual events include concerts, dance, theatre, and musical performances; art exhibitions; literary readings; craft activities; children's activities; outdoor ice-skating; and much more. Activities and events are either free or reasonably priced.

SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the Industry-Supported Symposium, "Multiple and Complex Presentations of Bipolar Disorder," Tuesday, May 23, 7:00 p.m.; and the Internet Village.

Alkermes: co-support of the Industry-Supported Symposium, "Diagnosing and Treating Alcohol Dependence in the Office," Wednesday, May 24, 7:00 p.m.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.

American Association of Chairs of Departments of Psychiatry: support of the APA/AACDP Research Mentorship Award.

American Psychiatric Association / Hurricane Disaster Relief Fund: support of the Disaster Psychiatry Fellowship.

American Psychiatric Foundation: support of the APIRE Practice Research Network.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, Monday, May 22, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Tuesday, May 23 2:00 p.m.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Pharmacotherapy of Psychotic and Mood Disorders With Co-Existing Medical Illness," Monday, May 22, 7:00 p.m.; and "Treating the Early Stages of Schizophrenia," Tuesday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Emerging Evidence in the Treatment of Bipolar Depression," Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and reception, Tuesday, May 23, 7:00 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 23, 5:30 p.m.; the George Tarjan Award Lecture, Wednesday, May 24, 9:00 a.m.; and the APA/AstraZeneca Young Minds in Psychiatry Award.

Avanir Pharmaceuticals: support of the Industry-Supported Symposium, "Pseudobulbar Affect: A Common Syndrome That Is Underrecognized, Misdiagnosed, and Undertreated," Sunday, May 21, 7:00 p.m.

Bristol-Myers Squibb Company: co-support of the Industry-Supported Symposia, "Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness," Saturday, May 20, 12:30 p.m.; "Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia," Saturday, May 20, 6:00 p.m.; "Atypical Depression: Merging Evidence and Public Policy," Sunday, May 21, 7:00 p.m.; "Helping Depressed Patients Achieve Remission: Advocacy for Improvement,"

Monday, May 22, 7:00 p.m.; and the Industry-Supported Breakfast Symposia, "Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths," Monday and Tuesday, May 22-23, 7:00 a.m.; and "Bipolar Illness: The Road to Remission," Wednesday and Thursday, May 24-25, 7:00 a.m.; support of the President's Dessert and Reception; and the Solomon Carter Fuller Award Lecture, Tuesday, May 23, 11:00 a.m., the Solomon Carter Fuller Award Reception; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Bristol-Myers Squibb Sweden: support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 21, 2:00 p.m.

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients."

Cephalon, Inc.: support of the Industry-Supported Symposia, "The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing Stigma," Sunday, May 21, 8:00 a.m.; "Advances in the Neurobiology and Therapeutics of ADHD," Sunday, May 21, 7:00 p.m.; "The Cognition, Neurocircuitry, and Disability Interface: Bringing Evidence to Practice," Monday, May 22, 7:00 p.m.; and "Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD," Tuesday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Evidence, Outcomes, and Advocacy: Shaping the Management of GAD," Monday and Tuesday, May 22-23, 7:00 a.m.; and co-support of the Industry-Supported Symposium, "Diagnosing and Treating Alcohol Dependence in the Office," Wednesday, May 24, 7:00 p.m.

Cyberonics, Inc.: support of the Industry-Supported Symposium, "Treatment-Resistant Depression: New Data, New Approaches," Saturday, May 20, 6:00 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Eisai, Inc.: co-support of the Industry-Supported Symposia, "Advances in the Understanding of the Dementia Spectrum," Sunday, May 21, 1:30 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Fibromyalgia: Scientific Advances to Reduce the Burden of Illness," Sunday, May 21, 8:00 a.m.; and "Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE Trial," Sunday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Monday, May 22, 11:00 a.m.; support of the APIRE/Lilly Psychiatric Research Fellowship; the symposium entitled, "Strengthening of Mental Health Systems in Low and Middle Income Countries," Monday, May 22, 2006,

SPECIAL ACKNOWLEDGMENTS

7:00 p.m.; and the APA/Lilly Resident Research Awards.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Monday, May 22, 9:00 a.m.

Psychiatric Foundation's Fund for Research in Psychiatry: co-support of the Research in Psychiatry Award Lecture, Monday, May 22, 9:00 a.m.;

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric Research," Saturday, May 20, 12:30 p.m.; "Interrupting the Cycle of Vascular Disease and Depression," Sunday, May 21, 1:30 p.m.; and "Alzheimer's Disease: Challenging the Practice Paradigm," Sunday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the registration portfolios.

GlaxoSmithKline: support of the Industry-Supported Symposia, "New Augmentation Strategies in Depression for Better Outcomes," Saturday, May 20, 12:30 p.m.; "Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar Disorder," Sunday, May 21, 1:30 p.m.; and "The Maze of Mood and Anxiety in the Elderly Patient: A Case Series," Tuesday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders," Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception; and the APIRE/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Merck & Co., Inc.: support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

National Institute of Mental Health: co-support of the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP).

National Institute on Alcohol Abuse and Alcoholism (NIAAA): support of annual meeting research track, "Rethinking Alcohol Use Disorders: Science, Diagnosis, Treatment, and Policy."

National Institute on Drug Abuse: support of annual meeting activities of trainees of the APIRE Drug Abuse Research Scholars Program.

Neurocrine Biosciences, Inc.: co-support of the Industry-Supported Symposium, "Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy," Sunday, May 21, 7:00 p.m.

Organon USA, Inc.: co-support of the Industry-Supported Symposium, "Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia," Monday, May 22, 7:00 p.m.

Otsuka America Pharmaceutical, Inc.: co-support of the Industry-Supported Symposia, "Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness," Saturday, May 20, 12:30 p.m.; "Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia," Saturday, May 20, 6:00 p.m.; and the Industry-Supported Breakfast Symposia, "Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths," Monday and Tuesday, May 22-23, 7:00 a.m.; and "Bipolar Illness: The Road to Remission," Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the APF Awards for Advancing Minority Mental Health.

Pfizer, Inc.: support of the Industry-Supported Symposia, "Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia: From Theory to Practice," Sunday, May 21, 8:00 a.m.; and "New Vistas in Treatment-Resistant Depression," Sunday, May 21, 8:00 a.m.; and "Remission and Recovery in Schizophrenia: Advocating for Our Patients," Wednesday, May 24, 7:00 p.m.; and co-support of the Industry-Supported Symposia, "Advances in the Understanding of the Dementia Spectrum," Sunday, May 21, 1:30 p.m.; "Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy," Sunday, May 21, 7:00 p.m.; and "Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia," Monday, May 22, 7:00 p.m.; support of the Psychiatric Services Achievement Awards; the "Abstracts-On-Disk" Program; and the APA/Pfizer Minority Psychiatric Research Fellowship Award; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Monday, May 22, 11:00 a.m.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Sepracor, Inc.: support of the Industry-Supported Symposium, "Vital Signs in Psychiatry: A Perspective on Sleep Across the Life Cycle," Sunday, May 21, 1:30 p.m.

SPECIAL ACKNOWLEDGMENTS

Shire US, Inc.: support of the Industry-Supported Symposia, "Mania in Special Populations," Saturday, May 20, 6:00 p.m.; "Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice," Sunday, May 21, 8:00 a.m.; and "Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder," Monday, May 22, 7:00 p.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 22, 7:00 a.m.; the APA/Shire Child and Adolescent Psychiatry Fellowships; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Solvay Pharmaceuticals Inc.: co-support of the Industry-Supported Symposia, "Bipolar Disorder: Creating a Consensus From Science to Public Policy," Saturday, May 20, 6:00 p.m.; "New Developments in Schizophrenia: From Neurobiology to Public Health," Sunday, May 21, 1:30 p.m.; "Management of Psychosis in the Elderly: The Science and the Art," Tuesday, May 23, 7:00 p.m.; and "Managing Unmet Needs in Psychiatric Illnesses: A Critical Look at Disorders and Public Policy," Wednesday, May 24, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "New Frontiers in Depression: Providing Solutions to Unmet Needs," Wednesday and Thursday, May 24-25, 7:00 a.m.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposium, "Bridging Sleep, Science, and Public Policy," Saturday, May 20, 12:30 p.m.; and the APA Shuttle Bus Service.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, "The Long-Term Clinical Course and Treatment of Recurrent Major Depression in 2006: New Data and Future Directions," Sunday, May 21, 1:30 p.m.; and "What Is the Role of Somatic and Physical Symptoms in Depression?," Wednesday, May 24, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety," Monday and Tuesday, May 22-23, 7:00 a.m.; co-support of the Industry-Supported Symposia, "Bipolar Disorder: Creating a Consensus From Science to Public Policy," Saturday, May 20, 6:00 p.m.; "New Developments in Schizophrenia: From Neurobiology to Public Health," Sunday, May 21, 1:30 p.m.; "Management of Psychosis in the Elderly: The Science and the Art," Tuesday, May 23, 7:00 p.m.; and "Managing Unmet Needs in Psychiatric Illnesses: A Critical Look at Disorders and Public Policy," Wednesday, May 24, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "New Frontiers in Depression: Providing Solutions to Unmet Needs," Wednesday and Thursday, May 24-25, 7:00 a.m.; support of the APIRE/Wyeth Laboratories M.D., Ph.D., Psychiatric Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, *APA TV News Program*; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Tuesday, May 23, 2:00 p.m.

FORMAT DESCRIPTIONS

ADVANCES IN... SERIES

These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online at www.appi.org.

CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATE

Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this *Program Book*.

WORKSHOPS

Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.



AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2006 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

Presenter	Manufacturer(s)
Gene G. Abel, M.D.	Abel Screening, Inc. ⁶
Anissa Abi-Dargham, M.D.	Bristol-Myers Squibb Company ^{3,4} ; Eli Lilly and Company ³ ; Lieber Center for Schizophrenia ³ ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ⁴ ; Sanofi-Aventis ⁴
Jean Addington, Ph.D.	Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ¹ ; PharmaStar, LLC ¹
Lawrence W. Adler, M.D.	GlaxoSmithKline ^{1,3}
David E. Adson, M.D.	AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{3,4} ; Cyberonics, Inc. ^{3,4} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{3,4} ; Pfizer Inc. ³
Hagop S. Akiskal, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ^{1,4} ; Sanofi-Aventis ^{1,4}
Jonathan E. Alpert, M.D.	Aspect Medical Systems ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; Organon Pharmaceuticals Inc ^{3,4} ; Pfizer Inc. ³ ; Pharmavite LLC ^{1,3}
Sonia Ancoli-Israel	Acadia Pharmaceuticals Inc ¹ ; Cephalon Inc. ^{1,4} ; King Pharmaceuticals, Inc. ^{1,4} ; Merck & Co., Inc. ¹ ; Neurocrine Biosciences Inc. ^{1,4} ; Neurogen ¹ ; Pfizer Inc. ^{1,4} ; Sanofi-Aventis ^{1,4} ; Sepracor, Inc. ^{1,4} ; Somaxon Pharmaceuticals ¹ ; Takeda Pharmaceuticals North America, Inc. ^{1,4}
Allan A. Anderson, M.D.	Forest Laboratories, Inc. ⁴ ; Pfizer Inc. ^{4,5}
Nancy C. Andreasen, M.D.	Janssen Pharmaceutica Products, LP ⁶ ; Pfizer Inc. ¹
Terrance H. Andree, Ph.D.	Wyeth Pharmaceuticals ²
David B. Arciniegas, M.D.	Avanir Pharmaceuticals ¹ ; Eisai Inc. ³ ; Forest Laboratories, Inc. ³
Lesley M. Arnold, M.D.	Boehringer-Ingelheim Pharmaceuticals GmbH ³ ; Cypress Bioscience Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ¹ ; Pfizer Inc. ^{1,3,4} ; Sanofi-Synthelabo ^{1,3} ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,4}
Amy Arnsten, Ph.D.	Shire Pharmaceuticals Group plc. ^{3,6}
George Awad	AstraZeneca Pharmaceuticals LP ⁴ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Pfizer Inc. ¹
Jerald Bain, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Eli Lilly and Company ⁴ ; Organon Pharmaceuticals Inc ^{1,3,4} ; Pfizer Inc. ⁴ ; Solvay Pharmaceuticals, Inc. ^{1,4}
F M. Baker, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Pfizer Inc. ³
Claudia F. Baldassano, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Elan Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴
Ross J. Baldessarini, M.D.	Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3}
Nigel Bark, M.D.	Bristol-Myers Squibb Company ¹ ; Pfizer Inc. ³
David Baron, D.O.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³ ; Shire Pharmaceuticals Group plc. ¹
Steven L. Batki, M.D.	GlaxoSmithKline ⁴ ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ³ ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{3,4}

Presenter	Manufacturer(s)
Elizabeth A. Baxter, M.D. Philip M. Becker, M.D.	Pfizer Inc. ⁴ AstraZeneca Pharmaceuticals LP ³ ; Boehringer-Ingelheim Pharmaceuticals GmbH ^{1,3} ; Cephalon Inc. ³ ; GlaxoSmithKline ^{1,3,4} ; Orphan Medical ⁴ ; Sanofi-Aventis ^{1,3,4} ; Takeda Pharmaceuticals North America, Inc. ^{1,3} ; XenoPort, Inc. ³
Julian Beezhold, M.B. Bernard D. Beitman, M.D. Gregory Belenky, M.D. John L. Beyers, M.D.	AstraZeneca Pharmaceuticals LP ⁶ ; Eli Lilly and Company ⁶ ; Janssen-Cilag ⁶ ; Lundbeck Pharmaceuticals ⁶ ; Pfizer Inc. ⁶ Bristol-Myers Squibb Company ⁴ Boeing Corporation ¹ Avanir Pharmaceuticals ¹ ; Boehringer-Ingelheim Pharmaceuticals GmbH ³ ; Bristol-Myers Squibb Company ⁴ ; Eisai Inc. ³ ; Eli Lilly and Company ^{4,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Myriad Genetics, Inc. ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Ono Pharmaceuticals, Inc. ³ ; Sanofi-Aventis ¹ ; Sanofi-Synthelabo ³
Joseph Biederman, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ³ ; Cephalon Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; McNeil Consumer Healthcare ^{1,3,4} ; McNeil Pharmaceutical ⁴ ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; New River Pharmaceuticals ¹ ; NIH Institute ³ ; NIMH ³ ; Novartis Pharmaceuticals Corporation ^{1,4} ; NRP ³ ; Pfizer Inc. ^{1,3} ; Shire Laboratories Inc. ⁴ ; Shire Laboratories ^{1,3,4} ; Shire Pharmaceuticals Group plc. ^{1,3,4} ; Stanley Foundation ³ ; Stanley Medical Research Institute ³ ; UCB Pharmaceuticals ⁴
Robert M. Bilder, Ph.D. Adam M. Bisaga Donald W. Black, M.D.	Acadia Pharmaceuticals Inc ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ^{1,3} Forest Laboratories, Inc. ⁴ AstraZeneca Pharmaceuticals LP ^{1,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Shire Pharmaceuticals Group plc. ^{1,4}
Carlos Blanco-Jerez M.D. Dan G. Blazer II, M.D. Michael Blumenfield, M.D. Samuel W. Boellner, M.D. John J. Boronow, M.D.	Pfizer Inc. ³ ; Somaxon Pharmaceuticals ³ National Institute of Mental Health ³ Forest Laboratories, Inc. ³ ; Gerson Lehrman Group ¹ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ Cephalon Inc. ¹ ; Wyeth Pharmaceuticals ¹ AstraZeneca Pharmaceuticals LP ² ; Bristol-Myers Squibb Company ² ; Janssen Pharmaceutica Products, LP ² ; Pfizer Inc. ² ; Stanley Medical Research Institute ³
Jeff Q. Bostic, M.D. Guylain Bouchard, M.D.	Abbott Laboratories, Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ³ ; Pfizer Inc. ³ AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ¹ ; Organon Pharmaceuticals Inc ¹ ; Wyeth Pharmaceuticals ¹
Charles L. Bowden, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ³ ; Pfizer Inc. ⁴ ; Robert Wood Johnson Foundation ³ ; Sanofi-Synthelabo ¹ ; Stanley Medical Research Institute ³ ; UCB Pharmaceuticals ¹
Richard Bowskill Dianne Bradford, M.D. John M. Bradford, M.B. Kathleen T. Brady, M.D.	AstraZeneca Pharmaceuticals LP ^{3,4} ; Eli Lilly and Company ⁴ GlaxoSmithKline ¹ Canadian Institutes of Health Research ³ ; Eli Lilly and Company ¹ Abbott Laboratories, Inc. ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Glaxo-Wellcome ¹ ; Ovation Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ³
E. Sherwood Brown, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ¹ ; UCB Pharmaceuticals ³
Thomas E. Brown, Ph.D.	American Psychiatric Publishing, Inc. ⁶ ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,4} ; McNeil Consumer Healthcare ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Shire Pharmaceuticals Group plc. ¹
Peter F. Buckley, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ^{1,3} ; Pharmaceutical Product Development, Inc ³
Ronald M. Burd, M.D. George Bush, M.D.	Blue Cross Blue Shield Association ¹ Janssen Pharmaceutica Products, LP ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; McNeil Consumer Healthcare ³ ; Pfizer Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹
Marian I. Butterfield, M.D. Daniel J. Buysse, M.D.	Bristol-Myers Squibb Company ^{1,3} Eli Lilly and Company ⁴ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ¹ ; Pfizer Inc. ^{1,3} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Servier ¹ ; Takeda Pharmaceuticals North America, Inc. ^{1,3}
Joseph R. Calabrese, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ^{1,3} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Parke-Davis ^{1,3} ; Pfizer Inc. ^{1,3} ; Robert Wood Johnson Foundation ^{1,3} ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Foundation ³ ; TAP Pharmaceuticals Product, Inc ^{1,3} ; Teva Pharmaceutical Industries Ltd. ¹ ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ³
William E. Callahan, Jr., M.D. William H. Campbell, M.D.	Bristol-Myers Squibb Company ^{1,4} ; Otsuka America Pharmaceutical, Inc. ^{1,4} Pfizer Inc. ⁴

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Joseph C. Cappelleri, Ph.D. Linda L. Carpenter, M.D.	Pfizer Inc. ² AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ¹ ; Cephalon Inc. ⁴ ; Corcept Therapeutics ³ ; Cyberonics, Inc. ^{1,3,4} ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Medtronic, Inc. ^{1,3} ; National Foundation for Mental Health ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3,4} ; Sepracor, Inc. ¹ ; U.S. Department of Defense ³ ; UCB Pharmaceuticals ³ ; Wyeth Pharmaceuticals ^{1,4}
William T. Carpenter, Jr., M.D.	Eli Lilly and Company ¹ ; H. Lundbeck A/S ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Diana Carter, M.D. Daniel E. Casey, M.D.	GlaxoSmithKline ⁴ ; H. Lundbeck A/S ³ ; Janssen Pharmaceutica Products, LP ⁴ ; Wyeth Pharmaceuticals ³ Abbott Laboratories, Inc. ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Pfizer Inc. ^{1,4} ; Solvay Pharmaceuticals, Inc. ¹ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ¹
Robert A. Chambers, M.D. Kiki D. Chang, M.D.	National Institute on Drug Abuse ³ Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Heinz C. Prechter Foundation ³ ; Janssen Pharmaceutica Products, LP ¹ ; Klingenstein Third Generation Foundation ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; NIH Institute ³ ; Ortho-McNeil Pharmaceutical, Inc. ⁴ ; Otsuka America Pharmaceutical, Inc. ³ ; Shire Pharmaceuticals Group plc. ¹
Linda Chang, M.D. Joseph A. Cheong, M.D. Dennis S. Charney, M.D. Henry Chung, M.D. Leslie L. Citrome, M.D.	National Institute on Drug Abuse ³ Creative Educational Concepts – CME program development ^{1,6} Pfizer Inc. ¹ AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{1,3,4,5} ; Canadian Institutes of Health Research ¹ ; Eli Lilly and Company ^{1,3,4,5} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ^{3,5} ; Merck & Co., Inc. ⁵ ; Pfizer Inc. ^{1,3,4,5}
Duncan B. Clark, M.D. Jane Clatworthy Anita H. Clayton, M.D.	Forest Laboratories, Inc. ¹ AstraZeneca Pharmaceuticals LP ^{3,4} ; Eli Lilly and Company ⁴ Boehringer-Ingelheim Pharmaceuticals GmbH ^{1,3} ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,4} ; Jazz Pharmaceuticals, Inc. ¹ ; Neuronetics, Inc. ³ ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ³
Michael Cohen Cynthia L. Comella, M.D.	EEG Spectrum International Inc. ² Allergan Inc ¹ ; AstraZeneca Pharmaceuticals LP ³ ; Boehringer-Ingelheim Pharmaceuticals GmbH ^{1,3} ; Jazz Pharmaceuticals, Inc. ¹ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ³ ; Ovation Pharmaceuticals, Inc. ¹ ; UCB Pharmaceuticals ¹
Robert R. Conley, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; National Institute of Mental Health ^{1,3} ; National Institute on Drug Abuse ^{1,3} ; Repligen Corporation ³ ; Stanley Foundation ³
Kathryn M. Connor, M.D.	Allergan, Inc. ⁵ ; Cephalon Inc. ^{1,4,5} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,4} ; Jazz Pharmaceuticals ¹ ; Nordic Naturals, Inc. ⁵ ; Nutrition 21, Inc. ⁵ ; Ortho McNeil Pharmaceutical Inc. ^{1,4} ; Pfizer, Inc. ^{1,3,4} ; Predix Pharmaceuticals ¹ ; Dr. Wilmar Schwabe ⁵ ; Schwarz Pharma Inc. ¹ ; Solvay Pharmaceuticals, Inc. ^{1,5} ; Wyeth Pharmaceuticals ⁴
Barbara A. Cornblatt, Ph.D. Maria R. Corral, M.D. Christoph U. Correll, M.D.	Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} AstraZeneca Pharmaceuticals LP ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ⁴
Joseph T. Coyle, Jr., M.D.	Abbott Laboratories, Inc. ¹ ; Avera Pharmaceuticals, Inc. ¹ ; Cephalon Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ³ ; Prestwick Pharmaceuticals, Inc. ¹ ; Proctor & Gamble Company ⁶
Leslie J. Grofford, M.D.	Abbott Laboratories, Inc. ³ ; Eli Lilly and Company ¹ ; Orphan Medical ¹ ; Pfizer Inc. ^{1,3} ; Proctor & Gamble Company ³ ; Sanofi-Synthelabo ¹ ; Wyeth Pharmaceuticals ¹
Thomas J. Crowley, M.D. Jeffrey L. Cummings, M.D.	Reckitt Benckiser plc ¹ AstraZeneca Pharmaceuticals LP ¹ ; Avanir Pharmaceuticals ¹ ; Bristol-Myers Squibb Company ¹ ; Cortex Pharmaceuticals, Inc. ^{1,3} ; Eisai Inc. ^{1,4} ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ^{1,4} ; Genentech ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lundbeck Pharmaceuticals ¹ ; Memory Pharmaceuticals ¹ ; Merz Pharmaceuticals ^{1,4} ; Myriad Genetics, Inc. ¹ ; Neurochem, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,4} ; Ono Pharmaceuticals, Inc. ¹ ; Ovation Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,4} ; Praevis Pharmaceuticals Incorporated ¹ ; Sanofi-Aventis ¹ ; Takeda Pharmaceuticals North America, Inc. ¹
Itai Danovitch, M.D. Jonathan S. Davine, M.D.	GlaxoSmithKline ⁶ Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ ; H. Lundbeck A/S ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Organon Pharmaceuticals Inc ⁴ ; Wyeth Pharmaceuticals ⁴
Deborah Deas, M.D.	Eli Lilly and Company ⁴ ; National Institute of Alcohol Abuse and Alcoholism ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
Charles Debatista, M.D. Melissa P. Delbello, M.D.	Corcept Therapeutics ⁵ ; Eli Lilly and Company ³ Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Pharmaceuticals Group plc. ¹

Presenter	Manufacturer(s)
Pedro L. Delgado, M.D.	Boehringer-Ingelheim Pharmaceuticals GmbH ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Corcept Therapeutics ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3} ; National Institute of Health ¹ ; National Institute of Mental Health ^{1,3} ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ¹
Nicholas Demartinis, M.D.	Wyeth Pharmaceuticals ^{1,3}
Mark Demitrack, M.D.	Eli Lilly and Company ⁶ ; Neuronetics, Inc. ^{2,5} ; Wyeth Pharmaceuticals ⁵
Mantosh J. Dewan, M.D.	Eli Lilly and Company ³
Naakesh A. Dewan, M.D.	Collaborate on Projects with Gold Standard ⁶
P. Murali Doraiswamy, M.D.	Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³ ; Myriad Genetics, Inc. ¹ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3,4} ; Saegis ¹
Martin Dossenbach	Eli Lilly and Company ²
Robert Drake, Ph.D.	Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ³
Roxanne Dryden-Edwards, M.D.	Eli Lilly and Company ³
Sanjay Dube, M.D.	Eli Lilly and Company ²
Hector J. Duenas, M.D.	Eli Lilly and Company ²
Boadie W. Dunlop, M.D.	Cephalon ³ ; Forest Laboratories, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ³ ; Wyeth Pharmaceuticals ³
David L. Dunner, M.D.	Bristol-Myers Squibb Company ^{1,3,4} ; Corcept Therapeutics ¹ ; Cyberonics, Inc. ^{3,4} ; Cypress Bioscience Inc. ¹ ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ⁴ ; Otsuka America Pharmaceutical, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Sanofi-Aventis ⁴ ; Shire Pharmaceuticals Group plc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,4}
Esther Eisenberg, M.D.	Merck & Co., Inc. ¹
James M. Ellison, M.D.	Bristol-Myers Squibb Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{3,4} ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
Larry Ereshefsky, Pharm.D.	AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ³ ; Celgene Corporation ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Merck & Co., Inc. ³ ; Ono Pharmaceuticals, Inc. ³ ; Organon Pharmaceuticals Inc. ³ ; Pfizer Inc. ^{3,5} ; Quintiles Transnational Corp. ³ ; Sanofi-Aventis ³ ; Sepracor, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Somaxon Pharmaceuticals ³ ; Sumitomo Pharmaceuticals Co., Ltd ³ ; Wyeth Pharmaceuticals ^{3,4}
Milton Erman, M.D.	Cephalon Inc. ^{1,3,5}
Javier I. Escobar, M.D.	American Association of Geriatric Psychiatry ⁴ ; Bristol-Myers Squibb Company ⁶ ; Eli Lilly and Company ^{1,4} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{4,5} ; Wyeth Pharmaceuticals ^{1,4}
Randall T. Espinoza, M.D.	Janssen Medical Affairs, LLC ³
Raymond A. Faber, M.D.	Bristol-Myers Squibb Company ⁴ ; Forest Laboratories, Inc. ⁴ ; Pfizer Inc. ⁴
Warachal E. Faison, M.D.	Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁶ ; Janssen Medical Affairs, LLC ² ; Janssen Pharmaceutica Products, LP ^{1,4} ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Organon Pharmaceuticals Inc. ³ ; Otsuka America Pharmaceutical, Inc. ^{1,4} ; Pfizer Inc. ⁴
Alexander H. Fan, M.D.	Bristol-Myers Squibb Company ⁶ ; Pfizer Inc. ⁵ ; Shire Pharmaceuticals Group plc. ⁴ ; Stanley Medical Research Institute ³
Stephen V. Faraone, Ph.D.	Eli Lilly and Company ^{1,3} ; McNeil Consumer Healthcare ^{1,3,4} ; Novartis Pharmaceuticals Corporation ⁴ ; Shire Pharmaceuticals Group plc. ^{1,3,4}
Maurizio Fava, M.D.	Abbott Laboratories, Inc. ³ ; Aspect Medical Systems ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bayer Corporation, Pharmaceutical Division ¹ ; Biovail Corporation ¹ ; Brain Cells ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon Inc. ^{1,3} ; Compellis ^{1,5} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; H. Lundbeck A/S ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Lichtwer Pharma GmbH ³ ; Lorex ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Parke-Davis ¹ ; Pfizer Inc. ^{1,3} ; Pharmacia & Upjohn ^{1,3} ; Pharmavite LLC ^{1,3} ; Roche ^{1,3} ; Sanofi-Synthelabo ^{1,3} ; Sepracor, Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Howard Feldman, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Eisai Inc. ^{1,3,4} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lundbeck Pharmaceuticals ¹ ; Myriad Genetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,4} ; Pfizer Inc. ^{1,3,4} ; Sanofi-Synthelabo ^{1,3} ; Servier ¹ ; Targacept, Inc. ¹
Stephen J. Ferrando, M.D.	Bristol-Myers Squibb Company ⁴ ; Cephalon Inc. ⁴ ; Forest Laboratories, Inc. ⁴ ; National Institute of Health ³ ; Pfizer Inc. ⁴
Marie-Josée Filteau, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Biovail Corporation ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,4} ; H. Lundbeck A/S ^{1,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Merck & Co., Inc. ^{1,4} ; Shire Pharmaceuticals Group plc. ¹ ; Wyeth Pharmaceuticals ^{1,3,4}
Robert L. Findling, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Otsuka America Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Sanofi-Synthelabo ¹ ; Shire Pharmaceuticals Group plc. ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ^{1,3}
Naomi A. Fineberg, M.A.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cephalon Inc. ³ ; H. Lundbeck A/S ^{1,3} ; Janssen Pharmaceutica Products, LP ³
Mary Jo Fitz-Gerald, M.D.	Cephalon Inc. ³

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Edna B. Foa, Ph.D.	American Psychiatric Association ⁴ ; Bristol-Myers Squibb Company ³ ; Cephalon Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{3,4} ; Solvay Pharmaceuticals, Inc. ³
Peter Fonagy, M.D.	Borderline Personality Disorder Research Foundation ³ ; Community Fund ³ ; Diana, Princess of Wales Memorial Fund ³ ; FHL Foundation, Inc. ³ ; National Institute for Clinical Excellence ³
Brent P. Forester, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ⁴ ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; National Alliance for Research in Schizophrenia and Depression ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ^{3,4}
Richard J. Frances, M.D.	Amgen, Inc. ⁵ ; Forest Laboratories, Inc. ^{1,4}
Ellen Frank, Ph.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ¹ ; Pittsburgh Foundation ¹ ; Servier ¹
W. Gordon Frankle, M.D.	Bristol-Myers Squibb Company ^{3,4} ; Ono Pharmaceuticals, Inc. ³ ; Pfizer Inc. ³
Marlene P. Freeman, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ⁴ ; Pronova Biocare ³ ; U.S. Food and Drug Administration ³
Frederick J. Frese, Ph.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; National Institute of Mental Health ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Pfizer Inc. ⁴ ; Stanley Medical Research Institute ^{1,4}
Joseph Friedman, M.D.	Eli Lilly and Company ³
Wolfgang Gaebel, Prof. Dr.	Janssen Pharmaceutica Products, LP ^{1,3} ; Wyeth Pharmaceuticals ³
Joseph M. Garbely, D.O.	AstraZeneca Pharmaceuticals LP ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴
Susan Shur-Fen Gau, M.D.	Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{3,4}
Alan J. Gelenberg, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Best Practice ¹ ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ¹ ; Pfizer Inc. ^{1,3,4} ; Roche ¹ ; Vela Pharmaceuticals, Inc. ^{1,5} ; Wyeth Pharmaceuticals ^{1,3}
Barbara Geller, M.D.	Abbott Laboratories, Inc. ⁶
Mark S. George, M.D.	Advanced Neuromodulation Systems, Inc. ³ ; Aventis Pharmaceuticals, Inc. ¹ ; Cephos Corporation ³ ; Cortex Pharmaceuticals, Inc. ³ ; Cyberonics, Inc. ^{1,3,4} ; Dana Foundation ³ ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ¹ ; Medtronic, Inc. ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; Neuronetics, Inc. ^{1,3} ; NeuroPace, Inc. ¹ ; Stanley Foundation ³ ; Stanley Medical Research Institute ³ ; U.S. Department of Defense ³
Tony P. George, M.D.	National Alliance for Research in Schizophrenia and Depression ³ ; National Institute on Drug Abuse ³ ; Targacept, Inc. ³
S. Nassir Ghaemi, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eisai Inc. ³ ; GlaxoSmithKline ^{1,3,4,6} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ¹
Martin Gignac, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Shire Pharmaceuticals Group plc. ¹
Rachel L. Glick, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ¹
Donald C. Goff, M.D.	Bristol-Myers Squibb Company ¹ ; Cephalon Inc. ³ ; Cortex Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Pfizer Inc. ³
Stephen M. Goldfinger, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; GlaxoSmithKline ³ ; Ivax Corporation ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Foundation for Mental Health ¹ ; Otsuka America Pharmaceutical, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Teva Pharmaceutical Industries Ltd. ^{1,5} ; Vanda Pharmaceuticals ^{1,3}
Morris B. Goldman, M.D.	Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Health ³ ; Novartis Pharmaceuticals Corporation ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,3,4}
Marion Zucker Goldstein, M.D.	GlaxoSmithKline ¹
Wayne K. Goodman, M.D.	Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,3} ; Forest Laboratories, Inc. ¹ ; Janssen Pharmaceutica Products, LP ³
Frederick K. Goodwin, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3,4} ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ^{1,3,4}
Ken Graap, M.Ed.	Virtually Better ²
Tana A. Grady-Weliky, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3,6} ; GlaxoSmithKline ¹ ; Pfizer Inc. ^{3,4}
Jon E. Grant, M.D.	Somaxon Pharmaceuticals ¹
Michael C. Graves, M.D.	Amgen, Inc. ³ ; Genentech ³ ; Guillain-Barre Support Group International ³ ; National Institute of Health ³ ; Sanofi-Aventis ³
Kevin F. Gray, M.D.	Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴
Michael Green, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ¹
Benjamin D. Greenberg, M.D.	Dana Foundation ³ ; Forest Laboratories, Inc. ⁴ ; Medtronic, Inc. ^{1,3} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ⁴
Lawrence S. Gross, M.D.	Aspect Medical Systems ³ ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ¹ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc. ³ ; Solvay Pharmaceuticals, Inc. ³
George T. Grossberg, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Alzheimer Association ¹ ; AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3}
Ellen Haller, M.D.	Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴

Presenter	Manufacturer(s)
Basil D. Halliday, M.S.C. Thomas E. Hansen, M.D. Philip D. Harvey, Ph.D.	GlaxoSmithKline ⁶ ; Otsuka America Pharmaceutical, Inc. ⁶ Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3} ; Sanofi-Aventis ¹ ; Solvay Pharmaceuticals, Inc. ¹
Peter Hauser, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals LP ^{3,4} ; Eli Lilly and Company ^{3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Roche ^{3,4}
David C. Henderson, M.D.	AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{3,4} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Otsuka America Pharmaceutical, Inc. ⁴ ; Pfizer Inc. ^{3,4}
Alan R. Hirsch, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Parke-Davis ¹ ; Pharmacia & Upjohn ¹ ; Proctor & Gamble Company ¹
Robert M.A. Hirschfeld, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ¹
Steven K. Hoge, M.D.	Life-Pool, LLC ⁵
Eric Hollander, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Eli Lilly and Company ³ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ³ ; Somaxon Pharmaceuticals ^{1,3} ; UCB Pharmaceuticals ³ ; Wyeth Pharmaceuticals ^{1,3,4}
Rob Horne	AstraZeneca Pharmaceuticals LP ^{3,4} ; Eli Lilly and Company ⁴
Robert H. Howland, M.D.	Cyberonics, Inc. ^{3,4}
William Huang, M.D.	Bristol-Myers Squibb Company ⁴
James J. Hudziak, M.D.	GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴
Steven Hull, M.D.	Cephalon Inc. ¹
Mustafa Hussain	AstraZeneca Pharmaceuticals LP ⁴ ; Cyberonics, Inc. ^{3,4} ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ⁴ ; National Institute of Mental Health ³ ; Neuronetics, Inc. ³ ; Novartis Pharmaceuticals Corporation ⁴
Michael Y. Hwang, M.D.	Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴
Steven E. Hyman	Merck & Co., Inc. ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹
Dan V. Iosifescu, M.D.	Aspect Medical Systems ³ ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,4}
Waguih W. Ishak, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Janssen Pharmaceutica Products, LP ³
M. Saleem Ismail, M.D.	Eisai Inc. ⁴ ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; National Institute of Mental Health ³ ; NIA ³ ; Pfizer Inc. ³
Shaily Jain, M.D.	UT Southwestern Medical Center at Dallas ²
Philip G. Janicak, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Neuronetics, Inc. ³ ; Pfizer Inc. ^{1,4} ; Sanofi-Synthelabo ³ ; Shire Pharmaceuticals Group plc. ^{1,4}
Daniel C. Javitt, M.D.	Janssen Pharmaceutica Products, LP ⁶ ; Medifoods, LLC ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; NPS Pharmaceuticals ⁶ ; Organon Pharmaceuticals Inc ^{1,6} ; Prestwick Pharmaceuticals, Inc. ⁶ ; Stanley Medical Research Institute ³
Geetha Jayaram, M.D.	Cephalon Inc. ⁴ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Wyeth Pharmaceuticals ⁴
Dilip V. Jeste, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Medical Affairs, LLC ³ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Peter B. Jones, M.D.	Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹
Rima F. Kaddurah-Daouk, Ph.D.	Metabolon Inc. ¹
René S. Kahn, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{3,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ^{1,3,4}
Ned H. Kalin, M.D.	Amgen, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Corcept Therapeutics ^{1,6} ; Cypress Bioscience Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ³ ; Neurocrine Biosciences ^{1,6} ; Neuronetics, Inc. ¹ ; Pfizer Inc. ¹ ; Promoter Neurosciences, LLC ⁶ ; Stanley Foundation ³ ; Wyeth Pharmaceuticals ^{1,3}
John M. Kane, M.D.	Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,4} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; MDS Pharma ¹ ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹
Shitij Kapur, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; EMD Biosciences, Inc. ³ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ³ ; Neuromolecular Inc. ³ ; Pfizer Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Wayne J. Katon, M.D.	Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{1,4} ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
Cornelius Katona, M.D.	Eli Lilly and Company ^{1,3,4} ; H. Lundbeck A/S ⁴ ; Shire Pharmaceuticals Group plc. ⁴
Nathaniel P. Katz, M.D.	Abbott Laboratories, Inc. ⁶ ; Allergan Inc ⁶ ; Biovail Corporation ⁶ ; Cephalon Inc. ⁶ ; Forest Laboratories, Inc. ⁶ ; GlaxoSmithKline ⁶ ; Janssen Pharmaceutica Products, LP ⁶ ; Ligand Pharmaceuticals ⁶ ; Pfizer Inc. ⁶ ; Purdue Pharma L.P. ⁶

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Paul E. Keck, Jr., M.D.	Abbott Laboratories, Inc. ^{1,3} ; American Diabetes Association ³ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Memory Pharmaceuticals ¹ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Neurocrine Biosciences Inc. ¹ ; Organon Pharmaceuticals Inc ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Medical Research Institute ³ ; UCB Pharmaceuticals ³
Richard S.E. Keefe, Ph.D.	Abbott Laboratories, Inc. ^{1,6} ; Acadia Pharmaceuticals Inc ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3,4,6} ; Forest Laboratories, Inc. ^{1,6} ; GlaxoSmithKline ^{1,6} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,4,6} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3,6} ; Repligen Corporation ^{1,6} ; Saegis ¹ ; Sanofi-Aventis ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Martin B. Keller, M.D.	Abbott Laboratories, Inc. ⁶ ; Bristol-Myers Squibb Company ^{1,6} ; Cephalon Inc. ⁶ ; Collegium ¹ ; Crirex ⁶ ; Cyberonics, Inc. ^{1,6} ; Cypress Bioscience Inc. ^{1,6} ; Eli Lilly and Company ^{1,3,6} ; Forest Laboratories, Inc. ^{1,3,6} ; GlaxoSmithKline ⁶ ; Janssen Pharmaceutica Products, LP ^{1,6} ; Merck & Co., Inc. ^{1,3,6} ; Mitsubishi Pharma Corporation ⁶ ; Novartis Pharmaceuticals Corporation ⁶ ; Organon Pharmaceuticals Inc ^{1,3,6} ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3,6} ; PharmaStar, LLC ¹ ; Sanofi-Synthelabo ⁶ ; SCIREX Corporation ⁶ ; Sepracor, Inc. ^{1,6} ; Somerset Pharmaceuticals Inc. ⁶ ; Vela Pharmaceuticals, Inc. ^{1,6} ; Wyeth Pharmaceuticals ^{1,3,6}
Sidney H. Kennedy, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ^{1,4} ; Boehringer-Ingelheim Pharmaceuticals GmbH ¹ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; H. Lundbeck A/S ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Merck & Co., Inc. ³ ; Organon Pharmaceuticals Inc ^{1,4} ; Pfizer Inc. ¹ ; Servier ¹ ; Wyeth Pharmaceuticals ^{1,4}
Ronald Kessler	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³ ; Wyeth Pharmaceuticals ³
Terence A. Ketter, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Cephalon Inc. ¹ ; Corcept Therapeutics ¹ ; Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Jazz Pharmaceuticals, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,4} ; Shire Pharmaceuticals Group plc. ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3}
James H. Kocsis, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{3,4} ; Wyeth Pharmaceuticals ^{3,4}
Robert Kohn, M.D.	Forest Laboratories, Inc. ⁴ ; National Alliance for Research in Schizophrenia and Depression ³ ; Pfizer Inc. ⁴
Scott Kollins, Pharm.D.	Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ¹ ; McNeil Consumer Healthcare ^{1,4} ; Pfizer Inc. ³ ; Shire Pharmaceuticals Group plc. ^{1,3} ; UCB Pharmaceuticals ³
George F. Koob	Alkermes, Inc. ¹ ; Forest Laboratories, Inc. ¹ ; Merck & Co., Inc. ¹
Lorrin M. M. Koran, M.D.	Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ³ ; Pfizer Inc. ⁴ ; Somaxon Pharmaceuticals ³
Robert A. Kowatch, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ³ ; Cephalon Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Shire Pharmaceuticals Group plc. ⁴ ; Stanley Medical Research Institute ³
Chad Y. Koyanagi, M.D.	Janssen Pharmaceutica Products, LP ⁴
Frank A. Kozel, M.D.	National Institute of Mental Health ³ ; U.S. Department of Defense ³
Henry R. Krantzler, M.D.	Alkermes, Inc. ¹ ; Bristol-Myers Squibb Company ³ ; DrugAbuse Sciences, Inc. ¹ ; Forest Laboratories, Inc. ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³
Christopher J. Kratochvil, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Cephalon ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ³ ; McNeil Consumer Healthcare ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹
K. Ranga R. Krishnan, M.D.	Abbott Laboratories, Inc. ¹ ; Amgen, Inc. ¹ ; CeNeRx ⁵ ; Concept Therapeutics ¹ ; Cyberonics, Inc. ¹ ; Cypress Bioscience Inc. ⁵ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3} ; NPS Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Psychme ⁵ ; Sepracor, Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ¹
Andrew D. Krystal, M.D.	Cephalon Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} ; King Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ^{1,3} ; National Institute of Mental Health ³ ; Neurocrine Biosciences Inc. ^{1,3} ; Neuronetics, Inc. ³ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Respiroics, Inc. ^{1,3} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Somaxon Pharmaceuticals ^{1,3} ; Takeda Pharmaceuticals North America, Inc. ¹
John H. Krystal, M.D.	Alkermes, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Merz Pharmaceuticals ¹ ; Pfizer Inc. ¹ ; Takeda Pharmaceuticals North America, Inc. ¹ ; Titan Pharmaceutical, Inc ¹ ; UCB Pharmaceuticals ¹
Elisabeth J.S. Kunkel, M.D.	Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
David J. Kupfer, M.D.	Eli Lilly and Company ^{1,6} ; F. Hoffmann-La Roche & Co. ⁶ ; Forest Laboratories, Inc. ^{1,6} ; Pfizer Inc. ^{1,6} ; Servier ¹ ; Solvay Pharmaceuticals, Inc. ^{1,6}
Clete A. Kushida, M.D.	GlaxoSmithKline ³ ; Schwartz Pharmaceuticals ³ ; XenoPort, Inc. ³
Anthony E. Lang, M.D.	Medtronics, Inc. ³
Marc Laruelle, M.D.	Bristol-Myers Squibb Company ¹ ; GlaxoSmithKline ^{1,3}
Erika Lauronen, M.D.	GlaxoSmithKline ³
Edward C. Lauterbach, M.D.	Accel Health ^{1,4} ; Avanir Pharmaceuticals ¹ ; Cerebrio ^{1,4} ; Forest Laboratories, Inc. ⁴

Presenter	Manufacturer(s)
Helen Lavretsky, M.D.	Eisai Inc. ⁴ ; Forest Laboratories, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; National Institute of Mental Health ³ ; Pfizer Inc. ⁴
William B. Lawson, M.D.	Abbott Laboratories, Inc. ^{3,4} ; Bristol-Myers Squibb Company ⁴ ; Pfizer Inc. ^{1,4} ; Shire Pharmaceuticals Group plc. ^{3,4}
Arthur L. Lazarus, M.D.	AstraZeneca Pharmaceuticals LP ^{2,5}
Gerard A. Leblanc, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Biovail Corporation ¹ ; Canadian Network for Mood and Anxiety Treatments ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Prestwick Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
James F. Leckman	National Institute of Mental Health ³
Matthias K. Lee, M.D.	Pfizer Inc. ³ ; Sanofi-Aventis ⁴
Eric J. Lenze, M.D.	Forest Laboratories, Inc. ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Pfizer Inc. ³
Alan I. Levenson, M.D.	Addex Pharmaceuticals ⁶
Frances R. Levin, M.D.	Eli Lilly and Company ^{1,3} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; UCB Pharmaceuticals ^{1,3}
Petros Levounis, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Forest Laboratories, Inc. ^{1,4} ; Reckitt Benckiser plc ^{1,4}
Roberto Lewis-Fernandez, M.D.	GlaxoSmithKline ³ ; Pfizer Inc. ³
Jeffrey A. Lieberman, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{1,3} ; Repligen Corporation ⁶ ; Sanofi-Synthelabo ³ ; Solvay Pharmaceuticals, Inc. ¹
Susan J. Loeff, M.D.	Eli Lilly and Company ⁶
Russell F. Lim, M.D.	Abbott Laboratories, Inc. ⁴ ; Cephalon Inc. ¹
Jean-Pierre Lindenmayer, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ³
Sarah H.H. Lisanby, M.D.	American Federation for Aging Research ³ ; Cyberonics, Inc. ^{3,4} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Neuronetics, Inc. ³ ; Stanley Medical Research Institute ³
Shari Lusskin, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; GlaxoSmithKline ⁴ ; Wyeth Pharmaceuticals ⁴
Constantine Lyketsos, M.D.	Eisai Inc. ^{1,3} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Pfizer Inc. ³
Avram H. Mack, M.D.	Forest Laboratories, Inc. ^{1,4}
Glenda M. MacQueen	AstraZeneca Pharmaceuticals LP ^{3,4} ; Biovail Corporation ⁴ ; Canadian Institutes of Health Research ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ⁴ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Oryx Pharmaceuticals, Inc. ¹ ; Stanley Medical Research Institute ³ ; Wyeth Pharmaceuticals ^{3,4}
Bertha K. Madras, Ph.D.	Boston Life Sciences, Inc. ⁶
Anil K. Malhotra, M.D.	Eli Lilly and Company ³ ; Pfizer Inc. ^{3,4}
Donald A. Malone, Jr., M.D.	Bristol-Myers Squibb Company ^{3,4} ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Medtronic, Inc. ^{1,3} ; Pfizer Inc. ⁴
Catherine Mancini, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon Inc. ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ³
G. Kent Mangelson, B.S.	National Medical Foundation ⁴
Karl F. Mann, M.D.	Sanofi-Synthelabo ¹
Theo C. Manschreck, M.D.	Pfizer Inc. ⁴
Lauren B. Marangell, M.D.	Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{1,4} ; Medtronic, Inc. ¹ ; National Institute of Mental Health ^{1,3} ; Neuronetics, Inc. ³ ; Pfizer Inc. ¹ ; Stanley Foundation ³
Stephen R. Marder, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; H. Lundbeck A/S ¹ ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ^{1,3} ; Organon Pharmaceuticals Inc ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹
Humberto Marin, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; National Institute of Neurological Disorders and Stroke ³ ; Pfizer Inc. ³ ; Sanofi-Aventis ³ ; Sepracor, Inc. ³ ; Takeda Pharmaceuticals North America, Inc. ³
James M. Martinez, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{1,3,4} ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; National Institute of Health ³ ; Neuronetics, Inc. ³ ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{3,4} ; Sanofi-Aventis ³ ; Stanley Foundation ³ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ⁴
Christine E. Marx, M.D.	Eli Lilly and Company ^{3,6}
Prakash S. Masand, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{1,3,4,5} ; Cephalon Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Healthcare Technology Systems, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; M-Science ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Organon Pharmaceuticals Inc ^{1,4} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,3,4} ; Psychcme ⁵ ; Wyeth Pharmaceuticals ^{1,3,4}
Barbara J. Mason, Ph.D.	Addex Pharmaceuticals ¹ ; Alkermes, Inc. ¹ ; Forest Laboratories, Inc. ^{1,4} ; Somaxon Pharmaceuticals ¹
Sanjay Mathew, M.D.	Cephalon Inc. ⁴ ; Pfizer Inc. ¹
Annette M. Matthews, M.D.	Bristol-Myers Squibb Company ⁶

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Paulo E. Mattos, M.D.	Eli Lilly and Company ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Wyeth Pharmaceuticals ⁴
Elinore F. McCance-Katz, M.D.	Reckitt Benckiser plc ¹
Gregory McCarthy	GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³
Stephen P. McDermott, M.D.	Shire Pharmaceuticals Group plc ⁴
William M. McDonald, M.D.	Abbott Laboratories, Inc. ⁵ ; American Foundation for Suicide Prevention ^{3,3} ; Amgen, Inc. ⁵ ; Bristol-Myers Squibb Company ¹ ; Cyberonics, Inc. ¹ ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Millenium Pharmaceuticals, Inc. ⁵ ; National Institute of Mental Health ^{1,3} ; National Institute of Neurological Disorders and Stroke ^{1,3} ; Neurobiological Technology, Inc. ⁵ ; Neuronetics, Inc. ^{1,3} ; Pfizer Inc. ⁵ ; Teva Pharmaceutical Industries Ltd. ⁵
David M. McDowell, M.D.	Bristol-Myers Squibb Company ^{1,4} ; Mallinckrodt Inc. ⁴ ; Reckitt Benckiser plc ⁴ ; Wyeth Pharmaceuticals ^{1,4}
Susan L. McElroy, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ³ ; Eisai Inc. ³ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ¹ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,3} ; Stanley Foundation ³ ; Wyeth Pharmaceuticals ¹
Joseph McEvoy, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ³
Joseph P. McEvoy, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4}
Thomas H. McGlashan, M.D.	Eli Lilly and Company ^{1,3} ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹
James J. McGough, M.D.	Eli Lilly and Company ^{3,4} ; McNeil Consumer Healthcare ^{3,4} ; National Institute of Health ³ ; Novartis Pharmaceuticals Corporation ^{3,4} ; Pfizer Inc. ³ ; Shire Pharmaceuticals Group plc. ^{1,3,4}
Roger S. McIntyre, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Biovail Corporation ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Merck & Co., Inc. ³ ; Organon Pharmaceuticals Inc ^{1,4} ; Pfizer Inc. ^{1,4} ; Servier ³ ; Wyeth Pharmaceuticals ^{1,3}
A. Thomas McLellan, Ph.D.	Alkermes, Inc. ¹ ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³ ; Robert Wood Johnson Foundation ³
Jacqueline M. Melonas, J.D.	Professional Risk Management Services, Inc ²
Herbert Y. Meltzer, M.D.	Acadia Pharmaceuticals Inc ⁵ ; Wyeth Pharmaceuticals ^{1,3}
Samantha E. Meltzer-Brody, M.D.	GlaxoSmithKline ³
Matthew A. Menza, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,4} ; Cephalon Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Kyowa Pharmaceuticals ¹ ; Merck & Co., Inc. ³ ; Pfizer Inc. ^{1,3,4} ; Sepracor, Inc. ^{1,3,4} ; Takeda Pharmaceuticals North America, Inc. ⁴
David Michelson, M.D.	Eli Lilly and Company ^{2,5}
Jodi A. Mindell, Ph.D.	Johnson and Johnson Pharmaceutical Research and Development ^{1,4} ; King Pharmaceuticals, Inc. ⁴ ; Sepracor, Inc. ^{3,4}
Jacobo E. Mintzer, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Biovail Corporation ¹ ; Boehringer-Ingelheim Pharmaceuticals GmbH ³ ; Bristol-Myers Squibb Company ^{1,3,4} ; Eisai Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Otsuka America Pharmaceutical, Inc. ¹ ; Parexel International ³ ; Pfizer Inc. ^{1,3,4} ; Predix Pharmaceuticals ¹ ; Sanofi-Synthelabo ¹ ; Schering-Plough Corporation ⁴ ; Targacept, Inc. ¹ ; Teva Pharmaceutical Industries Ltd. ¹ ; Voyager Pharmaceutical Corp ^{1,3}
Shaila Misri, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ^{1,4} ; H. Lundbeck A/S ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Lundbeck Pharmaceuticals ^{3,4} ; Wyeth Pharmaceuticals ⁴
Hans-Juergen Moeller, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; H. Lundbeck A/S ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Janssen-Cilag ^{1,3,4} ; Merck & Co., Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Sanofi-Aventis ^{3,4} ; Sanofi-Synthelabo ^{1,3,4} ; Servier ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4}
Francisco A. Moreno, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Cyberonics, Inc. ^{1,3,4} ; Forest Laboratories, Inc. ^{1,4} ; Wyeth Pharmaceuticals ⁴
Elena Moro, M.D.	Medtronics, Inc. ⁴
Eric D. Morse, M.D.	Forest Laboratories, Inc. ⁴ ; Pfizer Inc. ⁴ ; Reckitt Benckiser plc ⁴
Quinton E. Moss, M.D.	Pfizer Pharmaceuticals, Janssen Pharmaceuticals ⁴
Rodrigo A. Munoz, M.D.	Eli Lilly and Company ³
Philip R. Muskin, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Cephalon Inc. ⁴ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Orphan Medical ^{1,4} ; Pfizer Inc. ^{1,4}
Dominique L. Musselman, M.D.	Dana Foundation ³ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ³ ; NIH Institute ³ ; Organon Pharmaceuticals Inc ⁴ ; Pfizer Inc. ⁴ ; Pharmacia & Upjohn ³ ; Schering-Plough Corporation ³
Hugh Myrick, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{3,4} ; Forest Laboratories, Inc. ⁴ ; National Institute of Alcohol Abuse and Alcoholism ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
David K. Nace, M.D.	McKesson Corporation ² ; United Health Group ⁵
Ziad H. Nahas, M.D.	Avanir Pharmaceuticals ¹ ; Aventis Pharmaceuticals, Inc. ¹ ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ³ ; Medtronics, Inc. ³ ; National Institute of Mental Health ³ ; Neuronetics, Inc. ^{1,3}
Joseph C. Napoli, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴

Presenter	Manufacturer(s)
Meera Narasimhan, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{3,4} ; Janssen Medical Affairs, LLC ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Pfizer Inc. ^{3,4}
Henry A. Nasrallah, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Pharmaceuticals Group plc. ^{1,4}
J. Craig Nelson, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{1,3} ; Corcept Therapeutics ¹ ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Orexigen Therapeutics, Inc. ¹ ; Organon Pharmaceuticals Inc. ^{1,4} ; Pfizer Inc. ^{1,3,4} ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ⁴
Charles B. Nemeroff, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Acadia Pharmaceuticals Inc. ^{1,5} ; American Foundation for Suicide Prevention ^{3,3} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; CeNeRx ⁶ ; Corcept Therapeutics ^{1,5} ; Cyberonics, Inc. ¹ ; Cypress Bioscience Inc. ^{1,5} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,3} ; George West Health Foundation ⁶ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; NovaDel Pharma Inc. ⁶ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3,4} ; Quintiles Transnational Corp. ¹ ; Reevax ^{5,6} ; Stanley Foundation ³ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3}
David N. Neubauer, M.D.	Neurocrine Biosciences Inc. ¹ ; Orphan Medical ⁴ ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,4} ; Takeda Pharmaceuticals North America, Inc. ^{1,4}
John W. Newcomer, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3} ; Sidney Baer Foundation ³
Anthony T. Ng, M.D.	Pfizer Inc. ⁴
Andrew A. Nierenberg, M.D.	Bristol-Myers Squibb Company ³ ; Cederroth International ³ ; Cyberonics, Inc. ^{3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ³ ; Genaisance Pharmaceuticals ¹ ; GlaxoSmithKline ^{1,3,4} ; Innapharma, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Lichtwer Pharma GmbH ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{3,4} ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,4}
Frank G. Njenga, M.D.	Eli Lilly and Company ⁴ ; GlaxoSmithKline ³ ; UCB Pharmaceuticals ⁶
Eric A. Nofzinger, M.D.	Pfizer Inc. ⁴ ; Respiroics, Inc. ^{1,3} ; Sanofi-Aventis ⁴ ; Sepracor, Inc. ⁴ ; Takeda Pharmaceuticals North America, Inc. ⁴
Douglas Noordsy, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ^{4,4} ; Forest Laboratories, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴
Carol S. North, M.D.	GlaxoSmithKline ^{3,4} ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³
H. George Nurnberg, M.D.	Pfizer Inc. ³
David J. Nutt, M.D.	Bristol-Myers Squibb Company ^{1,3} ; GlaxoSmithKline ^{1,3,5} ; Organon Pharmaceuticals Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Charles P. O'Brien, M.D.	Consultant for Cephalon Inc. ¹ ; Forest Laboratories, Inc. ¹ ; McNeil Consumer Healthcare ¹
Christopher M. O'Connor, M.D.	Amgen, Inc ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ⁴ ; Medtronic, Inc. ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹
Claire M. O'Donovan, M.B.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Biovail Corporation ^{1,3,4} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹
Lewis A. Opler, M.D.	Multi-Health Systems, Inc. ⁶
John P. O'Reardon, M.D.	Cyberonics, Inc. ^{3,4} ; Eli Lilly and Company ^{3,4} ; Magstim Company Ltd ³ ; Neuronetics, Inc. ^{1,3} ; Sanofi-Aventis ³
Judith Owens, M.D.	Cephalon Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,4} ; Sepracor, Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹
Anand Pandya, M.D.	Janssen Pharmaceutica Products, LP ⁴
George I. Papakostas, M.D.	Bristol-Myers Squibb Company ³ ; GlaxoSmithKline ^{1,4} ; Pfizer Inc. ^{1,3,4}
Jose V. Pardo, M.D.	Cyberonics, Inc. ³
Sagar V. Parikh, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Biovail Corporation ¹ ; Canadian Institutes of Health Research ³ ; Canadian Network for Mood and Anxiety Treatments ³ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ³ ; Stanley Foundation ³ ; Wyeth Pharmaceuticals ¹
Joseph J. Parks III, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ^{3,5} ; Janssen Pharmaceutica Products, LP ³
Ashwin A. Patkar, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,4} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³ ; Jazz Pharmaceuticals, Inc. ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Organon Pharmaceuticals Inc ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{3,4}
Simon Patry, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Biovail Corporation ⁴ ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Organon Pharmaceuticals Inc ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
Diana O. Perkins, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Organon Pharmaceuticals Inc ¹ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹
Eric D. Peselow, M.D.	Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴
Francois C.F. Petitjean, Psy.D.	Bristol-Myers Squibb Company ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Sanofi-Aventis ⁴
Joseph M. Pierre, M.D.	Bristol-Myers Squibb Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Teresa A. Pigott, M.D. Bruce G. Pollock Steven G. Potkin, M.D.	Eli Lilly and Company ¹ Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; National Institute of Mental Health ³ ; Sepracor, Inc. ⁴ Acadia Pharmaceuticals Inc ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3} ; Fujisawa Pharmaceutical, Co. ³ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Mitsubishi Pharma Corporation ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Ono Pharmaceuticals, Inc. ³ ; Organon Pharmaceuticals Inc ^{1,3} ; Otsuka America Pharmaceutical, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Praecis Pharmaceuticals Incorporated ¹ ; Roche ¹ ; Sanofi-Synthelabo ³ ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Wyeth Pharmaceuticals ³
Annelle B. Primm, M.D. Jefferson B. Prince, M.D.	Eli Lilly and Company ¹ ; Pfizer Inc. ^{3,4,6} Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; McNeil Consumer Healthcare ^{1,3,4} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3}
Andres J. Pumariega, M.D. Paul M. Ramirez, Ph.D. Carrie L. Randall, Ph.D. Mark H. Rapaport, M.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ⁴ Multi-Health Systems, Inc. ⁶ Eli Lilly and Company ⁶ ; Pfizer Inc. ⁵ Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ³ ; Corcept Therapeutics ³ ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4,5} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Cancer Institute Advisory Board ¹ ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ¹ ; Neurocrine Biosciences Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Pharmacia & Upjohn ³ ; Roche ¹ ; Sanofi-Synthelabo ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ¹
Natalie L. Rasgon, M.D.	Abbott Laboratories, Inc. ^{1,3,4,6} ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ^{4,6} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ^{4,6}
Joel Raskin, M.D. Arun V. Ravindran, M.D. Burton V. Reifler, M.D. John A. Renner, Jr., M.D. Roy O. Resnikoff, M.D.	Eli Lilly and Company ^{2,5} AstraZeneca Pharmaceuticals LP ^{1,3} ; GlaxoSmithKline ^{1,3} ; Pfizer Inc. ^{1,3} ; Roche ^{1,3} ; Servier ^{1,3} ; Wyeth Pharmaceuticals ^{1,3} Johnson and Johnson Pharmaceutical Research and Development ⁵ Eli Lilly and Company ⁴ ; Shire Pharmaceuticals Group plc. ¹ Wyeth Pharmaceuticals ⁶
Victor I. Reus, M.D. Charles F. Reynolds III, M.D. Ali R. Rezai, M.D.	Corcept Therapeutics ¹ ; Gerson Lehrman Group ¹ Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ Medtronic, Inc. ³
Michelle B. Riba, M.D. Steven H. Richeimer, M.D. Elliott Richelson, M.D. Judith A. Richman, Ph.D. Muhamad A. Rifai, M.D. Thomas Rinne, Ph.D. Trevor Robbins, Ph.D.	Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ Janssen Pharmaceutica Products, LP ⁴ ; Merck & Co., Inc. ⁴ ; Pfizer Inc. ⁴ ; Purdue Pharma L.P. ⁴ Cyberonics, Inc. ⁴ ; Neuronetics, Inc. ³ National Institute of Alcohol Abuse and Alcoholism ³ American Psychiatric Association ³ ; National Institute of Mental Health ⁶ Solvay Pharmaceuticals, Inc. ³ Cambridge Cognition ¹ ; CeNeS Pharmaceuticals pic ⁵ ; Cephalon Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Lundbeck Pharmaceuticals ¹ ; Merck & Co., Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Roche ¹
Laura Roberts, M.D.	National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; NIH Institute ³
Delbert G. Robinson, M.D. Robert G. Robinson, M.D. Timothy A. Roehrs Steven P. Roose, M.D. Russell Rosenberg, Ph.D.	Bristol-Myers Squibb Company ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; National Institute of Mental Health ³ Forest Laboratories, Inc. ⁴ ; Pfizer Inc. ⁴ ; PharmaStar, LLC ¹ Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3,4} Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; Wyeth Pharmaceuticals ¹ Cephalon Inc. ^{1,3}
Paul J. Rosenfield, M.D. Robert A. Rosenheck Richard N. Rosenthal MD, M.D. Heather Ross, M.D.	Amgen, Inc. ⁵ ; Medtronic, Inc. ⁵ ; Pfizer Inc. ⁵ Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ¹ Alkermes, Inc. ¹ ; Forest Laboratories, Inc. ¹ Fujisawa Pharmaceutical, Co. ³ ; Novartis Pharmaceuticals Corporation ³ ; Wyeth Pharmaceuticals ³
Stephen Ross Anthony L. Rostain, M.D. Thomas Roth	Forest Laboratories, Inc. ⁴ Eli Lilly and Company ⁴ ; McNeil Consumer Healthcare ⁴ ; Shire Pharmaceuticals Group plc. ¹ Acadia Pharmaceuticals Inc ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Aventis Pharmaceuticals, Inc. ^{1,3} ; Cephalon Inc. ^{1,3} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} ; King Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ¹ ; Neurocrine Biosciences Inc. ^{1,3} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Roche ¹ ; Sanofi-Synthelabo ^{1,4} ; Sepracor, Inc. ^{1,3} ; Somaxon Pharmaceuticals ^{1,3} ; Takeda Pharmaceuticals North America, Inc. ^{1,3} ; Wyeth Pharmaceuticals ¹
Anthony Rothschild, M.D.	Forest Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer, Inc. ⁴ ; Bristol-Myers Squibb ^{1,4} ; GlaxoSmithKline ¹ ; AstraZeneca Pharmaceuticals ³ ; Cyberonics, Inc. ³ ; Wyeth Pharmaceuticals ³
Eugenio M. Rothe, M.D. Melisa D. Rowland, M.D. Peter P. Roy-Byrne, M.D. XXX	McNeil Consumer Healthcare ^{1,4} MST Services, Inc. ⁵ Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ¹ ; Wyeth Pharmaceuticals ¹

Presenter	Manufacturer(s)
Pedro Ruiz, M.D.	Eli Lilly and Company ¹
A. John Rush, M.D.	Bristol-Myers Squibb Company ¹ ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ¹ ; Stanley Foundation ³ ; Stanley Medical Research Institute ³ ; Urban Institute ¹
Joni L. Rutter, Ph.D.	NIH Institute ²
Deirdre M. Ryan, M.D.	H. Lundbeck A/S ³ ; Wyeth Pharmaceuticals ³
Gary S. Sachs, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4}
Martha Sajatovic, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Pfizer Inc. ⁴
Carl Salzman, M.D.	Bristol-Myers Squibb Company ³ ; Pfizer Inc. ¹ ; Takeda Pharmaceuticals North America, Inc. ¹
Shirlene M. Sampson, M.D.	Neuronetics, Inc. ³
David Satcher, M.D.	American Program Bureau ⁴ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Wyeth Pharmaceuticals ³
Sanjaya Saxena, M.D.	Ortho-McNeil Pharmaceutical, Inc. ³
Alan F. Schatzberg, M.D.	Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Corcept Therapeutics ^{1,5} ; Elan Pharmaceuticals, Inc. ⁵ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ⁵ ; Neuronetics, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Pathway Diagnostics ⁵ ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ¹ ; Somaxon Pharmaceuticals ^{1,5} ; Somerset Pharmaceuticals Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Randolph B. Schiffer, M.D.	Avanir Corp ^{1,4,5}
Lon S. Schneider, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Forest Laboratories, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹
Marc A. Schuckit, M.D.	Forest Laboratories, Inc. ¹ ; Ortho-McNeil Pharmaceutical, Inc. ¹
S. Charles Schulz, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ³
Larry J. Seidman, Ph.D.	National Institute of Mental Health ³
Lydia Sermons-Ward	American Psychiatric Association ²
David Shannahoff-Khalsa, B.A.	W.W. Norton & Co., Inc. ⁶
Shawn Shea, M.D.	GlaxoSmithKline ⁴
M. Katherine Shear, M.D.	Forest Laboratories, Inc. ^{3,4} ; Pfizer Inc. ¹
David V. Sheehan, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Alexza MDC ¹ ; American Psychiatric Association ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Avera Pharmaceuticals, Inc. ¹ ; Best Practice ¹ ; Boehringer-Ingelheim Pharmaceuticals GmbH ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon Inc. ¹ ; Corcept Therapeutics ¹ ; Cortex Pharmaceuticals, Inc. ¹ ; Cyberonics, Inc. ¹ ; Cypress Bioscience Inc. ¹ ; Eisai Inc. ³ ; Eli Lilly and Company ^{1,3} ; F. Hoffmann-La Roche & Co. ¹ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Glaxo-Wellcome ¹ ; H. Lundbeck A/S ¹ ; Indevus Pharmaceuticals, Inc. ^{1,3} ; Janssen Medical Affairs, LLC ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Jazz Pharmaceuticals, Inc. ^{1,3} ; Layton Biosciences, Inc. ^{1,5} ; McNeil Consumer Healthcare ¹ ; Mead Johnson ¹ ; Medical Outcome Systems, Inc. ^{1,5} ; Merck & Co., Inc. ¹ ; National Institute of Health ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ³ ; Novo Nordisk A/S ¹ ; Organon Pharmaceuticals Inc ¹ ; Parexel International ¹ ; Pfizer Inc. ^{1,3,4} ; Psychcme ¹ ; Quintiles Transnational Corp. ^{1,3} ; Roche ¹ ; Sanofi-Aventis ^{1,3} ; Sanofi-Synthelabo ¹ ; Schering-Plough Corporation ¹ ; Schwartz Pharmaceuticals ¹ ; Sepracor, Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; TAP Pharmaceuticals Product, Inc. ^{1,3} ; Warner Chilcott PLC ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
David Shurtleff	National Institute on Drug Abuse ²
Richard L. Siegel, M.D.	Pfizer Inc. ²
Gary W. Small, M.D.	Abbott Laboratories, Inc. ^{1,4} ; Eisai Inc. ^{1,4} ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Ortho-McNeil Pharmaceutical, Inc. ^{1,4} ; Pfizer Inc. ¹
Thomas J. Spencer, M.D.	Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; McNeil Consumer Healthcare ^{1,3,4} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ³ ; Shire Pharmaceuticals Group plc. ^{1,3,4}
David Spiegel, M.D.	National Institute of Health ³ ; National Institute of Mental Health ³
Krishnamachari Srinivasan, M.D.	Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Pfizer Inc. ³ ; Targacept, Inc. ³
Stephen M. Stahl, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ¹ ; Boehringer-Ingelheim Pharmaceuticals GmbH ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} ; Cypress Bioscience Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; H. Lundbeck A/S ¹ ; NovaDel Pharma Inc. ¹ ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{1,3} ; Sanofi-Aventis ¹ ; Sepracor, Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ³ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Sharon B. Stanford, M.D.	Boehringer-Ingelheim Pharmaceuticals GmbH ¹ ; Cypress Bioscience Inc. ³ ; Eli Lilly and Company ³ ; Pfizer Inc. ³ ; Sanofi-Synthelabo ³ ; Wyeth Pharmaceuticals ³
David C. Steffens, M.D.	Forest Laboratories, Inc. ⁴
Dan J. Stein, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,4} ; Pfizer Inc. ³ ; Servier ¹ ; Solvay Pharmaceuticals, Inc. ^{1,4} ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ¹

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Murray B. Stein, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Avera Pharmaceuticals, Inc. ¹ ; Cephalon Inc. ¹ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Pfizer Inc. ¹ ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ¹
Hans Steiner, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Eli Lilly and Company ^{3,4} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; McNeil Consumer Healthcare ³ ; Novartis Pharmaceuticals Corporation ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ³
Altha J. Stewart, M.D.	Pfizer Inc. ⁴
Donna E. Stewart, M.D.	Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4}
Jonathan T. Stewart, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; Pfizer Inc. ⁵
Frederick Stoddard	Pfizer Inc. ³
Frederick J. Stoddard, Jr., M.D.	Pfizer Inc. ³
Eric C. Strain, M.D.	GlaxoSmithKline ¹ ; National Institute on Drug Abuse ³ ; Reckitt Benckiser plc ⁶ ; The Oak Group ¹ ; Titan Pharmaceutical, Inc. ¹
T. Scott Stroup, M.D.	Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Thomas S. Stroup, M.D.	Eli Lilly and Company ³ ; GlaxoSmithKline ¹
Rima Styra, M.D.	GlaxoSmithKline ³
Steve Sugden, M.D.	GlaxoSmithKline ³
Calvin R. Sumner, M.D.	Eli Lilly and Company ²
Craig B.H. Surman, M.D.	McNeil Consumer Healthcare ³ ; National Institute of Health ³
Conrad M. Swartz, M.D.	Somatics, LLC ^{1,5}
Holly A. Swartz, M.D.	Eli Lilly and Company ⁶ ; Pfizer Inc. ⁴
Marvin S. Swartz, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ^{1,3} ; Pfizer Inc. ⁴
Robert M. Swift, M.D.	Alkermes, Inc. ¹ ; Bristol-Myers Squibb Company ³ ; Drug Abuse Sciences, Inc. ³ ; Forest Laboratories, Inc. ^{1,4} ; National Institute of Alcohol Abuse and Alcoholism ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
Robyn Sysko, M.S.	Pfizer Inc. ⁵
Carol A. Tamminga, M.D.	Abbott Laboratories, Inc. ¹ ; Acadia Pharmaceuticals Inc ¹ ; Avera Pharmaceuticals, Inc. ¹ ; Intercellular Therapies ¹ ; Janssen Pharmaceutica Products, LP ⁶ ; National Institute of Mental Health ³ ; Neurogen ¹ ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; UT Southwestern Medical Center at Dallas ²
Pierre N. Tariot, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Amgen, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3} ; Eisai Inc. ^{1,3,4} ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ³ ; Mitsubishi Pharma Corporation ³ ; Myriad Genetics, Inc. ^{1,3} ; Neurochem, Inc. ³ ; Novartis Pharmaceuticals Corporation ¹ ; Ono Pharmaceuticals, Inc. ³ ; Pfizer Inc. ^{1,3,4} ; Sanofi-Aventis ^{1,3} ; Sanofi-Synthelabo ¹ ; Schwabe ¹ ; Takeda Pharmaceuticals North America, Inc. ¹
Warren D. Taylor, M.D.	GlaxoSmithKline ^{3,6} ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ¹
George E. Tesar, M.D.	Medtronics, Inc. ⁵
Michael E. Thase, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Cephalon Inc. ¹ ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,4} ; Pfizer Inc. ¹ ; Sepracor, Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ ; Wyeth Pharmaceuticals ^{1,4}
Nicole Thibodeau, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ¹
Martin G. Tracy, J.D.	Professional Risk Management Services, Inc ²
Patrick T. Triplett, M.D.	Forest Laboratories, Inc. ³
Madhukar H. Trivedi, M.D.	Abbott Laboratories, Inc. ³ ; Bayer Corporation, Pharmaceutical Division ³ ; Bristol-Myers Squibb Company ^{1,3,4} ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ^{1,3,4} ; Parke-Davis ³ ; Pfizer Inc. ^{1,3,4} ; Pharmacia & Upjohn ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4}
Douglas Turkington, M.D.	Pfizer Inc. ³
Audrey R. Tyrka, M.D.	Cephalon ³ ; Corcept Therapeutics ³ ; Cyberonics, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Medtronics, Inc. ³ ; Pfizer Inc. ³ ; UCB Pharmaceuticals ³
Donna Vanderpool, J.D.	Professional Risk Management Services, Inc ²
Dawn I. Velligan, Ph.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; InforMedix ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3}
Jeff Victoroff, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc ^{1,4} ; Pfizer Inc. ^{1,4} ; Sanofi-Aventis ^{1,4} ; Servier ¹ ; Stanley Medical Research Institute ³ ; UCB Pharmaceuticals ¹
Eduard Vieta, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4} ; Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc ^{1,4} ; Pfizer Inc. ^{1,4} ; Sanofi-Aventis ^{1,4} ; Stanley Foundation ³ ; UCB Pharmaceuticals ^{1,4}

Presenter	Manufacturer(s)
Frank Vocci, Ph.D.	Amgen, Inc. ⁵ ; Dupont E I De Nemours & Co. ⁵ ; Proctor & Gamble Company ⁵
Suzanne E. Vogel-Scibilia, M.D.	GlaxoSmithKline ⁵ ; National Institute of Mental Health ¹ ; Pfizer Inc. ⁵
Karen D. Wagner, M.D.	Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; National Institute of Mental Health ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ³ ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ¹
B. Timothy Walsh, M.D.	Eli Lilly and Company ³ ; Ortho-McNeil Pharmaceutical, Inc. ³
Roger T. Webb, M.S.C.	Wellcome Trust ³
Peter J. Weiden, M.D.	Alkermes, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ^{1,3,4,5} ; Bristol-Myers Squibb Company ^{1,3,4,5,6} ; Janssen Medical Affairs, LLC ¹ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; Otsuka America Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{3,4,5} ; Virtually Better ¹
Elyse D. Weiner, M.D.	Wyeth Pharmaceuticals ⁴
Risa B. Weisberg, Ph.D.	Eli Lilly and Company ⁶ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3}
Roger D. Weiss, M.D.	Abbott Laboratories, Inc. ⁴ ; Alkermes, Inc. ^{3,6} ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³ ; Ortho-McNeil Pharmaceutical, Inc. ³
Keith Wesnes, Ph.D.	Cephalon Inc. ^{1,3}
Sharon B. Wigal, Ph.D.	CellTech ^{1,3,4} ; NRP ¹
Timothy E. Wilens, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Alza Corporation ^{1,3,4} ; Celltech ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ^{1,3} ; National Institute on Drug Abuse ³ ; NeuroSearch ³ ; NICMH ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Ortho-McNeil Pharmaceutical, Inc. ^{3,4} ; Pfizer Inc. ^{1,3,4} ; Saegis ¹ ; Sanofi-Synthelabo ¹ ; Seagis ¹ ; Shire Pharmaceuticals Group plc. ^{1,3,4}
Jeffery N. Wilkins, M.D.	Alkermes, Inc. ³ ; AstraZeneca Pharmaceuticals LP ³ ; Forest Laboratories, Inc. ³ ; Hythium ³
David Wilkinson, M.B.	Eisai Inc. ^{1,3,4} ; GlaxoSmithKline ¹ ; H. Lundbeck A/S ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ^{3,4} ; Pfizer Inc. ^{1,3,4}
Adedapo B. Williams, M.D.	Abbott Laboratories, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ³
Jill Williams, M.D.	National Institute on Drug Abuse ³
John W. Winkelman, M.D.	Boehringer-Ingelheim Pharmaceuticals GmbH ^{1,3} ; Cephalon Inc. ^{1,4,6} ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ^{1,3,4,6} ; King Pharmaceuticals, Inc. ^{4,6} ; NovaDel Pharma Inc. ¹ ; Novartis Pharmaceuticals Corporation ⁶ ; Pfizer Inc. ^{1,3,6} ; Pharmacia & Upjohn ⁶ ; Sanofi-Aventis ^{4,6} ; Sanofi-Synthelabo ^{1,4} ; Schering-Plough Corporation ⁶ ; Schwartz Pharmaceuticals ⁶ ; Sepracor, Inc. ^{1,4,6} ; Takeda Pharmaceuticals North America, Inc. ¹ ; UCB Pharmaceuticals ³ ; Wyeth Pharmaceuticals ⁴
Daniel K. Winstead, M.D.	Forest Laboratories, Inc. ⁴
Madelaine M. Wohlreich, M.D.	Eli Lilly and Company ²
Scott W. Woods, M.D.	Bristol-Myers Squibb Company ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Stanley Medical Research Institute ³
Jesse H. Wright III, M.D.	Mindstreet ⁵
Lakshmi N. Yatham, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3}
Robert C. Young, M.D.	Janssen Pharmaceutica Products, LP ³ ; Otsuka America Pharmaceutical, Inc. ³
Stuart C. Yudofsky, M.D.	Bristol-Myers Squibb Company ⁶
Sun Young. Yum, M.D.	American Medical Association Foundation ³
Mary C. Zanarini, M.D.	Eli Lilly and Company ^{1,3}
Phyllis C. Zee, M.D.	Boehringer-Ingelheim Pharmaceuticals GmbH ^{1,3} ; Neurocrine Biosciences Inc. ³ ; Pfizer Inc. ¹ ; Sanofi-Synthelabo ^{1,3,4} ; Sepracor, Inc. ⁴ ; Takeda Pharmaceuticals North America, Inc. ^{1,3,4}
Douglas M. Ziedonis, M.D.	Bristol-Myers Squibb Company ^{1,3,4} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ³ ; Pfizer Inc. ¹
Sidney Zisook, M.D.	Cyberonics, Inc. ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ^{1,4} ; National Institute of Mental Health ³ ; Pfizer Inc. ⁴
Joseph Zohar, M.D.	Pfizer Inc. ^{1,3}
Allen Zweben, D.S.W.	Alkermes, Inc. ³ ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³

The following presenters did not provide us with their disclosure information.

Joseph Califano, M.D.
Angela M. Cheung, M.D.
Ponjola Coney
Diana Dell, M.D.

Jeffrey L. Geller, M.D.
Adrian Grounds
Alyson R. Kuroski-Mazzei, D.O.
David A. Lewis

Christian D. Perring, Ph.D.
Norman Sartorius, M.D.
Jacob Widroff, M.D.
Theresa A. Yuschok, M.D.

DISCLOSURE INDEX

The following presenters indicated neither they nor an immediate family member has any significant relationship to disclose.

Susan Abbey, M.D.
Karen M. Abrams, M.D.
Ronald D. Abramson
Margo S. Adams
Babatunde A. Adetunji
Iqbal Ahmed, M.D.
Dov Aizenberg, M.D.
Jeffrey Akaka, M.D.
Evaristo O. Akerele, M.D.
Antti S. Alaraisänen, M.B.
Renato D. Alarcon, M.D.
David B. Albert, Ph.D.
Margarita Alegria, Ph.D.
George S. Alexopoulos, M.D.
Ian E. Alger, M.D.
Jon G. Allen, Ph.D.
Sadiq H. Al-Samarrai, M.D.
Steven I. Altchuler, M.D.
Margaret Altemus, M.D.
Carol L. Alter, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Chris Ambidge
Shahrad R. Amiri, M.D.
Lisa F. Andermann, M.D.
Tanya R. Anderson, M.D.
Naleen N. Andrade, M.D.
Diana Antia, M.D.
Joan M. Anzia, M.D.
Paul S. Appelbaum, M.D.
Gisèle Apter-Danon, M.D.
Julio Arboleda-Florez, M.D.
Britton A. Arey, M.D.
Kimberly A. Arlinghaus, M.D.
William Arroyo, M.D.
Seyed Mohammad Assadi, M.D.
Robert Atkins, M.D.
Nutan Atre-Vaidya, M.D.
Evelyn Attia, M.D.
R. Robert Auger, M.D.
Alex Aviv, M.D.
R. Michael Bagby, Ph.D.
Bruce C. Ballon, M.D.
Azziza O. Bankole, M.D.
Elisabeth Banon
Yoram Barak, M.D.
Mary E. Barber, M.D.
David A. Baron, D.O.
Paul J. Barreira, M.D.
Monica A. Basco, M.D.
Anne S. Bassett, M.D.
Dorothy Bates
G. William Bates, M.D.
Antonia L. Baum, M.D.
Aaron T. Beck, M.D.
Judith S. Beck, Ph.D.
Daniel F. Becker, M.D.
Judith V. Becker, Ph.D.
Alan R. Beeber, M.D.
Edgard Belfort M.D.
Carl C. Bell, M.D.
Alan S. Bellack, Ph.D.
Selim Benbadis, M.D.
Donna S. Bender, Ph.D.
David Benedek, M.D.
Elissa P. Benedek, M.D.
Lana M. Benedek, M.D.
David A. Bennett, M.D.
Jon S. Berlin, M.D.
Carol A. Bernstein, M.D.
David P. Bernstein, Ph.D.
Vladimir Berthaud
Nadeem H. Bhanji, M.D.
Shyam Bhar, M.D.
Laura J. Bierut, M.D.
Renee L. Binder, M.D.
Sarah Birmingham, M.D.
Catherine A. Bimdorf, M.D.
Nancy M. Bivens, M.D.
Edward Bixler, M.D.
Aurelia Bizamcer, M.D.
Thorstur Bjorgvinsson, Ph.D.
John L. Black, M.D.
Vincent J. Blanch, M.D.
Roger Bland, M.B.
Karen Blank, M.D.
Mel Blaustein, M.D.
Efrain Bleiberg, M.D.
Barton J. Blinder, M.D.
Floyd E. Bloom, M.D.
Nancee Blum, M.S.W.
Sheila B. Blume, M.D.
Martin Bohus, M.D.
Vladimir Bokarius, M.D.
Robert J. Boland, M.D.
Angelo S. Bolea, Ph.D.
Michael P. Bond, M.D.
Richard Bonnie, J.D.
Howard E. Book, M.D.
Soo Borson, M.D.
Jonathan F. Borus, M.D.
Pierre Boulanger, M.D.
Stephanie J. Brister, M.D.
Thomas M. Brod, M.D.
Edward S. Brodtkin, M.D.
David W. Brook, M.D.
Beth Ann Brooks, M.D.
Glenn A. Brotzman, M.D.
Richard P. Brown, M.D.
Kumaraswamy Budur, M.D.
Viet Q. Bui, M.D.
Stephen E. Buie, M.D.
Page Burkholder, M.D.
Harold J. Bursztajn, M.D.
Vivien K. Burt, M.D.
Kenneth G. Busch, M.D.
Jeremy R. Butler, M.D.
Victor J.A. Buwalda, M.D.
Robert P. Cabaj, M.D.
Consuelo C. Cagande, M.D.
Norana I. Caivano, M.D.
Jose M. Caldas de Almeida, Ph.D.
Eve Caligor, M.D.
Nioaka N. Campbell, M.D.
Ana E. Campo, M.D.
Adalberto Campo-Arias, M.D.
Francesca Cannavo Antognini, Ph.D.
Angel A. Caraballo, M.D.
Alex A. Cardoni, M.S.
Daniel J. Carlat M.D.
Rosaland D. Cartwright, Ph.D.
Brady G. Case, M.D.
Delane E. Casiano, M.D.
Daniel Castellanos, M.D.
Lisa A. Catapano, M.D.
Josephine M. Caubel, M.D.
Andrea Celenza, Ph.D.
Leon-Patrice Celestin, M.D.
Smadar Celestin-Westreich, Ph.D.
Kenneth M. Certa, M.D.
Carlyle H. Chan, M.D.
Prabha S. Chandra, M.D.
Grace Chang, M.D.
Laura M. Chapman, M.D.
Irene Chatoor, M.D.
Haroon R. Chaudhry, M.D.
Joseph A. Cheong, M.D.
Anna R. Childress, M.D.
Lois W. Choi-Kain, M.D.
Steve Choong Kam Chong, M.D.
Frank H. Chou, M.D.
Eva W.C. Chow, M.D.
George Christodoulou, M.D.
Henry T. Chuang, M.D.
Roberto Ciccocioppo, Ph.D.
J. Richard Ciccone
Domenic Ciraulo, M.D.
Connie L. Clark, M.Ed.
David Clarke
Norma V. Clarke, M.D.
John F. Clarkin, Ph.D.
Norman A. Clemens, M.D.
Marylene Cloitre, Ph.D.
C. Robert Cloninger, M.D.
Susan D. Cochran, Ph.D.
C. Edward Coffey, M.D.
Carl I. Cohen, M.D.
Judith Cohen, M.D.
Yolonda R. Coleman, M.D.
Pierre Collart, Ph.D.
Gary R. Collins, M.D.
Pamela Y. Collins
Joan M. Collison, M.D.
James D. Colliver, Ph.D.
Lillian Comas-Diaz, Ph.D.
Lee Combrinck-Graham, M.D.
James P. Comer, M.D.
Wilson M. Compton, M.D.
Kevin Conway Ph.D.
Gabriella Cora-Locatelli, M.D.
Cheryl Corcoran, M.D.
Maurice Corcos, Ph.D.
Jack R. Cornelius, M.D.
Bernadette M. Cortese, M.D.
William H. Coryell, M.D.
Linda B. Cottler, Ph.D.
Francine Cournos, M.D.
Jennifer Covino, M.P.A.
John L. Cox, M.D.
Stephen J. Cozza, M.D.
Marilyn Craven, M.D.
Margaret Creal, LL.B.
Brian Crowley, M.D.
Anne Marie Crustolo, B.S.N.
Mario Cruz, M.D.
Pim Cuijpers, M.D.
Cristina Cusin, M.D.
Ronald E. Dahl, M.D.
Richard E. D'Alli, M.D.
Arthur Dalton Ph.D.
Patricia A. Daly, M.D.
Kien T. Dang, M.D.
Pinhas N. Dannon, M.D.
Deborah Danoff, M.D.
Donald A. Davidoff, Ph.D.
Larry Davidson, Ph.D.
Leah Davidson, M.D.
Max Day, M.D.
John M. De Figueiredo, M.D.
Roger J. Debeus, Ph.D.
Prashaant Debipersad, B.A.
Jack J. Dekker, Ph.D.
Salvador R. Del Rosario, Jr., M.D.
Mary Lynn Dell, M.D.
Mark A. Demidovich, M.D.
Wayne H. Denton, M.D., Ph.D.
Yves Depauw, M.D.
Abhilash K. Desai, M.D.
Parameshvara P. Deva, M.D.
Michael J. Devlin, M.D.
Vasant P. Dhopes, M.D.
Danielle M. Dick, Ph.D.
Daniel P. Dickstein, M.D.
Leah Dickstein, M.D.
Steven G. Dickstein, M.D.
Lawrence H. Diller M.D.
Rosalinda Dirienzo, M.D.
Brent Diverty
Shilpa P. Diwan, M.D.
Nisha Dogra, M.D.
Antoine B. Douaihy, M.D.
Jennifer I. Downey, M.D.
Jennifer E. Drake, M.A.
Jack Drescher, M.D.
Nehama Dresner, M.D.
Laura Drury, M.S.W.
Stacy S. Drury, M.D.
Benjamin G. Druss, M.D.
Russell F. D'Souza, M.D.
Drake Duane, M.D.
Kenneth Duckworth, M.D.
Scott Dudgeon, M.B.A.
Farifteh F. Duffy, Ph.D.
Laura B. Dunn, M.D.
Joanne Dunning, M.S.W.
Stephanie S. Durruthy, M.D.
Loretta E. Duvall
Gregg Dwyer, M.D.
Howard J. Edenberg, Ph.D.
Christopher Edwards, Ph.D.
Anke A. Ehrhardt, Ph.D.
Jane L. Eisen, M.D.
Leon Eisenberg, M.D.
Harold I. Eist, M.D.
Juliana I. Ekong, M.D.
Zeinab S. Elbaz, M.D.
Todd Elwyn, M.D.
Mary Jane England, M.D.
Spencer Eth, M.D.
Amit Etkin, M.D.
Amy Farabaugh, Ph.D.
Tiffany R. Farchione, M.D.
Larry R. Faulkner, M.D.
Fawzy I. Fawzy, M.D.
Paul Fearon
Paul Feheley
Rudolf A. Feijen, M.D.
Theodore B. Feldman, M.D.
Leah A. Fennell, M.D.
Francisco Fernandez, M.D.
Donald C. Fidler, M.D.
Sanford I. Finkel, M.D.
Michael B. First, M.D.
Ellen R. Fischbein, M.D.
Bernard A. Fischer IV, M.D.
Alison Fleming, Ph.D.
Candace M. Fleming, Ph.D.
Julianne Flynn, M.D.
Laura J. Fochtmann, M.D.
Timothy W. Fong, M.D.
Julian Ford

DISCLOSURE INDEX

- Marshall Forstein, M.D.
 Edward F. Foulks, M.D.
 Christopher Fowler
 Sophia Frangou, M.D.
 Daniel Frank, M.D.
 Julia B. Frank, M.D.
 Robert Freedman, M.D.
 Andrew J. Freinkel, M.D.
 Gregory L. Fricchione
 Ronna Fried, Ed.D.
 Richard C. Friedman, M.D.
 Leslie E. Frinks, M.D.
 John A. Fromson, M.D.
 Mark A. Frye, M.D.
 K.W.M. Fulford, M.D.
 Esme Fuller-Thomson, Ph.D.
 Kenneth P. Fung, M.D.
 Abby Fyer, M.D.
 Glen O. Gabbard, M.D.
 Harvinia Gahunia, M.D.
 Marc Galanter, M.D.
 Leo L. Gallofin, M.D.
 Igor I. Galynker, M.D.
 Peter D. Ganime, M.D.
 Keming Gao, M.D.
 Dolores Garcia-Moreno, M.D.
 Michael Garrett, M.D.
 Michael D. Garrett, M.D.
 Daniel Garza, M.D.
 Albert C. Gaw, M.D.
 Michael H. Gendel
 Karen G. Gennaro, M.D.
 Sander G. Genser, M.D.
 Larry Gentilello
 Lindsey George, M.D.
 Patricia L. Gerberg, M.D.
 Andrew J. Gerber, M.D.
 Christine Germain
 Elizabeth V. Getter, M.D.
 Hamid Ghodse, M.D.
 Ludovic A. Gicquel, Ph.D.
 Marisa A. Giggie, M.D.
 Cecilia M.T. Gijbers van Wijk, Ph.D.
 Renato Gilioli, M.D.
 Jay A. Gingrich, M.D.
 Graham Glancy, M.D.
 Helen M. Glover, B.S.W.
 John W. Goethe, M.D.
 R. Rao Gogineni, M.D.
 Marcia K. Goin
 Robert M. Goisman, M.D.
 Ian Gold, Ph.D.
 Liza H. Gold, M.D.
 Jeffrey Goldberg, D.O.
 Howard Goldman, M.D.
 Marina Goldman, M.D.
 Benjamin I. Goldstein, M.D.
 Marion Zucker Goldstein, M.D.
 Rachel Goldstein, M.D.
 Rise B. Goldstein, Ph.D.
 John-Paul Gomez, M.D.
 Junius J. Gonzales, M.D.
 Jose L. Gonzalez de Rivera, M.D.
 Gerardo Gonzalez, M.D.
 Edward Gordon, M.D.
 Susan M. Gordon, Ph.D.
 Tracy R. Gordy, M.D.
 Bonnie Gorscak, Ph.D.
 Diane B. Gottlieb, M.D.
 Gary Lloyd. Gottlieb, M.D.
 Peter Gouch, M.D.
 Andrea D. Grabovac, M.D.
 Cheryl L. Grady, Ph.D.
 Robert P. Granacher, Jr., M.D.
 Bridget F. Grant, Ph.D.
 Bridget F. Grant Ph.D.
 Sheila H. Gray, M.D.
 Melva I. Green, M.D.
 Roger P. Greenberg
 Shelly F. Greenfield, M.D.
 Brian A. Greenlee, M.D.
 Carl B. Greiner, M.D.
 Dauda A. Griffin, M.D.
 James L. Griffith, M.D.
 Bernadette M. Grosjean, M.D.
 Linda S. Grossman, Ph.D.
 Beth A. Grube, Ph.D.
 John G. Gunderson
 Raquel E. Gur, M.D.
 Oye Gureje
 Thomas G. Gutheil, M.D.
 Ann P. Haas, Ph.D.
 Lawrence Haber, Ph.D.
 Ann L. Hackman, M.D.
 Mohammad Hafez
 Silvia Hafliger, M.D.
 Deborah J. Hales, M.D.
 Robert E. Hales, M.D.
 Perry Halkitis
 Heather M. Hall, M.D.
 Lacresha L. Hall, M.D.
 Molly J. Hall, M.D.
 Katherine A. Halmi, M.D.
 James P. Halper, M.D.
 Abraham L. Halpern, M.D.
 Stephanie Hamarman, M.D.
 Joseph D. Hamilton, M.D.
 Tom Hamilton
 Paul G. Hammerness, M.D.
 Edward Hanin, M.D.
 William F. Haning III, M.D.
 Helga Hannesdottir, M.D.
 Kelli J.R. Harding, M.D.
 Richard K. Harding, M.D.
 Daniel W. Hardy, M.D.
 Roy Harker
 Gregory G. Harris, M.D.
 Martin Harrow, Ph.D.
 Dionne A. Hart, M.D.
 David E. Hartman, Ph.D.
 Lawrence Hartmann, M.D.
 Deborah S. Hasin, Ph.D.
 Susan J. Hatters-Friedman, M.D.
 Shivkumar S. Hatti, M.D.
 David S. Heath, M.B.
 Markus Heilig, M.D.
 Gary Heiman, Ph.D.
 David J. Hellerstein, M.D.
 John E. Helzer
 Rene Hen, M.D.
 Gail Henderson
 Mariëlle Hendriksen, M.D.
 Grace Hennessy, M.D.
 Sass Henning, M.D.
 Paula Hensley, M.D.
 Brian M. Hepburn, M.D.
 Judith L. Herman, M.D.
 Richard C. Hermann, M.D.
 Helen Herrman, M.D.
 Alison M. Heru, M.D.
 Alfred Herzog, M.D.
 David B. Herzog, M.D.
 Victor M. Hesselbrock, Ph.D.
 Nicolaas F. Hettinga, M.D.
 Frederick W. Hickling
 Napoleon B. Higgins, Jr., M.D.
 Darryl B. Hill, Ph.D.
 Donald M. Hilty, M.D.
 John K. Hines
 Ralph Hingson
 John P. Hirdes, Ph.D.
 Laura D. Hirshbein, M.D.
 Laurence M. Hirshberg, Ph.D.
 Michael F. Hogan, Ph.D.
 Charles W. Hoge
 Milton C. Hollar, M.D.
 Michael A. Hollifield, M.D.
 Suzanne Hollingshead, B.A.
 Sheila Hollins, M.D.
 Abram M. Hostetter, M.D.
 Rory P. Houghtalen, M.D.
 Edmund G. Howe, M.D.
 Robert C. Hsuang, M.D.
 Suena W. Huang, M.D.
 Robert Huebner, Ph.D.
 Michael Hughes, M.D.
 Jonathan J. Hunter, M.D.
 Damir Huremovic, M.D.
 Matthew O. Hurford, M.D.
 Robin A. Hurley, M.D.
 Nisba F. Husain, M.D.
 Syed A. Husain, M.D.
 Steven E. Hyler, M.D.
 Ruksana Iftekhar
 Lawrence B. Inderbitzin, M.D.
 David Indest, Psy.D.
 Theo Ingenhoven, M.D.
 Constantine Ioannou, M.D.
 Joanne Isbey
 Joshua A. Israel, M.D.
 Suma Jacob, M.D.
 Frederick M. Jacobsen, M.D.
 Leslie K. Jacobsen
 Sandra A. Jacobson
 Vivek Jain, M.D.
 Kerry L. Jang, Ph.D.
 Afzal Javed, M.D.
 Aruna Jha, Ph.D.
 Gregory A. Jicha, M.D.
 David C. Jimerson, M.D.
 Bankole A. Johnson, M.D.
 Bradley R. Johnson, M.D.
 Susan M. Johnson, Ed.D.
 Linda M. Jorgenson, J.D.
 Allan M. Josephson, M.D.
 Javed A. Joy, M.D.
 Sheila Judge, M.D.
 Tony Juneja, M.D.
 Nalini V. Juthani, M.D.
 Edward M. Kantor, M.D.
 Allan S. Kaplan, M.D.
 Gabriel Kaplan, M.D.
 T. Byram Karasu, M.D.
 Pamela Karlan
 Jason Karlawish
 Niranjan S. Karnik, M.D.
 Jerome P. Kassirer M.D.
 Nick Kates, M.B.
 Joan Kaufman, Ph.D.
 Molly R. Kaufman
 Jerald Kay, M.D.
 Rex Kay, M.D.
 Walter H. Kaye
 Loreleigh Keashly, Ph.D.
 V. Alex Kehayan, Ed.D.
 Gabor I. Keitner, M.D.
 Robert E. Kelly, Jr., M.D.
 James A. Kennedy, M.D.
 Robert S. Kennedy, M.A.
 Justine M. Kent, M.D.
 Otto F. Kernberg, M.D.
 Robert M. Kertzner
 Clance J. Kestenbaum, M.D.
 Alexander Keyssar, Ph.D.
 Arif Khan
 Yeshashwork Kibour
 Kevin C. Kiley, M.D.
 Moddy H. Kiluvia, M.D.
 Jin-Hun Kim
 Scott Y. Kim, M.D.
 Scholastica Kimaryo
 Jean King, Ph.D.
 David G. Kingdon, M.D.
 Darrell G. Kirch, M.D.
 Debra F. Kirsch, M.D.
 Stephen R. Kisely, M.D.
 Anita R. Kishore, M.D.
 David W. Kissane, M.D.
 Herbert D. Kleber, M.D.
 Tara Klein, M.D.
 Mitchel A. Kling, M.D.
 Raymond Kloss, M.D.
 Richard P. Kluft, M.D.
 Kerry J. Knickle, B.A.
 Richard Kogan, M.D.
 George Kolodner, M.D.
 Simone Kool, M.D.
 Brett A. Koplin, M.D.
 Hannu J. Koponen, M.D.
 Susan G. Kornstein, M.D.
 Johanna Koskinen, M.B.
 Thomas R. Kosten, M.D.
 Paul Krack, M.D.
 Helena C. Kraemer, Ph.D.
 Milton Kramer, M.D.
 Peter D. Kramer
 Thomas A.M. Kramer, M.D.
 Louis J. Kraus, M.D.
 Brunhild Kring, M.D.
 Richard B. Krueger, M.D.
 Terry Krupa, Ph.D.
 Meir Kryger, M.D.
 Harold Kudler, M.D.
 Thomas Kuechler, Ph.D.
 Jack Kuo, M.D.
 Mary Kurien, M.D.
 Dennis Kussin, M.D.
 Helen H. Kyomen, M.D.
 James H. Lake, M.D.
 H. Richard Lamb, M.D.
 Ruth M. Laman, M.D.
 Jeffrey M. Lammers, M.D.
 Christophe Lancon
 Yulia Landa, Ph.D.
 Alan Langlieb, M.D.
 Margo D. Lauterbach, M.D.
 Leslie E. Lawrence, M.D.
 Aaron Lazare, M.D.
 Jeremy A. Lazarus, M.D.
 Robert Leahy, Ph.D.
 Kimberlyn Leary, Ph.D.
 Benjamin D. Lederer, M.D.
 James E. Lee, Jr., M.D.
 Karen L. Lee, M.A.
 Eve Leeman MD
 Steve Leff
 Laurent S. Lehmann, M.D.
 Ellen Leibenluft, M.Ed.

DISCLOSURE INDEX

Hoyle Leigh, M.D.
 Stephanie Lemelle, M.D.
 Francine L. Lemire, M.D.
 Sherry Leonard, Ph.D.
 Caryn Lerman, Ph.D.
 Alain D. Lesage, M.D.
 Molyn Leszcz, M.D.
 Philip G. Levendusky, Ph.D.
 John B. Levine, M.D.
 Stephen B. Levine, M.D.
 Robert D. Levitan, M.D.
 Kenneth M. Levy, Ph.D.
 Bradley E. Lewis
 Alfred J. Lewy, M.D.
 Eric C. Li, M.D.
 T-K Li, M.D.
 Robert P. Liberman, M.D.
 Charles W. Lidz, Ph.D.
 Gregory A. Light, Ph.D.
 Ching-Hua Lin, M.D.
 Jean P. Lindenmayer, M.D.
 Paul S. Links, M.D.
 Don R. Lipsitt, M.D.
 John Livesley
 Ted Lo, M.D.
 Gwenole Loas, M.D.
 Jodi S. Lofchy, M.D.
 Lina M. Lopez, M.D.
 Juan J. Lopez-Ibor, Jr., M.D.
 Eugene M. Lowenkopf, M.D.
 Nasser F. Loza, M.D.
 Andres M. Lozano, M.D.
 Francis G. Lu, M.D.
 Joan L. Luby, M.D.
 Raquel Lugo, M.D.
 Michael Lukasiewicz, M.D.
 Beatriz Luna
 John Luo, M.D.
 Rohini Luthra, Ph.D.
 Minda R. Lynch, Ph.D.
 David J. Lynn, M.D.
 Michele Mach, M.S.W.
 Phillip Maerov, M.D.
 Pirjo H. Maki, M.D.
 Dolores Malaspina, M.D.
 Jose R. Maldonado, M.D.
 Edward A. Malloy, Ph.D.
 Carl P. Malmquist, M.D.
 Alan Z.A. Manevitz, M.D.
 Christina V. Mangurian, M.D.
 Myrl R.S. Manley, M.D.
 John Manring
 Peter Manu, M.D.
 Donatella Marazziti, M.D.
 Eric R. Marcus, M.D.
 Dimitri D. Markov, M.D.
 John C. Markowitz, M.D.
 Tracey I. Marks, M.D.
 Andreas Marmeros, M.D.
 Janet A. Martin, M.D.
 Michael J. Martin, M.D.
 Jorge A. Martínez-Mantilla
 Christine Marx, M.D.
 Mary Jane Massie, M.D.
 Daniel H. Mathalon, M.D.
 Yogi Matharu, DPT
 Maju Mathews
 Travis D. Mathews, MA.
 Patricia Matthews-Juarez, Ph.D.
 Anu A. Matorin, M.D.
 Annette Matthews, M.D.
 Patricia Matthews-Juarez, Ph.D.
 Robert Maunder, M.D.
 Matthew May, M.D.
 Laurel Mayer, M.D.
 Cheryl F. McCartney, M.D.
 Benjamin H. McCommon, M.D.
 Miles McFall, Ph.D.
 Thomas McGuire, Ph.D.
 Jack S. McIntyre, M.D.
 Karen McKinnon, M.A.
 Jennifer L. McLain, M.D.
 Alexandra B. McLean, M.D.
 Andy McLean, M.D.
 Diane E. McLean, M.D.
 Melissa McMullin, B.A.
 Nancy L. McNaughton, M.Ed.
 Laura F. McNicholas, M.D.
 Roger L. McRoberts III, M.D.
 Michael Meaney, Ph.D.
 David Mee-Lee, M.D.
 Karen L. Melendez, M.D.
 Cesar Mella Mejias, M.D.
 Ingrid Melle, M.D.
 Claudia Meneses, M.D.
 Anita Menfi, R.N.
 Edgardo J. Menvielle, M.D.
 Philip T. Merideth, M.D.
 Nicholas Meyers
 Sami Meyerson-Bernstein
 Juan E. Mezzich, M.D.
 Ayesha I. Mian, M.D.
 Danni Z. Michaeli, M.D.
 Robert Michels, M.D.
 Eric Mick, Sc.D.
 Cecilia M. Mikalac, M.D.
 Claudia Miller, M.D.
 Franklin G. Miller, Ph.D.
 Gary E. Miller, M.D.
 Laura J. Miller, M.D.
 Michael M. Miller, M.D.
 Paul R. Miller, M.D.
 Sheldon I. Miller, M.D.
 Robert B. Millman, M.D.
 Richard D. Milone, M.D.
 David L. Mintz, M.D.
 Karen Miotto, M.D.
 David Mischoulon, M.D.
 James E. Mitchell III, M.D.
 David A. Mitnick, M.D.
 Janis Miyasaki, M.D.
 Ramin Mojtabai, M.D.
 Henry J. Moller, M.D.
 Richard A. Montgomery, M.D.
 Ivan D. Montoya, M.D.
 Scott D. Moore
 Leslie C. Morey, Ph.D.
 Rajendra A. Morey, M.D.
 Jessica C. Morgan, M.D.
 A. Leslie Morrow, Ph.D.
 Patricia M. Morse, Ph.D.
 Howard B. Moss, M.D.
 Vanessa Moss, L.C.S.W.
 Robert K. Moyzis
 David A. Mrazek, M.D.
 Khalid A. Mufti, M.D.
 Cornelis Mulder, M.D.
 Wijnand Mulder MD
 Cheryl C. Munday, Ph.D.
 Richard L. Munich, M.D.
 Farah Munir, D.O.
 Alicia A. Munoz
 Kali Munro, M.Ed.
 Jessica L. Murakami, M.S.
 Patricia E. Murphy, Ph.D.
 Matthew Muskin
 Michael F. Myers, M.D.
 Wade C. Myers, M.D.
 Mireya Nadal-Vicens, M.D.
 Carol C. Nadelson, M.D.
 Tricia M. Nagel
 Gene A. Nakajima, M.D.
 Theodore S. Nam, M.D.
 Surinder Nand, M.D.
 Syed S.A. Naqvi, M.D.
 Antonio E. Nardi, M.D.
 William E. Narrow, M.D.
 Margaret J. Nasarey, M.S.N.
 Jeffrey A. Naser, M.D.
 J. Charles Ndlela, M.D.
 Julie Nelligan, Ph.D.
 Ali Nemat, M.D.
 Gerald Nestadt, M.D.
 Cassandra F. Newkirk, M.D.
 Alan W. Newman, M.D.
 Fugen Neziroglu, Ph.D.
 Alphonso Nichols III, M.D.
 Darlene Nipper
 Richard L. Noel, M.D.
 Michael Norko, M.D.
 Donna M. Norris, M.D.
 Colleen J. Northcott, M.D.
 Malkah T. Notman, M.D.
 Ellen M. Notz
 Marta Novak M.D.
 Edward V. Nunes, M.D.
 John I. Nurnberger, Jr., M.D.
 Hans Nusselder, M.D.
 Charles P. O'Brien, M.D.
 Bastiaan L. Oele, M.D.
 Tarek A. Okasha, M.D.
 Linda J. O'keefe-Wood, M.S.
 Gloria N. Okorochoa, M.D.
 Joseph Okpaku, M.D.
 Samuel O. Okpaku, M.D.
 Silvia Olarte, M.D.
 John M. Oldham, M.D.
 Josie L. Olympia, M.D.
 Erica L. O'Neal, M.D.
 Chiadi Onyike
 Maria A. Oquendo, M.D.
 Patricia Ordorica
 Edward F. Ormston
 Urban P. Osby, M.D.
 Hogni Oskarsson, M.D.
 David W. Oslin, M.D.
 Ossama T. Osman, M.D.
 Howard J. Osofsky, M.D.
 Joy D. Osofsky, M.D.
 David N. Osser, M.D.
 Britta Ostermeyer, M.D.
 Laura Otto-Salaj, Ph.D.
 Eugene A. Oulvey, Ph.D.
 Ann E.K. Page
 Clare M. Pain, M.D.
 Derek Pallandi, M.D.
 Stefano Pallanti
 Brian A. Palmer, M.D.
 Pamela A. Pappas, M.D.
 Michael Pare, M.D.
 Rajesh M. Parikh, M.D.
 Joel F. Paris, M.D.
 Sung-Hyouk Park, M.D.
 Malini Patel, M.D.
 Shirish V. Patel, M.D.
 Michele T. Pato, M.D.
 Mallika Patri, M.D.
 Ellen Patterson, L.C.S.W.
 Robindra K. Paul, M.D.
 Cort A. Pedersen, M.D.
 Roger Peele, M.D.
 Jennifer D. Pender, M.D.
 Maribeth Pender, Ph.D.
 Edgardo L. Perez, M.D.
 Roy H. Perlis, M.D.
 John C. Perry, M.D.
 Giulio Perugi, M.D.
 John R. Peteet, M.D.
 Allan D. Peterkin, M.D.
 Bruce M. Pfohl, M.D.
 Alexandra Pham-Scottetz
 Edmond H. Pi, M.D.
 Melissa P. Piasecki, M.D.
 Stephen Pinals, M.D.
 Harold Alan. Pincus, M.D.
 Stefano Pini, M.D.
 Vivian W. Pinn, M.D.
 Narisimha R. Pinninti, M.D.
 Mary Pittman, M.S.
 Eric M. Plakun, M.D.
 Richard R. Pleak, M.D.
 Robert M. Plovnick, M.D.
 Bernice Porjesz, Ph.D.
 Jerrold M. Post, M.D.
 Robert M. Post, M.D.
 Seth M. Powsner, M.D.
 Sudha Prathikanti, M.D.
 Sarah Pratt, Ph.D.
 Jason Pray
 Marilyn Price, M.D.
 Holly G. Prigerson, Ph.D.
 Christina M. Puchalski, M.D.
 Myron L. Pulier, M.D.
 Robert S. Pynoos, M.D.
 Cameron D. Quanbeck, M.D.
 Terry Rabinowitz, M.D.
 Jiri Raboch, M.D.
 Marcus Raichle, M.D.
 Charles J. Rainey, M.D.
 Rekha Raja, D.O.
 Luis F. Ramirez, M.D.
 Gamaliel Ramos
 J. Russell Ramsay, Ph.D.
 Aruna S. Rao, M.D.
 Nyapati R. Rao, M.D.
 Sam Raskin
 Solomon Rataemane
 Shanaya Rathod, M.D.
 Paula Ravitz, M.D.
 Richard Rawson, M.D.
 Maryam Razavi, M.D.
 Mary E. Read, M.D.
 Neil A. Rector, Ph.D.
 Patricia R. Recupero, M.D.
 Donald Redelmeier, M.D.
 Jeffrey D. Rediger, M.D.
 James J. Reeves, M.D.
 Nicole Regent, M.D.
 Darrel A. Regier, M.D.
 James H. Reich, M.D.
 William H. Reid, M.D.
 Shauna P. Reinblatt, M.D.
 Barry Reisberg, M.D.
 Cynthia I. Resendez, M.D.
 Phillip J. Resnick, M.D.
 Raymond M. Reyes, M.D.
 Yanni C. Rho, M.D.
 Lawrence K. Richards, M.D.

DISCLOSURE INDEX

Ronald O. Rieder, M.D.
 Marie-Claude Rigaud, M.D.
 Huijun Z. Ring, Ph.D.
 Candace B. Risen, L.C.S.W.
 Eva C. Ritvo, M.D.
 Claire P. Rivlin, M.A.
 Albert A. Rizzo, Ph.D.
 Esther P. Roberts, M.D.
 Brian M. Robertson, M.D.
 Carolyn B. Robinowitz, M.D.
 Lee N. Robins, D.Phil.
 Alexandra Robinson
 David J. Robinson, M.D.
 Gail E. Robinson, M.D.
 Robert P. Roca, M.D.
 Patricia Rockman, M.D.
 Jerome Rogoff, M.D.
 John S. Rolland, M.D.
 Marta B. Rondon, M.D.
 Elsa F. Ronningstam, Ph.D.
 Cherise Rosen, Ph.D.
 Michael B. Rosenbluth, M.D.
 Richard N. Rosenthal
 Erik J. Roskes, M.D.
 Isabelle M. Rosso, Ph.D.
 Albert Rothenberg, M.D.
 David A. Rothstein, M.D.
 Samuel E. Roura, M.D.
 Jeffrey Rubin MD, M.D.
 Gabriel Rubio, M.D.
 Maritza Rubio-Stipec, Sc.D.
 Alicia R. Ruelaz, M.D.
 James Ray R. Rundell, M.D.
 Mark Russakoff, M.D.
 Bret R. Rutherford, M.D.
 Abe M. Rychik, J.D.
 Gregory B. Saathoff, M.D.
 Wolfgang Sadee
 Sy A. Saeed, M.D.
 Daniel J. Safer, M.D.
 Isaac Sakinofsky, M.D.
 Cheryl Y. Salary, M.D.
 Anat Salomon
 Alicia J. Salzer, M.D.
 Francis M. Sanchez, M.D.
 Hans Sanders, M.D.
 Theodoros G.M. Sandfort, Ph.D.
 Mary Sano, Ph.D.
 Glenn Saxe, M.D.
 David L. Scasta, M.D.
 Stephen C. Scheiber, M.D.
 Abigail B. Schlesinger, M.D.
 Chester W. Schmidt, Jr., M.D.
 Richard D. Schneider
 Gary R. Schoener, Psy.D.
 Robert A. Schoevers, Ph.D.
 James Q. Schubmehl, M.D.
 Nicole Schupf
 Mary Schwab-Stone, M.D.
 Bruce J. Schwartz, M.D.
 Joseph M. Schwartz, M.D.
 Steven B. Schwarzkopf, M.D.
 Marcia Scott, M.D.
 Nakia G. Scott, M.D.
 James H. Scully, Jr., M.D.
 Lloyd I. Sederer, M.D.
 Aura R. Seidler, M.S.W.
 Dallas P. Seitz, M.D.
 Roslyn Seligman, M.D.
 Jonathan G. Shack, M.D.
 David Shaffer, M.D.
 Colin M. Shapiro, Ph.D.
 Edward R. Shapiro, M.D.
 Steven S. Sharfstein, M.D.
 John Sharkey, M.D.
 Carla Sharp, Ph.D.
 Jon A. Shaw, M.D.
 Shoshana L. Shear, M.D.
 Lina S. Shihabuddin, M.D.
 Rebecca L. Shiner, Ph.D.
 Naotaka Shinfuku, M.D.
 Tony B. Shivers
 Aditi M. Shrikhande, M.D.
 Glenn N. Siegel, M.D.
 Larry J. Siever, M.D.
 Kenneth R. Silk, M.D.
 Ivan Silver, M.D.
 Stuart B. Silver, M.D.
 Joel J. Silverman, M.D.
 Morton M. Silverman, M.D.
 Sherri M. Simpson, M.D.
 Ravi K. Singareddy, M.D.
 Bruce S. Singh, M.D.
 Priti Sinha
 E. Yusuf Sivrioglu, M.D.
 Andrew E. Skodol II, M.D.
 Andrew E. Slaby, M.D.
 Filip E. Smit, M.S.C.
 Mary K. Smith, M.D.
 Trevor F. Smith, Ph.D.
 Joel R. Sneed, Ph.D.
 Roman Snihurowych, M.D.
 Paul H. Soloff, M.D.
 Stephen M. Soltys, M.D.
 Aradhana B. Sood, M.D.
 Eliot Sorel, M.D.
 Renee M. Sorrentino, M.D.
 Wesley E. Sowers, M.D.
 Jeffrey Spector, M.D.
 Mario Speranza, M.D.
 Deborah Spitz, M.D.
 Henry I. Spitz, M.D.
 Melanie E. Spritz, D.O.
 Jorge C. Strabstein, M.D.
 Jagannathan Srinivasaraghavan, M.D.
 Manit Srisurapanont, M.D.
 Susan Stabinsky, M.D.
 Laurence R. Stanford, Ph.D.
 Joy E. Stankowski, M.D.
 Barbara H. Stanley
 Brett Steenbarger
 Otto Steenfheldt-Foss, M.D.
 Michael Stefanek, Ph.D.
 Bradley D. Stein, M.D.
 Harriet C. Stern, M.D.
 Frances Stewart
 Stephanie M. Stewart, M.D.
 Frederick S. Stinson, Ph.D.
 Andrea G. Stolar, M.D.
 Alan A. Stone, M.D.
 Michael H. Stone, M.D.
 Nada L. Stotland, M.D.
 Zachary N. Stowe, M.D.
 Keith R. Stowell, M.D.
 Norman Straker, M.D.
 Joshua L. Straus, M.D.
 John S. Strauss, M.D.
 Jon M. Streltzer, M.D.
 Werner Strik, M.D.
 Scott P. Stuart, M.D.
 Dorothy E. Stubbe, M.D.
 Craig A. Stuck, M.D.
 Raymond E. Suarez, M.D.
 Richard T. Suchinsky, M.D.
 Donna M. Sudak, M.D.
 Patrick F. Sullivan, M.D.
 Alan L. Summers, M.D.
 Trey Sunderland, M.D.
 Ezra S. Susser, M.D.
 David T. Suzuki, Ph.D.
 Jeffrey Sverd, M.D.
 Bonnie L. Szarek, R.N.
 Ana Szarfman, M.D.
 Eva M. Szigethy, M.D.
 Zebulun C. Taintor, M.D.
 John A. Talbott, M.D.
 Robyn Taylor, B.S.C.
 Martin H. Teicher, M.D.
 Scott Temple, Ph.D.
 Samuel B. Thielman, M.D.
 Ole Thienhaus, M.D.
 Prakash K. Thomas, M.D.
 Brett D. Thombs, Ph.D.
 Mindy Thompson Fullilove, M.D.
 Ann Thompson, M.S.W.
 Tavi Thongdy, M.D.
 Joshua T. Thornhill IV, M.D.
 Maria L. A. Tiamson-Kassab, M.D.
 Jennifer W. Tidey, Ph.D.
 Jane G. Tillman, Ph.D.
 Christine Timko, Ph.D.
 Kay Titchenal, SPHR
 Mary Titus-Villedrouin
 Lowell D. Tong, M.D.
 Glenn J. Treisman, M.D.
 Nhi-Ha T. Trinh, M.D.
 Harsh K. Trivedi, M.D.
 Guochuan E. Tsai, M.D.
 Kuan-Yi Tsai, M.D.
 Werner Tschan, M.D.
 John W. Tsuang, M.D.
 Phebe Tucker, M.D.
 Terrie Tucker
 Willem C. Tuinebreijer, M.D.
 Endel Tulving, Ph.D.
 Gustavo Turecki, Ph.D.
 Ann R. Turkel, M.D.
 Stuart W. Twemlow, M.D.
 Thomas W. Uhde MD
 Phil Upshall
 John C. Urbaitis, M.D.
 Amy Ursano, M.D.
 Robert J. Ursano, M.D.
 Per Vaglum, M.D.
 Ipsit Vahia, M.D.
 Angel Valmaggia M.D.
 Gerda Van Aalst, M.D.
 Henk Van Den Berg, M.D.
 Bessel A. Van der Kolk, M.D.
 Henricus L. Van, M.D.
 Monisha R. Vasa, M.D.
 Juha M. Veijola, M.D.
 Ricardo M. Vela, M.D.
 Antonio Vela-Bueno MD
 Maria A. Velazquez, M.D.
 Vytas P. Velyvis, M.A.
 Michael J. Vergara, M.D.
 Alexandros Vgontzas MD
 George I. Viamontes, M.D.
 Lisa Victor, Ph.D.
 Lakshmi Vijayakumar, D.P.M.
 Jose P. Vito, M.D.
 Nora D. Volkow, M.D.
 Susan F. Volman, Ph.D.
 Serena Y. Volpp, M.D.
 Valerie Voon, M.D.
 Andrea Waddell, M.D.
 Andrea E. Waddell, M.D.
 William Waggoner, Ph.D.
 Carl M. Wahlstrom, Jr., M.D.
 Harold J. Wain, Ph.D.
 Milton L. Wainberg, M.D.
 Cynthia Wainscott, B.A.
 Marjorie E. Waldbaum, M.D.
 Amy Waldman
 David J. Walick, M.D.
 Sandra C. Walker, M.D.
 Elizabeth Walsh, M.D.
 Eugene Wang, M.D.
 Khakasa H. Wapenyi, M.D.
 Carole Warshaw, M.D.
 Col. Terry C. Washam, L.I.S.W.
 LaShondra T. Washington, M.D.
 G. Scott Waterman, M.D.
 Darryl P. Watson, M.D.
 Priyanthy Weerasekera, M.D.
 Daniel R. Weinberger, M.D.
 Stevan M. Weine, M.D.
 Richard D. Weiner, M.D.
 Henry C. Weinstein, M.D.
 Lydia E. Weisser, D.O.
 Kenneth B. Wells, M.D.
 Christopher J. Welsh, M.D.
 Steven P. Wengel, M.D.
 John J. Wernert III, M.D.
 Sara G. West, M.D.
 Drew Westen, Ph.D.
 O.C. White III, M.D.
 Paul H. Wick, M.D.
 Thomas A. Widiger, Ph.D.
 Mark L. Willenbring, M.D.
 Caroline B. Williams, M.D.
 Eric R. Williams, M.D.
 David J. Williamson, Ph.D.
 Peter C. Williamson, M.D.
 M.E. Jan. Wise, M.D.
 Katherine L. Wisner, M.D.
 Wolfgang Woelwer, Ph.D.
 Mary K. Wolf, OI
 Nicole F. Wolfe, M.D.
 Philip Wong, M.D.
 Ikwunga Wonodi, M.D.
 William C. Wood, M.D.
 Steve H. Woodward, Ph.D.
 Stephen B. Woolley, M.P.H.
 Linda L.M. Worley, M.D.
 Jesse H. Wright III, M.D.
 Harry H. Wright, M.D.
 Guohua Xia, M.D.
 Juliana Yacubian, Ph.D.
 Joel Yager
 David Yamada, J.D.
 Jose A. Yaryura-Tobias, M.D.
 Rachel Yehuda, M.D.
 Frank E. Yeomans, M.D.
 Albert Yeung, M.D.
 Alvelth J. Young, M.D.
 Keith W. Young, M.D.
 Ari E. Zaretsky, M.D.
 Mary Zdanowicz, J.D.
 Charles H. Zeanah, Jr., M.D.
 Thomas C. Zelnik, M.D.
 Doug Ziedonis, M.D.
 Beata A. Zolovska, M.D.
 Howard V. Zonana, M.D.
 Allan Zuckoff, Ph.D.

Benefit Concert

Toronto Welsh Male Voice Choir

Lenard Whiting conducting



Kathryn Tremills accompanist

Giles Tomkins soloist

May 22, 2006 at 7:00 PM

Metro Toronto Convention Centre

Proceeds to the Disaster relief Fund





AMERICAN PSYCHIATRIC ASSOCIATION™

159TH ANNUAL MEETING, TORONTO, CANADA MAY 20-25, 2006

*Slides and Audio of the Top Annual Meeting
Sessions Captured On-Line*

2006 Annual Meeting Online

Your One-Stop Educational Resource Library

“APA Annual Meeting Online” is an e-resource for psychiatrists to learn and earn CME credits through the 2006 Annual Meeting Online library - providing state-of-the-art audio-visual programs that offer a dynamic learning experience 24/7.

- **FREE access for those attending APA 2006**
- **100+ hours of content to review from the 2006 and 2005 Annual Meetings**
- **Vast online, searchable database**
- **Review presentations from world renowned faculty**
- **Participate online and earn CME credit**
- **Free admission to everyone for Industry-supported Symposia**
- **Select sessions also available on DVD-ROMs**

More information will be available post-meeting. Look for more details to follow.
Save your meeting badge for your access number to the site.

Visit the APA Annual Meeting Online

www.psych.org/amlibrary

SATURDAY, MAY 20, 2006

159TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 1-3

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 1 8:00 a.m.-12 noon
Room 703, Level 700, Toronto Convention Centre South

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman Straker, M.D.

Course 2 8:00 a.m.-12 noon
Room 705, Level 700, Toronto Convention Centre South

RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Stephen V. Faraone, Ph.D.

Course 3 8:00 a.m.-12 noon
Room 715 A, Level 700, Toronto Convention Centre South

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright III, M.D.
Faculty: David G. Kingdon, M.D., Douglas Turkington, M.D.

9:00 a.m. Sessions



COURSES 4-9

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 4 9:00 a.m.-4:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

INTERPERSONAL PSYCHOTHERAPY

Co-Directors: Scott P. Stuart, M.D., Paula Ravitz, M.D.

Course 5 9:00 a.m.-4:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director: William H. Campbell, M.D.

Course 6 9:00 a.m.-4:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I: THE THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

Director: Shivkumar S. Hatti, M.D.
Faculty: Stuart B. Silver, M.D., Arthur L. Lazarus, M.D., Mark Russakoff, M.D., Sy A. Saeed, M.D.

Course 7 9:00 a.m.-4:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

TEACHING ADDICTION MEDICINE USING FILMS

Director: Petros Levounis, M.D.
Faculty: Christopher J. Welsh, M.D., Tony Juneja, M.D., Glenn A. Brottman, M.D.

Course 8 9:00 a.m.-4:00 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Joel Yager, M.D., Michael J. Devlin, M.D., James E. Mitchell, M.D., Katherine A. Halmi, M.D.

Course 9 9:00 a.m.-4:00 p.m.
Room 809, Level 800, Toronto Convention Centre South

A COMPREHENSIVE REVIEW OF HYPNOSIS USE IN CLINICAL PSYCHIATRY

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D., Matthew May, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-4

INDUSTRY-SUPPORTED SYMPOSIUM 1

12:30 p.m.-3:30 p.m.

John Basset Theatre, Level 100, Convention Centre North

NEW AUGMENTATION STRATEGIES IN DEPRESSION FOR BETTER OUTCOMES

Supported by GlaxoSmithKline

Chp.: Jonathan E. Alpert, M.D.

A Polypharmacy for Depression: How Often Is It Used and Why?

Joshua A. Israel, M.D.

(Continued on next page)

SATURDAY

- B "How To": Augmentation Strategies in Resistant Depression**
Charles DeBattista, M.D.
- C When Does Polypharmacy Lead to Higher Remission Rates?**
Jonathan E. Alpert, M.D.
- D Adding Psychotherapy: Pearls for Improved Outcomes**
Amy Farabaugh, Ph.D.
- E Pharmacological Antidotes for Antidepressant-Induced Side Effects**
Anita H. Clayton, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2

12:30 p.m.-3:30 p.m.

Canadian Room, Convention Floor, Royal York

STRATEGIES FOR MAINTAINING WELLNESS IN PATIENTS WITH BIPOLAR DISORDER: MOVING BEYOND EFFICACY TO EFFECTIVENESS

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Gary S. Sachs, M.D.

- A Brains and Genes: Implications for the Treatment of Bipolar Disorder**
Kiki D. Chang, M.D.
- B Impact of Patient Satisfaction With Treatment on Treatment Options**
Holly A. Swartz, M.D.
- C Evaluation of Bipolar Trials**
Gary S. Sachs, M.D.
- D Impact of Misdiagnosis of Bipolar Disorder**
Claudia F. Baldassano, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3

12:30 p.m.-3:30 p.m.

Concert Hall, Convention Floor, Royal York

NAVIGATING THE MAZE: UNDERSTANDING METHODS, RESULTS, AND RISKS IN PSYCHIATRIC RESEARCH

Supported by Forest Pharmaceuticals, Inc.

Chp.: David J. Kupfer, M.D.

- A Assessing Statistical and Clinical Significance in Medical Research**
David J. Kupfer, M.D.
- B All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care**
Helena C. Kraemer, Ph.D.

- C Determining Efficacy: Sound Clinical Trial Design and Interpretation**
Cornelius Katona, M.D.
- D Treating Depression in Children and Adolescents: What's a Clinician To Do?**
Jeff Q. Bostic, M.D.
- E How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly**
Eric J. Lenze, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4

12:30 p.m.-3:30 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre


BRIDGING SLEEP, SCIENCE, AND PUBLIC POLICY

Supported by Takeda Pharmaceuticals North America, Inc.

Chp.: David N. Neubauer, M.D.

- A The Science of Sleep**
David N. Neubauer, M.D.
- B Adolescents and School Start Times: The Intersection of Research and Public Policy**
R. Robert Auger, M.D.
- C Shiftwork, Sleep, and Performance**
Gregory Belenky, M.D.
- D Medical Education and Resident Duty Hours**
Phyllis C. Zee, M.D.
- E Insomnia and Public Policy**
Daniel J. Buysse, M.D.

1:00 p.m. Sessions



COURSES 10-14

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 10

1:00 p.m.-5:00 p.m.

Room 703, Level 700, Toronto Convention Centre South

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

Course 11

1:00 p.m.-5:00 p.m.

Room 705, Level 700, Toronto Convention Centre South

CLINICIAN ADMINISTERED RATING SCALES FOR MOOD AND ANXIETY DISORDERS

Co-Directors: Sagar V. Parikh, M.D., Vytas P. Velyvis, M.A.

Course 12 1:00 p.m.-5:00 p.m.

Room 713 A, Level 700, Toronto Convention Centre South

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Director: Ziad H. Nahas, M.D.

Faculty: Mark Demitrack, M.D., Frank A. Kozel, M.D., John P. O'Reardon, M.D., Shirlene M. Sampson, M.D.

Course 13 1:00 p.m.-5:00 p.m.

Room 714 A, Level 700, Toronto Convention Centre South

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.

Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

Course 14 1:00 p.m.-5:00 p.m.

Room 717 B, Level 700, Toronto Convention Centre South

COLLABORATION BETWEEN MENTAL HEALTH AND PRIMARY CARE PROVIDERS: WHAT WORKS AND HOW TO DO IT

Director: Nick Kates, M.B.

Faculty: Marilyn Craven, M.D., Lindsey George, M.D., Jonathan S. Davine, M.D., Michele Mach, M.S.W., Anne Marie Crustolo, B.S.N., Roger Bland, M.B.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 5-8

INDUSTRY-SUPPORTED SYMPOSIUM 5

6:00 p.m.-9:00 p.m.

John Basset Theatre, Level 100, Convention Centre North

MANIA IN SPECIAL POPULATIONS

Supported by Shire US, Inc.

Chp.: Robert M.A. Hirschfeld, M.D.

- A Recent Developments in the Treatment of Mania**
Robert M.A. Hirschfeld, M.D.
- B Recognition and Management of Child and Adolescent Bipolar Disorder**
Karen D. Wagner, M.D.
- C Bipolar Disorders in Women: Clinical and Metabolic Correlates**
Natalie L. Rasgon, M.D.
- D Bipolar Disorders in the Older Patient**
Brent P. Forester, M.D.
- E Recognizing Bipolar Disorder in African Americans**
William B. Lawson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6

6:00 p.m.-9:00 p.m.

Canadian Room, Convention Floor, Royal York

VERGING ON REALITY: EMERGENT THERAPEUTIC ADVANCES IN SCHIZOPHRENIA

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Peter F. Buckley, M.D.

- A Functional Genomics and the Therapeutic Effects of Antipsychotics**
Anil K. Malhotra, M.D.
- B Brain Imaging Techniques as Clinical Tools**
Carol A. Tamminga, M.D.
- C In Search of Wellness: Subjective Tolerability of Second Generation Antipsychotics**
Meera Narasimhan, M.D.
- D Recovery and Remission: Definitions, Dilemmas, and the Emergent Role of Peer Support Specialists**
Peter F. Buckley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7

6:00 p.m.-9:00 p.m.

Concert Hall, Convention Floor, Royal York

BIPOLAR DISORDER: CREATING A CONSENSUS FROM SCIENCE TO PUBLIC POLICY

Supported by Schering Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

- A The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder**
Ellen Frank, Ph.D.
- B A Rational Approach for the Longitudinal Pharmacologic Management of Patients With Bipolar Disorder: An Argument for Changing Public Policy**
Mark H. Rapaport, M.D.
- C Alternative Pharmacologic Approaches to the Care of Bipolar Patients**
Alexander H. Fan, M.D.
- D Treatment Considerations for Mania in Young Children**
Barbara Geller, M.D.
- E Treatment of Bipolar Disorder in U.S. Jails and Prisons**
Joseph R. Calabrese, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8

6:00 p.m.-9:00 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

TREATMENT-RESISTANT DEPRESSION: NEW DATA, NEW APPROACHES

Supported by Cyberonics, Inc.

Chp.: David L. Dunner, M.D.

A Definitions and Clinical Characteristics of Treatment-Resistant Depression

David L. Dunner, M.D.

B Treatment Resistance and Genes: The Biology Versus Pharmacology Enigma

Francisco A. Moreno, M.D.

C PET of Chronic Vagal Nerve Stimulation for Severe, Treatment-Resistant Depression

Jose V. Pardo, M.D.

D Augmentation Strategies for Patients With Difficult-to-Treat MDD

Alicia R. Ruelaz, M.D.

E Brain Stimulation Therapies for Treatment-Resistant Depression

Linda L. Carpenter, M.D.



SUNDAY, MAY 21, 2006

159TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 15-22

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 15 8:00 a.m.- 12 noon
Room 701 A, Level 700, Toronto Convention Centre South

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

Course 16 8:00 a.m.- 12 noon
Room 703, Level 700, Toronto Convention Centre South

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

Course 17 8:00 a.m.- 12 noon
Room 709, Level 700, Toronto Convention Centre South

HOME TREATMENT FOR ACUTE MENTAL DISORDERS: AN ALTERNATIVE TO HOSPITALIZATION

Director: David S. Heath, M.B.

Course 18 8:00 a.m.- 12 noon
Room 711, Level 700, Toronto Convention Centre South

RECOVERY AND SUPPORTED EMPLOYMENT: EVIDENCE-BASED INTEGRATION FOR PSYCHIATRY

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.
Faculty: Connie L. Clark, M.Ed., Michael J. Martin, M.D.

Course 19 8:00 a.m.- 12 noon
Room 713 B, Level 700, Toronto Convention Centre South

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM MOTHERS

Co-Directors: Shaila Misri, M.D., Diana Carter, M.D.
Faculty: Maria R. Corral, M.D., Shari Lusskin, M.D., Deirdre M. Ryan, M.D.

Course 20 8:00 a.m.- 12 noon
Room 714 B, Level 700, Toronto Convention Centre South

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

Course 21 8:00 a.m.- 12 noon
Room 715 A, Level 700, Toronto Convention Centre South

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

Course 22 8:00 a.m.- 12 noon
Room 717 A, Level 700, Toronto Convention Centre South

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

INDUSTRY-SUPPORTED SYMPOSIA 9-13

INDUSTRY-SUPPORTED SYMPOSIUM 9

8:00 a.m.- 11:00 a.m.

John Basset Theatre, Level 100, Convention Centre North

DIFFERENTIATING ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: FROM THEORY TO PRACTICE

Supported by Pfizer, Inc.

Chp.: Anissa Abi-Dargham, M.D.

A Pharmacodynamic Differences Among Antipsychotic Treatments

Anissa Abi-Dargham, M.D.

B The Antipsychotic Effect: Lessons From Occupancy Studies

W. Gordon Frankle, M.D.

C Evaluation of Metabolic Outcome During Antipsychotic Treatment: Lessons From CATIE and Other Recent Studies

John W. Newcomer, M.D.

D Cognitive Responses to Atypical Antipsychotic Medications: Factors Affecting the Potential to Differentiate Treatments

Philip D. Harvey, Ph.D.

E Clinical Integration in the Care for Patients With Schizophrenia: What Are the Current Best Practices?

Robert A. Rosenheck, M.D.

SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 10

8:00 a.m.-11:00 a.m.

Canadian Room, Convention Floor, Royal York

FIBROMYALGIA: SCIENTIFIC ADVANCES TO REDUCE THE BURDEN OF ILLNESS

Supported by Eli Lilly and Company

Chp.: Lesley M. Arnold, M.D.

- A **The Socioeconomic Burden of Fibromyalgia**
Sharon B. Stanford, M.D.
- B **New Evidence for the Pathophysiological Basis of Fibromyalgia**
Lesley M. Arnold, M.D.
- C **Current and Emerging Strategies for the Pharmacologic Management of Fibromyalgia**
Leslie J. Crofford, M.D.
- D **Living With Fibromyalgia: A Patient's Perspective**
Lesley M. Arnold, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11

8:00 a.m.-11:00 a.m.

Concert Hall, Convention Floor, Royal York

EXPANDING THE NEUROBIOLOGICAL AND NEUROPSYCHOLOGICAL FOUNDATION OF ADHD: IMPACT TO CLINICAL PRACTICE

Supported by Shire US, Inc.

Chp.: Thomas J. Spencer, M.D.

- A **ADHD Neuropsychology and Executive Function Deficits**
Larry J. Seidman, Ph.D.
- B **Stimulants: Therapeutic and Reinforcing Effects**
Nora D. Volkow, M.D.
- C **The Relevance of the Trace Amine Phenylethylamine (PEA) to ADHD**
Bertha K. Madras, Ph.D.
- D **New Insights Into the Noradrenergic System in ADHD**
Amy F. Arnsten, Ph.D.
- E **Advances in the Therapeutics of ADHD**
Paul G. Hammerness, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12

8:00 a.m.-11:00 a.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

THE IMPACT OF ANXIETY DISORDERS: A CASE-BASED APPROACH TO IMPROVING OUTCOMES AND REMOVING STIGMA

Supported by Cephalon, Inc.

Chp.: Ned H. Kalin, M.D.

A **Public Health Consequences of Anxiety: A Surgeon General's Perspective**
David Satcher, M.D.

B **Individual Consequences of Anxiety**
Risa B. Weisberg, Ph.D.

C **Anxiety Disorders: A Glimpse Inside the Brain**
Ned H. Kalin, M.D.

D **Linking Symptoms to Treatment Selection in Anxiety Disorders**
Murray B. Stein, M.D.

E **Nonpharmacologic Approach to the Treatment of Anxiety Disorders**
Edna B. Foa, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13

8:00 a.m.-11:00 a.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

NEW VISTAS IN TREATMENT-RESISTANT DEPRESSION

Supported by Pfizer, Inc.

Chp.: Charles B. Nemeroff, M.D.

- A **Evolving Concepts in Treatment-Resistant Depression**
Charles B. Nemeroff, M.D.
- B **Neuropharmacological Basis for Treatment Strategies in the Management of Refractory Depression**
Stephen M. Stahl, M.D.
- C **New Strategies for Treatment-Resistant Depression**
Linda L. Carpenter, M.D.
- D **Re-Evaluating Concepts of Depression: Bipolar Spectrum**
S. Nassir Ghaemi, M.D.

9:00 a.m. Sessions



COURSES 23-30

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 23

9:00 a.m.-4:00 p.m.

Room 705, Level 700, Toronto Convention Centre South

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehl, M.D.

Faculty: Alan R. Beeber, M.D.

Course 24 9:00 a.m.-4:00 p.m.

Room 707, Level 700, Toronto Convention Centre South

KUNDALINI YOGA MEDITATION TECHNIQUES FOR MENTAL HEALTH

Director: David Shannahoff-Khalsa, B.A.

Course 25 9:00 a.m.-4:00 p.m.

Room 713 A, Level 700, Toronto Convention Centre South

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

Course 26 9:00 a.m.-4:00 p.m.

Room 714 A, Level 700, Toronto Convention Centre South

THE MANAGEMENT OF THE SEXUAL ABUSE PHENOMENON: A GLOBAL PERSPECTIVE: A BELGIAN APPROACH

Director: Yves Depauw, M.D.
Faculty: Pierre Collart, Ph.D.

Course 27 9:00 a.m.-4:00 p.m.

Room 715 B, Level 700, Toronto Convention Centre South

PSYCHOTHERAPY FOR BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

Course 28 9:00 a.m.-4:00 p.m.

Room 716 A, Level 700, Toronto Convention Centre South

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY II: CARE MANAGEMENT, LAW, AND ETHICS

Director: Shivkumar S. Hatti, M.D.
Faculty: Arthur L. Lazarus, M.D., Robert Atkins, M.D., William H. Reid, M.D.

Course 29 9:00 a.m.-4:00 p.m.

Room 716 B, Level 700, Toronto Convention Centre South

TREATING BPD WITH THE SYSTEMS TRAINING FOR EMOTIONAL PREDICTABILITY AND PROBLEM SOLVING (STEPPS) MODEL

Director: Donald W. Black, M.D.
Faculty: Bruce M. Pfohl, M.D., Nancee Blum, M.S.W.

Course 30 9:00 a.m.-4:00 p.m.

Room 809, Level 800, Toronto Convention Centre South

UPDATES IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE/POST-MI DEPRESSION

Director: Jose R. Maldonado, M.D.

12:30 p.m. Session

BUSINESS MEETING

(Voting Members Only*)

12:30 p.m.-1:30 p.m.
Room 106, Level 100, Toronto Convention Centre North

CALL TO ORDER

Steven S. Shalhoub, M.D., *President*

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS

Liza H. Gold, M.D., *Chairperson, Committee of Fellows*

REPORTS TO THE MEMBERSHIP

Secretary-Treasurer Carolin B. Robinson, M.D.
Speaker, Assembly Joseph E. V. Rubin, M.D.
Speaker, Elect, Assembly Michael Blumenfeld, M.D.
Chairperson, Committee on Bylaws William C. Wood, M.D.
Chairperson, Election Committee David S. Wahl, M.D.
Chairperson, Membership Committee Mary K. Marrocco, M.D.
Medical Director and CEO James H. Scully Jr., M.D.
Chairperson of Council (Written Reports Only)

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions



COURSES 31-37

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

Course 31 1:00 p.m.-5:00 p.m.

Room 701 A, Level 700, Toronto Convention Centre South

DRUG TREATMENT OF SCHIZOPHRENIA

Co-Directors: Philip G. Janicak, M.D., Morris B. Goldman, M.D.
Faculty: Stephen R. Marder, M.D., Rajiv Tandon, M.D.

SUNDAY

Course 32 1:00 p.m.-5:00 p.m.
Room 703, Level 700, Toronto Convention Centre South

HOW TO PRACTICE BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

Course 33 1:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

BIOETHICS UPDATE 2006

Director: Edmund G. Howe, M.D.

Course 34 1:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

SHORT-TERM PSYCHOANALYTIC SUPPORTIVE PSYCHOTHERAPY IN THE TREATMENT OF DEPRESSION

Director: Henricus L. Van, M.D.
Faculty: Mariëlle Hendriksen, M.D., Simone Kool, M.D., Gerda van Aalst, M.D., Robert A. Schoevers, M.D., Jack Decker, Ph.D.

Course 35 1:00 p.m.-5:00 p.m.
Room 713 B, Level 700, Toronto Convention Centre South

PSYCHIATRIC INTERVENTIONS IN DISASTERS AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE

Supported by APA Committee on Psychiatric Dimensions of Disasters

Director: Anthony T. Ng, M.D.
Faculty: Judith Cohen, M.D., Phebe Tucker, M.D.

Course 36 1:00 p.m.-5:00 p.m.
Room 715 A, Level 700, Toronto Convention Centre South

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright III, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, M.D.

Course 37 1:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW

Co-Directors: Paul R. Miller, M.D., Margaret Nasarey, M.S.N.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 14-19

INDUSTRY-SUPPORTED SYMPOSIUM 14

1:30 p.m.-4:30 p.m.

John Basset Theatre, Level 100, Convention Centre North

NEW DEVELOPMENTS IN SCHIZOPHRENIA: FROM NEUROBIOLOGY TO PUBLIC HEALTH

Supported by Soluty Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: John M. Kane, M.D.

- A **Pharmacologic Treatment of Schizophrenia: The State-of-the-Art**
John M. Kane, M.D.
- B **From Dopamine to Delusions: Understanding Psychosis From the Bench to the Bedside**
Shitij Kapur, M.D.
- C **Cognitive Functioning in Schizophrenia: Cognitive Impairments as Clues for Treatment Development**
Robert M. Bilder, Ph.D.
- D **Metabolic Risks of Second-Generation Antipsychotic Medications**
Christoph U. Correll, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15

1:30 p.m.-4:30 p.m.

Canadian Room, Convention Floor, Royal York

VITAL SIGNS IN PSYCHIATRY: A PERSPECTIVE ON SLEEP ACROSS THE LIFE CYCLE

Supported by Sepracor, Inc.

Chp.: Eric A. Nofzinger, M.D.

- A **Sleep in Infancy, Childhood, and Adolescence: Normal Sleep Patterns, Developmental Issues, and Sleep Problems**
Jodi Mindell, M.D.
- B **Insomnia in Adulthood: Causes, Consequences, and Treatment**
Ned H. Kalin, M.D.
- C **Insomnia Secondary to Medical or Psychiatric Comorbidity: Implications for Evaluation and Management**
Matthias K. Lee, M.D.
- D **Sleep in Women Across the Life Cycle: How the Reproductive Cycle Impacts Sleep**
Meir Kryger, M.D.
- E **Sleep in the Elderly: Is Poor Sleep a Normal Concomitant of Advancing Age?**
Sanford Finkel, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16

1:30 p.m.-4:30 p.m.

Concert Hall, Convention Floor, Royal York

INTERRUPTING THE CYCLE OF VASCULAR DISEASE AND DEPRESSION

Supported by Forest Pharmaceuticals, Inc

Chp.: Steven P. Roose, M.D.

- A **Vascular Disease: Mechanisms Underlying the Relationship**
Dominique L. Musselman, M.D.
- B **The Bidirectional Relationship Between Diabetes and Depression**
Sanjay T. Mathew, M.D.
- C **Post-Stroke Depression and the Vascular Depression Hypothesis**
David C. Steffens, M.D.
- D **Vascular Disease and Depression: Challenges in Management and Treatment**
Christopher M. O'Connor, M.D.
- E **Clinical Treatment Perspectives: A Focus on Diagnosis and Safety**
J. Craig Nelson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17

1:30 p.m.-4:30 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

THE LONG-TERM CLINICAL COURSE AND TREATMENT OF RECURRENT MAJOR DEPRESSION IN 2006: NEW DATA AND FUTURE DIRECTIONS

Supported by Wyeth Pharmaceuticals

Chp.: Martin B. Keller, M.D.

- A **The Pernicious Course of Major Depression: New Findings From a 20-Year Prospective Follow-Up Study**
Martin B. Keller, M.D.
- B **Risk for Major Depression: Genes, Stress, and the HPA Axis**
Audrey R. Tyrka, M.D.
- C **Biological and Imaging Changes in Depression**
K. Ranga R. Krishnan, M.B.
- D **Using Pharmacogenetics in Practice**
Alan F. Schatzberg, M.D.
- E **Current State of Evidence-Based Treatment of Depression**
Madhukar H. Trivedi, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18

1:30 p.m.-4:30 p.m.

Frontenac Room, Street Level, Westin Harbour Castle

MISDIAGNOSIS OF BIPOLAR II: METHODS FOR SCREENING PATIENTS AT RISK FOR BIPOLAR DISORDER

Supported by GlaxoSmithKline

Chp.: Frederick K. Goodwin, M.D.

- A **Diagnosing Bipolar Disorder and the Role of Screening Instruments**
Terence A. Ketter, M.D.
- B **Major Depression: Clues to Bipolarity**
Hagop S. Akiskal, M.D.
- C **Bipolar Depression: Implications for Morbidity, Mortality, and Therapeutics**
Ross J. Baldessarini, M.D.
- D **Antidepressants and the Bipolar Spectrum**
S. Nassir Ghaemi, M.D.
- E **Depression and the Affective Spectrum: The Role of Mood Stabilizers**
Frederick K. Goodwin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19

1:30 p.m.-4:30 p.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

ADVANCES IN THE UNDERSTANDING OF THE DEMENTIA SPECTRUM

Supported by Eisai, Inc. and Pfizer, Inc

Chp.: Jeffrey L. Cummings, M.D.

- A **The Neurobiology of Alzheimer's Disease**
David A. Bennett, M.D.
- B **Therapeutic Options in the Management of Vascular Dementia**
David Wilkinson, M.B.
- C **Evolution in the Understanding and Treatment of Mild Cognitive Impairment**
Gregory A. Jicha, M.D.
- D **Improving Outcomes for Patients With Advanced Dementia**
Howard Feldman, M.D.
- E **Optimizing Behavioral Outcomes Across the Dementia Spectrum**
Jeffrey L. Cummings, M.D.

2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.
Room 107, Level 100
Toronto Convention Centre North

AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Liza H. Gold, M.D.

The Challenge of Employment-Related
Psychiatric Evaluations

Chp.: Michael A. Norbo, MD

Liza H. Gold, M.D., is Clinical Associate Professor of Psychiatry at Georgetown University School of Medicine in Washington, DC. She is Associate Director of the Georgetown Psychiatry Residency Program in Psychiatry and Law. She received her B.A. magna cum laude, from Harvard/Radcliffe College, a Masters of Philosophy Degree in the History of Medicine from Cambridge University, and her M.D. from the New York University School of Medicine. She completed her psychiatric residency training at Boston University. She has a private clinical and forensic practice in Arlington, VA. Dr. Gold is the author of *Social Management: Psychiatric Assessment in Employment Litigation* (2004). She is the coeditor of *The American Psychiatric Textbook of Forensic Psychiatry* (2004), to which she contributed chapters on the history of forensic psychiatry and on employment litigation. She has authored multiple articles and chapters for other books relating to employment litigation and other subjects in forensic psychiatry.

THIS SESSION WILL BE AUDIOTAPE D.

PRESIDENTIAL ADDRESS

Steven S. Shalstein, M.D.
To be introduced by Sheldon Roth, M.D.

RESPONSE OF THE PRESIDENT-ELECT

Pedro Ruiz, M.D.
To be introduced by Jack S. McIntyre, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 20-25

INDUSTRY-SUPPORTED SYMPOSIUM 20

7:00 p.m.-10:00 p.m.
John Basset Theatre, Level 100, Convention Centre North

ALZHEIMER'S DISEASE: CHALLENGING THE
PRACTICE PARADIGM

Supported by Forest Pharmaceuticals, Inc

Chp.: Pierre N. Tariot, M.D.

- A **Variability in the Clinical Presentation of Alzheimer's Disease**
M. Saleem Ismail, M.D.
- B **Treatment Initiation in Alzheimer's Disease**
Pierre N. Tariot, M.D.
- C **Individualizing Alzheimer's Disease Therapy Over the Disease Course**
Constantine Lyketsos, M.D.
- D **Neuropsychiatric Symptoms in Alzheimer's Disease: Preventing Emergence and Decreasing Severity**
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21

7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS IN
CHRONIC SCHIZOPHRENIA: COMPLETE RESULTS
OF THE CATIE TRIAL

Supported by Eli Lilly and Company

Chp.: Jeffrey A. Lieberman, M.D.

- A **Comparison of the Primary Outcome Measures of Efficacy and Safety**
Jeffrey A. Lieberman, M.D.
- B **Comparison of Clozapine Versus Other Atypical Drugs in Prospectively Defined, Unresponsive Patients**
Joseph P. McEvoy, M.D.
- C **Comparison of Ziprasidone Versus Other Atypical Drugs in Prospectively Defined, Unresponsive Patients**
Thomas S. Stroup, M.D.
- D **Comparison of Treatment Effects on Cognition**
Richard S.E. Keefe, Ph.D.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.
Exhibit Hall A, Level 305, Toronto Convention
Centre North

CALL TO ORDER

Steven S. Shalstein, M.D., *President*

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE

Marian I. Butterfield, M.D.
Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING

DIGNITARIES (*Please refer to pages 12-16 for a listing of
the presidents of allied organizations.*)

- E Comparison of Treatments on Health Service Utilization and Cost Effectiveness Measures**
Robert A. Rosenheck, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

PSEUDOBULBAR AFFECT: A COMMON SYNDROME THAT IS UNDERRECOGNIZED, MISDIAGNOSED, AND UNDERTREATED
Supported by Auran Pharmaceuticals

Chp.: Randolph B. Schiffer, M.D.

- A The Differential Diagnosis of Pseudobulbar Affect**
David B. Arciniegas, M.D.
- B The Pathophysiology of Pseudobulbar Affect**
Edward C. Lauterbach, M.D.
- C Treatment Options for Pseudobulbar Affect**
Michael C. Graves, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

ADVANCES IN THE NEUROBIOLOGY AND THERAPEUTICS OF ADHD
Supported by Cephalon, Inc.

Chp.: Joseph Biederman, M.D.

- A Sleep and ADHD**
Eric Mick, Sc.D.
- B New Therapeutic Developments in ADHD**
Joseph Biederman, M.D.
- C Defining Executive Function Deficits in ADHD**
Ronna Fried, Ed.D.
- D Advances in f-MRI Research in ADHD**
George Bush, M.D.
- E New Targets for Pharmacogenetic Research in ADHD**
Stephen V. Faraone, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Frontenac Room, Street Level, Westin Harbour Castle

ATYPICAL DEPRESSION: MERGING EVIDENCE AND PUBLIC POLICY
Supported by Bristol-Myers Squibb Company

Chp.: Michael E. Thase, M.D.

- A The Neurobiology of Depression: Bringing the Latest in Science to Clinicians**
Charles B. Nemeroff, M.D.
- B Phenomenology of Atypical Depression**
Hans-Juergen Moeller, M.D.
- C An Evidence-Based Approach to Managing the Disabilities of Atypical Depression**
Justine M. Kent, M.D.
- D Future Directions in the Treatment of Atypical Depression**
Michael E. Thase, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

INSOMNIA FROM THE INSIDE OUT: FROM NEUROSCIENCE TO CLINICAL EXPERIENCE TO PUBLIC POLICY
Supported by Pfizer, Inc. and Neurocrine Biosciences, Inc.

Chp.: Ellen Frank, Ph.D.
Co-Chp.: David J. Kupfer, M.D.

- A Insomnia: Symptom, Syndrome, or Disorder?**
Martin B. Keller, M.D.
- B The Science of Insomnia**
Phyllis C. Zee, M.D.
- C Putting the Science to Work**
Daniel J. Buysse, M.D.
- D Insomnia: Cost of Illness, Public Policy, and Medicolegal Issues**
Alan W. Newman, M.D.

2006 Presidents of Allied Organizations

Academy of Organizational and Occupational Psychiatry
Sandra Cohen, M.D.

Academy of Psychosomatic Medicine
Stephen M. Saravary, M.D.

Albanian Psychiatric Society
Professor Anastas Suli

American Academy of Addiction Psychiatry
Kathleen Brady, Ph.D.

American Academy of Child and Adolescent Psychiatry
Richard Sarles, M.D.

American Academy of Family Physicians
Mary E. Frank, M.D.

American Academy of Neurology
Thomas R. Swift, M.D.

American Academy of Psychiatry and the Law
Robert I. Simon, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry
Joseph P. Merlino, M.D.

American Association for Emergency Psychiatry
Jon S. Bertin, M.D.

American Association for Geriatric Psychiatry
Christopher Colenda, M.D.

American Association for Social Psychiatry
Zebulon C. Taintor, M.D.

American Association for the Advancement of Science
John Holdren, Ph.D.

American Association of Practicing Psychiatrists
Janis G. Chester, M.D.

American Association of Chairs of Departments of Psychiatry
John F. Greden, M.D.

American Association of Community Psychiatrists
Wesley Sowers, M.D.

American Association of Directors of Psychiatric Residency Training
Ronald Krasner, M.D.

American Association on Mental Retardation
Valerie J. Bradley

American Board of Psychiatry and Neurology, Inc.
Alan K. Percy, M.D.

American College of Emergency Physicians
Frederick C. Blum, M.D.

American College of Mental Health Administration
Sandra L. Forquer, Ph.D.

American College of Obstetricians and Gynecologists
Douglas W. Laube, M.D.

American College of Physicians-American Society of Internal Medicine
Lynne M. Kirk, M.D.

American College of Psychiatrists
Glen O. Gabbard, M.D.

American College of Psychoanalysis
David Edelstein, M.D.

American College of Surgeons
Kathryn D. Anderson, M.D.

American Group Psychotherapy Association
Elizabeth Knight, M.S.W.

American Medical Association
J. Edward Hill, M.D.

American Medical Women's Association
Susan L. Ivey, M.D.

American Neurological Association
John Griffin, M.D.

American Neuropsychiatric Association
Richard Restak, M.D.

American Nurses Association
Barbara Blakeney, M.S.

American Orthopsychiatric Association
Diane Willis, M.D.

American Psychiatric Association Alliance
Mary Thurrell

American Psychoanalytic Association
Jon Meyer, M.D.

American Psychological Association
Gerald P. Koobler, Ph.D.

American Psychosomatic Society
Peter Shapiro, M.D.

American Society for Adolescent Psychiatry
Dominic Ferro, M.D.

American Society of Addiction Medicine
Elizabeth F. Howell, M.D.

American Society of Clinical Psychopharmacology, Inc.
John M. Kane, M.D.

American Society of Hispanic Psychiatry
Manuel Trujillo, M.D.

American Society of Law, Medicine, and Ethics
Philip Reilly, M.D.

American Society of Psychoanalytic Physicians
Ernest Gosline, M.D.

Arab American Psychiatric Association
Donald Hilty, M.D.

Arab Federation of Psychiatrists
Dr. Ali Matar

Arab Gulf Psychiatric Association
Dr. M.K. Al Haddad

Argentinean Association of Psychiatrists
Dr. Nestor Marchant

2006 Presidents of Allied Organizations

Armenian Psychiatric Association
Dr. Marietta Melik-Pashayan

Association of Argentinean Psychiatrists
Dr. Gabriela Lucatelli

Association of Reformers in Psychiatry/ Former USSR and Eastern/ Central Europe
Professor Toma Tomov

Association for Academic Psychiatry
Linda Worley, M.D.

Association for Behavioral and Cognitive Therapies
Martin M. Antony, Ph.D.

Association of American Medical Colleges
Darrell G. Kirch, M.D.

Association of Chinese American Psychiatrists
Edmond Pi, M.D.

Association of Directors of Medical Student Education in Psychiatry
Myrl Manley, M.D.

Association of Free Psychiatrists in Romania
Dr. Aurel Romila

Association of Gay and Lesbian Psychiatrists
Dan Karasic, M.D.

Association of Psychiatrists in Nigeria
Professor Taiwo Adamson

Association of Psychiatrists of Tajikistan
Dr. Abdurukhid Baibubaev

Association of Women Psychiatrists
Mary Kay Smith, M.D.

Azerbaijan Psychiatric Association
Professor Nadir Ismayilov

Bangladesh Association of Psychiatrists
Dr. Abdus Sobhan

Barbados Association of Psychiatrists
Dr. George Mahy

Black Psychiatrists of America
Patrice A. Harris, M.D.

Bolivian Society of Psychiatry
Dr. Nils Noya-Tapia

Brazilian Association of Psychiatry
Dr. Josimar M.F. Franca

Bulgarian Psychiatric Association
Professor Eugeni Georgiev

Byelorussian Psychiatric Association
Dr. Roman A. Ersegnev

Canadian Psychiatric Association
A. Donald Milliken, M.D.

Caribbean Psychiatric Association
Dr. Jacqueline Sharpe

Chinese Society of Psychiatry
Professor Ming-Yuan Chang

Colombian Society of Psychiatry
Dr. Pedro Gomez Mendez

Costa Rican Psychiatric Association
Dr. Rosa M. Villalobos Rodriguez

Council of Medical Specialty Societies
Gerald B. Holzman, M.D.

Croatian Psychiatric Association
Professor Ljubomir Hotujac

Cuban Society of Psychiatrists
Dr. Ricardo Gonzalez Mendez

Cyprus Society of Psychiatry
Dr. Argyris Argyriou

Czech Psychiatric Association
Dr. Jiri Raboch

Danish Psychiatric Society
Dr. Merete Nordentoft

Danubian Psychiatric Association
Dr. Werner Schory

Depression and Bipolar Support Alliance
Lydia Lewis

Ecuadorian Psychiatric Association
Dr. Fabrizio V. Delgado Campodónico

Estonian Psychiatric Association
Dr. Valdur Jänes

Finnish Psychiatric Association
Professor Raimo Salokangas

Flemish Neurologists and Psychiatrists
Dr. J. Peuskens

Francophone International Federation of Psychiatry
Dr. Francois Caroli

French Association of Psychiatrists in Private Practice
Dr. Antoine Besse

French Association of Psychiatry
Dr. Christian C. Vasseur

French Scientific Association of Psychiatrists In Public Service
Professor J.C. Pascal

Georgian Psychaitric Association
Professor George Naneishvili

German Society for Psychiatry and Neurology
Dr. J. Vogt

Ghana Psychiatric Association
Dr. Sammy Here

Global Alliance of Mental Illness
Dr. Paolo Lucio Morseli

Group for the Advancement of Psychiatry
Paul J. Fink, M.D.

Haitian Society of Psychiatry
Dr. Max Desrosiers

Hellenic Psychiatric Association
Professor George N. Christodoulou

Hellenic Society of Neurology and Psychiatry
Professor Costas Sstefanis

Honduran Psychiatric Association
Dr. Octavio R. Sanchez Midence

Hong Kong College of Psychiatrist
Professor C.N. Chen

Hungarian Psychiatric Association
Dr. Attila Nemeth

Icelandic Psychiatric Association
Professor Sigurour Pall Palson

2006 Presidents of Allied Organizations

Independent Psychiatric Association

Dr. Yuri Sergeevich Savenko

Indian Association for Social Psychiatry

Professor Rambir Bhatti

Indian Psychiatric Society

Dr. Siva Nambi

Indo-American Psychiatric Association

Sanjay Dube, M.D.

Indonesian Psychiatric Association

Dr. Sasanto Wibisono

International Association of Ethno-Psychologists 7

Dr. Valentin Ya. Senke

International Society of Psychopathology of Expression

Dr. Guy Roux

Iranian Psychiatric Association

Dr. Haratun Davidian

Iraqi Society of Psychiatrists

Professor Muadhaffar Zubai Al-Qassim

Irish College of Psychiatrists

Dr. Kathleen Garter

Israeli Psychiatric Association

Dr. Micahel Schneidman

Italian Association for Research in Schizophrenia

Professor Carlo L. Cazzullo

Italian Psychiatric Association

Professor Eugenio Aguglia

Italian Psychiatric Society

Professor Mario Maj

Ivory Coast Association of Psychiatry

Professor Joseph Delafosse

Jamaican Psychiatric Association

Dr. G. Lutenidge

Japanese Society of Psychiatry & Neurology

Professor Toshio Yamauchi

Jordan Association of Psychiatrists

Professor Waud Shunwaigat

Kazakh Association of Psychiatrists and Narcologists

Professor Jouldizbek Alimkhanov

Korean Neuropsychiatric Association

Dr. Sung Kil Min

Kuwait Psychiatric Association

Professor Essam A. Al-Arsari

Kyrgyz Science and Practical Community of Psychiatrists 1

Professor Valery Solojenkina

Latin American Psychiatric Association

Dr. Rafael Navarro

Latvian Psychiatric Association

Dr. Elmars Rancars

Lebanese Psychiatric Association

Dr. Dora Hachrem

Lithuanian Psychiatric Association

Dr. Professor Habil Algirdas Dembinskas

Luxembourg Society of Neurology and Psychiatry

Dr. Chretien Jacoby

Malaysian Psychiatric Association

Professor Cheuk Ngen

Mauritius Psychiatric Association

Dr. Parmannun Jagannath

Mental Health Association of Tanzania

Dr. Gad P. Kilorzo

Mexican Psychiatric Association

Professor Enrique Camarena-Robles

Mexican Society of Neurology and Psychiatry

Dr. Sergio Sanchez-Pintado

Moroccan Society of Psychiatry

Professor Mohammed Foua Benchekeoum

National Alliance for Research on Schizophrenia and Depression

Constance E. Leiber

National Alliance on Mental Illness (NAMI)

Suzanne Vogel-Sabilia, M.D.

National Association of Psychiatric Health Systems

Patricia R. Recupero, J.D., M.D.

National Association of Social Workers, Inc.

Elena De Silva, D.S.W.

National Council for Community Behavioral Healthcare

Linda Rosenberg, M.S.W.

National Institute of Mental Health

Thomas Insel, M.D.

National Institute on Alcohol Abuse and Alcoholism

Ting-Kai Li, M.D.

National Institute on Drug Abuse, NIH

Nora D. Volkow, M.D.

National Mental Health Association

Michael Faerza, M.S.S.W.

Netherlands Psychiatric Association

Dr. Willem van Tilburg

Nicaraguan Psychiatric Association

Dr. Roberto Aguilar Briceño

Norwegian Psychiatric Association

Dr. Bjarte Stubhaug

Pakistan Psychiatric Association of North America

Zabid Inrnan, M.D.

Pakistan Psychiatric Society

Professor Khalid A. Mufti

Panamanian Psychiatric Society

Dr. Marcel Pennic

Papua New Guinea Psychiatric Association

Dr. Michael Mai

Paraguayan Society of Psychiatry

Dr. Joseph Vera Gomez

Peruvian Psychiatric Association

Dr. Dante Warthon-Grajeda

Psychiatric Association of Ecuador

Dr. Gonzalo Matovelle

Polish Psychiatric Association

Professor Janusz Rybakowski

Portuguese Association of Psychiatry

Dr. Jose Dias Cordeiro

2006 Presidents of Allied Organizations

Portuguese Society of Psychiatry and Mental Health

Professor Antonio Fernandes da Fonseca

Psychiatric Association of Austria

Dr. H.G. Zapotoczky

Psychiatric Association of Bosnia-Herzegovina

Professor Ismet Ceriac

Psychiatric Association of Guatamala

Dr. Ismeal Salazar

Psychiatric Association of Macedonia

Professor Predag Kirovski

Psychiatric Association of Rio de Janeiro State

Dr. Maria Fatima Vasconcellos

Psychiatric Association of Slovenia

Professor Andrej Zmitek

Psychiatric Association of Thailand

Dr. Pichet Udornratn

Psychiatric Association of Turkey

Dr. Haluk Özbay

Psychiatric Association of Zimbabwe

Dr. S.M. Nhirantira

Psychiatrists Association of Nepal

Dr. Desh Raj Babadur Karmar

Romanian League for Mental Health

Professor Bogdana Tudoradze

Romanian Psychiatric Association

Professor Vasile Chirita

Royal Australian and New Zealand College of Psychiatrists

Dr. Julian Freidin

Royal College of Psychiatrists

Professor Sheila Hollins

Royal College of Psychiatrists of Thailand

Lt. Gen. Aroon Shouwasai

Royal Society of Mental Medicine of Belgium

Professor A. Seguers

Russian Society of Psychiatrists

Professor Valery Krasnov

SA Society of Psychiatrists

Dr. Eugene Allers

Salvadorean Psychiatric Association

Dr. Miguel Fortin Magana

Saudi Psychiatric Association

Dr. Mahdi Abumadani

Singapore Psychiatric Association

Professor Thiew Chai Ong

Slovak Psychiatric Association

Professor Alojz Rakus

Sociedad Dominicana de Psiquiatria

Dr. Alejandro Uribe Peguero

Sociedad Espanola de Psiquiatria

Professor Carmen Leal-Ceros

Society of Biological Psychiatry

Alan F. Schatzberg, M.D.

Society of Iranian Psychiatrists in North America

Mohammad Jarud Naficy, M.D.

Society of Neurology/Psychiatry

Professor Freddie Halter

Society of Psychiatry of the Rio Grande Do Sul

Dr. Nausa Krnjnik Lucion

Society of Psychopathology and Mental Health of Dakar

Professor Daouda Sow

Society Settlement of Physically and Mentally Disabled

Daniel Larbi Professor

South African Society of Psychiatrists

Professor T. Zabow

Spanish Association of Neuropsychiatry

Professor Mariano Hernandez-Monslave

Sri Lanka Psychiatric Association

Dr. R. Kulanzaygam

Substance Abuse and Mental Health Services Administration

Charles Canie, M.A., A.C.S.W.

Swedish Psychiatric Association

Dr. Anna-Maria af Sandeberg

Swiss Society of Psychiatry & Psychotherapy

Dr. Tedy Hubschmid

Syrian Arab Association of Phychiatrists

Professor Mahmoud Abdul-Al

Taiwanese Society of Psychiatry

Professor Ru-Band Lu

Taiwanese Society of Psychiatry 7

Professor Ming-Been Lee

The Psychiatric Evolution

Professor Jean Garrabe

Tunisian Psychiatric Society

Professor Saida Douki

Turkish Neuropsychiatric Society

Professor Rasit Tukeel

Turkmen Scientific Society of Psychiatrists

Dr. Nina Kerimi

Ukraine Scientific Society of Neurologists, Psychiatrists & Narcologists

Professor Peter Voloshyn

Ukrainian Psychiatric Association

Professor Victor Shurhynsky

Uzbek Association of Psychiatrists

Dr. Shakeb-Zade Murtalibov

Venezuelan Society of Psychiatry

Dr. Robert Lespinasse Zuloaga

World Association for Dynamic Psychiatry

Dr. Maria Ammon

World Psychiatric Association

Juan E. Mezzich, M.D.

Yemen Psychiatrists and Neurologists Association

Dr. Abdelmagid Al-Khulaidi

Yugoslav Association of Psychiatric Institutions

Professor Ljubica Krasojevic

Yugoslav Psychiatric Association


Professor Mirko Pejovic

Zambian Neuropsychiatric Association

Professor A. Harworth

American Psychiatric Association

CDs and Audiotapes
Recorded Live!



*High Quality Continues for
the 2006 Annual Meeting ...*

**Live recordings will be available
for most of the following:**

- Lectures • Advances in... Series
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
- Advances in Research
- Research Advances in Medicine

CDs and tapes may be purchased/ordered on site
at Mobiltape's booth at the Toronto Metro Convention Centre.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com

MONDAY, MAY 22, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 26-28

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 1

7:00 a.m.-8:30 a.m.

Canadian Room, Convention Floor, Royal York

CLINICAL IMPLICATIONS OF CHOICES OF ATYPICAL ANTIPSYCHOTICS: REALITIES AND MYTHS

*Supported by Bristol-Myers Squibb Company and Otsuka America
Pharmaceutical, Inc.*

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A Impact of Short-Term Decision on Long-Term Outcomes

Stephen R. Marder, M.D.

B Neurocognition, Functional Outcomes, and Psychopharmacology

Michael Green, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING THE MANAGEMENT OF GAD

Supported by Cephalon, Inc.

Chp.: David V. Sheehan, M.D.

A Evidence-Based Advocacy: A Data-Driven Look at the Somatic Expression of GAD

Philip R. Muskin, M.D.

B Comorbidity in GAD: A Public Health Challenge

John L. Beyer, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1

7:00 a.m.-8:30 a.m.

Metro Grand Ballroom, Second Level, Westin Harbour
Castle

ATTAINING AND SUSTAINING REMISSION IN TREATMENT OF DEPRESSION WITH COMORBID OR RESIDUAL ANXIETY

Supported by Wyeth Pharmaceuticals

Chp.: Madhukar H. Trivedi, M.D.

A Impact of Associated Anxiety Symptoms on Depression

Peter P. Roy-Byrne, M.D.

B Collaborative Management Strategies for Patients With Comorbid Anxiety With Depression

Wayne J. Katon, M.D.

C Strategies to Achieve and Sustain Remission in Patients

Shaily Jain, M.D.

RESIDENTS' SESSION

7:00 a.m.-8:30 a.m.

Ballroom B, Lower Level, Intercontinental Hotel

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Steven S. Sharfstein, M.D.

Co-Chp.: Pedro Ruiz, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence; Forensic, Law and Ethics in Psychiatry, Geriatrics, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions



COURSES 38-44

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 38

8:00 a.m.-12 noon

Conference Room D/E, Mezzanine, Sheraton Centre

FAMILY SKILLS FOR A GENERAL PSYCHIATRIST

Director: Alison M. Heru, M.D.

Faculty: Laura Drury, M.S.W.

COURSE 39

8:00 a.m.-12 noon

Conference Room F, Mezzanine, Sheraton Centre

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.

Faculty: Karen Miotto, M.D., Timothy W. Fong, M.D.

MONDAY

COURSE 40 8:00 a.m.-12 noon
Conference Room G, Mezzanine, Sheraton Centre

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.,
Jeremy R. Butler, M.D.

COURSE 41 8:00 a.m.-12 noon
Windsor Room East, Mezzanine, Sheraton Centre

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: BASIC COURSE

Director: George T. Grossberg, M.D.
Faculty: Abhilash K. Desai, M.D.

COURSE 42 8:00 a.m.-12 noon
City Hall, Second Floor, Sheraton Centre

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 43 8:00 a.m.-12 noon
Kent Room, Second Floor, Sheraton Centre

ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS INTO COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.

COURSE 44 8:00 a.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Gerardo Gonzalez, M.D., Laura F. McNicholas, M.D.
Faculty: Eric C. Strain, M.D., Thomas R. Kosten, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCES 1-2

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

HONORABLE DISCHARGE: SEVERE BRAIN INJURY AND PSYCHOLOGICAL SYMPTOMS IN A FEMALE VETERAN

Moderator: Susan Stabinsky, M.D.
Presenters: Stephen Ferrando, M.D., Frances Stewart, M.D.,
Maria L.A. Tiamson-Kassab, M.D.

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Room 104 C, Level 100, Toronto Convention Centre North
SEALED WITH A KISS: USING THE SEXUAL HISTORY IN PSYCHODYNAMIC PSYCHOTHERAPY

Moderator: Jennifer I. Downey, M.D.
Presenters: Richard C. Friedman, M.D., Diane E. McLean, M.D.

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 45-50

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 45 9:00 a.m.-4:00 p.m.
Conference Rooms B/C, Mezzanine, Sheraton Centre

TREATING THE SELF AND INTERPERSONAL PROBLEMS OF PERSONALITY DISORDER

Director: John Livesley, M.D.

COURSE 46 9:00 a.m.-4:00 p.m.
Windsor Room West, Mezzanine, Sheraton Centre

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 47 9:00 a.m.-4:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre

ADVANCES IN NEUROPSYCHIATRY

Director: C. Edward Coffey, M.D.
Faculty: Jeffrey L. Cummings, M.D., Mark S. George, M.D.,
Matthew A. Menza, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.
Kenora Room, Second Floor, Sheraton Centre

COGNITIVE THERAPY ON THE FLY

Director: Ari E. Zaretsky, M.D.
Faculty: Phillip Maerov, M.D., Patricia Rockman, M.D.

COURSE 49 9:00 a.m.-4:00 p.m.
Simcoe/Dufferin Room, Second Floor, Sheraton Centre

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn Shea, M.D.

COURSE 50 9:00 a.m.-4:00 p.m.

Wentworth Room, Second Floor, Sheraton Centre

MANAGED CARE CONTRACTING FOR PSYCHIATRISTS

Director: William H. Campbell, M.D.

DEBATE 1

9:00 a.m.-10:30 a.m.

Room 716 A, Level 700, Toronto Convention Centre South

DOES CATIE REALLY INFORM THE PRACTICE OF PSYCHIATRY?

Moderator: Richard E. D'Alli, M.D.

Affirmative: Joseph P. McEvoy, M.D., William T. Carpenter, Jr., M.D.

Negative: Robert R. Conley, M.D., Herbert Y. Meltzer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-4

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 **Laura Roberts, M.D.**, on *The New Handbook on Professional Development for Academic Psychiatrists* (*Meet the Authors*)
Grenadier Room, Main Level, Intercontinental Hotel
- 2 **Donna E. Stewart, M.D.**, on *Why Women's Mental Health?* (*Meet the Authors*)
Halton Room, Main Level, Intercontinental Hotel
- 3 **Jesse H. Wright III, M.D.**, on *Learning From Cognitive-Behavior Therapy: What Are the Most Powerful Methods for Everyday Clinical Use?* (*Meet the Authors*)
Humber Room, Main Level, Intercontinental Hotel
- 4 **Michelle B. Riba, M.D.**, on *Leadership Opportunities: Where and How to Look* (*Meet the Authors*)
Kingsway Room, Main Level, Intercontinental Hotel

FOCUS LIVE SESSION 1

9:00 a.m.-10:30 a.m.

Room 714 A, Level 700, Toronto Convention Centre South

PERSONALITY DISORDERS

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.

Presenter: Glen O. Gabbard, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Personality Disorders, the

second session at 11:00 a.m. covers Eating Disorders and Sexual Disorders, and the third session at 2:00 p.m. covers Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2

9:00 a.m.-10:30 a.m.

Room 103, Level 100

Toronto Convention Centre North

Krishnamachari Srinivasan, M.D.

Heart Rate Variability and Psychiatry: Beyond Heart-Mind Link

Chp.: Geetha Jayaram, M.D.

Co-Chp.: Roman Snihsocwy, M.D.

Krishnamachari Srinivasan, M.D., is professor and chairman of the Department of Psychiatry at St. John's Medical College and Vice-Dean at the St. John's Research Institute, Bangalore, India. He completed his training in psychiatry at the National Institute of Mental Health and Neuroscience in Bangalore. He completed a two-year research fellowship at Lafayette Clinic, Wayne State University, Detroit, Michigan. He runs an outpatient and inpatient service and is involved in training of medical undergraduates, nursing students and psychiatry residents. He has several funded research projects to his credit. He has published approximately 60 publications in various national and international peer-reviewed journals. He is a reviewer for *Biological Psychology*, *Autonomic Neuroscience*, *Psychosomatics* and *Psychiatry Research*. His main research interests include the study of autonomic regulation in anxiety and panic disorder in both children and adults; psychological and physiological underpinning of anxiety vulnerability; and community-based outcome studies of anxiety and depression.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m. - 10:30 a.m.
 Exhibit Hall A, Level 300
 Toronto Convention Centre North

David T. Suzuki, Ph.D.

Rediscovering Our Place in the World

Chp.: Claudia S. Miller, M.D.
 Co-Chp.: Sherri M. Simpson, M.D.

David T. Suzuki, Ph.D., Chair of the David Suzuki Foundation, is an award-winning scientist, environmentalist, and broadcaster. He is renowned for his radio and television programs that explain the complexities of the natural sciences in a compelling, easily understood way. Dr. Suzuki is a geneticist. He graduated from Amherst College in 1958 with an Honors B.A. in Biology, followed by a Ph.D. in Zoology from the University of Chicago. He became a faculty member of the University of British Columbia in 1963, and is now Professor Emeritus of UBC, Sustainable Development Research Institute. Dr. Suzuki has written 42 books, and his 1976 textbook *An Introduction to Genetic Analysis* with A.J.F. Griffiths, remains the most widely used genetics textbook in the U.S. and has been translated into Italian, Spanish, Greek, Indonesian, Arabic, French, and German. Dr. Suzuki has received high acclaim for his 30 years of award-winning work in broadcasting. In 1974 he developed and hosted the CBC radio program *Quarks and Quarks*. In 1979 he became the host for the award-winning science show, *The Nature of Things With David Suzuki* on CBC television. Dr. Suzuki is also recognized as a world leader in sustainable ecology. For more information: www.davidsuzuki.org
Frontiers of Science Lecture Series

LECTURE 4

9:00 a.m. - 10:30 a.m.
 Room 718 A/B, Level 700
 Toronto Convention Centre South

**APA'S RESEARCH IN PSYCHIATRY
 AWARD LECTURE**

Kenneth B. Wells, M.D.

*The Search for Quality and Equity in
 Care for Psychiatric Disorders:
 A Story of Opportunity, Evidence, and Partners*

Chp.: Alan P. Schatzberg, M.D.

Kenneth B. Wells, M.D., received his medical degree from UCSF and his M.P.H. from UCLA. He is a psychiatrist, a Senior Scientist at RAND, Professor of Psychiatry and Biobehavioral Sciences at the Geffen School of Medicine, and Professor of Health Services at the UCLA School of Public Health. He directs the Health Services Research Center of the Semel Institute for Neuroscience and Human Behavior at UCLA, which focuses on improving quality of care for psychiatric and neurological disorders across the lifespan. He is Principal Investigator of the NIMH-UCLA/RAND Center for Research on Quality in Managed Care and the Robert Wood Johnson Foundation Community Partnership Initiative. He is Co-Director of the RWJF UCLA Clinical Scholars Program and Chair of the Community Health Improvement Collaborative. Dr. Wells is an elected member of the Institute of Medicine (IOM), and for four years chaired its Board on Neuroscience and Behavioral Health. He was the first recipient of the Young Investigator Award and received the Distinguished Investigator Award of Academy Health and the Senior Health Services Research Award from the American Psychiatric Association. His current research interests focus on improving quality of care and reducing mental health disparities through partnered, participatory research strategies with healthcare and community organizations.

THIS SESSION WILL BE AUDIOTAPE D.

**MASTER EDUCATOR CLINICAL
 CONSULTATIONS 1-3**

9:00 a.m. - 10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 **Renato D. Alarcon, M.D.**, on Clinical Dimensions of Cultural Psychiatry
 Room 201 A, Level 200, Toronto Convention Centre North
- 2 **Laura J. Miller, M.D.**, on Psychiatric Disorders Across the Female Reproductive Cycle
 Room 201 B, Level 200, Toronto Convention Centre North
- 3 **Meera Narasimhan, M.D.**, on Refractory Depression: Diagnostic and Treatment Implications
 Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.

Exhibit Hall B, Level 300, Toronto Convention Centre North

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

WORKSHOPS

COMPONENTS 1-9

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.

Room 104 A, Level 100, Toronto Convention Centre North

DISASTER PSYCHIATRY: PRACTICAL SKILLS TO HELP DISTRICT BRANCHES DEVELOP DISASTER PLANS FOR THEIR COMMUNITIES

APA Committee on Psychiatric Dimensions of Disasters

Co-Chps.: Christina V. Mangurian, M.D., Lisa A. Catapano, M.D.

Participants: Anthony T. Ng, M.D., Edward M. Kantor, M.D., Mary Jo Fitz-Gerald, M.D., Joseph C. Napoli, M.D., Jon S. Berlin, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.

Room 104 D, Level 100, Toronto Convention Centre North

PAY FOR PERFORMANCE: LINKING INCENTIVES TO PROVIDER PERFORMANCE ON QUALITY MEASURES

APA Council on Quality Care and APA Council on Healthcare Systems and Financing

Co-Chps.: Richard C. Hermann, M.D., Bruce J. Schwartz, M.D.

Participants: John M. Oldham, M.D., Nicholas Meyers

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.

Room 205 A, Level 200, Toronto Convention Centre North

CAREER CHOICES IN PSYCHIATRY: EXPLORING FELLOWSHIP TRAINING

APA Assembly Committee of Area Member-in-Training Representatives

Chp.: Vincent J. Blanch, M.D.

Participants: Chad Y. Koyanagi, M.D., Martin Gignac, M.D., William F. Haning III, M.D., Brian A. Greenlee, M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.

Room 205 B, Level 200, Toronto Convention Centre North

SEVERELY MENTALLY ILL PERSONS IN JAILS AND PRISONS: WHO SHOULD STAY?

APA Corresponding Committee on Jails and Prisons

Chp.: Henry C. Weinstein, M.D.

Participants: H. Richard Lamb, Cassandra F. Newkirk, M.D., Tom Hamilton, Erik J. Roskes, M.D.

COMPONENT WORKSHOP 5 9:00 a.m.-10:30 a.m.

Room 205 C, Level 200, Toronto Convention Centre North

CRIME AND CRUEL NOT UNUSUAL PUNISHMENT: THE NEED FOR JUVENILE JUSTICE MENTAL HEALTH CARE REFORM

APA Alliance

Chp.: Louis J. Kraus, M.D.

Participants: William Arroyo, M.D., Niranjan Karnik, M.D.

COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.

Room 205 D, Level 200, Toronto Convention Centre North

CLOSING A PRACTICE: WHAT EVERY PSYCHIATRIST'S OFFICE AND THEIR FAMILY SHOULD KNOW

APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: John A. Fromson, M.D.

Participants: Michael F. Myers, M.D., Margo S. Adams

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

CONQUERING THE SHAME, SECRECY, AND STIGMA OF SUICIDE IN YOUNG ASIAN-AMERICAN ADULTS

APA Committee of Asian-American Psychiatrists

Chp.: Surinder S. Nand, M.D.

Participants: Eric C. Li, M.D., Lois W. Choi-Kain, M.D., Aruna Jha, Ph.D.

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.

Room 701 A, Level 700, Toronto Convention Centre South

CPT CODING AND DOCUMENTATION UPDATE

APA Committee on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.

Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Napoleon B. Higgins, Jr., M.D., Ronald M. Burd, M.D., Allan A. Anderson, M.D., David K. Nace, M.D.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.

Room 713 A/B, Level 700, Toronto Convention Centre South

NEW DEVELOPMENTS IN APA PRACTICE GUIDELINES ON BIPOLAR DISORDER, MDD, AND PANIC DISORDER

APA Steering Committee on Practice Guidelines

Chp.: Jack S. McIntyre, M.D.

Participants: Laura J. Fochtmann, M.D., Robert M.A. Hirschfeld, M.D., Alan J. Gelenberg, M.D., Murray B. Stein, M.D.

MONDAY

ISSUES 1-15

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

A DIMENSION OF MIND: SIMULATIONS/
EMULATIONS OF PSYCHIATRIC SYMPTOMS USING
THE PERFORMING ART OF MAGIC

Chp.: Bruce C. Ballon, M.D.
Participant: Ivan Silver, M.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

WHAT DO YOU DO WITH A PATIENT WHO HAS
ACCESS TO A GUN?

Chp.: Donna M. Norris, M.D.
Participants: Marilyn Price, M.D., Thomas G. Gutheil, M.D.,
William H. Reid, M.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

MANAGING COMPLEX COMORBID PSYCHIATRIC
AND ALCOHOL USE DISORDERS IN PSYCHIATRIC
PRACTICE

*Collaborative Session With the National Institute on Alcohol Abuse and
Alcoholism*

Chp.: Mark L. Willenbring, M.D.
Participant: Robert Drake, Ph.D.

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

EXTRAPYRAMIDAL SIDE EFFECTS AND TARDIVE
DYSKINESIA IN THE ATYPICAL ANTIPSYCHOTIC
ERA

Chp.: Thomas E. Hansen, M.D.
Participants: Daniel E. Casey, M.D., Joseph P. McEvoy, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

NEUROCYBERNETICS: NOVEL APPROACH IN THE
TREATMENT OF PSYCHIATRIC DISORDERS

Chp.: Alan L. Summers, M.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

TREATMENT OF PREGNANCY-RELATED MOOD
DISORDERS: FROM PSYCHIATRY TO PEDIATRICS

Co-Chps.: Janet A. Martin, M.D., Syed S.A. Naqvi, M.D.
Participants: Shari Lusskin, M.D., Vivien K. Burt, M.D.,
Stephanie M. Stewart, M.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
Room 707, Level 700, Toronto Convention Centre South

RISK MANAGEMENT ISSUES IN PSYCHIATRIC
PRACTICE

Chp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D.,
Jacqueline M. Melonas, J.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

BUT CAN WE DO IT HERE? CHALLENGES OF
IMPLEMENTING COGNITIVE-BEHAVIOR
THERAPY FOR SCHIZOPHRENIA PROGRAMS IN
THE U.S.

Co-Chps.: Page Burkholder, M.D., Peter J. Weiden, M.D.
Participants: David G. Kingdon, M.D., Yulia Landa, Ph.D.,
Scott Temple, Ph.D., Narisimha R. Pinninti, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

RELIGIOUS AND SPIRITUAL ASSESSMENT IN
CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.
Room 716 B, Level 700, Toronto Convention Centre South

EARLY DETECTION AND TREATMENT OF
BIPOLAR ILLNESS

Chp.: Eric R. Marcus, M.D.
Participants: Clarice J. Kestenbaum, M.D., Lewis A. Opler, M.D.,
Ian E. Alger, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.
Room 717 A, Level 700, Toronto Convention Centre South

WHAT IS A MOOD STABILIZER?

Chp.: Eduard Vieta, M.D.
Participants: S. Nassir Ghaemi, M.D., Frederick K. Goodwin, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.
Room 717 B, Level 700, Toronto Convention Centre South

REINVENTING CAREERS: TRANSITIONS AND
LATER-LIFE STRATEGIES FOR PSYCHIATRISTS

Co-Chps.: Carolyn B. Robinowitz, M.D., Abram M. Hostetter, M.D.
Participants: Carol C. Nadelson, M.D., Edward Hanin, M.D.,
Zebulon C. Taintor, M.D., Joel Yager, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.
Room 801 A, Level 800, Toronto Convention Centre South

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY UPDATE: CERTIFICATION AND MAINTENANCE OF CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chp.: Stephen C. Scheiber, M.D.
Participants: Naleen N. Andrade, M.D., Beth Ann Brooks, M.D., Larry R. Faulkner, M.D., Burton V. Reifler, M.D., James H. Scully, Jr., M.D., Daniel K. Winstead, M.D.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.
Room 801 B, Level 800, Toronto Convention Centre South

NEW RESEARCH ADVANCES IN ETHNOPSYPHARMACOLOGY

Co-Chps.: Pedro Ruiz, M.D., William B. Lawson, M.D.
Participants: Edmond H. Pi, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

ONLINE PEER SUPPORT GROUPS AND SUPPORT GROUP MEMBERS

Chp.: Robert C. Hsiung, M.D.
Participant: Kali Munro, M.Ed.

MEDIA 1-2

MEDIA WORKSHOP 1 9:00 a.m.-12 noon
Alberta Room, Mezzanine Floor, Royal York

GO: A TRIPLE-TAKE IN THE WORLD OF DRUGS

Co-Chps.: Petros Levounis, M.D., Jose P. Vito, M.D.

MEDIA WORKSHOP 2 9:00 a.m.-12 noon
Quebec Room, Mezzanine Floor, Royal York

DO I LOOK FAT? EATING DISORDER PATHOLOGY IN GAY MEN

Chp.: Daniel Garza, M.D.
Participant: Travis D. Mathews, M.A.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

AN UPDATE FOR THE CLINICIAN
APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chps.: Marian I. Butterfield, M.D., David J. Kupfer, M.D., Leah J. Dickstein, M.D.

Participants: Floyd E. Bloom, M.D., Katherine L. Wisner, M.D., Jeffrey A. Lieberman, M.D., Martha L. Bruce, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 5-9

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 5 Jack Drescher, M.D., on the Psychology of the Closet
Grenadier Room, Main Level, Intercontinental Hotel
- 6 Russell F. Lim, M.D., on Culturally-Appropriate Diagnosis and Treatment (*Meet the Authors*)
Halton Room, Main Level, Intercontinental Hotel
- 7 Mary Jane Massie, M.D., on Psychotherapy With Women With Breast Cancer
Humber Room, Main Level, Intercontinental Hotel
- 8 Ashwin Patkar, M.D., on Alcohol Dependence: What Clinicians Need to Know
Kingsway Room, Main Level, Intercontinental Hotel
- 9 Christine E. Marx, M.D. and Kathryn M. Connor, M.D., on Your Research Career: Getting Started, Getting Funded (*For Residents Only*)
Niagara Room, Lower Level, Intercontinental Hotel

FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

EATING DISORDERS AND SEXUAL DISORDERS

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: Stephen B. Levine, M.D., Joel Yager, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. The 9:00 a.m session covered Personality Disorders, this session will cover Eating Disorders and Sexual Disorders, and the third session at 2:00 p.m. covers Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 5-7

LECTURE 5

11:00 a.m. - 12:30 p.m.
 Room 105, Level 100
 Toronto Convention Centre North

APA SIMON BOLIVAR AWARD LECTURE

Pedro L. Delgado, M.D.

Gene-Environment Interactions and Risk of Major Depression: Implications for Community-Based Prevention Strategies

Chp.: Ana E. Campo, M.D.

Pedro L. Delgado, M.D., is Dickmann Professor and Chairman of the Department of Psychiatry and Associate Dean for Faculty Development and Professionalism at the School of Medicine, The University of Texas Health Sciences Center at San Antonio. He earned his medical degree with election into AOA and a masters in pharmacology from the University of Texas in Galveston. His internship and residency in psychiatry were completed at Yale University after which he served for several years on the Yale faculty. Between 1992 and 2000, he served at the University of Arizona where he was Professor, Associate Department Head, and Director of Research in the Department of Psychiatry. From 2000-2005, he served as the Douglas Bond Professor and Chairman of the Department of Psychiatry at Case Western Reserve University. Dr. Delgado is an internationally renowned researcher and frequent lecturer on the neurobiology of major depression and the biological mechanisms underlying antidepressant action. He has had continuous federal funding for over 14 years for his research on the biology and treatment of depression. He is a Past President of the American Society for Hispanic Psychiatry and takes an active role in mentoring young physician scientists.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 6

11:00 a.m. - 12:30 p.m.
 Exhibit Hall A, Level 300
 Toronto Convention Centre North

Raquel E. Gur, M.D.

Emotion Processing and Schizophrenia: Neuropsychiatric Perspectives

Chp.: Susan G. Kornstein, M.D.
 Co-Chp.: Amy M. Ursano, M.D.

Raquel E. Gur, M.D., is a Karl and Linda Bickels Professor of Psychiatry, with appointments in neurology and radiology at the University of Pennsylvania. Her academic career has been devoted to

the study of brain function in schizophrenia. After completing her Ph.D. at Michigan State University in 1974, she joined the University of Pennsylvania, first as a Fellow, then as a medical student, a resident in neurology and psychiatry, and a faculty member. Dr. Gur has directed the Neuropsychiatry Section and the Schizophrenia Research Center and has established an interdisciplinary program dedicated to advancing the understanding of the pathophysiology of this complex disorder through the application of diverse strategies, from neurobehavioral to molecular. The research has been supported by the NIMH, where she is currently serving on Council. She has over 200 referred publications, and her accomplishment have been acknowledged by awards and membership in the Institute of Medicine. She is President-Elect of the Society of Biological Psychiatry.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7

11:00 a.m. - 12:30 p.m.
 Room 718 A/B, Level 700
 Toronto Convention Centre South

Anke A. Ehrhardt, Ph.D.

The Discourse on Human Sexuality in the Time of AIDS

Chp.: Robert M. Kertzner, M.D.
 Co-Chp.: Francine Cournois, M.D.

Anke A. Ehrhardt, Ph.D., is a Professor of Medical Psychology in the Department of Psychiatry at Columbia University and is the Director of the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute. She is an internationally known researcher in the field of sexual and gender development of children, adolescents, and adults. Her bibliography currently includes more than 200 scientific publications. Dr. Ehrhardt has been the Director of the HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University since 1987. The HIV Center's purpose is to study all aspects of HIV and AIDS with a special focus on sex and gender as it applies to women, children and adolescents, the chronically mentally ill, and the gay population. The Center is dedicated to multidisciplinary investigations with teams of scientists, clinicians, and health educators collaborating on research on HIV/AIDS in the U.S. and around the world. In 1981, Dr. Ehrhardt served as President of the International Academy of Sex Research and she is currently a trustee on the Board of Directors of the Ford Foundation.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 4-6

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 4 Shaila Misri, M.D., on Perinatal Psychiatric Disorders
Room 201 A, Level 200, Toronto Convention Centre North
- 5 Marion Zucker Goldstein, M.D., on Late-Life Aging Processes and Mental Illness
Room 201 B, Level 200, Toronto Convention Centre North
- 6 David Baron, D.O., and Geetha Jayaram, M.D., on Clinical Research Across Geographic Borders: Challenges and Opportunities
Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 1

11:00 a.m.-12:30 p.m.

Room 716 A, Level 700, Toronto Convention Centre South

CONGESTIVE HEART FAILURE

Presenter: Heather Ross, M.D.

Chp.: Donna E. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 1 Mark L. Willenbring, M.D., on Clinical Research on Alcohol Use Disorders
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Oakville Room, Main Level, Intercontinental Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-11

SCIENTIFIC AND CLINICAL REPORT SESSION 1

11:00 a.m.-12:30 p.m.

Room 104 B, Level 100, Toronto Convention Centre North

PRESIDENTIAL THEME: FROM SCIENCE TO PUBLIC POLICY: ADVOCACY FOR PATIENTS AND THE PROFESSION

Chp.: Jeffrey Janofsky, M.D.

Co-Chp.: Joshua Roffman, M.D.

11:00 a.m.

- 1 The Impact of an Integrated Community Arts Studio on Stigmatizing Beliefs and Experiences
Thomas C. Zelnik, M.D., Valerie L Howells, Ph.D.

11:30 a.m.

- 2 Health Policies and the Diagnostic and Statistical Manual
Roger Peele, M.D., Mozhdeh Roozegar, M.D., Maryam Razavi, M.D.

12 noon

- 3 The System for Classification of Inpatient Psychiatry: A New Case-Mix Methodology for Mental Health
John P Hirdes, Ph.D., Brant Fries, Ph.D., Edgardo L. Perez, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2

11:00 a.m.-12:30 p.m.

Room 104 D, Level 100, Toronto Convention Centre North

ETHICS AND HUMAN RIGHTS

Chp.: William Cardasis, M.D.

Co-Chp.: Zubin Bhagwager, M.D.

11:00 a.m.

- 4 Ethics and Psychobiological Research
Cherise Rosen, Ph.D., Linda S. Grossman, Ph.D., Henry W. Dove, M.D.

11:30 a.m.

- 5 Terrorism and Medical Ethics: Conflicting Loyalties for American Psychiatrists
David A. Rothstein, M.D.

12 noon

- 6 A New Mental Health Act: An Australian Experience
Darryl P. Watson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3

11:00 a.m.-12:30 p.m.

Room 201 D, Level 200, Toronto Convention Centre North

ATTENTION SPECTRUM DISORDERS

Chp.: Michael Demas, M.D.

Co-Chp.: Kareem Ghalib, M.D.

(Continued next page)

MONDAY

11:00 a.m.

- 7 **Transdermal Methylphenidate Versus Placebo in Pediatric ADHD**
Robert L. Findling, M.D., Frank A. Lopez, M.D.

11:30 a.m.

- 8 **Effects of Transdermal Methylphenidate in a Laboratory Classroom Study**
James J. McGough, M.D., Sharon B. Wigal, Ph.D., Howard Abikoff, Ph.D., John M. Turnbow, M.D., Kelly Posner, Ph.D., Eliot Moon, M.D.

12 noon

- 9 **Modafinil-ADHD: Long-Term Efficacy and Safety in Children and Adolescents With ADHD**
Samuel W. Boellner, M.D., James A. Knutson, M.D., John G. Jiang, Ph.D., Ronguha Yang, Ph.D., Craig Q. Earl, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m.-12:30 p.m.

Room 205 A, Level 200, Toronto Convention Centre North

CURRENT TRENDS IN SCHIZOPHRENIA

Chp.: Rajiv Tandon, M.D.
Co-Chp.: Peter F. Buckley, M.D.

11:00 a.m.

- 10 **Recurring Psychosis in Schizophrenia: A 20-Year Multi, Follow-Up Study**
Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Joseph F. Goldberg, M.D., Kalman J. Kaplan, Ph.D., Robert Faull, B.S.

11:30 a.m.

- 11 **Identifying the Neurobiological Basis for Schizophrenia**
Zeinab S. Elbaz, M.D.

12 noon

- 12 **Key Findings From the Intercontinental Schizophrenia Outpatients Health Outcomes Study (IC-SOHO): Disease Burden and Clinical Outcomes Associated With Antipsychotic Treatment for Schizophrenia**
Martin Dossenbach, Jan Pecenek, Urban Groleger, Agata Szulc, Yulia Dyachkova, Amanda J. Lowry
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5

11:00 a.m.-12:30 p.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

MEDICATION RESPONSE IN MDD

Chp.: Edward Kingstone, M.D.
Co-Chp.: Adel A. Gabriel, M.D.

11:00 a.m.

- 13 **Duloxetine Versus Escitalopram and Placebo in the Long-Term Treatment of Patients With MDD**
Teresa A. Pigott, M.D., Lesley M. Arnold, M.D., Scott T. Aaronson, M.D., Apurva Prakash, Craig H. Mallinckrodt, Michael J. Robinson, Madelaine M. Wohlreich, M.D.

11:30 a.m.

- 14 **Conditional Probability of Response to Placebo in MDD**
Jennifer Covino M.P.A., David Mischoulon, M.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., John M. Zajecka, M.D., Harald Murck, M.D., Jerrold F. Rosenbaum, M.D.

12 noon

- 15 **Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study**
David Michelson, M.D., Lenard A. Adler, M.D., Jay D. Amsterdam, M.D., David L. Dunner, M.D., Andrew A. Nierenberg, M.D., Frederick W. Reimherr, M.D., Alan F. Schatzberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.-12:30 p.m.

Room 206 E/F, Level 200, Toronto Convention Centre North

TREATMENT MANAGEMENT AND OUTCOMES IN MOOD DISORDERS

Chp.: John F. Greden, M.D.
Co-Chp.: Robert B. Shulman, M.D.

11:00 a.m.

- 16 **Management of Side Effects Associated With New Treatments for Bipolar Depression**
Joseph R. Calabrese, M.D., Robert M.A. Hirschfeld, M.D.

11:30 a.m.

- 17 **Treatment-Resistant Depression: Changes in Symptoms and Functioning in a Clinical Sample**
Alex A. Cardoni, M.S., Stephen B. Woolley, M.P.H., Deborah Piez, M.S., John W. Goethe, M.D.

12 noon

- 18 **Specificity of Effect of Quetiapine in Bipolar Depression**
Robert M.A. Hirschfeld, M.D., Joseph R. Calabrese, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.-12:30 p.m.

British Columbia Room, Mezzanine Floor, Royal York

DIAGNOSTIC ISSUES

Chp.: Suzane Renaud, M.D.
Co-Chp.: Paul Fedoroff, M.D.

11:00 a.m.

- 19 **Screening for History of Physical, Emotional, and Sexual Abuse: How Do We Ask About Abuse?**
Brett D. Thombs, Ph.D., Roy C. Ziegelstein, MD., David P. Bernstein, Ph.D., Christine D. Scher, Ph.D., David R. Forde, Ph.D., Edward A. Walker, MD., Murray B. Stein, M.D.

11:30 a.m.

- 20 **Kennedy Axis V: The Next Step for Axis V?**
James A. Kennedy, M.D.

12 noon

- 21 **Dimensional Approaches to *DSM* and the Impact on Diagnostic Instruments**
Maritza Rubio-Stipec, Sc.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8

11:00 a.m.-12:30 p.m.

Confederation 3 Room, Mezzanine Floor, Royal York

CONSULTATION-LIAISON PSYCHIATRY

Chp.: Asher Aledjem, M.D.

Co-Chp.: Daniel Chapman, M.D.

11:00 a.m.

- 22 **Teaching of Psychiatry in Primary Care Residencies: Do Training Directors of Primary Care and Psychiatry See Eye to Eye?**
Hoyle Leigh, M.D., Ronna Mallios, M.P.H., Deborah C. Stewart, M.D.

11:30 a.m.

- 23 **Unrecognized Post-Traumatic Symptoms Triggered by Routine Hospital Care in Patients With Previous Trauma Histories**
Sarah Birmingham, M.D., Lynne M. Gaby, M.D., James I. Griffith, M.D.

12 noon

- 24 **Is Asthma Severity Related to Current Major Depressive Episode and Generalized Anxiety Disorder? A Case-Control Study**
Claudia Meneses, M.D., Diana M.C. Padra, M.D., Adriana M. Martínez, M.D., Claudia Manchego, M.D., Carlos A. Machado-Romero, M.D., Luis A. Díaz-Martínez M.S., Adalberto Campo-Arias, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 9

11:00 a.m.-12:30 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

PSYCHIATRIC EDUCATION

Chp.: Laura W. Roberts, M.D.

Co-Chp.: Ronald F. Krasner, M.D.

11:00 a.m.

- 25 **Psychiatric CMEs and Commercial Bias: Are New ACCME Standards Effective?**
Daniel J. Carlat, M.D.

11:30 a.m.

- 26 **Relationships Between Self-Assessment Skills, Test Performance, and Other Variables in Psychiatry Residents**
David J. Lynn, M.D., Patrick T. O'Neill, M.D.

12 noon

- 27 **Coaching Communication Using Standardized Patient Encounters: An Educational Research Study**
Paula Ravitz, M.D., William Lancee, Ph.D., Robert Maunder, M.D., Moly Leszcz, M.D., Jiahui Wong, M.D., Nancy L. McNaughton, MEd., Allan D. Peterkin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10

11:00 a.m.-12:30 p.m.

Library, Mezzanine Floor, Royal York

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

Chp.: Anton C. Trinidad, M.D.

Co-Chp.: Hamada Hamid, D.O.

11:00 a.m.

- 28 **From Synapse to Psychotherapy: The Fascinating Evolution of Neuroscience**
Bernadette Grosjean, M.D.

11:30 a.m.

- 29 **Can Neurological Soft Signs Discriminate Between Four Axis-I Diagnostic Categories in the Prison Population?**
Seyed Mohammad Assadi, M.D., Mohammad Reza Nakhaei, M.D.

12 noon

- 30 **An Association Study of a Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Zotepine Response of Inpatients With Acute Schizophrenia**
Ching-Hua Lin, M.D., Li-Shiu Chou, M.D., Chieh-Hsin Lin, M.D., Ming-Chao Chen, M.D., Gwo-Jen Wei

SCIENTIFIC AND CLINICAL REPORT SESSION 11

11:00 a.m.-12:30 p.m.

Toronto Room, Convention Floor, Royal York

GERIATRIC PSYCHIATRY

Chp.: Kathy Kim, M.D.

Co-Chp.: Raquel Lugo, M.D.

(Continued next page)

MONDAY

11:00 a.m.

- 31 **The Influence of Dementia on the Treatment of Depression in Geriatric Inpatients**
Karen Blank, M.D., Bonnie L. Szarek R.N., John W. Goethe, M.D.

11:30 a.m.

- 32 **Overall Efficacy and Time to Response for Duloxetine 60mg Once Daily Versus Placebo in Elderly Patients With MDD**
Ira R. Katz, M.D., Joel Raskin, M.D., Jimmy Y. Xu, Ph.D., Daniel K. Kajdasz, Ph.D.

12 noon

- 33 **Safety and Efficacy of Intra-Muscular Ziprasidone Treatment of Acute Psychotic Agitation in Elderly Patients With Schizophrenia**
Alex Aviv, M.D., Yoram Barak, M.D., Yehuda Baruch, M.D.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 10-19

COMPONENT WORKSHOP 10 11:00 a.m.-12:30 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

THE GIFT OF LIFE: A PSYCHIATRIC PERSPECTIVE ON LIVING HEPATIC ORGAN DONATION
APA Council on Psychosomatic Medicine

Co-Chps.: Philip R. Muskin, M.D., Silvia Hafliger, M.D.
Participants: Beth A. Grube, Ph.D., Matthew Muskin

COMPONENT WORKSHOP 11 11:00 a.m.-12:30 p.m.
Room 205 B, Level 200, Toronto Convention Centre North

TOWARDS A BETTER UNDERSTANDING OF CULTURAL ISSUES IN CLINICAL PRACTICE: RESIDENTS PERSPECTIVE OF A MODEL CURRICULUM FOR RESIDENCY TRAINING PROGRAMS
APA/AstraZeneca Minority Fellows

Chp.: Angel A. Caraballo, M.D.
Participants: Lois W. Choi-Kain, M.D., Alphonso Nichols III, M.D., Jennifer D. Pender, M.D., Yanni C. Rho, M.D., Francis G. Lu, M.D.

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Room 205 C, Level 200, Toronto Convention Centre North

ETHNICITY AND CAREGIVING ACROSS THE PSYCHIATRIC SPECTRUM
APA Committee on Ethnic Minority Elderly

Co-Chps.: Iqbal Ahmed, M.D., Warachal E. Faison, M.D.
Participants: Carl I. Cohen, M.D., Alveth J. Young, M.D., Yolonda R. Coleman, M.D., Cynthia I. Resendez, M.D., Nhi-Ha T. Trinh, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 205 D, Level 200, Toronto Convention Centre North

SEXUALITY AND ITS IMPACT ON THE HIV PANDEMIC
APA Committee on HIV/AIDS

Chp.: Marshall Forstein, M.D.
Participants: Milton L. Wainberg, M.D., Khakasa H. Wapenyi, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

PSYCHIATRIC ETHICS IN THE UNITED STATES AND THROUGHOUT THE WORLD
APA Ethics Committee

Co-Chps.: Spencer Eth, M.D., George Christodoulou, M.D.
Participants: Wade C. Myers, M.D., Julio Arboleda-Florez, M.D., Philip T. Merideth, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

TEACHING THE WORKING ALLIANCE AS A CORE PROCESS ACROSS THE PSYCHOTHERAPIES
APA Committee on Psychotherapy by Psychiatrists

Chp.: Eric M. Plakun, M.D.
Participants: Bernard D. Beitman, M.D., Donna M. Sudak, M.D., Norman A. Clemens, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South

SCALES IN THE CLINICAL PRACTICE OF GERIATRIC PSYCHIATRY
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: Allan A. Anderson, M.D.
Participants: Lina S. Shihabuddin, M.D., Colleen J. Northcott, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South

WINNING THE FIGHT FOR MENTAL HEALTH BENEFITS: PARTNERING WITH EMPLOYERS
APA Committee on APA/Business Relationships

Chp.: Dauda A. Griffin, M.D.
Participants: Avram H. Mack, M.D., Alan Langlieb, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South

CULTURE AS A RATIONALIZATION FOR VIOLENCE AGAINST WOMEN
APA Committee on Family Violence and Abuse

Chp.: Gail E. Robinson, M.D.

COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

**FACILITATING MINORITY TO EXCEL IN
ACADEMIC PSYCHIATRY**

*APA Assembly Committee of Representatives of Minority/
Underrepresented Groups*

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Pedro Ruiz, M.D., Nutan Atre-Vaidya, M.D.,
Stephen M. Goldfinger, M.D., Carl C. Bell, M.D.

ISSUES 16-28

ISSUE WORKSHOP 16 11:00 a.m.-12:30 p.m.
Room 709, Level 700, Toronto Convention Centre South

**ASSESSMENT OF CAPACITY: DEVELOPMENTS,
DVDS, AND DEFENSE ORGANIZATIONS**

Chp.: M.E. Jan Wise, M.D.
Participant: Julian Beezhold, M.B.

ISSUE WORKSHOP 17 11:00 a.m.-12:30 p.m.
Room 711, Level 700, Toronto Convention Centre South

**BIOPSYCHOSOCIAL AND SPIRITUAL ASPECTS OF
TREATING OUR PHYSICIAN COLLEAGUES**

Co-Chps.: Monisha R. Vasa, M.D., Syed S.A. Naqvi, M.D.
Participants: Michael F. Myers, M.D., Leo L. Gallofin, M.D.

ISSUE WORKSHOP 18 11:00 a.m.-12:30 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

ORAL BOARDS BOOT CAMP: 2006

Chp.: Elyse D. Weiner, M.D.
Participant: Eric D. Peselow, M.D.

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

**THE OTHER DESPERATE HOUSE WIVES: HIDDEN
VIOLENCE IN THE HOME**

Chp.: Susan J. Hatters-Friedman, M.D.
Participants: Renee M. Sorrentino, M.D., Joy E. Stankowski, M.D.

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

**TREATING FIRST AND SECOND GENERATION
IMMIGRANTS WITH PSYCHOTHERAPY DURING
RESIDENCY TRAINING**

Chp.: Anu A. Matorin, M.D.
Participants: Andres J. Pumariega, M.D., Aradhana B.
Sood, M.D., Lina M. Lopez, M.D., Ayesha I. Mian, M.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

**PHYSICIAN HEAL THYSELF: WORKPLACE
BURNOUT AMONG PSYCHIATRISTS**

Co-Chps.: John Sharkey, M.D., Steve Choong Kam Chong, M.D.

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

**PSYCHOTHERAPY TRAINING AND
INTERNATIONAL MEDICAL GRADUATES: THE
INFLUENCE OF CULTURAL FACTORS**

Chp.: Nyapati R. Rao, M.D.
Participants: Jerald Kay, M.D., Stephen M. Goldfinger, M.D.,
Michael D. Garrett, M.D., Damir Huremovic, M.D.

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.
Room 810, Level 800, Toronto Convention Centre South

**COGNITIVE-BEHAVIOR THERAPY FOR
PSYCHOSIS: BASIC TECHNIQUES FOR
PSYCHIATRISTS**

Chp.: Shanaya Rathod, M.D.
Participants: David G. Kingdon, M.D., Douglas Turkington, M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.
Manitoba Room, Mezzanine Floor, Royal York

DOES BEAUTY EQUAL HAPPINESS?

Co-Chps.: Stephanie M. Stewart, M.D., Alicia R. Ruelaz, M.D.
Participants: Norana I. Caivano, M.D., Tara Klein, M.D.,
Suzanne Hollingshead, B.A.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.
Tudor 7 Room, Mezzanine Floor, Royal York

**ESTABLISHING A WOMEN'S MENTAL HEALTH
PROGRAM IN AN ACADEMIC OR PRIVATE
SETTING**

Co-Chps.: Catherine A. Birndorf, M.D., Nehama Dresner, M.D.
Participants: Margaret Altemus, M.D., Nicole Regent, M.D.,
Rachel Goldstein, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York

**SECRETS IN FAMILY THERAPY: TO TELL OR NOT
TO TELL**

Co-Chps.: Eva C. Ritvo, M.D., Michael Hughes, M.D.
Participant: Jon A. Shaw, M.D.

MONDAY

ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.
Salon A, Convention Floor, Royal York

VIRTUAL REALITY AND VIDEO GAMES IN THE TREATMENT OF MENTAL HEALTH DISORDERS AND ADDICTIONS: AN EVIDENCE-BASED ANALYSIS

Co-Chps.: William Huang, M.D., Jeffery N. Wilkins, M.D.
Participant: Jack Kuo, M.D.

ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m.
Salon B, Convention Floor, Royal York

MULTIDISCIPLINARY TREATMENT OF ADULTS WITH ASPERGER'S SYNDROME AND RELATED DISORDERS: LESSONS FROM THE UNIVERSITY OF PENNSYLVANIA SOCIAL LEARNING DISORDERS PROGRAM

Co-Chps.: Anthony L. Rostain, M.D., Edward S. Brodtkin, M.D.
Participant: J. Russell Ramsay, Ph.D.

12 noon Sessions

FORUMS 1-6

FORUM 1 12 noon-1:30 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

HARRY POTTER AND THE HALF-BLOOD PRINCE: HARRY GROWS UP

Chp.: JoAnne Isbey
Participants: Daniel P. Dickstein, M.D., Cheryl C. Munday, Ph.D., Steven G. Dickstein, M.D., Theresa A. Yuschok, Eva M. Szigethy, M.D., Leah J. Dickstein, M.D., Dorothy Bates

FORUM 2 12 noon-1:30 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

RESEARCH PLANNING FOR *DSM-V*

Chp.: Darrel A. Regier, M.D.
Participants: Wilson M. Compton, M.D., Carol A. Tamminga, M.D., Trey Sunderland, Dennis S. Charney, Norman Satorius, M.D.

FORUM 3 12 noon-1:30 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South

MOZART AT 250: THE MIND AND MUSIC OF A GENIUS

Chp.: Richard Kogan, M.D.

FORUM 4 12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

WOMEN AND ALCOHOL USE DISORDERS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Shelly F. Greenfield, M.D.
Participants: Grace Chang, M.D., Susan M. Gordon, Ph.D., Carrie L. Randall, Ph.D.

FORUM 5 12 noon-1:30 p.m.
Ballroom, Lower Level, Intercontinental Hotel

ANTIPSYCHOTIC DRUGS EFFECTIVENESS: RESULTS OF THE NIMH CATIE TRIAL

Chp.: Jeffrey A. Lieberman, M.D.
Participants: Joseph P. McEvoy, M.D., Richard S.E. Keefe, Ph.D., Robert A. Rosenheck, M.D.

FORUM 6 12 noon-1:30 p.m.
Territories Room, Mezzanine Floor, Royal York

THE THEORY AND PRACTICE OF APOLOGY

Chp.: Aaron Lazare, M.D.
Participants: David Spiegel, M.D., Jeffrey L. Geller, M.D.

1:00 p.m. Sessions



COURSES 51-57

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 51 1:00 p.m.-5:00 p.m.
Conference Room D/E, Mezzanine, Sheraton Centre

CONTEMPORARY MALPRACTICE LIABILITY 2006: A PRACTICAL GUIDE

Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Jacqueline M. Melonas, J.D.

COURSE 52 1:00 p.m.-5:00 p.m.
Conference Room F, Mezzanine, Sheraton Centre

FAMILIES COPING WITH MEDICAL ILLNESS: A TREATMENT APPROACH FOR PSYCHIATRY

Director: John S. Rolland, M.D.

COURSE 53 1:00 p.m.-5:00 p.m.
Conference Room G, Mezzanine, Sheraton Centre

**PERSONALITY DISORDERS: COMBINING
RELATIONAL THERAPY AND
PSYCHOPHARMACOLOGY**

Director: Roy O. Resnikoff, M.D.

COURSE 54 1:00 p.m.-5:00 p.m.
Windsor Room East, Mezzanine, Sheraton Centre

THE ADVANCED PRACTICE OF PSYCHOTHERAPY

Director: T. Byram Karasu, M.D.

COURSE 55 1:00 p.m.-5:00 p.m.
City Hall, Second Floor, Sheraton Centre

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

COURSE 56 1:00 p.m.-5:00 p.m.
Dominion Ballroom South, Second Floor, Sheraton Centre

MOOD DISORDERS IN LATER LIFE

Director: James M. Ellison, M.D.

Faculty: E. Yusuf Sivrioglu, M.D., Donald A. Davidoff, Ph.D.,
Brent P. Forester, M.D., Francesca Cannavo Antognini, Ph.D.

COURSE 57 1:00 p.m.-5:00 p.m.
Kent Room, Second Floor, Sheraton Centre

OVERVIEW OF CORRECTIONAL PSYCHIATRY

Co-Directors: Melissa P. Piasecki, M.D., Ole Thienhaus, M.D.
Faculty: Eugene Wang, M.D., Todd Elwyn, M.D.

**NEW RESEARCH YOUNG INVESTIGATORS'
ORAL/SLIDE SESSION 2-4**
1:00 p.m.-2:30 p.m.

- 2 **Biology**
Room 205 B, Level 200, Toronto Convention Centre North
- 3 **Clinical**
Room 205 C, Level 200, Toronto Convention Centre North
- 4 **Clinical**
Room 205 D, Level 200, Toronto Convention Centre North

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

2:00 p.m. Sessions

ADVANCES IN PSYCHOPHARMACOLOGY

2:00 p.m.-5:30 p.m.

Room 107, Level 100, Toronto Convention Centre North

Chp.: Alan F. Schatzberg, M.D.

A Pharmacological Treatment of Bipolar Disorder

Paul E. Keck, Jr.

B Brain Stimulation Techniques in Psychiatry

William M. McDonald, M.D.

C Advances in the Pharmacotherapy of GAD

David V. Sheehan, M.D.

FOCUS LIVE SESSION 3

2:00 p.m.-3:30 p.m.

Room 714 A, Level 700, Toronto Convention Centre South

PSYCHOTHERAPY

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.

Presenter: Jerald Kay, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. The 9:00 a.m. session covered Personality Disorders, the 11:00 a.m. session covered Eating Disorders and Sexual Disorders, and this session will cover Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 8-9

LECTURE 8
2:00 p.m.-3:30 p.m.
Room 105, Level 100
Toronto Convention Centre North

APA'S KUN PO SOO AWARD LECTURE

Albert C. Gaw, M.D.

**Culture, Spirituality, and Psychiatry: A
Psycho-Historical Study of King Saul**

Chp.: Surinder S. Nami, M.D.

Albert C. Gaw, M.D., was born in the Philippines of Chinese parentage. Dr. Gaw obtained his medical degree from the University of the East Medical Center in the Philippines; interned at Rochester General
(Continued next page)

Hospital, NY, and completed a psychiatric residency at the University of Rochester, Strong Memorial Hospital and a fellowship in Community Psychiatry at Harvard Medical School. An APA Distinguished Life Fellow, Dr. Gaw is a Clinical Professor of Psychiatry at the University of California at San Francisco, Medical Director of San Francisco's Community Behavioral Health Services, and was a Speaker of the APA Assembly. Dr. Gaw helped establish a health and mental program for the Greater Boston's Asian American Community. He has published on cross-cultural psychiatry, including three books: *Cross-Cultural Psychiatry, Culture, Ethnicity, and Mental Illness*, and *Casebook to Cross-Cultural Psychiatry*. At Bedford VA and in San Francisco, Dr. Gaw provided innovative care for persons with serious mental illnesses. He fostered scientific exchanges between the APA and the Chinese Psychiatric Association. An Assembly Speaker, Dr. Gaw promoted relationship between the APA and the VA, psychiatric preparedness for disaster, and care for the seriously mentally ill persons.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 9

2:00 p.m.-3:30 p.m.

Room 718 A/B, Level 700
Toronto Convention Centre South

APA'S ADOLF MEYER AWARD LECTURE

Aaron T. Beck, M.D.

New Advances in Cognitive Therapy

Chp.: Jesse H. Wright III, M.D.

University Professor of Psychiatry Emeritus at the University of Pennsylvania School of Medicine, Dr. Beck is the founder of cognitive therapy. He has received numerous awards, including research awards from the American Psychiatric Association, the American Psychological Association, and the Institute of Medicine. He has also been listed as one of the ten Americans with the greatest influence in the history of American psychiatry. Dr. Beck is the author or co-author of over 500 publications, including 17 books. His cognitive therapy, the most heavily researched form of psychotherapy, represents a major advance in the understanding and treatment of a variety of psychiatric disorders, including affective disorders, anxiety disorders, substance abuse, personality disorders, and schizophrenia.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room 701 A, Level 700, Toronto Convention Centre South

**THE PUBLIC MENTAL HEALTH SYSTEM:
CRITICAL ISSUES**

APA Committee on Family Violence and Abuse and Council on Social Issues and Public Psychiatry

Chp.: Yvonne B. Ferguson, M.D.

- A **Domestic Violence, Lifetime Trauma, and Public Mental Health: Critical Issues for Policy, Prevention, and Service Delivery**
Carole Warshaw, M.D.
- B **Ballot Initiative Creates New Services for Children and Youth**
William Arroyo, M.D.

Discussant: Steven S. Sharfstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-33

SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room 104 A, Level 100, Toronto Convention Centre North

**HIV PREVENTION INTERVENTIONS WITH
PSYCHIATRIC PATIENTS FROM AROUND THE
WORLD: TURNING RESEARCH INTO PRACTICE**

Chp.: Milton L. Wainberg, M.D.

Co-Chp.: Francine Cournos, M.D.

- A **Severe Mental Illness: HIV Research Trajectory and Needs**
Karen McKinnon, M.A.
- B **Ethnography of HIV Risk in Two Psychiatric Settings**
Paulo E. Mattos
- C **Severe Mental Illness and HIV Risk in India With an Emphasis on the Special Threats to Women**
Prabha S. Chandra, M.D., Michael P. Carey, Ph.D.
- D **HIV Prevention and People With Mental Illness in South Africa: Prevalence, Policies, and Practice**
Pamela Y. Collins, Kezziah Mestry LL.B., Alan Berkman, M.D., David Hoos, M.D.
- E **HIV Risk and Risk-Reduction Efforts Among Persons Having Serious Mental Illness and Substance Use Issues in the U.S.**
Laura Otto-Salaj, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

THERAPEUTIC MISCONCEPTION IN CLINICAL RESEARCH

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Charles Lidz, Ph.D.

- A **Therapeutic Misconception: An Overview of the Phenomenon**
Paul S. Appelbaum, M.D.
- B **How Prevalent Is Therapeutic Misconception?**
Charles W. Lidz, Ph.D.
- C **Assessment of Therapeutic Misconception in Older Patients With Schizophrenia**
Laura B. Dunn, M.D., Barton W. Palmer, Ph.D., Monique Keehan, B.S., Dilip V. Jeste, M.D., Paul S. Appelbaum, M.D.
- D **Reaching Consensus on the Conceptual Definition of Therapeutic Misconception**
Gail Henderson
- E **The Ethical Significance of the Therapeutic Misconception**
Franklin G. Miller, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

MIGRATION AND MENTAL ILLNESS AROUND THE WORLD

Royal College of Psychiatrists

Chp.: Nigel Bark, M.D.
Co-Chp.: Hamid Ghodse, M.D.

- A **Refugee Mental Health Challenges in Africa**
Frank G. Njenga, M.D.
- B **Mental Health of Sudanese Refugees: An Egyptian Perspective**
Nasser F. Loza, M.D., Nael Hassan, M.D.
- C **PTSD Among a Group of Afghan Refugees Attending a Psychiatric Service in Peshawar, Pakistan**
Khalid A. Mufti, M.D., Haroon R. Chaudhry, M.D.
- D **Immigration-Repatriation and Mental Health: The Case of Greece**
George G. Christodoulou, M.D., Michael G. Madianos, M.D.
- E **Raised Incidence of Psychosis in Ethnic Minority Groups in the UK: The AESOP Study**
Paul Fearon
- F **Migration and Mental Health in Canada: Can Provincial Policy Help?**
Stephen R. Kisely, M.D.

Discussant: Ezra S. Susser, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

PSYCHOSOCIAL INTERVENTION AND CANCER SURVIVAL

Chp.: David Spiegel, M.D.
Co-Chp.: Fawzy Fawzy, M.D.

- A **Supportive-Expressive Group Therapy and Survival in Patients With Metastatic Breast Cancer: A Randomized Clinical Intervention Trial**
David Spiegel, M.D., Lisa D. Butler, Ph.D., Janine Giese-Davis, Ph.D., Cheryl Koopman, Ph.D., Sue DiMiceli B.A., Catherine Classen, Ph.D., Pat Fobair M.P.H., Robert W. Carlson, M.D., Helena C. Kraemer, Ph.D.
- B **RCT of Supportive-Expressive Group Therapy in Advanced Breast Cancer: Survival, Psychosocial, and Anti-Cancer Treatment Adherence Outcomes**
David W. Kissane, M.D., Brenda Grabsch M.S.W., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Anthony Love, Ph.D., Sidney Bloch, M.D.
- C **Treatment Outcomes of Group Supportive-Expressive Therapy for Women With Metastatic Breast Cancer**
Molyn Leszcz, M.D.
- D **Impact of Psychotherapeutic Support on Gastrointestinal Cancer Patients Undergoing Surgery: Ten-Year Follow-Up Survival Results of a Randomized Trial**
Thomas Kuechler, Ph.D.
- E **Malignant Melanoma: Effects of a Brief, Structured Psychiatric Intervention on Survival and Recurrence at Ten-Year Follow-Up**
Fawzy I. Fawzy, M.D.

Discussant: Michael Stefanek, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

SEXUAL ORIENTATION AND SPORTS

International Society for Sport Psychiatry

Chp.: Eric D Morse, M.D.

- A **Being Gay in Sports**
Eric D. Morse, M.D.
 - B **Gender Role Conflict in Female Athletes**
Altha J. Stewart, M.D.
 - C **Suicide and the Homosexual Athlete**
Antonia L. Baum, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

MONDAY

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

INSOMNIA: WHAT IS IT?

Chp.: Thomas W. Uhde, M.D.

- A **Insomnia: Diagnosis and Treatment Challenges**
Thomas W. Uhde, M.D.
- B **Epidemiology of Chronic Insomnia**
Edward Bixler, Ph.D.
- C **Chronic Insomnia: Cause-Effect Relationship to Depression and Anxiety Disorders**
Ravi K. Singareddy, M.D.
- D **Biological Models of Chronic Insomnia: Clinical Implications**
Alexandros Vgontzas, M.D.
- E **Health Correlates of Insomnia in Young Adults**
Antonio Vela-Bueno, M.D., Sara Olavarrieta-Bernardino, Psy.D., Julio Fernandez-Mendoza, Psy.D., Alfredo Rodriguez-Muñoz, Psy.D.

Discussant: Thomas Roth
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

THE AFRICAN DIASPORA: IDENTIFYING AND ELIMINATING BARRIERS TO MENTAL HEALTH

Chp.: Annelle B. Primm, M.D.
Co-Chp.: G. Chiadi U. Onyike, M.D.

- A **African Belief Systems and Corresponding Healing Practices**
Samuel O. Okpaku, M.D.
- B **Why Is Stigma so Rife in Nigeria?**
Oye Gureje
- C **The Haitian Diaspora: Barriers in Accessing Mental Health Services**
Mary Titus-Villedrouin
- D **Barriers to Mental Health Service Delivery to Ethiopian Immigrants and Refugees in the U.S.: How Should We Tackle This Problem?**
Yeshashwork Kibour
- E **The Postcolonial Challenge to the Stigma of Mental Illness in Jamaica**
Frederick W. Hickling
- F **Stigma and Mental Health: A South African Perspective**
Solomon Rataemane
- G **Recruitment of Minorities into Clinical Trials in Neuropsychiatry: The ADAPT Experience**
G. Chiadi U. Onyike, M.D.

Discussant: Ikwunga Wonodi, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

TREATMENT ISSUES IN SCHIZOPHRENIA WITH COMORBID DISORDERS

American Association of Practicing Psychiatrists

Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Leslie Citrome, M.D.

- A **Depressive Symptoms in People With Schizophrenia**
Robert R. Conley
- B **Treatment of Schizophrenia With OCD**
Michael Y. Hwang, M.D.
- C **Substance Abuse Among Patients With Schizophrenia Spectrum Disorders**
Douglas Noordsy, M.D.
- D **Cognitive Functioning and Outcome in Schizophrenia**
Philip D. Harvey, Ph.D.
- E **Schizophrenia and Comorbid Aggressive Behavior: Update 2006**
Leslie L. Citrome, M.D.
- F **Eating Disorders in Schizophrenia**
Sun Young Yum, M.D., David P. Law, M.D., Sandra Denis, M.D., Sun Young Yum, M.D., Marcia Klein, Ph.D., Michael Y. Hwang, M.D.

Discussant: Lewis A. Opler, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

REHABILITATION IN FRANCE, CANADA, AND THE U.S.: FROM SCIENCE TO RECOVERY: VIVE LA DIFFERENCE

French Psychiatric Association

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois Petitjean, Psy.D.

- A **Neuropsychological Therapy Protocol on Young Schizophrenic Patients in Day Hospitals**
Christine Germain
- B **Implementing Innovative Rehabilitation Modules: The Case of IPT in Canadian Province Sites**
Alain D. Lesage, M.D.
- C **Recovery From Schizophrenia: Current Research**
Robert P. Liberman, M.D.
- D **Evidence-Based Practices and Recovery in Schizophrenia**
Alan S. Bellack, Ph.D.
- E **A New Rehabilitation Program for Patients With Schizophrenia: Development and Preliminary Results**
Christophe Lancon, Christophe Boulanger, M.D.

Discussant: Ann Thompson, M.S.W.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

MODEL CURRICULA ON RELIGION AND SPIRITUALITY FOR PSYCHIATRY RESIDENCY TRAINING PROGRAMS

Chp.: Francis G. Lu, M.D.
Co-Chp.: Christina M. Puchalski, M.D.

- A **Development of a Departmental-Based Curriculum of Spirituality in Healthcare for Psychiatry Residents, Other Healthcare Professionals, and Clergy/Pastoral Care Professionals**
Joan M. Collison, M.D.
- B **Incorporating a Spiritual Worldview Within Psychiatry in the Bible Belt: University of South Carolina/ Palmetto Health Curriculum on Spirituality**
Nioaka N. Campbell, M.D., Craig A. Stuck, M.D.
- C **Bridging the Gap: Science and Spirituality**
Patricia E. Murphy, Ph.D.
- D **The Interface Between Spirituality, Religion, and Psychiatry: A Course for Psychiatry Residents at the University of British Columbia**
Andrea D. Grabovac, M.D.
- E **Spirituality and Psychiatry: The Harvard Longwood Psychiatry Residency Course: Eight Years Later**
John R. Peteet, M.D.

Discussant: Allan M. Josephson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

THE LONG-TERM CARE AND TREATMENT OF ELDERLY PATIENTS WITH BIPOLAR DISORDER
APA Council on Aging

Chp.: Helen H. Kyomen, M.D.

- A **The Impact of Elderly Patients With Bipolar Disorder on the Health Care System**
Helen H. Kyomen, M.D.
- B **Predictors of Functioning and Treatment of Community Dwelling Older People With Bipolar Disorder**
Sarah Pratt, Ph.D.
- C **Treatment Interventions for Elderly Patients With Bipolar Disorder**
Stephen Pinals, M.D.
- D **Ethnic and Cultural Issues in the Care of Elderly Patients With Bipolar Disorder**
Iqbal Ahmed, M.D.

Discussant: Robert C. Young, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

WHEN USUAL TREATMENTS FAIL: AUGMENTATION STRATEGIES FOR REFRACTORY SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.
Co-Chp.: Joseph Friedman, M.D.

- A **Herbal Medicinal Strategies in Refractory Schizophrenia**
Richard P. Brown, M.D.
 - B **NMDA Intervention Strategies in Refractory Schizophrenia**
Guochuan E. Tsai, M.D.
 - C **Augmentation Strategies for the Patient With Treatment Refractory Schizophrenia**
Peter F. Buckley, M.D.
 - D **High Dose Antipsychotic Strategies**
Jean-Pierre Lindenmayer, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

SUBSTANCE USE DISORDERS IN THE U.S.
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Deborah S. Hasin, Ph.D.
Co-Chp.: Bridget F. Grant, Ph.D.

- A **Prevalence and Correlates of Prescription Drugs Nonmedical Use and Use Disorders in the U.S.: 1991-1992 and 2001-2002**
Carlos Blanco-Jerez, M.D.
- B **Alcohol and Drug Dependence and the Specificity of Family History**
Deborah S. Hasin, Ph.D.
- C **Prevalence, Correlates, and Comorbidity of *DSM-IV* Drug Use Disorders**
Bridget F. Grant, Ph.D.
- D **Lifetime Comorbidity of *DSM-IV* Mood and Anxiety Disorders and Specific Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions**
Kevin Conway, Ph.D., Wilson M. Compton III, M.D., Frederick S. Stinson, Ph.D., Bridget F. Grant, Ph.D.
- E **The Relationship of Family History to Cocaine and Cannabis First Use and Dependence**
Gary Heiman, Ph.D.

Discussant: Wilson M. Compton, M.D.
THIS SESSION WILL BE AUDIOTAPED.

MONDAY

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.

Room 714 B, Level 700, Toronto Convention Centre South

THE MID-LIFE CRISIS AS INTERPRETED IN FILM AND TELEVISION

Chp.: Anton C. Trinidad, M.D.

Co-Chp.: Robert Boland, M.D.

A Depression and Other Psychopathology at Mid Life
Anton C. Trinidad, M.D.

B The Mind of the Mid-Life TV Addict
Robert J. Boland, M.D.

C TBD
Josepha A. Cheong, M.D.

Discussant: Peter D. Kramer

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.

Room 716 A, Level 700, Toronto Convention Centre South

FIRST-EPISODE SCHIZOPHRENIA: HOW CAN WE IMPROVE TREATMENT OUTCOME?

Chp.: Wolfgang Gaebel, M.D.

Co-Chp.: George Awad

A Measures to Prevent Relapse in Long-Term Treatment: Results From the German Research Network on Schizophrenia
Wolfgang Gaebel, M.D., Hans-Jurgen Moeller, M.D.

B The European First-Episode Schizophrenia Trial
René S Kahn, M.D., Wolfgang W. Fleischhacker, M.D.

C Management of Impaired Cognition
Stephen R. Marder, M.D.

D Social Cognition in Schizophrenia: Impairments and Psychological Treatment
Wolfgang Woelwer, Ph.D., Nicole Frommann, Ph.D., Wolfgang Gaebel, M.D.

E Effects of Pharmacological Treatment on the Quality of Life
George Awad

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.

Room 716 B, Level 700, Toronto Convention Centre South

ADOLESCENT BRAIN DEVELOPMENT: IMPLICATIONS FOR PSYCHIATRIC TREATMENT

National Institute on Drug Abuse

Chp.: Minda R. Lynch, Ph.D.

Co-Chp.: David Shurleff

A Adolescent Brain Development: A Period of Vulnerabilities and Opportunities

Ronald E. Dahl, M.D.

B Interacting Effects of Cannabis and Tobacco Use on Brain Function in Adolescents.

Leslie K. Jacobsen, Kenneth R. Pugh, Ph.D., Robert T. Constable, Ph.D., Michael Westerveld, Ph.D., W. Einar Mencl, Ph.D.

C Prefrontal-Limbic Brain Maturation and Risk for Psychopathology in Adolescence

Isabelle M. Rosso, Ph.D., Marisa M. Silveri, Ph.D., Staci A. Gruber, Ph.D., Deborah A. Yurgelun-Todd, Ph.D.

D The Immature Adolescent Brain and Cognitive Control
Beatriz Luna

Discussant: Laurence R. Stanford, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17

2:00 p.m.-5:00 p.m.

Room 717 A, Level 700, Toronto Convention Centre South

ETHNICITY, AGE, AND GENDER AS FACTORS IN THE MANAGEMENT OF ANXIETY AND DEPRESSION

Chp.: S. Charles Schulz, M.D.

A A Clinical Update on Response Rates in Psychiatric Disorders and Ethnicity
DiAnne Bradford, M.D.

B Identifying and Treating Depressive and Anxiety Disorders in Children and Adolescents
Melissa P. DelBello, M.D.

C Treatment Considerations in Special Populations: Sex Differences
Diana O. Perkins, M.D.

D New Pharmacologic Approaches in Treating Depression and Anxiety
David E. Adson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18

2:00 p.m.-5:00 p.m.

Room 717 B, Level 700, Toronto Convention Centre South

PERSONALITY DISORDERS AND COMORBIDITY: PREDICTIVE FACTORS AND CLINICAL IMPLICATIONS

Chp.: Simone Kool, Ph.D.

Co-Chp.: S. Charles Schulz, M.D.

A Personality Disorders and Affective Disorders: Ploughing the Sands or Fertile Soil? Predictors and Clinical Implications

Simone Kool, Ph.D., Jack Dekker, Ph.D.

B Efficacy of Depression Treatment in Patients With or Without Comorbid Personality Disorders: Does Clinical Lore Reflect the Findings From the Literature?
Robert A. Schoevers, Ph.D., Simone Kool, Ph.D., Henricus L. Van, M.D., Prof. Dr. Jack J. Dekker, Mariëlle Hendriksen M.S.C.

C The Relation Between Personality, Pathology, and Pathological Gambling
R. Michael Bagby, Ph.D., Peter Farvolden, Ph.D., Tony Toneatto, Ph.D., Eric Bulmash, B.A.

D Gender Differences in Personality Disorders Among Depressed Outpatients as Compared to the General Population
Cecilia M.T. Gijsbers Van Wijk, Ph.D.

E Drug Treatment of Personality Disorder: A Critical Review
Theo Ingenhoven, M.D., Thomas Rinne, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

TOWARDS A DEVELOPMENTAL TRAUMA DISORDER

Chp.: Bessel A. Van Der Kolk, M.D.

Co-Chp.: Robert S. Pynoos, M.D.

A Childhood Abuse, Regional Brain Development, and Psychiatric Vulnerabilities: Evidence for Sensitive Periods
Martin H. Teicher, M.D., Susan L. Andersen, Ph.D., Akemi Tomoda, M.D., Elizabeth Valente M.A., Ann M. Polcani, Ph.D.

B Developmental Trauma Disorder: Evidence From the Adolescent Years
Marylene Cloitre, Ph.D.

C Empirical Foundations for a Developmental Trauma Disorder
Bessel A. Van Der Kolk, M.D.

D Developmental Trauma Disorder: A Missing Link in Child Psychiatric Nosology and Treatment Planning
Julian Ford

E Child Trauma History Profile, Interference With Developmental Competencies, and Influence on Other Major Psychiatric Disorders in Children and Adolescents
Robert S. Pynoos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

BORDERLINE MOTHERS AND INFANT INTERACTIONS: CHAOTIC CONTINGENCY

Chp.: Gisèle Apter-Danon, M.D.

A Neurobiological Insights Into the Consequences of Early Nurturing Experience
Cort A. Pedersen, M.D.

B Distortion of Borderline Mothers and Infant Interaction and Emotional Regulation at Three Months
Gisèle Apter-Danon, M.D., Marina Gianoli-Valente M.A., Rozenn Graignic-Philippe, Ph.D., Emmanuel Devouche, Ph.D., Maya Gratier, Ph.D., Annick Le Nestour, M.D.

C Practical Applications of Treating Women in the Postpartum Period
Samantha E. Meltzer-Brody

D Interventions for New Mothers With PTSD and BPD
Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D.

Discussant: Carol C. Nadelson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

CRIMINALIZATION OF MENTAL ILLNESS: GETTING IN AND OUT IN NEW YORK

American Association for Social Psychiatry

Chp.: Zebulon C. Taintor, M.D.

Co-Chp.: Henry C. Weinstein, M.D.

A Only Some People With Mental Illness Are Criminalized
Zebulon C. Taintor, M.D.

B Substance Abuse, Spirituality, and Deviant Behavior
Richard J. Frances, M.D.

C Mental Health Treatment in New York State Prisons and Outcome
Abraham L. Halpern, M.D.

D Alternatives to Incarceration: Assisted Outpatient Treatment and Drug Courts
Gary R. Collins, M.D.

THIS SESSION WILL BE AUDIOTAPED.

MONDAY

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Imperial Room, Main Floor, Royal York

PSYCHOCULTURAL FOUNDATIONS OF POLITICAL TERRORISM

APA Council on Global Psychiatry and International Society of Political Psychology

Chp.: Jerrold M. Post, M.D.
Co-Chp.: Stevan M. Weine, M.D.

- A **Combating the Virus of Islamist Militancy: A Public Health Perspective**
Jerrold M. Post, M.D.
- B **Toward a Scientific Revolution in the Application of Behavioral Sciences to the Study of the Deep Roots of Terrorism**
Jeff Victoroff, M.D.
- C **The Appeal of Radical Islam for Young British Muslims**
Amy Waldman
- D **Terrorism and Diasporas**
Stevan M. Weine, M.D.
- E **Religion and Terrorism in U.S. Prisons: Crucible for Commitment or Contagion?**
Gregory B. Saathoff
- F **Moral Agents, Immoral Violence: Mechanisms of Moral Disengagement in Islamic Suicide Missions**
Mohammad Hafez

Discussant: David A. Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine Floor, Royal York

SCIENCE, DIAGNOSES, AND THE CLINICIAN
World Psychiatric Association

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: G. Scott Waterman, M.D.

- A **A Proposal to Include a Dimensional Component in *DSM-V***
John E. Helzer
- B **Dualism and the *DSM*: Emerging From the Shadow of the 17th Century**
G. Scott Waterman, M.D.
- C ***DSM* in the 21st Century and Beyond: The Interface of Genomics and Neuroscience With Our Diagnostic System**
James J. Hudziak, M.D.
- D **Improving the Validity of *DSM* Categories**
Lee N. Robins, D.Phil.

Discussant: Darrel A. Regier, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine Floor, Royal York

THE EFFECTIVE PSYCHOTHERAPIST: THE ROLE OF COMMON AND SPECIFIC FACTORS

Chp.: Mantosh J. Dewan, M.D.

- A **Factors Common to All Evidence-Based Psychotherapies**
John Manring, Priyanthy Weerasekera, M.D.
 - B **Cognitive-Behavioral Therapy for Anxiety Disorders: Common and Specific Aspects**
Edna B. Foa, Ph.D.
 - C **Integrating Common and Specific Factors in Psychotherapy Training: McMaster and Syracuse Models**
Priyanthy Weerasekera, M.D., John Manring, M.D.
 - D **Interpersonal Therapy: Common and Specific Factors**
Scott P. Stuart, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

DEVELOPING STRATEGIES IN PSYCHOTHERAPY RESEARCH

Chp.: Andrew J. Gerber, M.D.
Co-Chp.: James H. Kocsis, M.D.

- A **Assessing The Quality of Randomized Controlled Trials of Psychotherapy**
Andrew J. Gerber, M.D., James H. Kocsis, M.D., Jacques Barber, Ph.D., Steven D. Hollon, Ph.D., Barbara L. Milrod, M.D., Steven P. Roose, M.D., Michael E. Thase, M.D.
- B **Long-Term Outcome in Psychotherapy Research**
James H. Kocsis, M.D.
- C **An Outcome Study for Psychoanalysis**
Steven P. Roose, M.D., Andrew J. Gerber, M.D., Bret R. Rutherford, M.D.
- D **Comparison and Combination of Psychotherapy and Medication in Outcome Trials**
Michael E. Thase, M.D.

Discussant: M. Katherine Shear, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.

Manitoba Room, Mezzanine Floor, Royal York

TAKING SCIENCE TO POLICY: EFFORTS TO REDUCE HARMS RELATED TO ALCOHOL MISUSE
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Mark L. Willenbring, M.D.

Co-Chp.: Ralph Hingson

- A The Magnitude and Prevention of Underage Drinking Problems**
Ralph Hingson
- B Pragmatic Science: The New NIAAA Clinicians Guide**
Mark L. Willenbring, M.D.
- C Alcohol Interventions in Trauma Centers Reduce Reinjury Rates: State Laws and Insurance Regulations Prevent Their Implementation**
Larry Gentilello
- D Implementing Alcohol Treatment for People With Co-Occurring Disorders in Psychiatric Treatment Settings**
Robert Drake, Mary F. Brunette, M.D., Kim T. Mueser, Ph.D., Gregory J. McHugo, Ph.D.
- E What Kind of Treatment System Is Necessary to Implement Evidence-Based Practices?**
A. Thomas McLellan, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.

Quebec Room, Mezzanine Floor, Royal York

NOT JUST DOPAMINE ANY MORE: EMERGING GLUTAMATERGIC THERAPIES FOR SCHIZOPHRENIA

Chp.: Daniel C. Javitt, M.D.

- A Endogenous Modulators of Glutamatergic Neurotransmission and the Pathophysiology of Schizophrenia**
Joseph T. Coyle, Jr.
- B AMPA Agonists (Ampakines) in Schizophrenia**
Donald C. Goff
- C The PCP Model of Schizophrenia: 45 Years and Counting**
Daniel Javitt, M.D.
- D NMDA Glycine Site Agonists in the Treatment of the Schizophrenia Prodrome**
Scott W. Woods, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.

Territories Room, Mezzanine Floor, Royal York

CANMAT GUIDELINES FOR THE MANAGEMENT OF BIPOLAR DISORDER: AN EFFORT TOWARDS INTERNATIONAL CONSENSUS

Chp.: Sidney H. Kennedy, M.D.

- A Foundations of Management: Applying Chronic Disease Models and Psychosocial Interventions to Bipolar Disorder**
Sagar V. Parikh, M.D.
- B CANMAT Guidelines for Acute and Continuation Treatment of Mania**
Lakshmi N. Yatham, M.D.
- C Acute Management of Bipolar Depression**
Sidney H. Kennedy, M.D.
- D Bipolar II Disorder: Emerging Guidelines for Treatment**
Claire M. O'Donovan, M.B.
- E A U.S. and International Perspective on CANMAT Guidelines for Bipolar Disorder**
Joseph R. Calabrese, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.

Tudor 7 Room, Mezzanine Floor, Royal York

DEMENTIA IN PATIENTS WITH DOWN SYNDROME: RISK FACTORS, BIOMARKERS, DIAGNOSIS, AND TREATMENT

Chp.: John M. de Figueiredo, M.D.

- A Risk Factors and Biomarkers for Dementia in Adults With Down Syndrome**
Nicole Schupf, Deborah Pang, M.P.H., Bindu N. Patel, M.P.H., Warren B. Zigman, Ph.D., Wayne Silverman, Ph.D.
- B Cognitive Assessment of Aging Persons With Down Syndrome**
Arthur Dalton, Ph.D.
- C Trials to Assess Treatment Strategies for Dementia in Down Syndrome**
Mary Sano, Ph.D., Paul Aisen, M.D., Arthur Dalton, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.**

MONDAY

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York

GERIATRIC PSYCHIATRY: NEW IDEAS AND NEW PRACTICES FOR THE 21ST CENTURY

Chp.: Sandra A. Jacobson
Co-Chp.: Larry Ereshefsky, Pharm.D.

- A Pharmacogenomics in Clinical Practice and Research**
Larry Ereshefsky, Pharm.D., Stanford Jhee, Pharm.D.
- B The Future of Magnetic and Electrical Stimulation Therapies in Geriatrics**
Sarah H. Lisanby, M.D.
- C New Pharmaceuticals**
Sandra A. Jacobson, M.D.
- D Best New Technologies For Improved Patient Care**
Myron L. Pulier, M.D.

Discussant: Trey Sunderland, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.
Ballroom, Convention Floor, Royal York

NANCY C. ANDREASEN, M.D.: FESTSCHRIFT FOR HER 13 YEARS AS JOURNAL EDITOR

Chp.: Robert Freedman, M.D.

- A Scientific Journals and the Transmission of Knowledge to Clinicians**
Floyd E. Bloom
- B Interaction Between Gene Expression and Social Behavior**
Leon Eisenberg, M.D.
- C Brain Imaging and the Human Brain at Work**
Marcus Raichle, M.D.
- D The History of Episodic Memory**
Endel Tulving, Ph.D.

Discussant: Nancy C. Andreasen M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.
Salon A, Convention Floor, Royal York

A SPANISH LANGUAGE UPDATE ON THE ASSESSMENT AND MANAGEMENT OF DEPRESSION

American Society of Hispanic Psychiatry

Chp.: Gabriel Kaplan, M.D.
Co-Chp.: Javier I. Escobar, M.D.

A Update on the Neurobiology of Depression
Pedro L. Delgado, M.D.

B Suicide
Maria A. Oquendo, M.D.

C Treatment of Depression in Parkinson's Disease
Humberto Marin, M.D.

D Depression in Cognitive Intact and Cognitive Impaired Elderly Persons
Jacobo E. Mintzer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.
Salon B, Convention Floor, Royal York

RECENT ADVANCES IN CLINICAL CARE AND CLINICAL RESEARCH IN BPD

Chp.: Mary C. Zanarini, M.D.
Co-Chp.: John G. Gunderson, M.D.

A Course of Acute and Temperamental Symptoms of BPD Over Ten Years of Prospective Follow-Up
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., D. Bradford Reich, M.D., Kenneth R. Silk, M.D.

B Randomized Controlled Trial Comparing DBT to APA Practice Guidelines for BPD: Clinician Adherence
Paul S. Links, M.D., Shelley McMain, Ph.D., Michele Cook R.N., Andrea Januszewski, B.S.C., Nathan J. Kolla, M.D.

C Effectiveness of Inpatient DBT for BPD: A Controlled Trial and Follow-Up Data
Martin Bohus, M.D.

D Empirical Observations on the Relationship Between BPD and Bipolar Disorders
John G. Gunderson, M.D.

E Randomized Controlled Trial of Psychodynamic Treatments Compared to DBT for BPD
John F. Clarkin, Ph.D., Kenneth N. Levy, Ph.D., Mark F. Lenzenweger, Ph.D.

Discussant: Kenneth R. Silk, M.D.
THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00p.m.

Exhibit Hall B, Level 300, Toronto Convention Centre North

MOOD DISORDERS

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

5:30 p.m. Session

CONVOCATION OF
DISTINGUISHED FELLOWS

5:30 p.m. - 6:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, members, and registered guests are invited.

Presiding: Steven S. Sharfstein, M.D., President

Grand Marshals: Jack S. Brandes, M.D., Gerald Schneiderman, M.D.

Marshals: Howard E. Bock, M.D., Donna E. Stewart, MD

INTRODUCTION OF DISTINGUISHED LIFE
FELLOWS

Pedro Ruiz, M.D., *President Elect*

INDUCTION OF DISTINGUISHED FELLOWS

Pedro Ruiz, M.D.

INTRODUCTION OF FIFTY-YEAR
DISTINGUISHED LIFE FELLOWS, FIFTY-
YEAR LIFE MEMBERS, AND
INTERNATIONAL FELLOWS

Steven S. Sharfstein, M.D.

INTRODUCTION OF FELLOWS

Steven S. Sharfstein, M.D.

PRESENTATION OF SPECIAL
PRESIDENTIAL COMMENDATIONS

Steven S. Sharfstein, M.D.

PRESENTATION OF DISTINGUISHED
SERVICE AWARDS

Steven S. Sharfstein, M.D.

INTRODUCTION OF THE MEMBERSHIP
COMMITTEE CHAIRPERSON AND AWARD
BOARD CHAIRPERSONS

Steven S. Sharfstein, M.D.

PRESENTATION OF AWARDS

Steven S. Sharfstein, M.D.

APA/Lilly Resident Research Awards
Human Rights Awards
Blanche F. Itelson Award for Research in Child Psychiatry
APRE/Kempf Fund Awards for Research
Development in Psychobiological Psychiatry
Agnes Purcell McGavin Awards
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric
Psychiatry

WILLIAM C. MENNINGER MEMORIAL
CONVOCATION LECTURE

David K. Shipler

LECTURE 10

5:30 p.m. - 6:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

WILLIAM C. MENNINGER
MEMORIAL LECTURE

David K. Shipler

Connecting the Dots: The Interacting
Problems of Poverty

David K. Shipler, a Pulitzer Prize winning author, reported for 20 years for *The New York Times* from New York, Saigon, Moscow, Jerusalem, and Washington. He has written four books: *Ramona: Broken Idols*, *Solemn Dreams* (a national best-seller), *Arab and Jew: Wounded Spirits in a Promised Land* (winner of the 1987 Pulitzer Prize), *A Country of Strangers: Black and Whites in America*, and *The Working Poor: Invisible in America* (also a best-seller). His lecture will trace the chain reactions among afflictions of the poor, including physical disease, depression, sexual abuse, inferior housing, malnutrition, and repeated failure in school, and relationships and jobs. Families he followed for five years illustrate the cascading problems that can lead, for example, from a mother's housing conditions to her child's asthma, to unembursed emergency treatment, to a bad credit rating, and to exorbitant interest on a car loan or, in another case, from a father's depression, to alcoholism, to his failure to complete a financial aid form, and to his son's entrance into the Air Force instead of college. To address the problems of poverty, Shipler argues, we have to connect the dots.

THIS SESSION WILL BE AUDIOTAPED.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 29-33

INDUSTRY-SUPPORTED SYMPOSIUM 29

7:00 p.m. - 10:00 p.m.

Room 106, Level 100, Toronto Convention Centre North

PHARMACOTHERAPY OF PSYCHOTIC AND MOOD
DISORDERS WITH CO-EXISTING MEDICAL ILLNESS
Supported by AstraZeneca Pharmaceuticals

Chp.: Michelle B. Riba, M.D.

Co-Chp.: Henry A. Nasrallah, M.D.

A Optimal Selection of Pharmacotherapy in Psychotic
and Mood Disorders With Coexisting Metabolic
Disorders

Henry A. Nasrallah, M.D.

(Continued next page)

MONDAY

B Management Approaches to Schizophrenia With Co-Occurring Cancer
Diana O. Perkins, M.D.

C Pharmacotherapy of Psychotic and Mood Disorders in the Context of Thromboembolic Disease
Quinton E. Moss, M.D.

D When Mental Illness Is Complicated By Respiratory Symptoms: Management Implications
Peter J. Weiden, M.D.

E When HIV Complicates Serious Psychiatric Disorders
Glenn J. Treisman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30

7:00 p.m.-10:00 p.m.

Canadian Room, Convention Floor, Royal York

HELPING DEPRESSED PATIENTS ACHIEVE REMISSION: ADVOCACY FOR IMPROVEMENT

Supported by Bristol-Myers Squibb Company

Chp.: A. John Rush, M.D.

A Heterogeneity in Response and Remission: Implications for Optimizing Treatment
A. John Rush, M.D.

B Switching Treatments: For Whom and to What Effect?
Maurizio Fava, M.D.

C Optimizing Antidepressant Treatments: Use of Augmentations and Combinations to Achieve Remission
Andrew A. Nierenberg, M.D.

D Psychotherapy: For Whom and to What Effect?
Michael E. Thase, M.D.

E Pharmacogenetics: Can We Customize the Treatments of Depression?
Roy H. Perlis, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 31

7:00 p.m.-10:00 p.m.

Concert Hall, Convention Floor, Royal York

UNDERSTANDING AND MANAGING THE TRANSITION OF ADHD FROM ADOLESCENCE TO YOUNG ADULTHOOD: THE MATURATION OF THE DISORDER

Supported by Shire US, Inc

Chp.: Timothy E. Wilens, M.D.

A Imaging the Brains of ADHD Adults: New Findings
George Bush, M.D.

B ADHD 'Not Otherwise Specified': Conceptual Issues
Stephen V. Faraone, Ph.D.

C ADHD Behind the Wheel: Driving With ADHD
Craig B. Surman, M.D.

D ADHD Goes to College: Planning, Protecting, and Prospering
Sharon B. Wigal, Ph.D.

E Emerging Therapies in the Treatment of ADHD
Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 32

7:00 p.m.-10:00 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

THE COGNITION, NEUROCIRCUITRY, AND DISABILITY INTERFACE: BRINGING EVIDENCE TO PRACTICE

Supported by Cephalon, Inc

Chp.: John H. Krystal, M.D.

A The Neurocircuitry of Cognition
John H. Krystal, M.D.

B Cognition: What Is the Role of Genetics?
Daniel R. Weinberger, M.D.

C Cognition, Attention, and Executive Function: How Do They Translate in Our Patients?
Philip D. Harvey, Ph.D.

D From Brain to Bedside: Understanding the Clinical Interface of Cognition and Neurocircuitry of Depression
Boadie W. Dunlop, M.D.

E Novel Treatments for Cognitive Enhancement: Can Drugs Make People Smarter?
Trevor Robbins, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 33

7:00 p.m.-10:00 p.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

TAKING CONTROL OF NEGATIVE SYMPTOMS: THE NEXT STEP FOR IMPROVED PATIENT OUTCOMES IN SCHIZOPHRENIA

Supported by Organon USA Inc and Pfizer Inc

Chp.: Steven G. Potkin, M.D.

A Recognizing Negative Symptoms and Their Importance
Joseph M. Pierre, M.D.

B Psychosis Circuits, Negative Symptoms, and Brain Imaging
Steven G. Potkin, M.D.

C Positive Outcomes With Negative Symptoms: Measuring and Monitoring Your Patients
Dawn I. Velligan, Ph.D.


D Treatment of Negative Symptoms
Hans-Juergen Moeller, M.D.

American Psychiatric Association

2007 Annual Meeting

May 19-24, 2007 • San Diego, CA

Whatever your specialty, whatever your background, there's something for you at the 160th Annual Meeting of the American Psychiatric Association in one of the world's most beautiful cities.



**Learn from the experts...
Earn up to 66 hours of Category 1 CME credits...
Meet colleagues from around the world...
Visit hundreds of commercial and educational exhibits...
Experience San Diego's beautiful beaches, gentle climate, and
world renowned San Diego Zoo.**

FOR MEMBERS ONLY

**Small clinically-based seminars led by outstanding educators...
Save up to \$515 on registration fees compared to nonmember rates...
Enjoy discounts at APPI Bookstore...
Early member-only housing and registration
December 1-31, 2006**

The advance registration packet and housing information
will be available online January 2, 2007 at www.psych.org.
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington • VA 22209-3901


American Psychiatric Association

2007 Annual Meeting

May 19–24, 2007 • San Diego, CA

More than 1,000 sessions...

- **Advances in Research**
- **Symposia**
- **Scientific and Clinical Reports**
- **Medical Updates**
- **Forms**
- **Workshops**
- **New Research Posters & Oral/Slide Sessions**
- **Research Advances in Medicine**
- **CME Courses**
- **Debates**
- **Distinguished Lecturers**



Continuing Medical Education Credit

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 hours in Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Contact Information

<http://www.psych.org>

E-mail: apa@psych.org

or call the APA toll free at: **1.888.357.7924**

TUESDAY, MAY 23, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 26-28

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 2

7:00 a.m.-8:30 a.m.

Canadian Room, Convention Floor, Royal York

CLINICAL IMPLICATIONS OF CHOICES OF ATYPICAL ANTIPSYCHOTICS: REALITIES AND MYTHS

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A Bridging Pharmacology and Clinical Effectiveness in Schizophrenia

Anissa Abi-Dargham, M.D.

B Advances in Pharmacotherapy for Maintenance Treatment in Bipolar Disorder

Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING THE MANAGEMENT OF GAD

Supported by Cephalon, Inc.

Chp.: David V. Sheehan, M.D.

A The Cognitive Expression of GAD

David J. Nutt, M.D.

B Gender Differences in GAD From Menarche to Menopause

Marlene P. Freeman, M.D.

C The Evidence Supporting Targeted Pharmacotherapy in GAD

David V. Sheehan, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2

7:00 a.m.-8:30 a.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

ATTAINING AND SUSTAINING REMISSION IN TREATMENT OF DEPRESSION WITH COMORBID OR RESIDUAL ANXIETY

Supported by Wyeth Pharmaceuticals

Chp.: Madhukar H. Trivedi, M.D.

A New Strategies to Address Anxiety and Resistant Somatic Symptoms

Mark H. Rapaport, M.D.

B How to Monitor Progress of Treatment of Depression With Anxiety

Madhukar H. Trivedi, M.D.

8:00 a.m. Sessions



COURSES 58-64

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 58 8:00 a.m.-12 noon

Conference Room F, Mezzanine, Sheraton Centre

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: INTRODUCTORY COURSE

Co-Directors: John Luo, M.D., Richard A. Montgomery, M.D.

Faculty: Robert C. Hsuing, M.D., Carlyle H. Chan, M.D., Jeffrey Spector, M.D.

COURSE 59 8:00 a.m.-12 noon

Essex Room, Mezzanine, Sheraton Centre

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.

Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 60 8:00 a.m.-12 noon

Windsor Room East, Mezzanine, Sheraton Centre

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: ADVANCED COURSE

Director: George T. Grossberg, M.D.

Faculty: Abhilash K. Desai, M.D.

COURSE 61 8:00 a.m.-12 noon

Windsor Room West, Mezzanine, Sheraton Centre

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

Director: Joseph C. Napoli, M.D.

Faculty: Michael Blumenfeld, M.D., V. Alex Kehayan, Ed.D.

TUESDAY

COURSE 62 8:00 a.m.-12 noon

City Hall, Second Floor, Sheraton Centre

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 63 8:00 a.m.-12 noon

Dominion Ballroom North, Second Floor, Sheraton Centre

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

COURSE 64 8:00 a.m.-12 noon

Kent Room, Second Floor, Sheraton Centre

COGNITIVE BEHAVIORAL THERAPY BOOT CAMP FOR PSYCHIATRISTS: EMPHASIZING THE PRACTICAL

Director: Anton C. Trinidad, M.D.

Faculty: Stephen P. McDermott, M.D., Robert Leahy, Ph.D.

9:00 a.m. Sessions

ADVANCES IN PERSONALITY DISORDERS

9:00 a.m.-12:30 p.m.

Room 107, Level 100, Toronto Convention Centre North

Chp.: John M. Oldham, M.D.

A Theories of Personality and Personality Disorders
Drew Westen, Ph.D.

B Manifestations and Clinical Diagnosis: Recent Findings From the Collaborative Longitudinal Personality Disorders Study
Andrew E. Skodol II, M.D.

C Boundary Issues and Personality Disorders
Thomas G. Gutheil, M.D.

D Gender and Personality Disorder
Leslie C. Morey, Ph.D.

E Update on Neurobiology and Neuroimaging In BPD and Related Personality Disorders
Martin Bohus, M.D.

Discussant: Glen O. Gabbard, M.D.

CLINICAL CASE CONFERENCE 3

9:00 a.m.-10:30 a.m.

Room 104 B, Level 100, Toronto Convention Centre North

ROCKING THE CRADLE: A CASE OF POSTPARTUM INFANTICIDE

Moderator: Nicole F. Wolfe, M.D.

Presenters: Alyson R. Kuroski-Mazzei, D.O., Donna M. Norris, M.D., Diana Dell, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1

9:00 a.m.-12:30 p.m.

Room 104 C, Level 100, Toronto Convention Centre North

TWENTY THERAPIES LATER: ADDRESSING TRANSFERENCE RESISTANCE

Moderator: R. Rao Gogineni, M.D.

Presenters: Robert Michels, M.D., Richard P. Kluft, M.D., Sheila Judge, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 65-70

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 65 9:00 a.m.-4:00 p.m.

Conference Rooms B/C, Mezzanine, Sheraton Centre

PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

COURSE 66 9:00 a.m.-4:00 p.m.

Conference Room D/E, Mezzanine, Sheraton Centre

A PSYCHODYNAMIC APPROACH TO TREATMENT REFRACTORY MOOD DISORDERS

Director: Eric M. Plakun, M.D.

Faculty: Edward R. Shapiro, M.D., David L. Mintz, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.
 Conference Room G, Mezzanine, Sheraton Centre

MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
 Dominion Ballroom South, Second Floor, Sheraton Centre

ACHIEVING AND SUSTAINING PSYCHOTHERAPY EFFECTIVENESS

Director: Paula Ravitz, M.D.
 Faculty: Melyn Leszcz, M.D., Nancy L. McNaughton, M.Ed., Allan D. Peterkin, M.D., Clare M. Pain, M.D., Robert Maunder, M.D., Jonathan J. Hunter, M.D., Rex Kay, M.D.

COURSE 69 9:00 a.m.-4:00 p.m.
 Kenora Room, Second Floor, Sheraton Centre

PERSONNEL MANAGEMENT FOR CLINICIAN-ADMINISTRATORS

Director: Stephen M. Soltys, M.D.
 Faculty: Kay Titchenal, SPHR, Joseph J. Parks III, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.
 Simcoe/Dufferin Room, Second Floor, Sheraton Centre

UNDERSTANDING THE PERSON BEHIND THE ILLNESS: AN APPROACH TO PSYCHODYNAMIC FORMULATION

Director: William H. Campbell, M.D.

DEBATE 2
 9:00 a.m.-10:30 a.m.
 Room 716 A, Level 700, Toronto Convention Centre South

MEDICATIONS IN PREGNANCY AND LACTATION: WHAT HAVE WE LEARNED?

Moderator: Linda L.M. Worley, M.D.
 Presenters: Zachary N. Stowe, M.D., Donna E. Stewart, M.D., Jay A. Gingrich, M.D.
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 10-13

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 10 Eric Hollander, M.D., on New Developments in Impulse-Control Disorders and Autism (*Meet the Author*)
 Grenadier Room, Main Level, Intercontinental Hotel

- 11 John F. Clarkin, Ph.D., on the Therapists' Experience With Borderline Patients (*Meet the Author*)
 Halton Room, Main Level, Intercontinental Hotel
- 12 Robert P. Cabaj, M.D., on Gay Men and Crystal Meth Abuse
 Humber Room, Main Level, Intercontinental Hotel
- 13 Carol A. Bernstein, M.D., on Directing a Residency Program: All You Ever Wanted to Know But Were Afraid to Ask
 Kingsway Room, Main Level, Intercontinental Hotel

LECTURES 11-13

LECTURE 11
 9:00 a.m.-10:30 a.m.
 Room 105, Level 100
 Toronto Convention Centre North

APA'S PATIENT ADVOCACY AWARD LECTURE
 Loretta E. Duvall
 Prevention, Early Intervention,
 and Elimination

Chp.: Andy McLean, M.D.

Loretta E. Duvall is a registered nurse with a half century of varied nursing and advocacy experiences, particularly for children's health. She is the President of the Stamford/Greenwich, Connecticut NAMI (2002-05) and the mother of four, three of whom were diagnosed, suffered, and died from schizophrenia. Ms. Duvall founded the Margaret Kay Memorial in memory of her daughter to eliminate stigma and promote understanding of mental illness through education in Connecticut and was deservedly honored with the 2003 NAMI, Connecticut Lifetime Achievement Award.
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 12
 9:00 a.m.-10:30 a.m.
 Exhibit Hall A, Level 300
 Toronto Convention Centre North

Joel Paris, M.D.
 Personality Disorders: Psychiatry's
 Stepchildren Come of Age

Chp.: Rozlyn Seligman, M.D.
 Co-Chp.: Vincent J. Blanch, M.D.

Joel Paris has been Professor and Chair of the Department of Psychiatry at McGill University (Montreal, Canada) since 1997. Dr Paris is a Past President of the Association for Research in Personality Disorders, and is currently Editor-in-Chief of the *Canadian Journal of Psychiatry*. He is also an active
(Continued next page)

educator and clinician. The main focus of Dr. Paris' research has been borderline personality disorders. He is best known for his longitudinal follow-up studies of patients with BPD. Other major areas of research include psychosocial risk factors in BPD, studies of children with borderline pathology, the neurobiological correlates of BPD in adults, as well as the predictors of suicidality. Dr. Paris' publications have been almost entirely devoted to the study of personality disorders, resulting in 120 peer reviewed articles, 23 book chapters, and eight books. *Distinguished Psychiatrist Lectures Series*. THIS SESSION WILL BE AUDIOTAPED.

LECTURE B

9:00 a.m.-10:30 a.m.
Room 718 A/B, Level 700
Toronto Convention Centre South

T-K.LI, M.D.

What Have We Learned About Alcoholism From Animal Models?

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Charles P. O'Brien, MD
Co-Chp.: Richard Suchinsky, MD

Ting-Kai (T. K.) Li, M.D., is the Director of the National Institute on Alcohol Abuse and Alcoholism, a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services. Previous to his appointment, Dr. Li was Distinguished Professor of Medicine at Indiana University School of Medicine and the Director of the Indiana University School of Medicine Alcohol Research Center. Dr. Li's distinguished research career includes advances that have transformed the way alcoholism is understood and the means of investigating alcohol's effects on the body and brain, including the characterization of the structure and dynamics of the multiple genetic variants of alcohol dehydrogenase (ADH), the enzyme that catalyzes the first step in the metabolism of ethanol, and the differences among individuals in ADH-related physiology. Dr. Li also pioneered the development of animal models of alcohol consumption. These animal lines helped cement the once radical notion that alcohol consumption behavior was genetically influenced. Dr. Li is the author of more than 400 journal articles and book chapters, the recipient of numerous prestigious awards for his scientific accomplishments, including the Jellinek Award, the James B. Isaacson Award for Research in Chemical Dependency Diseases, and the R. Brudley Smithers Distinguished Science Award. He is a past member of the National Advisory Council on Alcohol Abuse and Alcoholism and the Advisory Committee to the Director, NIH, and a Past President of the Research Society on Alcoholism. Dr. Li was elected to membership in the Institute of Medicine of the National Academy of Sciences in 1999.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 7-9

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 7 Ronald O. Rieder, M.D., on Building a Research Career in Psychiatry
Room 201 A, Level 200, Toronto Convention Centre North
- 8 Michael Myers, M.D., on Treating Physicians and Their Families: Clinical Dilemmas
Room 201 B, Level 200, Toronto Convention Centre North
- 9 Zebulon Taintor, on Internet Addiction
Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE

9:00 a.m.-11:00 a.m.

Room 716 B, Level 700, Toronto Convention Centre South

AGING, LONGEVITY, AND NEUROLOGICAL DISORDERS

Chp.: Anand Pandya, M.D.

- Participants: Donald Redelmeier, M.D., on Death Rates and Success
- Janis Miyasaki, M.D., on Just Do It Again and Again and Again: The Dopamine Dysregulation Syndrome in Parkinson's Disease
- Angela M. Cheung, M.D., on Research Advances in Osteoporosis
- Stephanie J. Brister, M.D., on Neurobehavioral Outcomes Following Cardiac Surgery: How Can They Be Improved?

WORKSHOPS

COMPONENTS 20-28

COMPONENT WORKSHOP 20 9:00 a.m.-10:30 a.m.

Room 104 A, Level 100, Toronto Convention Centre North

THE END OF HOSPITALIZATION? TRENDS IN INTENSIVE MENTAL HEALTH SERVICES FOR CHILDREN AND ADOLESCENTS

APA Council on Children, Adolescents, and Their Families

Co-Chps.: Harold Alan Pincus, M.D., Brady G. Case, M.D.
Participants: Bradley D. Stein, M.D., Melisa D. Rowland, M.D., Mark A. Demidovich, M.D.

COMPONENT WORKSHOP 21 9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

BRIDGE SUICIDE: THE PRINCE EDWARD VIADUCT IN TORONTO AND THE GOLDEN GATE BRIDGE IN SAN FRANCISCO

APA Northern California Psychiatric Society

Chp.: Mel Blaustein, M.D.
Participant: John K. Hines

COMPONENT WORKSHOP 22 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

YOU CAN BE LEADERS TOO: A WORKSHOP FOR IMGs AND MINORITIES

APA Committee on International Medical Graduates

Chp.: Josie L. Olympia, M.D.
Participants: Sanjay Dube, M.D., Albert C. Gaw, M.D., Rodrigo A. Munoz, M.D., Annel B. Primm, M.D., Francis M. Sanchez, M.D.

COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

MANAGED PHARMACY AND PAY FOR PERFORMANCE: THE NEW MANAGED CARE

APA Committee on Managed Care

Chp.: Paul H. Wick, M.D.
Participants: Carol L. Alter, M.D., Gregory G. Harris, M.D., David K. Nace, M.D.

COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

DOING IT IN PUBLIC: OPPORTUNITIES IN PUBLIC SECTOR PSYCHIATRY

APA Council on Social Issues and Public Psychiatry

Co-Chps.: Cassandra F. Newkirk, M.D., Matthew O. Hurford, M.D.
Participants: Delane E. Casiano, M.D., Jagannathan Srinivasaraghavan, M.D., Debra F. Kirsch, M.D.

COMPONENT WORKSHOP 25 9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

IT TAKES A VILLAGE: ASSESSING BEHAVIORAL AND PSYCHIATRIC DISORDERS IN MENTALLY RETARDED INDIVIDUALS

APA Committee on Developmental Disabilities

Chp.: Roxanne Dryden-Edwards, M.D.
Participants: Steve Sugden, M.D., Stephanie Hamarman, M.D., Karen G. Gennaro, M.D., Lee Combrinck-Graham, M.D.

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

MEDIA OUTREACH TO LATINOS: ENHANCING ACCESS AND REDUCING STIGMA

APA Committee of Hispanic Psychiatrists

Co-Chps.: Andres J. Pumariega, M.D., Ana E. Campo, M.D.
Participants: Gabriella Cora-Locatelli, M.D., Gamaliel Ramos, Lydia Sermons-Ward

COMPONENT WORKSHOP 27 9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

BUPRENORPHINE: CLINICAL ISSUES AND MANAGING MORE COMPLICATED PATIENTS

APA Corresponding Committee on Training and Education in Addiction Psychiatry

Chp.: John A. Renner, Jr., M.D.
Participants: Herbert D. Kleber, M.D., Eric C. Strain, M.D., George Kolodner, M.D.

COMPONENT WORKSHOP 28 9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

TEN WAYS TO STAY OUT OF TROUBLE: ETHICS AND ETIQUETTE

APA Ethics Committee and APA Ethics Appeal Board

Chp.: Spencer Eth, M.D.
Participants: Wade C. Myers, M.D., William Arroyo, M.D., Laura W. Roberts, M.D., Harriet C. Stern, M.D., Scott Y. Kim, M.D., Richard D. Milone, M.D.

ISSUES 29-41

ISSUE WORKSHOP 29 9:00 a.m.-10:30 a.m.
Room 701 A, Level 700, Toronto Convention Centre South

PHARMACEUTICAL BIAS IN PRESENTATIONS: DO'S AND DON'TS FOR EDUCATORS

Association for Academic Psychiatry

Co-Chps.: Donald M. Hilty, M.D., Kelli J.R. Harding, M.D.
Participant: Philip R. Muskin, M.D.

ISSUE WORKSHOP 30 9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

WHEN PSYCHIATRISTS GET CANCER

Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.
Participants: Marion Zucker Goldstein, MD, Lawrence Hartmann, M.D., Abigail B. Schlesinger, M.D., Madelaine M. Wohlreich, M.D.

TUESDAY

ISSUE WORKSHOP 31 9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

THE CREATION AND FUNCTION OF A MENTAL HEALTH COURT

Co-Chps.: Lawrence K. Richards, M.D., Roger Peele, M.D.
Participants: Edward F. Ornston, Richard D. Schneider, Margaret Creal LL.B., Derek Pallandi, M.D., Sander G. Genser, M.D.

ISSUE WORKSHOP 32 9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

METABOLIC SCREENING OF PATIENTS ON ANTIPSYCHOTIC MEDICATIONS: DEVELOPMENT OF A QUALITY IMPROVEMENT PROGRAM IN AN URBAN TRAINING CLINIC

Co-Chps.: Diane B. Gottlieb, M.D., Karen L. Melendez, M.D.
Participants: Aurelia Bizamcer, M.D., Mallika Patri, M.D., Harvinia Gahunia, M.D., Diana Antia, M.D.

ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room 707, Level 700, Toronto Convention Centre South

THE DIFFICULT-TO-TREAT BULIMIA NERVOSA

Chp.: Jennifer L. McLain, M.D.
Participant: Waguiah W. Ishak, M.D.

ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

INITIATING COUPLES THERAPY TODAY

Chp.: Ian E. Alger, M.D.
Participant: Anita Menfi, R.N.

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 711, Level 700, Toronto Convention Centre South

LEGAL ISSUES IN CONSULTATION-LIAISON PSYCHIATRY

Chp.: Renee M. Sorrentino, M.D.

ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

COMPULSIVE HOARDING: CONCEPTUALIZATION AND TREATMENT

Chp.: Jose A. Yaryura-Tobias, M.D.
Participant: Fugen Neziroglu, Ph.D.

ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 714 A, Level 700, Toronto Convention Centre South

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

EVIDENCE-SUPPORTED, RISK-MINIMIZING, AND COST-CONSCIOUS APPROACHES IN PSYCHOPHARMACOLOGY

Chp.: David N. Osser, M.D.
Participants: Andrew A. Nierenberg, M.D., Theo C. Manschreck, M.D., Dan V. Iosifescu, M.D.

ISSUE WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room 717 A, Level 700, Toronto Convention Centre South

MURDER MYSTERIES, GAMES, AND PSYCHIATRIC EDUCATION: HOW AND WHY TO DO A "WHO DONE IT?"

Chp.: Andrea Waddell, M.D.
Participants: Susan Abbey, M.D., Lana M. Benedek, M.D., Bruce C. Ballon, M.D.

ISSUE WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room 717 B, Level 700, Toronto Convention Centre South

PRACTICAL PHARMACOTHERAPY FOR THE TREATMENT OF ALCOHOL DEPENDENCE
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Robert M. Swift, M.D.
Participants: Roger D. Weiss, M.D., Allen Zweben, D.S.W.

ISSUE WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room 801 A, Level 800, Toronto Convention Centre South

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 1

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Donna Vanderpool, J.D., Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

MEDIA WORKSHOP 3
9:00 a.m.-10:30 a.m.
Quebec Room, Mezzanine Floor, Royal York

CRASH: A PORTRAIT OF MULTICULTURAL AMERICA AT THE FLASHPOINT
APA Council on Minority Mental Health and Health Disparities

Co-Chps.: Francis G. Lu, M.D., Heather M. Hall, M.D.
Participants: Lilliam Comas-Diaz, Ph.D., Frederick M. Jacobsen, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 14-17

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 14 David M. McDowell, M.D., on the Clinical Use of Buprenorphine
Grenadier Room, Main Level, Intercontinental Hotel
- 15 Nada L. Stotland, M.D., on Getting the Psychiatric Message to the Public: You Can Do It
Halton Room, Main Level, Intercontinental Hotel
- 16 Avram H. Mack, M.D., on Killer Adolescents: Drugs, School, and the Courts
Humber Room, Main Level, Intercontinental Hotel
- 17 Randall D. Marshall, on Trauma in the Modern World: The Role of the Psychiatrist (*Residents Only*)
Niagara Room, Lower Level, Intercontinental Hotel

LECTURES 14-16

LECTURE 14

11:00 a.m.-12:30 p.m.

Room 105, Level 105

Toronto Convention Centre North

APA'S SOLOMON CARTER FULLER AWARD LECTURE

Milton C. Hollar, M.D.

History of and Corrective Proposals for Disparities in Mental Health Care

Chp.: Sandra C. Walker, M.D.

Dr. Hollar was raised in Newark, N.J., spending summers in Durham, N.C., with his aunts, uncles, and cousins. At graduation, Dr. Hollar received the Class of 1948 Award for outstanding excellence and a scholarship to Syracuse University. In January, 1951, Dr. Hollar started a military stint with the U.S. Army that lasted through the Korean Conflict ending September 1953, with enrollment at the University College of New York University. Currently, Dr. Hollar is a retired Major, U.S. Army Medical Corps. Service time included training as a pilot at San Marcos Texas Air Force Base and positions as Executive and Commanding Officer of the Ordnance Corps training school for noncommissioned officers. Following a bachelor's degree in 1955, Dr. Hollar earned a master's degree at NYU and completed a psychology internship

at The State Island Mental Health Center. During the following four years at Howard University College of Medicine, Dr. Hollar worked as a psychologist at the Department of Psychiatry, served as summer externship at Walter Reed Army Hospital and was the F.Y. Williams Award Recipient. Since 1975, Dr. Hollar has worked at the Bronx Psychiatric Center, a public mental health facility, as a supervisor in training and mentoring psychiatry residents.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15

11:00 a.m.-12:30 p.m.

Exhibit Hall A, Level 300

Toronto Convention Centre North

Vivian W. Pinn, M.D.

Priorities, Initiatives, and Women's Health Research

Chp.: Leah J. Dickstein, M.D.

Co-Chp.: David Benedek, M.D.

Vivian W. Pinn, M.D., has been the Director of NIH's Office of Research on Women's Health since 1991, when it was established, and in 1994, was also named Associate Director for Research on Women's Health, NIH. Graduating from Wellesley College, then the University of Virginia School of Medicine, she completed pathology postgraduate training at Harvard's Massachusetts General Hospital, was Assistant Dean for Student Affairs at Tufts University School of Medicine, and then Professor and Pathology Department Chair at Howard University, Washington, D.C. Her career goals focused primarily on health and career opportunities for women and minorities and more recently include educating the scientific community about the importance of sex and gender factors in basic science, clinical research, and health care.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 16

11:00 a.m.-12:30 p.m.

Room 718 A/B, Level 700

Toronto Convention Centre South

Mindy Thompson Fullilove, M.D.

Psychiatric Implications of Displacement: The Emotional Costs of Losing Human Habitat

Chp.: Mary Kay Smith, M.D.

Co-Chp.: Silvia W. Clark, M.D.

Mindy Thompson Fullilove, M.D. is a research psychiatrist at New York State Psychiatric Institute and a professor of clinical psychiatry and public health at Columbia University. She was educated at Bryn Mawr

(Continued next page)

College (AB, 1971) and Columbia University (MS, 1971; MD 1978). She is a board certified psychiatrist, having received her training at New York Hospital-Westchester Division (1978-1981) and Montefiore Hospital (1981-1982). She has conducted research on AIDS and other epidemics of poor communities, with a special interest in the relationship between the collapse of communities and decline in health. From her research, she has published *Root Shock: How Tearing Up City Neighborhoods Hurts America and What We Can Do About It*, and *The House of Jacob: Medications on Family and Place*. She has also published numerous articles, book chapters, and monographs. She has received many awards, including inclusion on *Best Doctors* lists and two honorary doctorates (Catham College, 1999, and Bank Street College of Education, 2002). She has served as a visiting professor at the University of Pittsburgh Graduate School of Public Health (1997-1998) and in 2006 she was appointed *professeure invitée* at the National Conservatory of Arts and Trades in Paris, France. Her work in AIDS is featured in Jacob Levenson's *The Secret Epidemic: The Story of AIDS in Black America*. Her current work focuses on the connection between urban dysfunction and mental health.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 10-12

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 10 Prakash S. Masand, M.D., on Atypical Antipsychotics: 2006 and Beyond
Room 201 A, Level 200, Toronto Convention Centre North
- 11 John Livesley, M.D., on Current Issues in the Treatment of Personality Disorder
Room 201 B, Level 200, Toronto Convention Centre North
- 12 Robin A. Hurley, M.D., on Neuropsychiatric Aspects of Traumatic Brain Injury
Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 2

11:00 a.m.-12:30 p.m.

Room 716 A, Level 700, Toronto Convention Centre South

ADD KIDS GET SMART NATURALLY

Presenters: Richard P. Brown, M.D.

Chp.: Patricia L. Gerbarg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 2 Paul S. Links, M.D., on Clinical Research Into Suicide
Oakville Room, Main Level, Intercontinental Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 12-22

SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.-12:30 p.m.

Room 104 B, Level 100, Toronto Convention Centre North

GENDER DIFFERENCES IN CHILD AND ADOLESCENT BEHAVIORS

Chp.: Kimberly A. Yonkers, M.D.

Co-Chp.: Daniel Chapman, M.D.

11:00 a.m.

- 34 Prediction of Suicidality and Violence in Hospitalized Adolescents: Comparisons by Gender
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.

11:30 a.m.

- 35 Daily Cigarette Smoking Among Colombian High School Students: Gender Related Factors
Jorge A. Martínez-Mantilla, Walter Amaya-Naranjo, Horacio A. Campillo, Luis A. Díaz-Martínez M.S., Adalberto Campo-Arias, M.D.

12 noon

- 36 Subtypes of Aggression: Incidence and Gender Differences in Adolescents
Melissa McMullin, B.A., Arne Popma, M.D., Niranjana S. Karnik, M.D., Katie Araujo, Ph.D., Hans Steiner, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 13

11:00 a.m.-12:30 p.m.

Room 104 D, Level 100, Toronto Convention Centre North

VIOLENCE, TRAUMA, AND VICTIMIZATION

Chp.: Pierre W. Gagne, M.D.

Co-Chp.: Peter B. Gruenberg, M.D.

11:00 a.m.

- 37 Terrorism: A Phenomenon at the Interface Between Individual and Group Psychology
David A. Rothstein, M.D.

11:30 a.m.

- 38 The Role of the Psychiatrist in Hospital Emergency Planning
Julia B. Frank, M.D.

12 noon

- 39 **Psychopathological Effects of Work Place Harassment**
Jose L. Gonzalez de Rivera, M.D., Manuel J. Rodriguez-
Abuin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14

11:00 a.m.-12:30 p.m.

Room 201 D, Level 200, Toronto Convention Centre North

EMOTIONALITY, GENDER, AND LIFE
SATISFACTION IN ADOLESCENTS

Chp.: Earnest Poortinga, M.D.

Co-Chp.: Kathryn J. Ednie, M.D.

11:00 a.m.

- 40 **The Role of Subjective Emotional Reactivity to Affective
Pictures in Predicting Emotional-Behavior Disorders
Over a One-Year Period in an Unselected Community
Sample of Children Between the Ages of 7 to 11**
Carla Sharp, Ph.D.

11:30 a.m.

- 41 **Life Satisfaction in Young Urban Adolescents**
Maribeth Pender, Ph.D.

12 noon

- 42 **Effectiveness of Group Interventions for Parents of
Gender-Variant Children**
Edgardo J. Menvielle, M.D., Darryl B. Hill, Ph.D., Catherine
Tuerk, M.A., Tyrone Hanley, B.S., Joseph Henry, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15

11:00 a.m.-12:30 p.m.

Room 205 A, Level 200, Toronto Convention Centre North

NEUROBIOLOGY AND PSYCHOIMMUNOLOGY

Chp.: Edward Kingstone, M.D.

Co-Chp.: Yasir Khan, M.D.

11:00 a.m.

- 43 **Lymphocyte and Platelet Alteration of the 5HT
Transporter in Patients With Psychosis**
Donatella Marazziti, M.D., Mario Catena, M.D., Stefano
Baroni, D.Sc., Bernardo Dell'Osso, M.Ed., Gino
Giannaccini, D.Sc., Gino Giannaccini, D.Sc.

11:30 a.m.

- 44 **Potential Role of Interleukin-6 and HPA Axis in Breast
Cancer Patients With MDD**
Haldun Soygur, M.D., Ozden Palaoglug, M.D., Eyup Akarsu,
M.D., Elvan Ozalp, MD., Eylem Cankurtaran, M.D., Levent
Turhan, M.D., Ismail Hakki Ayhan, M.D.

12 noon

- 45 **NMDA Receptors and BPD: A Critical Mediator**
Bernadette M. Grosjean, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16

11:00 a.m.-12:30 p.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

MEDICATION RESPONSE IN BIPOLAR DISORDER

Chp.: Adel A. Gabriel, M.D.

Co-Chp.: Janet L. Tekell, M.D.

11:00 a.m.

- 46 **Galantamine-CR for Cognitive Dysfunction in Bipolar
Disorder: Efficacy And Biological Correlates**
Dan V. Iosifescu, M.D., Constance Moore, Ph.D., Thilo
Deckersbach, Ph.D., Perry F. Renshaw, MD., Maurizio
Fava, M.D., Andrew A. Nierenberg, M.D., Gary S. Sachs, M.D.

11:30 a.m.

- 47 **Rate of Improvement With Quetiapine Across Different
Symptoms and Symptom Clusters in Bipolar Disorder**
Terence A. Ketter, M.D., Joseph R. Calabrese, M.D.,
Robert M.A. Hirschfeld, M.D.

12 noon

- 48 **Efficacy of the Antipsychotics in Anxiety Symptoms
With or Without Bipolar Disorder**

Keming Gao, M.D., Joseph R. Calabrese, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17

11:00 a.m.-12:30 p.m.

Room 206 E/F, Level 200, Toronto Convention Centre North

PRESCRIPTION AND COMPLIANCE IN BIPOLAR
DISORDER

Chp.: Joseph Berger, M.D.

Co-Chp.: Gary S. Sachs, M.D.

11:00 a.m.

- 49 **Prescription Patterns for Latin Americans Treated for
MDD in Naturalistic Clinical Practice Settings**
Alan J. Brnabic, Margaret McBride, Manuel O. Sanchez,
Florence Kerr-Correa, M.D., Antonio Celis-Perdomo,
Hector J. Duenas

11:30 a.m.

- 50 **Nonadherence in Bipolar Disorder: A Qualitative Study
Exploring Perceptual and Practical Barriers to Taking
Medication**
Jane Clatworthy, Richard Bowskill, Tim Rank, Rhian Parham,
Rob Horne

12 noon

- 51 **Patient Dissatisfaction With Information Received
About Medicines Prescribed for Bipolar Disorder**
Richard Bowskill, Jane Clatworthy, Rhian Parham, Tim Rank,
Rob Horne

THIS SESSION WILL BE AUDIOTAPED.

TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 18

11:00 a.m.-12:30 p.m.

Alberta Room, Mezzanine Floor, Royal York

SPECIAL POPULATIONS AND MOOD DISORDERS

Chp.: Norman E. Alessi, M.D.

Co-Chp.: Adrienne O. Tan, M.D.

11:00 a.m.

52 **Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic Distinction**

Giulio Perugi, M.D., Gabriele Masi, M.D., Cristina Toni, M.D., Stefania Millepiedi, M.D., Maria Mucci, M.D., Hagop S. Akiskal, M.D.

11:30 a.m.

53 **Treatment of SAD With a Carbohydrate-Rich Nutrient Mixture**

David Mischoulon, M.D., Judith Wurtman, Ph.D., Mark Vangel, Ph.D., Richard Wurtman, M.D.

12 noon

54 **Impaired Mood and Social Functioning Among Adult Children of Parents With Depression**

Ruth C. Cronkite, Ph.D., Ralph W. Swindle, Ph.D., Rebecca L. Robinson, M.S., Rudolf H. Moos, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19

11:00 a.m.-12:30 p.m.

Confederation 3 Room, Mezzanine Floor, Royal York

BRAIN IMAGING

Chp.: Paul Fedoroff, M.D.

Co-Chp.: Sarah J. Thompson, M.D.

11:00 a.m.

55 **fMRI of the Brain Reward System: Manipulation of Risk and Reward Value**

Juliana Yacubian, Ph.D., Katrin Schroeder, Tobias Sommer, Jan Glaescher, Dieter F. Braus, Ph.D., Christian Buechel, Ph.D.

11:30 a.m.

56 **Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort**

Erika Lauronen, M.D., Jouko Miettunen, Ph.D., Juha M. Veijola, M.D., Matti K. Isohanni, M.D.

12 noon

57 **Progressive Glutamatergic and Gray Matter Changes in First-Episode Patients With Schizophrenia and High Field Proton MRS**

Peter C. Williamson, M.D., Jean Théberge, Ph.D., Kathryn E. Williamson, B.S., Naoko Aoyama, M.S., Rahul Manchanda, M.D., Maria Densmore, B.S., Dick J. Drost, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20

11:00 a.m.-12:30 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

MEDICAL ISSUES IN THE TREATMENT OF SCHIZOPHRENIA

Chp.: Norman C. Moore, M.D.

Co-Chp.: Michael Demas, M.D.

11:00 a.m.

58 **Metabolic Syndrome in Thai Patients With Schizophrenia: Prevalence and Incidence**

Manit Srisurapanont, M.D., Surinporn Likhitsathian, M.D., Vudhichai Boonyanaruthee, M.D., Chawanant Charnsilp, M.D.

11:30 a.m.

59 **The Swedish Study of Metabolic Risks in Psychiatry**

Urban P. Osby, M.D.

12 noon

60 **Olanzapine Treatment Does Not Increase Ten-Year Cardiovascular Risk: Comparison With Haloperidol in Patients With Schizophrenia**

Yoram Barak, M.D., Marmina Swartz, M.D., Igor Plopsy, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21

11:00 a.m.-12:30 p.m.

Library, Mezzanine Floor, Royal York

NEUROPSYCHIATRY

Chp.: Robert B. Shulman, M.D.

Co-Chp.: Jeffrey D. Beitel, M.D.

11:00 a.m.

61 **Psychosocial Treatment of Depression in Parkinson's Disease**

Amy Farabaugh, Ph.D., Aila J. McCutchen, Psy.D., Jacqueline Buchin, Ph.D., John Growdon, M.D., Liang Yap, Ph.D., Joel A. Pava, Ph.D., Maurizio Fava, M.D.

11:30 a.m.

62 **Frequency of EEG Abnormalities and Results of Antiepileptic Drug Therapy in Unstable Mood Disorders**

Drake Duane, M.D.

12 noon

63 **How to FACE® Juvenile Epilepsy and Bipolar Disorder: Clinical Challenges**

Smadar Celestin-Westreich, Ph.D., Leon-Patrice Celestin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22

11:00 a.m.-12:30 p.m.

Salon B, Convention Floor, Royal York

INTERNATIONAL EPIDEMIOLOGY**Chp.:** Derya I. Akbiyik, M.D.**Co-Chp.:** Meera Vaswani, Ph.D.

11:00 a.m.

64 Mental Health in Iranian Medical Students and Doctors

Seyed M. Assadi, M.D., Maryam Noroozian, M.D., Sayed Vahid Shariat, M.D.

11:30 a.m.

65 Three-Year, Follow-Up Study of the Psychosocial Predictors of Delayed and Unresolved Post-Traumatic Stress Symptoms of Geriatric Earthquake Survivors in Yu-Chi, Taiwan

Frank H. Chou, M.D.

12 noon

66 Three-Year, Follow-Up Study of the Relationship Between Post-Traumatic Stress Symptoms and Quality of Life Among Geriatric Earthquake Survivors in Yu-Chi, Taiwan

Kuan-Yi Tsai, M.D.

WORKSHOPS**COMPONENTS 29-36****COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.**

Room 104 A, Level 100, Toronto Convention Centre North

ADVANCES IN THE TREATMENT OF INTIMATE PARTNER VIOLENCE*APA Rhode Island Psychiatric Society's Committee on Women***Chp.:** Alison M. Heru, M.D.**Participants:** Patricia R. Recupero, M.D., Marilyn Price, M.D.**COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.**

Room 205 B, Level 200, Toronto Convention Centre North

EMPLOYMENT IN THE POST-RESIDENCY YEARS: GETTING WHAT YOU WANT*APA Committee of Residents and Fellows***Chp.:** William C. Wood, M.D.**Participants:** Jonathan F. Borus, M.D., Robert P. Roca, M.D., Tanya R. Anderson, M.D.**COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.**

Room 205 C, Level 200, Toronto Convention Centre North

CAN WE TALK? A MODEL FOR CONSTRUCTIVE CONVERSATION BETWEEN OPPONENTS AND ADVOCATES OF SAME SEX RELATIONSHIPS*APA Corresponding Committee on Religion, Spirituality, and Psychiatry***Co-Chps.:** John R. Peteet, M.D., Allan M. Josephson, M.D.**Participants:** Paul Feheley, Chris Ambidge, Jack Drescher, M.D.**COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m.**

Room 205 D, Level 200, Toronto Convention Centre North

FROM DIAGNOSIS TO TREATMENT OF INFANTS AND YOUNG CHILDREN*APA Corresponding Committee on Infancy and Early Childhood***Chp.:** Irene Chatoor, M.D.**Participants:** Joan L. Luby, M.D., Harry H. Wright III, M.D.**COMPONENT WORKSHOP 33 11:00 a.m.-12:30 p.m.**

Room 206 C/D, Level 200, Toronto Convention Centre North

MOVING THE PSYCHIATRIC AGENDA IN THE HOUSE OF MEDICINE*APA/AMA Delegation Section Council on Psychiatry***Chp.:** Jack S. McIntyre, M.D.**Participants:** Carolyn B. Robinowitz, M.D., Jeffrey Akaka, M.D., John J. Wernert III, M.D., Karen G. Gennaro, M.D., Nakia G. Scott, M.D.**COMPONENT WORKSHOP 34 11:00 a.m.-12:30 p.m.**

Room 703, Level 700, Toronto Convention Centre South

EUROPEAN PSYCHIATRY: HEALTH AND MENTAL HEALTH POLICY AFTER THE HELSINKI SUMMIT*APA Council on Global Psychiatry and the World Psychiatric Association Conflict Management and Conflict Resolution Section***Co-Chps.:** Eliot Sorel, M.D., Rodrigo A. Munoz, M.D.**Participants:** Juan J. Lopez-Ibor, Jr., M.D., Sheila Hollins, M.D., Sass Henning, M.D., Jiri Raboch, M.D.**COMPONENT WORKSHOP 35 11:00 a.m.-12:30 p.m.**

Room 705, Level 700, Toronto Convention Centre South

FROM FANTASY TO REALITY: RECRUITMENT OF MINORITIES IN CLINICAL RESEARCH*APA Council on Minority Mental Health and Health Disparities***Co-Chps.:** Annelle B. Primm, M.D., Sanjay Dube, M.D.**Participants:** Darlene Nipper, Christopher Edwards, Ph.D., Basil D. Halliday M.S.C., William Waggoner, Ph.D.**COMPONENT WORKSHOP 36 11:00 a.m.-12:30 p.m.**

Room 707, Level 700, Toronto Convention Centre South

INTEGRATING EVIDENCE-BASED PSYCHIATRY WITH CLINICAL INTELLIGENCE*APA Lifers***Co-Chps.:** Abram M. Hostetter, M.D., Sheila H. Gray, M.D.**Participant:** Carl C. Bell, M.D.

TUESDAY

ISSUES 42-53

ISSUE WORKSHOP 42 11:00 a.m.-12:30 p.m.

Room 709, Level 700, Toronto Convention Centre South

TEACHING COGNITIVE BEHAVIOR THERAPY TO RESIDENTS

Co-Chps.: Judith S. Beck, Ph.D., Donna M. Sudak, M.D.

Participant: Jesse H. Wright III, M.D.

ISSUE WORKSHOP 43 11:00 a.m.-12:30 p.m.

Room 711, Level 700, Toronto Convention Centre South

TEACHING ON THE FLY: PRACTICAL TIPS FOR TEACHING MEDICAL STUDENTS ONE-TO-ONE

Co-Chps.: Andrea E. Waddell, M.D., Jodi S. Lofchy, M.D.

Participants: Lana M. Benedek, M.D., Kien T. Dang, M.D.

ISSUE WORKSHOP 44 11:00 a.m.-12:30 p.m.

Room 714 A, Level 700, Toronto Convention Centre South

INFERTILITY: FROM PATIENT CARE TO ADVOCACY AND PUBLIC POLICY

Chp.: Roxanne Dryden-Edwards, M.D.

Participant: Ellen Patterson, L.C.S.W.

ISSUE WORKSHOP 45 11:00 a.m.-12:30 p.m.

Room 717 A, Level 700, Toronto Convention Centre South

AN INTEGRATIVE APPROACH TO CULTURAL COMPETENCE TRAINING FOR RESIDENT AND STAFF PSYCHIATRISTS

Co-Chps.: Kenneth P. Fung, M.D., Ted Lo, M.D.

Participants: Lisa F. Andermann, M.D., Ari E. Zaretsky, M.D.

ISSUE WORKSHOP 46 11:00 a.m.-12:30 p.m.

Room 717 B, Level 700, Toronto Convention Centre South

CAREER ADVANCEMENT IN ACADEMIC PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS

Co-Chps.: Dimitri D. Markov, M.D., Elisabeth J.S. Kunkel, M.D.

Participants: Michelle B. Riba, M.D., David J. Lynn, M.D., Marina Goldman, M.D., John-Paul Gomez, M.D., Michael J. Vergare, M.D.

ISSUE WORKSHOP 47 11:00 a.m.-12:30 p.m.

Room 801 A, Level 800, Toronto Convention Centre South

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 2

Chp.: William E. Callahan, Jr., M.D.

Participants: Keith W. Young, M.D., Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 48 11:00 a.m.-12:30 p.m.

Room 803 A/B, Level 800, Toronto Convention Centre South

GRASSROOTS ADVOCACY FOR PATIENTS AND FOR THE PSYCHIATRIC PROFESSION: HOW MEDICAL STUDENTS, RESIDENTS, AND EARLY CAREER PSYCHIATRISTS CAN AFFECT THE LEGISLATIVE, REGULATORY, AND POLITICAL PROCESS

Co-Chps.: Jose P. Vito, M.D., Tony B. Shivers

Participants: Jason Pray, Harsh K. Trivedi, M.D.

ISSUE WORKSHOP 49 11:00 a.m.-12:30 p.m.

Room 810, Level 800, Toronto Convention Centre South

TEACHING BOUNDARIES TO PRACTICING CLINICIANS

Chp.: Werner Tschan, M.D.

Participants: Gail E. Robinson, M.D., Michael F. Myers, M.D., Gary R. Schoener, Psy.D., Andrea Celenza, Ph.D.

ISSUE WORKSHOP 50 11:00 a.m.-12:30 p.m.

Manitoba Room, Mezzanine Floor, Royal York

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

Co-Chps.: Vladimir Bokarius, M.D., Steven H. Richeimer, M.D.

Participants: Ali Nemat, M.D., Lisa Victor, Ph.D., Yogi Matharu, DPT, Mary K. Wolf, OTD

ISSUE WORKSHOP 51 11:00 a.m.-12:30 p.m.

Tudor 7 Room, Mezzanine Floor, Royal York

ARE THERE LIMITS TO BOUNDARY LIMITS?

Chp.: Malkah T. Notman, M.D.

Participants: Carl P. Malmquist, M.D., Linda M. Jorgenson J.D., Elissa P. Benedek, M.D., Lawrence B. Inderbitzin, M.D.

ISSUE WORKSHOP 52 11:00 a.m.-12:30 p.m.

Tudor 8 Room, Mezzanine Floor, Royal York

SEXUAL HISTORY: THE ART AND THE SCIENCE

Co-Chps.: Shahrar R. Amiri, M.D., Danni Z. Michaeli, M.D.

Participants: Waguuh W. Ishak, M.D., Monisha R. Vasa, M.D., Stephanie M. Stewart, M.D., Rekha Raja, D.O.

ISSUE WORKSHOP 53 11:00 a.m.-12:30 p.m.

Salon A, Convention Floor, Royal York

THE PSYCHIATRY RESIDENT AS ADVOCATE: PRACTICAL STEPS FROM THE CLINIC TO THE CAPITOL

Co-Chps.: Joan M. Anzia, M.D., James L. Griffith, M.D.

Participants: Suena W. Huang, M.D., Jeremy A. Lazarus, M.D., Tiffany R. Farchione, M.D., Joel J. Silverman, M.D.

12 noon Sessions

FORUMS 7-11

FORUM 7 12 noon-1:30 p.m.

Room 701 A, Level 700, Toronto Convention Centre South

WHO PRESCRIBES WHAT TO WHOM AND WHY? UNDERSTANDING AND ASSESSING THE COMPLEX ISSUE OF ADDICTION TO PRESCRIPTION MEDICATIONS

National Institute on Drug Abuse

Chp.: Nora D Volkow, M.D.

Co-Chp.: Eric C. Strain, M.D.

Participants: Nathaniel P. Katz, M.D., Joseph Califano, Charles P. O'Brien

FORUM 8 12 noon-1:30 p.m.

Room 701 B, Level 700, Toronto Convention Centre South

IMPROVING THE QUALITY OF HEALTH CARE FOR MENTAL AND SUBSTANCE USE CONDITIONS

Chp.: Mary Jane England, M.D.

Participants: Cynthia Wainscott, B.A., Harold Alan

Pincus, M.D., Gary L. Gottlieb, M.D., Benjamin G.

Druss, M.D., Ann E.K. Page

FORUM 9 12 noon-1:30 p.m.

Room 714 B, Level 700, Toronto Convention Centre South

HOT TOPICS IN PSYCHIATRIC DRUG SAFETY

Chp.: P. Murali Doraiswamy, M.D.

Participants: Ana Szarfman, M.D., Rima F. Kaddurah-

Daouk, Ph.D., David Shaffer, M.D., Arif Khan

FORUM 10 12 noon-1:30 p.m.

Room 801 B, Level 800, Toronto Convention Centre South

WORLDWIDE INTERPERSONAL AND GROUP TERRORISM TOWARD WOMEN

Chp.: Leah J. Dickstein, M.D.

Participants: Geetha Jayaram, M.D., Marta B. Rondon, M.D.,

Gail E. Robinson, M.D., Gloria N. Okorochoa, M.D.

FORUM 11 12 noon-1:30 p.m.

Territories Room, Mezzanine Level, Royal York

THE FUTURE OF ALCOHOL RESEARCH: NIAAA RESIDENT TRAVEL AWARD WINNERS WITH DISCUSSION BY A PANEL OF SENIOR RESEARCHERS

*Collaborative Session With the National Institute on Alcohol Abuse and
Alcoholism*

Chp.: Mark L. Willenbring, M.D.

Participants: Andrew C.H.Chen, M.D., Tara Wright, M.D.,

Ellen J. Hoffman, M.D.

Discussants: Bankole O. Johnson, M.D., Markus Heilig, M.D.,
Howard Moss, M.D.

NEW RESEARCH POSTER SESSION 6

12 noon-2:00 p.m.

Exhibit Hall B, Level 300, Toronto Convention Centre North

SCHIZOPHRENIA AND COMMUNITY PSYCHIATRY

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 71-78

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 71 1:00 p.m.-5:00 p.m.

Conference Room F, Mezzanine, Sheraton Centre

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: ADVANCED COURSE

Director: John Luo, M.D.

Faculty: Richard A. Montgomery, M.D., Charles J. Rainey, M.D.,
Steven I. Althuler, M.D., Raymond Kloss, M.D.

COURSE 72 1:00 p.m.-5:00 p.m.

Essex Room, Mezzanine, Sheraton Centre

THE WAY OF YOGA AND HERBS IN TREATMENT OF STRESS, DEPRESSION, AGGRESSION, PTSD, AND MASS TRAUMA

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 73 1:00 p.m.-5:00 p.m.

Windsor Room East, Mezzanine, Sheraton Centre

ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN PSYCHOSIS WITH THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS)

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 74 1:00 p.m.-5:00 p.m.

Windsor Room West, Mezzanine, Sheraton Centre

OVERCOMING CHALLENGES IN THE TREATMENT OF HEPATITIS C PATIENTS WITH PSYCHIATRIC ILLNESS

Co-Director: Muhamad A. Rifai, M.D., Peter Hauser, M.D.

Faculty: David Indest, Psy.D., Julie Nelligan, Ph.D.

COURSE 75 1:00 p.m.-5:00 p.m.

City Hall, Second Floor, Sheraton Centre

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.

TUESDAY

COURSE 76 1:00 p.m.-5:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre

PSYCHOGENIC SYMPTOMS: A CHALLENGE FOR ALL SPECIALTIES

Director: Selim Benbadis, M.D.
Faculty: Francisco Fernandez, M.D., David J. Williamson, Ph.D.

COURSE 77 1:00 p.m.-5:00 p.m.
Huron Room, Second Floor, Sheraton Centre

NEUROCIRCUITS IN PSYCHOTHERAPY

Director: Barton J. Blinder, M.D.
Faculty: Bernard D. Beitman, M.D., George I. Viamontes, M.D., Amit Etkin, M.D.

COURSE 78 1:00 p.m.-5:00 p.m.
Kent Room, Second Floor, Sheraton Centre

ASSESSING THE RISK OF VIOLENCE IN FORENSIC AND SEX OFFENDER SETTINGS

Co-Directors: Bradley R. Johnson, M.D., Judith V. Becker, Ph.D.

2:00 p.m. Sessions

ADVANCES IN PSYCHODYNAMIC PSYCHOTHERAPY: THE STATE OF THE ART
2:00 p.m.-5:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: Glen O. Gabbard, M.D.

- A **The Psychiatric Interview: New Perspectives From Psychodynamic Psychiatry**
Robert Michels, M.D.
- B **Transference-Focused Psychotherapy for BPD: Symptom and Structural Change**
Kenneth M. Levy, M.D.
- C **Transference and Countertransference in Personality Disorders: Turning Clinical Observations Into Replicable Data**
Drew Westen, Ph.D.
- D **The Mentalization-Based Treatment Approach to BPD: Emerging Outcomes From a New Psychodynamic Therapy**
Peter Fonagy

LECTURES 17-19

LECTURE 17

2:00 p.m.-3:30 p.m.
Room 105, Level 100
Toronto Convention Centre North
**APA'S ALEXANDRA SYMONDS
AWARD LECTURE**

Altha J. Stewart, M.D.

Changing the Landscape of American Psychiatry: An African-American Perspective on Expansive Personality in Women

Chp.: Melva I. Green, MD

Altha J. Stewart, M.D., a psychiatric administrator and nationally-recognized expert in public sector behavioral health care is President of *SPIA*, a behavioral healthcare consulting group. Prior to this Dr. Stewart was Executive Director of one of the nation's largest public mental health systems in Detroit. Dr. Stewart worked for over two decades, developing and managing public mental health programs in Pennsylvania, New York, and Michigan. A native of Memphis, Tennessee, Dr. Stewart completed her medical degree at Temple University and residency at Hahnemann University Hospital. She maintains a private consulting practice, serving as Medical Director of the Women's National Basketball Association since the 1997 inaugural season. She lectures nationally on mental health issues, including psychosocial factors affecting the mental health of women and minorities. She is President of the American Psychiatric Foundation (APF) and serves on the advisory board of the APA journal, *FOCUS*. Dr. Stewart is Past President of the Association of Women Psychiatrists and Black Psychiatrists of America and recipient of numerous awards including the 2001 *Welcome Back Award in Psychiatry* sponsored by Eli Lilly and Company, 2002 *NAMI Exemplary Psychiatrist Award*, and the 2003 *Pathfinder in Medicine Award* from Wayne State University in Detroit, Michigan.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 18

2:00 p.m.-3:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

Henry R. Kranzler, M.D.

Pharmacogenetics of Alcohol: Are We There Yet?

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Domenic Ciraulo, M.D.
Co-Chp.: Marc Galanter, M.D.

Henry R. Kranzler, M.D., is Professor of Psychiatry, Associate Scientific Director of the Alcohol Research Center, Program Director of the General Clinical Research Center, and Assistant Dean for Clinical Research at the University of Connecticut School of Medicine. After receiving his medical degree from Robert Wood Johnson Medical School, Dr. Kranzler completed a psychiatric residency and a fellowship in alcohol research at the University of Connecticut. A

clinical addiction psychiatrist for nearly 20 years. Dr. Kranzler now devotes his time primarily to research and teaching. Dr. Kranzler's current research focuses on the genetics and pharmacological treatment of alcohol and drug dependence and common comorbid psychiatric disorders. His research is supported by grants from the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse. Dr. Kranzler has authored more than 200 journal articles and book chapters. He serves as a research mentor for psychiatric residents, postdoctoral fellows and faculty in the Departments of Psychiatry and Medicine.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 19

2:00 p.m. - 3:30 p.m.

Room 718 A/B, Level 700
Toronto Convention Centre South

Barbara J. Mason, Ph.D.

*An Evidence-Based Clinician's Guide to the New
Pharmacotherapies for Alcoholism*

Chp.: Evaristo O. Aberle, M.D.

Co-Chp.: Annette Matthews, M.D.

Barbara J. Mason, Ph.D., is Professor and Director of the Laboratory of Clinical Psychopharmacology in the Molecular and Integrative Neurosciences Department and Co-Director of The Pearson Center for Alcoholism and Addiction Research at The Scripps Research Institute. Dr. Mason's work in alcohol dependence has been recognized with a MERIT Award from NIH, Dean's Senior Clinical Research Award from University of Miami School of Medicine, and Andrew W. Mellon Foundation Teacher-Scientist Award from Cornell University Medical College. Dr. Mason is a field editor for *Neuropsychopharmacology* and served on the editorial boards for *Alcoholism: Clinical and Experimental Research*, *Journal of Substance Abuse*, and the Ninth and Tenth Special Reports to U.S. Congress on Alcohol and Health. Dr. Mason's program of NIH-funded research at TSRI includes human laboratory studies to screen potential relapse prevention medications and clinical trials to evaluate the safety and efficacy of novel medications to prevent relapse in recovering alcoholics.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2

2:00 p.m.-5:00 p.m.

Room 701 A, Level 700, Toronto Convention Centre South

INTERNATIONAL ADVOCACY TOWARDS A PSYCHIATRY FOR THE PERSON

World Psychiatric Association

Chp.: Steven S. Sharfstein, M.D.

- A **Towards a Person-Centered Comprehensive Diagnosis**
Juan E. Mezzich, M.D.
- B **General Perspectives on National and International Advocacy**
Steven S. Sharfstein, M.D.
- C **Science, Faith, and Values in Healthcare Provisions: A Medicine of the Person**
John L. Cox, M.D.
- D **Person and Community-Centered Mental Health Care in Developing Countries**
Parameshvara Deva, M.D.
- E **Advocacy for Women's and Children's Mental Health**
Marta B. Rondon, M.D.
- F **International Advocacy for Patient's Human Rights**
Otto Steinfeldt-Foss, M.D.

Discussants: Helen Herrman, M.D., K.W.M. Fulford, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 34-65

SYMPOSIUM 34

2:00 p.m.-5:00 p.m.

Room 104 A, Level 100, Toronto Convention Centre North

PREDICTORS OF OUTCOME AND TREATMENT RESPONSE IN EATING DISORDERS: RESULTS FROM NEW RESEARCH ON ANOREXIA NERVOSA, BULIMIA NERVOSA, AND BINGE EATING DISORDER

Chp.: Laurel Mayer, M.D.

Co-Chp.: Evelyn Attia, M.D.

- A **Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa**
B. Timothy Walsh, M.D., Allan S. Kaplan, M.D., Evelyn Attia, M.D., Michael J. Devlin, M.D., Kathleen M. Pike, Ph.D., Marion Olmsted, Ph.D., Jacqueline Carter, Ph.D., Blake Woodside, M.D., Michael Parides, Ph.D.
- B **Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa: Predictors of Outcome After One Year of Treatment**
Allan S. Kaplan, M.D., B. Timothy Walsh, M.D., Evelyn Attia, M.D., Jacqueline Carter, Ph.D., Michael Devlin, M.D., Marion Olmsted, Ph.D., Kathleen Pike, Ph.D., Blake Woodside, M.D., Michael Parides, Ph.D.
- C **Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa: Body Composition Predicts Outcome After One Year of Treatment**
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Deborah Glasofer, M.A., Sarah Etu, B.A., Christina Roberto, B.A., Dymrna Gallagher, Ed.D., Jack Wang, M.S., Steven B. Heymsfield, M.D., Richard N. Pierson, Jr., M.D.

(Continued next page)

TUESDAY

D Early Response to Medication Among Women With Bulimia Nervosa
Robyn Sysko, M.S., B. Timothy Walsh, M.D.

E Long-Term Outcome of Psychotherapy and Medication for Binge-Eating Disorder
Michael J. Devlin, M.D., Juli A. Goldfein, Ph.D., Linxu Liu, Ph.D., Eva Petkova, Ph.D., B. Timothy Walsh, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

IMPULSIVITY IN AXIS I AND AXIS II: COMMON SUBSTRATES, DIFFERENT PRESENTATIONS?

Chp.: Carlos Blanco-Jerez, M.D.
Co-Chp.: Jon E. Grant, M.D.

A Compulsive Shopping: Epidemiology, Comorbidity, and Treatment
Donald W. Black, M.D.

B Pathological Gambling: From Neurobiology to Evidence-Based Treatment
Carlos Blanco-Jerez, M.D.

C BPD: Affective or Impulse Control Disorder?
S. Charles Schulz, M.D., A. Adityanjee, M.D., Ann Romine, R.N.

D Kleptomania: Clinical Presentation, Neuroimaging, and Treatment
Jon E. Grant, M.D.

Discussant: Dan J Stein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

DIAGNOSTIC CRITERIA IN ALZHEIMER'S DISEASE AND DEMENTIA: RESEARCH CHALLENGES AND IMPLICATIONS FOR DSM-V

Chp.: Trey Sunderland, M.D.

A Neuroimaging as a Surrogate Marker of Dementia
Gary W. Small, M.D.

B Neuropsychological Testing in the Diagnosis of Dementia
Mary Sano, Ph.D.

C The Search for Biomarkers as Diagnostic Aides in Alzheimer's Disease
Trey Sunderland, M.D.

D Diagnostic Criteria in Alzheimer's Disease and Dementia: Research Challenges and Implications for DSM-V
Barry Reisberg, M.D.

Discussant: Dilip V. Jeste, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

BULLYING IN THE WORKPLACE: PSYCHIATRIC AND PUBLIC HEALTH PERSPECTIVES

Chp.: Jorge C. Srabstein, M.D.

A Setting the Stage: Prevalence, Antecedents, and Effects of Workplace Bullying
Loraleigh Keashly, Ph.D., Joel H. Neuman, Ph.D.

B Bullying at Work: Psychiatric Issues
Renato Gilioli, M.D., Silvia Punzi, Psy.D., Giuseppe P. Fichera, Psy.D., Paolo Campanini, Psy.D.

C Workplace Bullying, Alcohol Use and Abuse, and Service Utilization
Judith A. Richman, Ph.D.

D Workplace Bullying and Employee Benefits: Enabling the Traumatized Worker to Seek Help for Psychiatric Illness
David Yamada, J.D.

E Syndrome of Morbidity Associated With School Bullying: Implications for Adulthood
Jorge C. Srabstein, M.D.

Discussant: Jorge C. Srabstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

SCREENING, DIAGNOSIS, AND MANAGEMENT OF ALCOHOL USE DISORDERS IN PSYCHIATRIC PRACTICE

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Mark L. Willenbring, M.D.

A Screening, Assessment, and Management Using the NIAAA Clinicians Guide
Mark L. Willenbring, M.D.

B Motivational Enhancement Strategies to Address Substance Use Disorders
Douglas M. Ziedonis

C Integrating Pharmacotherapy for Alcohol Dependence Into General Psychiatric Practice
Hugh Myrick, M.D.

D Meeting the Addiction Medicine Needs of Patients in a General Psychiatric Practice
Michael M. Miller, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

THERAPEUTIC NEUROMODULATION: METHODS AND MECHANISMS

Chp.: Mark Demitrack, M.D.

- A Therapeutic Neuromodulation: The Arrival of a Paradigm Shift**
Mark Demitrack, M.D.
- B Vagal Nerve Stimulation: A Review of the Evidence**
Philip G. Janicak, M.D., Jeffrey T. Rado, M.D.
- C Repetitive Transcranial Magnetic Stimulation (rtms) at 10 Hz in the Treatment of Pharmacoresistant Major Depression: Results From a Controlled Multicenter Clinical Trial**
John P. O'Reardon, M.D.
- D Therapeutic Neuromodulation Mechanisms of Action**
Elliott Richelson, M.D.

Discussant: Alan F. Schatzberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

APA RESEARCH AGENDA FOR *DSM-V* PERSONALITY DISORDERS

Chp.: John Livesley
Co-Chp.: Thomas A. Widiger, Ph.D.

- A Alternative Dimensional Models: Toward an Integration**
Thomas A. Widiger, Ph.D.
- B Issues and Challenges in Developing an Etiologically-Based Dimensional Classification of Personality Disorder**
Kerry L. Jang, Ph.D.
- C Toward a Developmental View of Personality Pathology**
Rebecca L. Shiner, Ph.D.
- D The Major Dimensions of Personality: Cross-Cultural Evidence-Based on the Lexical Approach**
Kibeom Lee, Ph.D.
- E Clinical Application of a Dimensional Model of Personality Disorder**
John Livesley

Discussant: Michael B. First, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

SLEEP, FATIGUE, AND DEPRESSION IN MEDICALLY-ILL PATIENTS

Chp.: Colin M. Shapiro, M.D.
Co-Chp.: Marta Novak, MD

- A Sleep and Fatigue in Breast Cancer**
Sonia Ancoli-Israel
- B Sleep, Fatigue, Pain, and Depression in Patients With Diabetes Mellitus**
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth H.B. Lin, M.D., Gregory E. Simon, M.D., Paul S. Ciechanowski, M.D.
- C Insomnia, Depression, Quality of Life, and Survival in Patients With End-Stage Renal Disease and Following Renal Transplantation**
Marta Novak, M.D., Miklos Z. Molnar, M.D., Istvan Mucsi, M.D.
- D Sleep Disruption, Fatigue, and Depression in the Medically Ill**
Colin M. Shapiro, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

SCALING UP AGAINST HIV/AIDS: A CULTURALLY SENSITIVE AND COMPREHENSIVE APPROACH

Chp.: Samuel O. Okpaku, M.D.

- A Understanding the Linkages Between HIV/AIDS and Development**
Scholastica Kimaryo
- B Culture, Indigenous Knowledge and Information, and Communications Technology in the Response to the HIV/AIDS Challenge**
Joseph Okpaku, M.D.
- C Defining and Describing a Modern Epidemic: The Case of HIV/AIDS in Sub Sahara Africa**
Samuel O. Okpaku, M.D.
- D Challenges to Implement Culturally-Adapted HIV/AIDS Programs in Haiti**
Vladimir Berthaud

Discussant: Darrel A. Regier, M.D.
THIS SESSION WILL BE AUDIOTAPED.

TUESDAY

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.

Room 711, Level 700, Toronto Convention Centre South

SUICIDE RESEARCH IN CANADA

Chp.: Joel F. Paris, M.D.

- A Neurobiological Studies of Suicide Completers
Gustavo Turecki, Ph.D.
- B Prospective Community Study of Suicidality in Young Adults
Joel F. Paris, M.D.
- C Affective Instability and Suicidality in BPD
Paul S. Links, M.D.
- D Clinical Guidelines for Suicidality
Isaac Sakinofsky, M.D.

Discussant: Alain D. Lesage, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.

Room 713 A/B, Level 700, Toronto Convention Centre South

NEUROBIOLOGICAL BASIS FOR CO-OCCURRING
SUBSTANCE ABUSE AND OTHER PSYCHIATRIC
DISORDERS

National Institute on Drug Abuse

Chp.: Susan F. Volman, Ph.D.

- A Smoking and Schizophrenia: Does Co-Morbidity of Substance Abuse and Disease Suggest Self-Medication?
Sherry Leonard, Ph.D., Sharon Mexal, Ph.D., Ralph Berger, B.S.
 - B Insights From Animal Models of Dual Diagnosis: How Common Neurocircuit Abnormalities Underlie Both Mental Illness and Addiction Vulnerability
Robert A. Chambers, M.D.
 - C Nicotine-Induced Sensitization and ADHD
Jean King, Ph.D.
 - D Effects of Nicotine and Other Drugs of Abuse on Cognitive Dysfunction in Individuals With Schizophrenia
Tony P. George
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.

Room 714 A, Level 700, Toronto Convention Centre South

BIPOLAR DISORDER AND THE U.S. LEGAL SYSTEM

Chp.: Mark A. Frye, M.D.
Co-Chp.: Cameron Quanbeck, M.D.

- A Bipolar Disorder and the Legal System
Mark A. Frye, M.D.

- B Clinical and Legal Characteristics of Inmates With Bipolar Disorder
Cameron D. Quanbeck, M.D.

- C An Epidemiologic Perspective on Forensic History in Bipolar I Disorder
Benjamin I. Goldstein

- D Can Psychiatry Reduce the Criminalization of the Severely Mentally Ill?
Elizabeth Walsh, M.D.

Discussant: Susan L. McElroy, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.

Room 714 B, Level 700, Toronto Convention Centre South

APA/APAL: ADDRESSING PSYCHIATRIC PATIENTS' NEEDS IN LATIN AMERICA

APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Rodrigo Munoz, M.D.

- A APA/APAL Addressing Psychiatric Patients Needs in Latin America
Angel Valmaggia, M.D.
 - B Future Perspectives With Respect to APA/APAL
Cesar M. Mejias, M.D.
 - C Structure of Strategic Collaboration Between the APA and APAL
Edgard Belfort, M.D.
 - D Improving Mental Health Care in Latin America: The Role of International Cooperation
Jose M. Caldas de Almeida, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.

Room 715 A/B, Level 700, Toronto Convention Centre South

HELPING RETURNING VETERANS: VA COMMUNITY COLLABORATIONS

Chp.: Laurent S. Lehmann, M.D.

- A The Public Health Approach in DOD/VA Outreach to Service Members/Veterans and Their Families
Harold Kudler
- B A Model for Interagency Collaborative Care of Stress Disorders Related to Military Deployment
Miles McFall, Ph.D.
- C Collaborative Interventions Addressing Sexual Trauma in Female Veterans Post-Deployment
Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D.

D The OHIO CARES Initiative
Col. Terry C. Washam, L.I.S.W.

Discussant: Michael F. Hogan, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

SUBSTANCE USE DISORDERS: PLANNING A RESEARCH AGENDA FOR *DSM-V*
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Marc A. Schuckit, M.D.
Co-Chp.: Bridget Grant, Ph.D.

- A Adolescents and Substance Related Disorders: Research Agenda to Guide Decisions on *DSM-V***
Thomas J. Crowley, M.D.
- B Methods for *DSM-V* Research Work Groups to Address Key Diagnostic Issues for Substance Use Disorders**
Linda B. Cottler, Ph.D.
- C Substance Use Disorder Co-Morbidity and *DSM-V***
Deborah S. Hasin, Ph.D.
- D What Can Human Brain Imaging Tell Us About Addiction?**
Anna R. Childress, M.D.

Discussant: Wilson M. Compton, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

THE USE OF ATYPICAL ANTIPSYCHOTICS IN ELDERLY PATIENTS WITH DEMENTIA: WHAT NEXT?

Chp.: John M. de Figueiredo, M.D.

- A Use of Antipsychotics in Elderly Patients With Dementia: What's Next?**
Soo Borson, M.D.
- B Pharmacological Strategies for the Management of Behavior Disorders in Dementia**
Bruce G. Pollock
- C Thinking Outside the Black Box: Risk Management for Using Atypical Antipsychotic Medications With the Elderly**
Patricia R. Recupero, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

PREVENTION OF COMMON MENTAL DISORDERS: IS IT TIME TO START?

Chp.: Robert A. Schoevers, Ph.D.

- A Cost-Effectiveness of Preventing Depression in Primary Care Patients: Randomized Trial**
Filip E. Smit, M.S.C.
- B Prevention of New Cases of Mental Disorders: Problems and Solutions**
Pim Cuijpers, M.D.
- C Prevention of Late-Life Depression: Do We Know Where to Begin?**
Robert A. Schoevers, Ph.D., Filip Smit, M.S.C., Dorly Deeg, M.D., Pim Cuijpers, M.D., Jack Decker, M.D., Willem Van Tilburg, M.D., Aartjan Beekman, M.D.
- D Evidence-Based Prevention of Common Mental Disorders**
Aartjan T.F. Beekman, M.D.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 3

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith Young, M.D.

- A Personal Factors Leading to a Successful Private Practice**
William E. Callahan, Jr., M.D.
- B Office Location and Design for Efficiency and Success**
Keith W. Young, M.D.
- C Streamlining Overhead and Managing Your Business in Private Practice**
Keith W. Young, M.D.
- D Marketing Your Unique Private Practice**
William E. Callahan, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52 2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE

Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

- A Choosing the Right Treatment for Cocaine Dependence**
Adam M. Bisaga, M.D.

(Continued next page)

TUESDAY

- B **Treatment of Comorbid Conditions**
Frances R. Levin, M.D.
 - C **Marijuana and Club Drugs: Cutting Edge Developments, New and Potential Treatments**
David M. McDowell, M.D.
 - D **Behavioral Treatments for Substance Dependence and Integrating Behavioral Therapy With Medication**
Edward V. Nunes, M.D.
 - E **Choosing the Right Treatment for Opioid Dependence**
Herbert D. Kleber, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53 2:00 p.m.-5:00 p.m.

Room 803 A/B, Level 800, Toronto Convention Centre South

STRESS-INDUCED AND FEAR CIRCUITRY DISORDERS: PLANNING THE RESEARCH AGENDA FOR *DSM-V*

Chp.: Dennis S. Charney, M.D.

- A **The Role of Cognition in Stress-Induced and Fear Circuitry Disorders**
Edna B. Foa, Ph.D., Jonathan D. Huppert, Ph.D., Shawn Cahill, Ph.D.
- B **Overlap and Distinctiveness Among Stress-Induced and Fear-Circuitry Disorders**
Abby Fyer, M.D.
- C **Neurochemistry/Neuroendocrine Signals (and Noise) in Anxiety Disorders**
Rachel Yehuda, M.D.
- D **Serotonin, the Hippocampus, and Emotional Behavior**
Rene Hen, M.D.
- E **PTSD: Looking Towards *DSM-V***
Elie G. Karam

Discussant: Steven E. Hyman
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.

Imperial Room, Main Floor, Royal York

THE METHAMPHETAMINE EPIDEMIC IN THE U.S.
National Institute on Drug Abuse

Chp.: Nora D. Volkow, M.D.
Co-Chp.: Frank Vocci, Ph.D.

- A **Neurobiological Effects of Methamphetamine Abuse: Acute and Long Term**
Linda Chang, M.D., Napapon Sailasuta, Ph.D., Daniel A. Alicata, M.D., D. Christopher Derauf, M.D., Helenna Nakama, M.D., William F. Haning III, M.D., Kenneth Yue, Ph.D., V. Andrew Stenger, Ph.D., Thomas Ernst, Ph.D.

- B **Methamphetamine Use, Abuse, Dependence, and Treatment: Survey Findings, 2002-2004**
James D. Colliver, Ph.D.
 - C **Methamphetamine Abuse and HIV/AIDS Comorbidity: Treatment Implications**
Perry N. Halkitis, Ph.D.
 - D **Behavioral Treatment Approaches for Methamphetamine Dependence, Comorbid Psychiatric Disorders, and HIV-Related Risk Behaviors**
Richard Rawson, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.

Alberta Room, Mezzanine Floor, Royal York

PREVENTING SCHIZOPHRENIA: OPPORTUNITIES AND CHALLENGES

Chp.: Thomas H. McGlashan, M.D.

- A **Reducing the Damage of the First Psychosis Onset**
Ingrid Melle, M.D., Tor K. Larsen, M.D., Svein Friis, M.D., Ulrik Haahr, M.D., Jan O. Johannessen, M.D., Stein Opjordsmoen, M.D., Erik Simonsen, M.D., Per Vaglum, M.D., Thomas H. McGlashan, M.D.
 - B **Treatment of the Schizophrenia Prodrome: Update 2006**
Scott Woods
 - C **Predicting Schizophrenia: Early Risk Factors**
Barbara A. Cornblatt, Ph.D.
 - D **Psychological Interventions for Those at Ultra High Risk of Psychosis**
Jean Addington, Ph.D.
 - E **Prevention Research in Psychosis: Current State of the Art**
Thomas H. McGlashan, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.

British Columbia Room, Mezzanine Floor, Royal York

HIV UPDATE FOR PSYCHIATRIC CARE
APA Committee on AIDS

Chp.: Marshall Forstein, M.D.

- A **HIV Medical Update**
Peter Gouch, M.D.
 - B **Hepatitis C and HIV Infection**
Antoine B. Douaihy
 - C **Club Drugs and HIV**
Milton L. Wainberg, M.D.
 - D **Body Image and HIV**
Marshall Forstein, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57 2:00 p.m.-5:00 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

VOTING BY PERSONS WITH COGNITIVE IMPAIRMENT

Chp.: Paul S. Appelbaum, M.D.

Co-Chp.: Jason Karlawish

- A Voting by Persons With Cognitive Impairment: Overview of the Issues**
Richard Bonnie, J.D.
- B Voting by Persons With Cognitive Impairments: The Legal Issues**
Pamela Karlan
- C Assessing Competence to Vote in a Cognitively Impaired Population**
Paul S. Appelbaum, M.D.
- D Respecting Rights and Preserving the Integrity of Elections: The Challenges of Voting in Long-Term Care Facilities**
Jason Karlawish

Discussant: Alexander Keyssar, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.

Manitoba Room, Mezzanine Floor, Royal York

NOT YOUR PARENTS' EEG: CLINICAL APPLICATIONS OF AUDITORY AND VISUAL EVENT-RELATED POTENTIALS

Chp.: Daniel C. Javitt, M.D.

- A Event-Related Potential (ERP) Abnormalities in Schizophrenia**
Daniel C. Javitt, M.D.
- B Probing the Cognitive, Clinical, and Functional Impairments of Schizophrenia Patients With Mismatch Negativity**
Gregory A. Light, Ph.D., David L. Braff, M.D.
- C ERP P300 and Mismatch Negativity Abnormalities in Patients at Ultra-High Risk for Schizophrenia**
Daniel H. Mathalon, M.D., Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D.
- D Use of Auditory ERPs and Other Quantitative Measures in an Evidence-Based, Person-Centered Psychosis Treatment Program**
Steven B. Schwarzkopf, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59

2:00 p.m.-5:00 p.m.

Quebec Room, Mezzanine Floor, Royal York

GENETIC FINDINGS RELATED TO ALCOHOL DEPENDENCE AND RELATED CONDITIONS*Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism*

Chp.: Victor M. Hesselbrock, Ph.D.

- A Genetic Susceptibility for Alcohol Dependence: Recent Findings**
Howard J. Edenberg, Ph.D.
- B At Risk Families: A Multigenerational Study of Alcoholism**
Laura J. Bierut, M.D., Wendy Reich, Ph.D., Marc A. Schuckit, M.D., Kathleen K. Bucholz, Ph.D.
- C Further Characterization of the Risk Associated With GABA-A Receptor Genes**
Danielle M. Dick, Ph.D., Laura J. Bierut, M.D., Tatiana Foroud, Ph.D., Howard Edenberg, Ph.D.
- D Neurophysiological Endophenotypes and the Risk for Alcohol Dependence and Related Disorders**
Bernice Porjesz, Ph.D., Henri Begleiter, Ph.D., Kevin A. Jones, Ph.D., Laura Almasy, Ph.D., Howard Edenberg, Ph.D., Laura J. Bierut, M.D., John I. Nurnberger, Jr., M.D., Danielle M. Dick, Ph.D., Victor Hesselbrock, Ph.D.

- E Prediction of Alcohol Problems Using a Prospective Longitudinal Design Including Genotype**
John I. Nurnberger, Jr., M.D., Ryan Wiegand M.S., Laura J. Bierut, M.D., Kathleen Bucholz, Ph.D., Tatiana Foroud, Ph.D., Howard Edenberg, Ph.D., John Kramer, Ph.D., Samuel Kuperman, M.D., Danielle M. Dick, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60

2:00 p.m.-5:00 p.m.

Territories Room, Mezzanine Floor, Royal York

THE MEANINGS OF MEDICATION: ISSUES IN PATIENTS' COMPLIANCE WITH PSYCHOTROPIC DRUGS*American Academy of Psychoanalysis and Dynamic Psychiatry*

Chp.: Ann R. Turkel, M.D.

- A Medication Management: A Clinical Misnomer**
Leah Davidson, M.D.
- B Compliance as Accord, Not Submission**
Eve Leeman, MD
- C Transferences to Medication and Implications for the Structure of the Ego**
Eric R. Marcus, M.D.

(Continued next page)

D Poison or Cure? Meanings of Medication in Schizophrenia

Paul J. Rosenfield, M.D.

E The Meanings of Medication: Issues in Patients' Compliance With Psychotropic Drugs: Be Careful What You Wish For

Jeffrey Rubin, MD

Discussant: Jose L. Gonzalez de Rivera, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.

Tudor 8 Room, Mezzanine Floor, Royal York

PHARMACOGENETICS AND DRUG ABUSE RESEARCH

National Institute on Drug Abuse

Chp.: Joni L. Rutter, Ph.D.

Co-Chp.: David Shurtleff

A Allele Specific Gene Expression in Addiction Genes

Wolfgang Sadec

B Darwin's Fingerprint: Identifying Reent Functional Genetic Variations in Neuronal Genes

Robert K. Moyzis, Ph.D.

C Pharmacogenetics and Smoking Cessation With Nicotine Replacement Therapy

Caryn Lerman, Ph.D., Neal Benowitz, M.D., Peter Shields, M.D., Timothy Rebbeck, Ph.D., Wade H. Berrettini, M.D., Rachel Tyndale, Ph.D.

D Pharmacogenetics of Smoking Cessation Using Non-Nicotine Replacement Therapies

Huijun Z. Ring, Ph.D.

E Pharmacogenetics of Alcohol Treatment

David W. Oslin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.

Ballroom, Convention Floor, Royal York

EATING DISORDERS 2006: FROM SCIENCE TO PRACTICE

Chp.: Joel Yager, M.D.

Co-Chp.: David B. Herzog, M.D.

A Altered Dopamine and Optimal Stimulus Response in Anorexia Nervosa

Walter H. Kaye, Guido K.W. Frank, M.D., Angela Wagner, M.D., Ursula Bailer, M.D., Carolyn C. Meltzer, M.D., Julie C. Price, Ph.D., J. Christopher May, B.A., Howard J. Aizenstein, M.D.

B Gender Difference Comparisons of Eating Difference Comparisons of Eating and Other Psychiatric Disorders in Course of Illness

Katherine A. Halmi, M.D.

C Federal Advocacy for Eating Disorders

David B. Herzog, M.D., Debra L. Franko, Ph.D., Jeanine C. Cogan, Ph.D., Marc Lerro, M.L.A., Cynthia M. Bulik, Ph.D., Elizabeth Q. Ong, B.A., Kavita K. Tahlani, B.S.

D Night Eating Syndrome

James E. Mitchell III, M.Ed., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., Scott Engel, Ph.D., Albert J. Stunkard, M.D., Kelly Allison, Ph.D.

E The 2006 APA Practice Guidelines for Eating Disorders

Joel Yager, M.D., Michael J. Devlin, M.D., Katherine A. Halmi, M.D., David B. Herzog, M.D., James E. Mitchell III, M.Ed., Pauline Powers, M.Ed., Kathryn J. Zerbe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.

Ontario Room, Convention Floor, Royal York

VASCULAR DEPRESSION: MEASUREMENT AND TREATMENT ISSUES OF A PROPOSED DIAGNOSTIC ENTITY

Chp.: Joel R. Sneed, Ph.D.

Co-Chp.: Steven P. Roose, M.D.

A Vascular Risk Factors, Frontolimbic Dysfunction, and Course of Geriatric Depression

George S. Alexopoulos, M.D.

B Treatment of Vascular Depression Including New Data on rTMS

Robert G. Robinson, M.D., Ricardo E. Jorge, M.D.

C Neuroimaging of Cerebrovascular Disease

David C. Steffens, M.D.

D Vascular Depression: A Distinct Diagnostic Entity?

Joel R. Sneed, Ph.D., Steven P. Roose, M.D.

Discussant: Charles F. Reynolds III, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.

Salon A, Convention Floor, Royal York

DEEP BRAIN STIMULATION FOR TREATMENT-RESISTANT PSYCHIATRIC DISORDERS

Chp.: George E. Tesar, M.D.

Co-Chp.: Donald A. Malone, Jr. M.D.

A History and Ethics of Neurosurgery for Treatment-Refractory Psychiatric Disorders

George E. Tesar, M.D.

B Deep Brain Stimulation Surgery for Treatment of Intractable Psychiatric Disorders

Ali R. Rezai, M.D., Donald A. Malone, Jr., M.D., Steven A. Rasmussen, M.D., Cynthia Kubu, Ph.D., Gerhard Friehs, M.D., Andre Machado, M.D., Benjamin D. Greenberg, M.D.

- C **DBS for OCD: Targeting and Clinical Results**
Benjamin D. Greenberg, M.D.
- D **Deep-Brain Stimulation in Psychiatric Disorders:
Surgical Candidates and Preliminary Results in Major
Depression**
Donald A. Malone, Jr., M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.

Salon B, Convention Floor, Royal York

**COMPLEX DEPRESSION: THE INTERFACE
BETWEEN PERSONALITY DISORDERS AND MAJOR
DEPRESSION**

Chp.: Sidney H. Kennedy, M.D.

Co-Chp.: Maurice Corcos, Ph.D.

- A **The Neurobiology of the Links Between Personality
Traits and Depression**
Glenda M. MacQueen
- B **Patient Personality as a Differential Predictor of
Treatment Outcome to Psychotherapy Versus
Pharmacotherapy**
R. Michael Bagby, Ph.D., Carolina McBride, Ph.D.
- C **Managing Patients With Complex Depression**
Sidney H. Kennedy, M.D.
- D **Key Psychotherapy Issues in Complex Depression:
Patients With Major Depression and Personality
Psychopathology**
Michael B. Rosenbluth

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00 p.m.

Exhibit Hall B, Level 300, Toronto Convention Centre North

**PSYCHOPHARMACOLOGY AND BIOLOGICAL
PSYCHIATRY**

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 34-38

INDUSTRY-SUPPORTED SYMPOSIUM 34

7:00 p.m.-10:00 p.m.

Room 106, Level 100, Toronto Convention Centre North

**MANAGEMENT OF PSYCHOSIS IN THE ELDERLY:
THE SCIENCE AND THE ART**

Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Dilip V. Jeste, M.D.

- A **Evaluation of Psychosis in the Elderly**
Carl Salzman, M.D.
- B **Efficacy and Effectiveness of Antipsychotics in the
Elderly**
Lon S. Schneider, M.D.
- C **Safety of Antipsychotics in Elderly Patients**
Dilip V. Jeste, M.D.
- D **Novel Antipsychotic Strategies: Implications for
Biology and Future Treatment**
P. Murali Doraiswamy, M.D.
- E **Nonpharmacologic Interventions for Psychosis in the
Elderly**
Warachal E. Faison, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35

7:00 p.m.-10:00 p.m.

Canadian Room, Convention Floor, Royal York

**MULTIPLE AND COMPLEX PRESENTATIONS OF
BIPOLAR DISORDER**

Supported by Abbott Laboratories

Chp.: Charles L. Bowden, M.D.

- A **Presentations of Bipolar Disorder in Children and
Adolescents**
Kiki D. Chang, M.D.
- B **The Impulsive-Aggression Symptom Domain in
Personality Disorders**
Eric Hollander, M.D.
- C **Bipolar II Disorder and Suicidal Behaviors**
William H. Coryell, M.D.
- D **Predicting Maintenance Response From the Acute
Episode**
Charles L. Bowden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36

7:00 p.m.-10:00 p.m.

Concert Hall, Convention Floor, Royal York

**TREATING THE EARLY STAGES OF
SCHIZOPHRENIA**

Supported by AstraZeneca Pharmaceuticals

Chp.: Dolores Malaspina, M.D.

- A **Genetic and Clinical Risk Factors for Schizophrenia:
Predicting the Onset and Outcomes of the Illness and
Treatment Response**
Dolores Malaspina, M.D.

(Continued next page)

B Treatment of First Episode Schizophrenia: Tolerability and Adherence

Delbert G. Robinson, M.D.

C Evaluation of Prodromal Schizophrenia

Cheryl Corcoran, M.D.

D Pharmacologic Strategies for the Treatment of Prodromal Schizophrenia

Daniel C. Javitt, M.D.

E Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection

Jeffrey A. Lieberman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37

7:00 p.m.-10:00 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

ADVOCATING FOR CHANGE THROUGH EVIDENCE-BASED MEDICINE: A FOCUS ON ADHD

Supported by Cephalon, Inc.

Chp.: Christopher J. Kratochvil, M.D.

A Neurocircuitry of ADHD

James J. Hudziak, M.D.

B Phenomenology and Diagnosis of ADHD

Christopher J. Kratochvil, M.D.

C The Impact of Sleep/Wake Disturbances in ADHD

Judith Owens, M.D.

D Evidence-Based Pharmacotherapy of ADHD

Timothy E. Wilens, M.D.

E Role of Family and Social Support Systems in the Management of ADHD

Scott Kollins, Pharm.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38

7:00 p.m.-10:00 p.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

THE MAZE OF MOOD AND ANXIETY IN THE ELDERLY PATIENT: A CASE SERIES

Supported by GlaxoSmithKline

Chp.: Charles F. Reynolds III, M.D.

A Achieving a Better Understanding of the Neurobiology of Mood and Anxiety Disorders in the Elderly

Prakash S. Masand, M.D.

B The Impact of Medical Comorbidity on Mood and Anxiety Disorders in the Elderly Patient

Eric J. Lenze, M.D.

C An Evidence-Based Approach to the Acute Management of Mood and Anxiety Disorders in the Elderly Population

Warren D. Taylor, M.D.

D Optimizing Long-Term Treatment in Old-Age Depression

Charles F. Reynolds III, M.D.

WEDNESDAY, MAY 24, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 39-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 1

7:00 a.m.-8:30 a.m.

Room 106, Level 100, Toronto Convention Centre North

EMERGING EVIDENCE IN THE TREATMENT OF BIPOLAR DEPRESSION

Supported by AstraZeneca Pharmaceuticals

Chp.: Joseph R. Calabrese, M.D.

- A **The Clinical Management of Bipolar Disorder**
Frederick K. Goodwin, M.D.
- B **How Guidelines Influence Acute and Long-Term
Treatment of Bipolar Depression**
Robert M.A. Hirschfeld, M.D.
- C **Treatment of Alcohol and Drug Abuse in Bipolar
Disorder**
Kathleen T. Brady, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1

7:00 a.m.-8:30 a.m.

Canadian Room, Convention Floor, Royal York

BIPOLAR ILLNESS: THE ROAD TO REMISSION

*Supported by Bristol-Myers Squibb Company and Otsuka America
Pharmaceutical, Inc.*

Chp.: Prakash S. Masand, M.D.

- A **Is Remission Achievable in Bipolar Disorder?**
John L. Beyer, M.D.
- B **Roadblocks to Remission in the Bipolar Patient**
Prakash S. Masand, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

NEW FRONTIERS IN DEPRESSION: PROVIDING SOLUTIONS TO UNMET NEEDS

Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Stephen M. Stahl, M.D.

- A **Genetic Mechanisms of Mood and Temperament**
Daniel R. Weinberger, M.D.

- B **Chronic Pain and Major Depression**
Alan F. Schatzberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42, PART 1

7:00 a.m.-8:30 a.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

WHAT THE PSYCHIATRIST NEEDS TO KNOW ABOUT SLEEP-RELATED MOVEMENT DISORDERS

Supported by GlaxoSmithKline

Chp.: John W. Winkelman, M.D.

- A **Diagnosis, Epidemiology, and Natural History of
Restless Legs Syndrome and Periodic Limb
Movements of Sleep**
Philip M. Becker, M.D.
- B **Sleep, Health, and Quality of Life Consequences**
R. Robert Auger, M.D.
- C **Diagnostic Challenges and Initial Treatment Strategies**
Cynthia L. Comella, M.D.

8:00 a.m. Sessions



COURSES 79-84

Course descriptions are available in the *CME
Course Brochure* included in your registration
packet. Admission by ticket only.

COURSE 79

8:00 a.m.-12 noon

Conference Room D/E, Mezzanine, Sheraton Centre

COVER YOUR ASSETS: IMPROVED PATIENT CARE THROUGH MALPRACTICE PROTECTION

Director: G. Kent Mangelson, B.S.

COURSE 80

8:00 a.m.-12 noon

Conference Room F, Mezzanine, Sheraton Centre

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.

Faculty: Candace M. Fleming, Ph.D., David C. Henderson, M.D.,
Roberto Lewis-Fernandez, M.D., Francis G. Lu, M.D., J. Charles
Ndlela, M.D.

WEDNESDAY

COURSE 81 8:00 a.m.-12 noon
Windsor Room East, Mezzanine, Sheraton Centre

HOW TO USE YOUR POCKET PC PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE

Director: Robert J. Boland, M.D.
Faculty: Elizabeth V. Getter, M.D., Joshua L. Straus, M.D., Roger L. McRoberts III, M.D.

COURSE 82 8:00 a.m.-12 noon
Windsor Room West, Mezzanine, Sheraton Centre

CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Faculty: David K. Nace, M.D.

COURSE 83 8:00 a.m.-12 noon
City Hall, Second Floor, Sheraton Centre

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 84 8:00 a.m.-12 noon
Kent Room, Second Floor, Sheraton Centre

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

9:00 a.m. Sessions

ADVANCES IN MOOD DISORDERS
9:00 a.m.-12:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: David J. Kupfer, M.D.
Co-Chair: Dan J. Stein, M.D.

A Recent Approaches to Diagnosing and Treating Bipolar Disorder
David J. Kupfer, M.D.

B New Somatic Interventions for Mood Disorders
Mark S. George, M.D.

C Advances in Mood Disorders
A. John Rush, M.D.

CLINICAL CASE CONFERENCE 4
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

CROSSING THE LINE: DETERMINING YOUR PATIENT IS TOO DANGEROUS TO DRIVE

Moderator: Carl B. Greiner, M.D.
Presenters: Steven P. Wengel, M.D., Laura W. Roberts, M.D., Nicole F. Wolfe, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2

9:00 a.m.-12:30 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

TWENTY THERAPIES LATER: ADDRESSING TRANSFERENCE RESISTANCE

Moderator: R. Rao Gogineni, M.D.
Presenters: Robert Michels, M.D., Richard P. Kluff, M.D., Sheila Judge, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 85-91

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 85 9:00 a.m.-4:00 p.m.
Conference Rooms B/C, Mezzanine, Sheraton Centre

EEG NEUROFEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: Thomas M. Brod, M.D., Michael Cohen
Faculty: Samuel E. Roura, M.D., Laurence M. Hirshberg, Ph.D., David A. Mitnick, M.D., Angelo S. Bolea, Ph.D., Stephen E. Buie, M.D.

COURSE 86 9:00 a.m.-4:00 p.m.
Conference Room G, Mezzanine, Sheraton Centre

AN INTRODUCTION TO COMPLICATED GRIEF TREATMENT

Director: M. Katherine Shear, M.D.
Faculty: Mario Cruz, M.D., Bonnie Gorscak, Ph.D., Allan Zuckoff, Ph.D.

COURSE 87 9:00 a.m.-4:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

**LOVE, DESIRE, INTIMACY, AND INFIDELITY:
USEFUL CONCEPTS FOR THE PSYCHOTHERAPIST**

Director: Stephen B. Levine, M.D.
Faculty: Candace B. Risen, L.C.S.W.

COURSE 88 9:00 a.m.-4:00 p.m.
Dominion Ballroom South, Second Floor, Sheraton Centre

ESSENTIALS OF GERIATRIC PSYCHOPHARMACOLOGY

Co-Directors: Helen Lavretsky, M.D., Martha Sajatovic, M.D.
Faculty: Eric J. Lenze, M.D., Josepha A. Cheong, M.D.

COURSE 89 9:00 a.m.-4:00 p.m.
Huron Room, Second Floor, Sheraton Centre

**THE ASSESSMENT AND TREATMENT OF CHILD
SEXUAL ABUSERS**

Co-Directors: Gene G. Abel, M.D., John M. Bradford, M.B.
Faculty: Tracey I. Marks, M.D.

COURSE 90 9:00 a.m.-4:00 p.m.
Kenora Room, Second Floor, Sheraton Centre

**NEUROANATOMY OF EMOTIONS: FROM BRAIN
TO CLINICAL PRACTICE**

Director: Ricardo M. Vela, M.D.
Faculty: Cheryl L. Grady, Ph.D.

COURSE 91 9:00 a.m.-4:00 p.m.
Simcoe/Dufferin Room, Second Floor, Sheraton Centre

**SEEING THE FOREST AND THE TREES: A
BIOPSYCHOSOCIAL APPROACH TO THE ORAL
BOARD EXAMINATION**

Director: William H. Campbell, M.D.

DISCUSSION GROUPS 18-20

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

18 **Marc Galanter, M.D.**, on Substance Abuse: Network Therapy for Promoting Outpatient Compliance With Psychosocial and Pharmacologic Treatment
Grenadier Room, Main Level, Intercontinental Hotel

19 **Marcia K. Goin, M.D.**, on BPD: Talking With Patients About Their Illness, What Do You Say?
Halton Room, Main Level, Intercontinental Hotel

20 **John M. Oldham, M.D.**, on Personality Disorders and *DSM-V*
Humber Room, Main Level, Intercontinental Hotel

LECTURES 20-22

LECTURE 20

9:00 a.m.-10:30 a.m.

Room 105, Level 100

Toronto Convention Centre North

APA'S GEORGE TARJAN AWARD LECTURE

Dilip V. Jeste, M.D.

**Psychiatry and Aging: Contributions of the
International Medical Graduates**

Chp.: Sanjay Dube, M.D.

Dilip V. Jeste, M.D., is the Estelle and Edgar Levi Chair in Aging, Director of the Sam and Rose Stein Institute for Research on Aging, and Distinguished Professor of Psychiatry and Neurosciences, University of California, San Diego (UCSD) and VA San Diego Healthcare System. He is also the Director of the Advanced Center for Interventions and Services Research at UCSD, focusing on psychosis in late-life, funded by the National Institute of Mental Health (NIMH), and of the John A. Hartford Center of Excellence in Geriatric Psychiatry. Dr. Jeste obtained his medical education in Poona, and psychiatry training in Bombay, India. In the USA, he completed his psychiatry residency at Cornell University and neurology residency at George Washington University. He was a research fellow, and later, Chief of the Unit on Movement Disorders and Dementia at the NIMH before moving to San Diego. He has published six books, and over 400 articles in peer-reviewed journals and books. He is in the Institute of Scientific Information list of the "world's most cited authors" - comprising less than one-half of one percent of all publishing researchers of the last two decades. He is the Past President of the American Association for Geriatric Psychiatry (AAGP) and the West Coast College of Biological Psychiatry (WCCBP), and the Founding President of the International College of Geriatric Psychoneuropharmacology. He is the Editor-in-Chief of the *American Journal of Geriatric Psychiatry*. He has been listed in "The Best Doctors in America" and has received several awards including the A.E. Bennett Neuropsychiatric Research Award from the Society of Biological Psychiatry, MERIT Award from the NIMH, the American Psychiatric Association Research Award, Geriatric Research Award from the American College of Psychiatrists, and Distinguished Investigator Award from the National Alliance for Research in Schizophrenia and Affective Disorders.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21

9:00 a.m.-10:30 a.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

Karl P. Mann, M.D.

Combining Neuroimaging and Pharmacology
to Better Treat Alcoholism?
*Collaborative Session With the National Institute of
Alcohol Abuse and Alcoholism*

Chp.: Richard N. Rosenthal
Co-Chp.: Doug Ziedonis, M.D.

Karl P. Mann, M.D., studied medicine in Mainz, Germany and Vienna, Austria. He received his medical degree from the University of Mainz. In 1978 and 1979 he was a research fellow at the University René Descartes in Paris. From 1979 until 1985 he received his residency in psychiatry and neurology. Board certification in both domains as well as psychotherapy was attained in 1985. From 1985 he worked first as an assistant and then as an associate professor of psychiatry at the University of Tuebingen, Germany. There he concentrated on addiction research and built an interdisciplinary research group in alcohol and nicotine research. In 1989 he moved to the Central Institute of Mental Health in Mannheim, Germany which is part of the University of Heidelberg. Since then he holds the first and only chair in addiction research in Germany. Dr. Mann is currently the speaker of the German Addiction Research Network which is funded by the federal government of Germany. He is associate editor (Europe) of *Alcoholism Clinical & Experimental Research*. Since 2002 he is a member of the Executive Committee of the Association of European Psychiatrists where he acts as treasurer. Dr. Mann has received several research prizes. In 2004 the International Society for Biomedical Research on Alcoholism elected him as congress president for the 12th World Congress of Biomedical Alcohol Research. His main areas of research are neuroimaging and the pharmacology of alcoholism.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 22

9:00 a.m.-10:30 a.m.
Room 718 A/B, Level 700
Toronto Convention Centre South

James P. Comer, M.D.

Psychiatry and Education: When the Twain Meet

Chp.: Mary Schwab-Stone, M.D.
Co-Chp.: JoAnne M. Irbey

James P. Comer, M.D., grew up in a low-income family in East Chicago, Indiana, but credits his parents with leaving no doubt about the importance of education. He obtained a B.A. degree from Indiana University. He went on to obtain a degree in medicine from Howard University College of Medicine, a Master of Public Health degree from the University of Michigan School of Public Health, and psychiatry training at the Yale University School of Medicine's Child Study Center. He currently is the Maurice Falk Professor of Child Psychiatry at the Yale University Child Study Center and an associate dean at the Yale University School of Medicine. During his years at Yale, Dr. Comer has concentrated his career on promoting a focus on child and youth development as a way of improving schools. He is best known for founding the Yale Child Study Center School Development Program in 1968, which promotes the collaboration of parents, educators, and community to improve social, emotional, and academic outcomes for children. He has written numerous articles and books, lectured widely, and has received many honors. His efforts in support of healthy development of young people are known nationally and internationally, and his latest book, published by Yale Press, September 2004, is entitled *Learn No Child Behind: Preparing Today's Youth for Tomorrow's World*.
Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL
CONSULTATIONS 13-15

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 13 James L. Griffith, M.D., and Christina Puchalski, M.D., on the Role of Spirituality in the Care of Patients
Room 201 A, Level 200, Toronto Convention Centre North
- 14 Robert P. Cabaj, M.D., on Sexual Orientation and Gender Identity in Clinical Care
Room 201 B, Level 200, Toronto Convention Centre North
- 15 Helga Hannesdottir, M.D., on Doing Residency Training in Psychiatry in the U.S. and Returning Home to Practice
Room 201 C, Level 200, Toronto Convention Centre North

ROUND TABLE DISCUSSION

9:00 a.m.-10:30 a.m.

Room 716 A, Level 700, Toronto Convention Centre South

**CHILD AND ADOLESCENT BIPOLAR DISORDER:
OUT OF A DIAGNOSTIC QUANDRY****Moderator:** Richard E. D'Alli, M.D.**Participants:** Robert A. Kowatch, M.D., Barbara Geller, M.D., Joseph Biederman, M.D., Ellen Leibenluft, M.Ed.**WORKSHOPS****COMPONENTS 37-43****COMPONENT WORKSHOP 37** 9:00 a.m.-10:30 a.m.

Room 104 A, Level 100, Toronto Convention Centre North

**DATA COUPLED WITH ADVOCACY SHAPING
PUBLIC POLICY***APA Illinois Psychiatric Society***Co-Chps.:** Jagannathan Srinivasaraghavan, M.D., Daniel W. Hardy, M.D.**Participants:** Kenneth G. Busch, M.D., Malini Patel, M.D.**COMPONENT WORKSHOP 38** 9:00 a.m.-10:30 a.m.

Room 104 D, Level 100, Toronto Convention Centre North

**DISASTERS, DISPARITIES, AND CULTURAL
PSYCHIATRY***APA/SAMHSA Minority Fellows***Chp.:** Niranjan S. Karnik, M.D.**Participants:** Nakia G. Scott, M.D., Leah A. Fennell, M.D., Raquel Lugo, M.D., Nisba F. Husain, M.D., Cheryl Y. Salary, M.D.**COMPONENT WORKSHOP 39** 9:00 a.m.-10:30 a.m.

Room 201 D, Level 200, Toronto Convention Centre North

**DOING MORE WITH LESS: CHALLENGES AND
REWARDS OF BECOMING A PSYCHIATRIST
EXECUTIVE***APA Committee on Psychiatric Administration and Management***Chp.:** Sy A. Saeed, M.D.**Participants:** Brian M. Hepburn, M.D., Nalini V. Juthani, M.D., Arthur L. Lazarus, M.D., Shirish V. Patel, M.D., Lydia E. Weisser, D.O.**COMPONENT WORKSHOP 40** 9:00 a.m.-10:30 a.m.

Room 205 A, Level 200, Toronto Convention Centre North

**TEACHING THE HISTORY OF PSYCHIATRY TO
STUDENTS AND RESIDENTS: A WORKSHOP
DISCUSSION ON CONTENT, METHODS, AND
IDEALS***APA Corresponding Committee on History and Library***Chp.:** Avram H. Mack, M.D.**Participants:** Laura D. Hirshbein, M.D., David J. Lynn, M.D.**COMPONENT WORKSHOP 41** 9:00 a.m.-10:30 a.m.

Room 205 B, Level 200, Toronto Convention Centre North

**HOW TO BE A MORE CREATIVE TEACHER:
WINNING STRATEGIES FOR RESIDENTS AND
FACULTY***APA Council on Medical Education and Lifelong Learning***Co-Chps.:** Joan M. Anzia, M.D., Lowell D. Tong, M.D.**Participants:** Joshua T. Thornhill IV, M.D., Theodore B. Feldman, M.D., Margo D. Lauterbach, M.D., Suma Jacob, M.D.**COMPONENT WORKSHOP 42** 9:00 a.m.-10:30 a.m.

Room 205 D, Level 200, Toronto Convention Centre North

**THE NATIONAL HEALTH INFORMATION
NETWORK AND PSYCHIATRY: HOW WILL THE
COMING NATIONAL ELECTRONIC HEALTH
RECORD IMPACT OUR PATIENTS AND OUR
PRACTICE?***APA Corresponding Committee on Electronic Health Records***Chp.:** John J. Boronow, M.D.**Participants:** Zebulon Taintor, M.D., Robert M. Plovnick, M.D., Jerome Rogoff, M.D.**COMPONENT WORKSHOP 43** 9:00 a.m.-10:30 a.m.

Room 206 C/D, Level 200, Toronto Convention Centre North

**NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO
HAVE MADE THEIR OWN WAY***APA Committee on Women***Co-Chps.:** Marisa A. Giggie, M.D., Melva I. Green, M.D.**Participants:** Deborah Spitz, M.D., Stephanie S. Durruthy, M.D., Molly J. Hall, M.D., Julianne Flynn, M.D., Esther P. Roberts, M.D.**ISSUES 54-64****ISSUE WORKSHOP 54** 9:00 a.m.-10:30 a.m.

Room 205 C, Level 200, Toronto Convention Centre North

**SUPERVISING THE SUPERVISORS: SEE ONE, DO
ONE, TEACH ONE MODEL SHATTERED! AN
INNOVATIVE GROUP TO TRAIN FACULTY TO
TEACH MEDICAL STUDENTS****Co-Chps.:** Joseph M. Garbely, D.O., Javed A. Joy, M.D.**Participants:** Ruth M. Lamdan, M.D., Jonathan G. Shack, M.D., Mary Kurien, M.D.**ISSUE WORKSHOP 55** 9:00 a.m.-10:30 a.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

**PSYCHO-KILLERS: MENTAL ILLNESS AND
HOMICIDE****Chp.:** Renee M. Sorrentino, M.D.**Participants:** Joy E. Stankowski, M.D., Britta Ostermeyer, M.D., Susan J. Hatters-Friedman, M.D.

WEDNESDAY

ISSUE WORKSHOP 56 9:00 a.m.-10:30 a.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

PSYCHIATRIC ASPECTS OF DEEP BRAIN
STIMULATION FOR PARKINSON'S DISEASE

Chp.: Valerie Voon, M.D.
Participants: Anthony E. Lang, M.D., Andres M. Lozano, M.D.,
Elena Moro, M.D., Paul Krack, M.D.

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE
PATIENTS WITH BPD

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

TRAINING PSYCHIATRIC RESIDENTS IN THE
COGNITIVE THERAPY OF SCHIZOPHRENIA

Chp.: Page Burkholder, M.D.
Participants: Douglas Turkington, M.D., Michael Garrett, M.D.,
Neil A. Rector, Ph.D.

ISSUE WORKSHOP 59 9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

THE MIRROR HAS A REFLECTION: TEACHING
AND MODELING CULTURAL COMPETENCY TO
GENERAL PSYCHIATRY RESIDENTS

Co-Chps.: Dionne A. Hart, M.D., Renato D. Alarcon, M.D.
Participant: Annelle B. Primm, M.D.

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

ASSISTED OUTPATIENT TREATMENT AND ITS
ROLE IN THE FABRIC OF THE MENTAL HEALTH
SYSTEM

Chp.: Daniel Garza, M.D.
Participants: Constantine Ioannou, M.D., Mary Zdanowicz, J.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.
Room 711, Level 700, Toronto Convention Centre South

PSYCHIATRISTS IN THE DEAN'S OFFICE: CAREER
OPPORTUNITIES AND CAREER DEVELOPMENT

Chp.: Carolyn B. Robinowitz, M.D.
Participants: Tana A. Grady-Weliky, M.D., Cheryl F.
McCartney, M.D., Larry R. Faulkner, M.D., Darrell G. Kirch, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.
Room 714 A, Level 700, Toronto Convention Centre South

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: David E. Hartman, Ph.D., Carl M. Wahlstrom, Jr., MD.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

THE QUALITY INFORMATION SYSTEM: A NEW
SYSTEM FOR MEASURING PROGRESS IN THE
DOCTOR-PATIENT RELATIONSHIP

Chp.: Victor J.A. Buwalda, M.D.
Participants: Michelle B. Riba, M.D., Henk van den Berg, M.D.,
Prashaant Debipersad, B.A., Richard C. Hermann, M.D.

ISSUE WORKSHOP 64 9:00 a.m.-10:30 a.m.
Room 717 A, Level 700, Toronto Convention Centre South

CONNECTION IS THE CURE: TREATING
RELATIONAL DISORDERS

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

MEDIA 4-6

MEDIA WORKSHOP 4 9:00 a.m.-12 noon
Room 715 A/B, Level 700, Toronto Convention Centre South

I USED. I AM SORRY. CAN I COME BACK? *SISTER
HELENSAYS: PISS OFF*
*APA Corresponding Committee on Treatment Services for Patients With
Addictive Disorders*

Co-Chps.: Petros Levounis, M.D., Marjorie E. Waldbaum, M.D.
Participants: Moddy H. Kiluvia, M.D., Aditi M. Shrikhande, M.D.,
Monisha R. Vasa, M.D.

MEDIA WORKSHOP 5 9:00 a.m.-12 noon
Alberta Room, Mezzanine Floor, Royal York

THE MOVIE *FUN* AS A FRAME WORK FOR
EXPLORING CONDUCT DISORDER IN
ADOLESCENT GIRLS

Chp.: Jessica C. Morgan, M.D.
Participants: Patricia A. Daly, M.D., Erica L. O'Neal, M.D.

MEDIA WORKSHOP 6 9:00 a.m.-12 noon
Quebec Room, Mezzanine Floor, Royal York

*CARTER'S ADDICTION: SUBSTANCE USE
DISORDERS IN PHYSICIANS*
*Collaborative Session With the National Institute on Alcohol Abuse and
Alcoholism*

Chp.: Christopher J. Welsh, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 21-22

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 21 **Michelle B. Riba, M.D.**, on the Role of the Psychiatrist in End-of-Life Care
Grenadier Room, Main Level, Intercontinental Hotel
- 22 **Patricia Ordorica, M.D.**, on the Future of Psychiatry: What the Resident Should Know (*Residents Only*)
Niagara Room, Lower Level, Intercontinental Hotel

LECTURES 23-25

LECTURE 23

11:00 a.m.-12:30 p.m.

Room 105, Level 100

Toronto Convention Centre North

A. Leslie Morrow, Ph.D.

High on Neurosteroids: Mechanisms and Therapeutic Relevance

Chp.: Christine E. Marx, M.D.

Co-Chp.: Farah Monir, D.O.

Dr. A. Leslie Morrow received a Ph.D. in Neuroscience at the University of California, San Diego in 1985 and conducted her postdoctoral training with Dr. Steven Paul at NIMH in Bethesda, Maryland. She received a prestigious PRAT fellowship and National Academy of Science NRC Associate Award at NIH. Morrow joined the faculty of the University of North Carolina at Chapel Hill School of Medicine in 1995, and was promoted to professor of psychiatry and pharmacology in 2001. She served on the biomedical study section at NIAAA from 1997-2003, chairing the committee from 2001-03. Dr. Morrow has editorial responsibilities for *Pharmacology and Therapeutics*, *Psychopharmacology and Alcoholism*, and *Clinical and Experimental Research*. She received a Merit Award from NIH in 2001. She is associate director of the Bowles Center for Alcohol Studies and co-scientific director of an NIH-funded alcohol research center grant. Countless numbers of her trainees have developed successful independent research programs.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 24

11:00 a.m.-12:30 p.m.

Exhibit Hall A, Level 300

Toronto Convention Centre North

Father Edward A. Malloy, Ph.D.

A University President's Perspective on Alcohol-Related Research *Collaborative Session With the National Institute of Alcohol Abuse and Alcoholism*

Chp.: Deborah Deas, M.D.

Father Edward A. Malloy, Ph.D., completed his 18th year as president of the University of Notre Dame in 2005. As the University's 10th president, Father Malloy was elected by the Board of Trustees in 1986, having served five years as vice president and associate provost. Father Malloy is a full professor in the Department of Theology and has been a member of the faculty since 1974. Father Malloy has authored more than 50 articles and book chapters, is the editor or co-editor of two books, and has published six books. An ethicist by training, he is a member of the Catholic Theological Society of America and the Society of Christian Ethics. Father Malloy earned his doctorate in Christian ethics from Vanderbilt University in 1975, and Vanderbilt honored him in 1998 with the establishment of a chair in Catholic studies in his name. He was ordained to the priesthood in Sacred Heart Basilica on campus in 1970. Father Malloy's service to higher education has been long-standing and presently includes membership on the boards of Vanderbilt University, the University of Portland, St. Thomas University, and Notre Dame Australia. In addition, he has played a leadership role in many of the major higher education associations including the American Council on Education (ACE), the Association of Governing Boards of Universities and Colleges (AGB), Campus Compact, the International Federation of Catholic Universities (IFCU), the Association of Catholic Colleges and Universities (ACCU), the National Association of Independent Colleges and Universities (NAICU), and various committees of the SCAA. In combating substance abuse, Father Malloy has been a member of the National Advisory Council on Alcohol Abuse and Alcoholism, President Bush's Advisory Council on Drugs, the Community Anti-Drug Coalitions of America, the Governor's Commission for a Drug-Free Indiana, and a member of the board of the National Center on Addiction and Substance Abuse (CASA) at Columbia University, for which he has chaired a number of commissions, particularly dealing with substance abuse among adolescents and among college and university students. He has also been co-chair of a major study on college drinking for the National Institute on Alcohol Abuse and Alcoholism.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 25

11:00 a.m.-12:30 p.m.
Room 718 A/B, Level 700
Toronto Convention Centre South

Markus Heilig, M.D.

*Beyond Dopamine: Neuroadaptations,
Negative Affect, and Clinically Relevant
Treatment Targets in Alcoholism
Collaborative Session With the National Institute of
Alcohol Abuse and Alcoholism*

Chp.: Eric Stein, M.D.

Co-Chp.: Shelly Greenfield, M.D.

Markus Heilig, M.D., has been the Clinical Director of the National Institute on Alcohol Abuse and Alcoholism and Chief of the Laboratory of Clinical and Translational Studies at the National Institutes of Health in Bethesda, Maryland since 2004. Dr. Heilig obtained his medical degree from Lund University in Sweden in 1986 and his Ph.D. at the Department of Psychiatry and Neurochemistry at Lund University in 1989. His Ph.D. thesis described for the first time, the role of neuropeptide Y in stress and emotionality. Between 1990 and 1992, Dr. Heilig was a post-doctoral fellow with Professor George Koob at the Scripps Research Institute, La Jolla, California, where he continued to study neuropeptide systems in emotionality and stress. Following his return to Sweden, Dr. Heilig completed his clinical psychiatry training in 1995, and served in different clinical and academic leadership roles at the Karolinska Institute in Stockholm, Sweden from 1995-2004. Dr. Heilig's current research centers around development of novel pharmacological treatments for alcohol dependence, with a particular focus on target systems involved in long-term neuroadaptations following a prolonged history of dependence and recruitment of negative affect. Among key systems under study are neuropeptide systems involved in stress responses, such as neuropeptide Y, corticotropin-releasing hormone, substance P, and nociceptin. The intramural medications development effort led by Dr. Heilig spans from preclinical target discovery and validation, to early human proof-of-concept trials.

THIS SESSION IS TO BE AUDIOTAPED.

- 17 **Ellen Haller, M.D.**, on Working With Lesbian, Gay, Bisexual, and Transgendered Patients: What Do You Need to Know?
Room 201 B, Level 200, Toronto Convention Centre North

MEDICAL UPDATE 3

11:00 a.m.-12:30 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

TESTOSTERONE REPLACEMENT THERAPY IN THE AGING MALE: IMPLICATIONS FOR PSYCHIATRY AND OTHER DISCIPLINES

Presenters: Jerald Bain, M.D.

Chp.: Dennis Kussin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 3 **Howard Goldman**, on Mental Health Policy Research
Oakville Room, Main Level, Intercontinental Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 23-33

SCIENTIFIC AND CLINICAL REPORT SESSION 23

11:00 a.m.-12:30 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

SLEEP DISORDERS

Chp.: Karl Doghramji, M.D.

Co-Chp.: Darryl Appleton, M.D.

11:00 a.m.

- 67 **Effect of Armodafinil on Reducing Fatigue in Patients With Narcolepsy**
Russell Rosenberg, Ph.D.

11:30 a.m.

- 68 **Effect of Armodafinil on Attention in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder**
Keith Wesnes, Ph.D., Gwendolyn E. Niebler, D.O., Sanjay Arora, Ph.D.

12 noon

- 69 **Armodafinil Improves Wakefulness in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder**
Milton Erman, M.D., Gary Zammit, Ph.D., Gwendolyn E. Niebler D.O., Sanjay Arora, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 16-17

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 16 **David Baron, D.O.**, on Performance Enhancing Drug Use in Adolescent Athletes: A Sports Psychiatry Perspective
Room 201 A, Level 200, Toronto Convention Centre North

SCIENTIFIC AND CLINICAL REPORT SESSION 24

11:00 a.m.-12:30 p.m.

Room 104 D, Level 100, Toronto Convention Centre North

ECT

Chp.: Michael A. Kling, M.D.

Co-Chp.: Eric D. Peselow, M.D.

11:00 a.m.

70 Predictors of Referral for ECT

Bonnie L. Szarek, R.N., John W. Goethe, M.D., Joanna H. Fogg-Waberski, M.D.

11:30 a.m.

71 ECT Stimulus Dose as Physiological Volume of Seizure Foci

Conrad M. Swartz, M.D.

12 noon

72 The Efficacy and Outcome of Combining ECT and Atypical Antipsychotics for Treatment-Resistant Depression

Randall T. Espinoza, M.D., Joseph Morrow, B.A., Julie King, R.N., Juanita Jackson, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Room 201 D, Level 200, Toronto Convention Centre North

HEALTH, NUTRITION, AND WEIGHT IN SCHIZOPHRENIA

Chp.: Prakash S. Masand, M.D.

Co-Chp.: Rachel Glick, M.D.

11:00 a.m.

73 Assessing Health and Nutrition Status of Urban Psychiatric Outpatients

David J. Hellerstein, M.D., Goretti Almeida, M.B.A., Nathaniel Mendelsohn, A.B., Stacia Helfand, M.Ed., Michael J. Devlin, M.D., Dianna Dragatsi, M.D., Raquel Miranda, R.N.

11:30 a.m.

74 Are Females at Special Risk for Obesity If They Become Psychotic? The Longitudinal Northern Finland 1966 Birth Cohort Study

Hannu J. Koponen, M.D., Sari Lindeman, M.D., Kaisa Saari, M.D., Helinä Hakko, Ph.D.

12 noon

75 A 12-Week Open Label Trial of Topiramate for Limiting Weight Gain During Olanzapine Treatment in Patients With Schizophrenia

Jin-Hun Kim, Seonjin Yim, Junghyun Nam, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Room 205 A, Level 200, Toronto Convention Centre North

DEVELOPMENTAL ISSUES IN SCHIZOPHRENIA

Chp.: Mary V. Seeman, M.D.

Co-Chp.: Don Richardson, M.D.

11:00 a.m.

76 Altered Developmental Trajectories in Schizophrenia

Matti K. Isohanni, Med.Sc., Khanum Ridler, Ph.D., Jouko Miettunen, Ph.D., Graham Murray, M.D., Juha M. Veijola, Med.Sc., Edward Bullmore, Med.Sc., Peter B. Jones, Med.Sc.

11:30 a.m.

77 Characteristics of the Interpersonal Distance of Patients With Schizophrenia in the Virtual Environment

Sung-Hyook Park, M.D., Jae-Jin Kim, M.D., Hee-Jeong Jang, B.A., Chan-Hyung Kim, M.D., Jeonghun Ku, Ph.D., In-Young Kim, M.D., Sun I. Kim, Ph.D.

12 noon

78 Familial Risk of Psychosis and Prodromal Features of Psychosis at the Age of 15-16 Years

Juha M. Veijola, M.D., Pirjo H. Maki, M.D., Hanna Ebeling, M.D., Irma Moilanen, M.D., Anja Taanila, Ed.D., Erika Lauronen, M.D., Jouko Miettunen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m.-12:30 p.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

TREATMENT OF SCHIZOPHRENIA

Chp.: Michael Demas, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

79 An Effectiveness Trial of a Brief Cognitive Behavioral Intervention by Mental Health Nurses in Schizophrenia: Clinically Important Outcomes in the Medium Term

Shanaya Rathod, M.D., David G. Kingdon, M.D., Douglas Turkington, M.D.

11:30 a.m.

80 Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of First-Episode Psychosis: A Randomized, Double-Blind, 52-Week Comparison

Joseph P. McEvoy, M.D.

12 noon

81 Quetiapine for Bipolar Disorder and Schizophrenia: Appropriate Dose for Optimal Response

Arthur L. Lazarus, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28

11:00 a.m.-12:30 p.m.

Room 206 E/F, Level 200, Toronto Convention Centre North

RECENT RESEARCH ON SSRIS

Chp.: David V. Sheehan, M.D.

Co-Chp.: Derya Iren Akbiyik, M.D.

11:00 a.m.

82 Early Symptomatic Worsening During Treatment With Fluoxetine in MDD: A Replication Study

Cristina Cusin, M.D., Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D., Frederick M. Quitkin, M.D., Maurizio Fava, M.D.

11:30 a.m.

83 Meta-Analysis of Efficacy of Paroxetine Versus Placebo Utilizing the GlaxoSmithKline Clinical Trials Registry

Lawrence W. Adler, M.D., Lorri Cerro, Ph.D., Henri Zepp, R.N.C.

12 noon

84 Resolution of Sleepiness and Fatigue in the Treatment of MDD: A Comparison of Bupropion and SSRIs

George I. Papakostas, M.D., Rafe M. Donahue, Ph.D., Andrew A. Nierenberg, M.D., David J. Nutt, M.D., Maurizio Fava, M.D.,

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29

11:00 a.m.-12:30 p.m.

Algonquin Room, Mezzanine Floor, Royal York

EPIDEMIOLOGICAL STUDIES OF ADVERSE EVENTS IN INSTITUTIONALIZED POPULATIONS

Chp.: Rubaba Ansari, M.D.

Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

85 Death by Unnatural Causes During Childhood and Early Adulthood in Offspring of Psychiatric Inpatients

Roger T. Webb, M.S.C., Kathryn M. Abel, Ph.D., Louis Appleby, M.D., Preben B. Mortensen, Med. Sc., Sarah A. King-Hele, M.S.C., Andrew R. Pickles, Ph.D.

11:30 a.m.

86 The Incidence and Prevalence of Diabetes Mellitus Among Inpatients in State-Operated Psychiatric Hospitals in New York State 1997-2004

Leslie L. Citrome, M.D., Ari B. Jaffe, M.D., Jerome M. Levine, M.D., David Martello

12 noon

87 Associations Between Psychiatric Disorder and Commitment Criteria in Acute Involuntarily Admitted Patients in the Netherlands

Cornelis Mulder, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30

11:00 a.m.-12:30 p.m.

Confederation 3 Room, Mezzanine Floor, Royal York

TREATMENT OF ADVERSE EVENTS

Chp.: Elissa P. Benedek, M.D.

Co-Chp.: Zubin Bhagwagar, M.D.

11:00 a.m.

88 PDE5I Sildenafil Treatment of Serotonergic Antidepressant Associated Sexual Dysfunction (SRI-AASD) in Women With MDD in Remission: An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial With Eight-Week Open-Label Continuation

H. George Nurnberg, M.D., Paula L. Hensley, M.D., Maurizio Fava, M.D., Harry A. Croft, M.D., Julia R. Heiman, Ph.D., Matthew A. Menza, M.D., Julia K. Warnock, M.D.

11:30 a.m.

89 Theoretical Implications of Improved Depression Severity by PDE5I Sildenafil Treatment of Erectile Dysfunction Associated With Treated or Untreated MDD for Endothelial Dysfunction Mediation

Richard L. Siegel, M.D., H. George Nurnberg, M.D.

12 noon

90 Efficacy of Sildenafil for the Treatment of Erectile Dysfunction in Men Taking Antidepressant Medication: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies

Joseph C. Cappelleri, Ph.D., H. George Nurnberg, M.D., Li-Jung Tseng, Ph.D., Claude Tellier, B.S., Richard L. Siegel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31

11:00 a.m.-12:30 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

BPD

Chp.: Bernadette Grosgean, M.D.

Co-Chp.: Kenneth Silk, M.D.

11:00 a.m.

91 Structural Brain Abnormalities in BPD

Paul H. Soloff, M.D., Jeffrey Nutche, B.S., Vaibhav Diwadkar, Ph.D.

11:30 a.m.

92 Neurobiological Correlates of Diagnosis and Underlying Traits in Patients With BPD Compared With Normal Controls

Joel F. Paris, M.D., Hallie Zweig-Frank, Ph.D., Mien-Kwong Ng Ying Kin, Ph.D., George Schwartz, M.S., Howard Steiger, Ph.D., Vasavan N. Nair, M.D.

12 noon

93 BPD and Suicide Attempt: Are There Any Correlates Between Attempters and Non-Attempters?

Tavi Thongdy, M.D., Mark Zimmerman, M.D., Joseph McGlinchey, Ph.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 32

11:00 a.m.-12:30 p.m.

Manitoba Room, Mezzanine Floor, Royal York

WOMEN'S HEALTH ISSUES

Chp.: Nafisa Y. Ghadiali, M.D.

Co-Chp.: Evangeline J. Spindler, M.D.

11:00 a.m.

- 94 **Gender Differences in Schizophrenia and Other Psychotic Disorders: A 20-Year Follow-Up Study**
Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Cherise Rosen, Ph.D., Robert Faull, B.S.

11:30 a.m.

- 95 **Severe Personality Disorders in the Offspring of Antenatally-Depressed Mothers: A 31-Year Follow-Up of the Northern Finland 1966 Birth Cohort**
Pirjo H. Maki, M.D., Juha M. Veijola, M.D., Matti Joukamaa, M.D., Paula Rantakallio, M.D., Jari Jokelainen, M.S.C., Liisa Kantojarvi, M.D., Matti K. Isohanni, M.D.

12 noon

- 96 **Outcome of Prenatal Anxiety, Stress, and Depression**
Gisèle Apter-Danon, M.D., Rozenn Graignic-Philippe, Ph.D., Emmanuel Devouche, Ph.D., Marina Gianoli-Valente, M.A., Annick Le Nestour, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33

11:00 a.m.-12:30 p.m.

Salon B, Convention Floor, Royal York

CROSS-CULTURAL AND MINORITY ISSUES

Chp.: Leslie Horton, M.D.

Co-Chp.: Antony Fernandez, M.D.

11:00 a.m.

- 97 **All Equal? Advocating Equity in Mental Health Services in France to Ethnic-Minority Disadvantaged Youth and Their Families Through the Evidence-Based FACE[®] Protocol**
Leon-Patrice Celestin, M.D., Smadar Celestin-Westreich, Ph.D.

11:30 a.m.

- 98 **Stories About Mental Health: A Cross-Cultural Relapse Prevention Study in Northern Territory Aboriginal Communities**
Tricia M. Nagel, Carolyn Thompson

12 noon

- 99 **Recognizing and Engaging Depressed Chinese Americans in Treatment in a Primary Care Setting**
Albert Yeung, M.D., Jinny Yu, M.A., Freddy Fung, B.A., Sienna Vorono, B.A., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 44-49

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.

Room 104 A, Level 100, Toronto Convention Centre North

GLOBAL PSYCHIATRY: ESTABLISHING FORMAL AND INFORMAL MENTAL HEALTH EXCHANGES

APA Council on Global Psychiatry

Co-Chps.: Samuel O. Okpaku, M.D., William Lawson, M.D.

Participants: Mary K. Smith, M.D., Michael A. Hollifield, M.D., Robert Kohn, M.D., Rodrigo A. Munoz, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.

Room 205 B, Level 200, Toronto Convention Centre North

SCHOOL-BASED SUICIDE PREVENTION: EVIDENCE-BASED STRATEGIES AND NEW APPROACHES

APA Corresponding Committee on Mental Health and Schools

Co-Chps.: Eugenio M. Rothe, M.D., Daniel Castellanos, M.D.

Participants: Alicia A. Munoz, LaShondra T. Washington, M.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.

Room 205 C, Level 200, Toronto Convention Centre North

A RESEARCH AGENDA FOR *DSM-IV* MENTAL HEALTH IN THE GAY, LESBIAN, AND BISEXUAL POPULATIONS

APA Committee on Gay, Lesbian, and Bisexual Issues

Co-Chps.: Benjamin H. McCommon, M.D., Jack Drescher, M.D.

Participants: Theodorus G.M. Sandfort, Ph.D., Michael B. First, M.D., Susan D. Cochran, Ph.D., Serena Y. Volpp, M.D., Robert P. Cabaj, M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.

Room 205 D, Level 200, Toronto Convention Centre North

WELCOME TO THE JUNGLE: THE DYNAMICS BETWEEN RESIDENTS AND INDUSTRY

APA/GlaxoSmithKline Fellows

Co-Chps.: Lisa A. Catapano, M.D., Itai Danovitch, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.

Room 206 C/D, Level 200, Toronto Convention Centre North

TRAUMA OF HEARTS AND MINDS: RACISM AND PSYCHIATRY IN THE 21ST CENTURY

APA/SAMHSA and APA/AstraZeneca Minority Fellowships

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Jean-Marie E. Alves-Bradford, M.D.

Participants: Lachresha L. Hall, M.D., Aruna S. Rao, M.D., Eric R. Williams, M.D.

WEDNESDAY

COMPONENT WORKSHOP 49 11:00 a.m.-12:30 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

CURRENT ISSUES IN PSYCHIATRY AND LAW
APA Council on Psychiatry and Law

Chp.: Paul S. Appelbaum, M.D.
Participants: Howard V. Zonana, M.D., Steven K. Hoge, M.D.

ISSUES 65-75

ISSUE WORKSHOP 65 11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South

PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS: AN ONGOING CHALLENGE

Chp.: Hoyle Leigh, M.D.
Participants: Don R. Lipsitt, M.D., Seth M. Powsner, M.D., Jon M. Streltzer, M.D.

ISSUE WORKSHOP 66 11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South

WHEN THERAPEUTIC LIFESTYLE CHANGES FAIL: PHARMACOLOGIC MANAGEMENT OF METABOLIC SYNDROME IN PSYCHIATRY

Co-Chps.: Peter Manu, M.D., Raymond E. Suarez, M.D.
Participant: Christoph U. Correll, M.D.

ISSUE WORKSHOP 67 11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South

COUNTERTRANSFERENCE AND BOUNDARY ISSUES OF RESIDENTS TREATING MEDICAL STUDENTS, FELLOW RESIDENTS, AND ATTENDING

Chp.: Benjamin D. Lederer, M.D.
Participants: Julianne Flynn, M.D., Jeffrey M. Lammers, M.D., David J. Walick, M.D.

ISSUE WORKSHOP 68 11:00 a.m.-12:30 p.m.
Room 709, Level 700, Toronto Convention Centre South

APPLYING FOR NATIONAL INSTITUTE OF ALCOHOL ABUSE AND ALCOHOLISM RESEARCH MONEY: SOME THINGS YOU DIDN'T LEARN IN GRADUATE SCHOOL

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Robert Huebner, Ph.D.
Participant: Mark L. Willenbring, M.D.

ISSUE WORKSHOP 69 11:00 a.m.-12:30 p.m.
Room 711, Level 700, Toronto Convention Centre South

THE NATURE OF NURTURE: THE LONG-LASTING IMPACTS OF EARLY ADVERSE LIFE EVENTS

Co-Chps.: Mireya Nadal-Vicens, M.D., Stacy S. Drury, M.D.
Participants: Charles H. Zeanah, Jr., M.D., Joan Kaufman, Ph.D., Alison Fleming, Ph.D., Michael Meaney, Ph.D.

ISSUE WORKSHOP 70 11:00 a.m.-12:30 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

MAINTENANCE OF CERTIFICATION FOR DIPLOMATS OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Chp.: Stephen C. Scheiber, M.D.
Participants: Victor I. Reus, M.D., Naleen N. Andrade, M.D., Burton V. Reifler, M.D.

ISSUE WORKSHOP 71 11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Edward R. Shapiro, M.D., Jane G. Tillman, Ph.D.

ISSUE WORKSHOP 72 11:00 a.m.-12:30 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

NON-GOVERNMENTAL ORGANIZATIONS: RESPONSE TO MENTAL HEALTH CONSEQUENCES OF ASIAN TSUNAMI

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Syed A. Husain, M.D., Bruce S. Singh, M.D., Lakshmi Vijayakumar, D.P.M.

ISSUE WORKSHOP 73 11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

APPROACHES TO CHRONIC DISEASE MANAGEMENT : OPPORTUNITIES FOR PSYCHIATRY

Chp.: Nick Kates, M.B.
Participants: Michele Mach, M.S.W., Lindsey George, M.D., Anne Marie Crustolo, R.N.

ISSUE WORKSHOP 74 11:00 a.m.-12:30 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

THE KEY TO SUCCESS, MENTORSHIP MATTERS: A PRACTICAL GUIDE FOR TRAINEES AND EDUCATORS

Chp.: Anita R. Kishore, M.D.
Participants: Harold Alan Pincus, M.D., Dorothy E. Stubbe, M.D., Eva M. Szigethy, M.D.

ISSUE WORKSHOP 75 11:00 a.m.-12:30 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

THE EVOLUTION OF GRANDFAMILIES: THE PSYCHOLOGICAL, SOCIAL, AND FINANCIAL IMPACT OF GRANDPARENTS RAISING GRANDCHILDREN

American Academy of Child and Adolescent Psychiatry

Co-Chps.: Sandra C. Walker, M.D., James E. Lee, Jr., M.D.
Participants: O.C. White III, M.D., F.M. Baker, M.D., Esme Fuller-Thomson, Ph.D., Harry H. Wright, M.D.

12 noon Sessions

FORUMS 12-15

FORUM 12 12 noon-1:30 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

CORRECTIONAL MENTAL HEALTH ISSUES: AN INTERNATIONAL PERSPECTIVE

Chp.: Jeffrey L. Metzner, M.D.
Participant: Adrian Grounds, M.D.

FORUM 13 12 noon-1:30 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

KATRINA: PSYCHIATRIC RESPONSES AND CARE FOR INDIVIDUALS AND COMMUNITIES

Co-Chp.: Robert J. Ursano, M.D., Anthony T. Ng, M.D.
Participants: Carol S. North, M.D., Ronald Kessler, James Ray R. Rundell, M.D., Howard J. Osofsky, M.D.

FORUM 14 12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

ADDRESSING PSYCHIATRIC NEEDS IN ASIA
APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Participants: Russell F. D'Souza, M.D., Rodrigo A. Munoz, M.D., Afzal Javed, M.D., Bruce Singh, Ph.D., Haroon R. Chaudhry, M.D., Naotaka Shinfuku, M.D.

FORUM 15 12 noon-1:30 p.m.
Territories Room, Mezzanine Floor, Royal York

ENVIRONMENTAL PSYCHIATRY: FROM SICK BUILDINGS TO THE GULF WAR

Chp.: Claudia S. Miller, M.D.


NEW RESEARCH POSTER SESSION 8

12 noon-2:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

ANXIETY, ADHD, AND DISORDERS OF CHILDHOOD

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 92-97

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 92 1:00 p.m.-5:00 p.m.
Conference Room D/E, Mezzanine, Sheraton Centre

TREATING COMORBID ADULT ADHD BY COMBINING MEDICATION AND COGNITIVE THERAPY: PRACTICAL SOLUTIONS TO COMMON CLINICAL PROBLEMS

Co-Directors: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

COURSE 93 1:00 p.m.-5:00 p.m.
Windsor Room West, Mezzanine, Sheraton Centre

REEL PSYCHIATRY

Director: Luis F. Ramirez, M.D.
Faculty: David J. Robinson, M.D.

COURSE 94 1:00 p.m.-5:00 p.m.
City Hall, Second Floor, Sheraton Centre

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
Faculty: Robert D. Levitan, M.D.

COURSE 95 1:00 p.m.-5:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre

EMOTION FOCUSED THERAPY FOR COUPLES: INTRODUCTION TO THEORY AND CLINICAL SKILLS

Director: Wayne H. Denton, M.D.
Faculty: Susan M. Johnson, Ed.D.

WEDNESDAY

COURSE 96 1:00 p.m.-5:00 p.m.
Kent Room, Second Floor, Sheraton Centre

YOGA IN PSYCHIATRY: THEORY, CLINICAL APPLICATIONS, AND BEGINNING PRACTICE

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 97 1:00 p.m.-5:00 p.m.
Wentworth Room, Second Floor, Sheraton Centre

PSYCHIATRY AND THE INTERNET

Director: Robert S. Kennedy, M.A.
Faculty: Thomas A.M. Kramer, M.D., Carlyle H. Chan, M.D.

2:00 p.m. Sessions

ADVANCES IN SCHIZOPHRENIA
2:00 p.m.-5:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: Jeffrey A. Lieberman, M.D.

- A Pharmacotherapies for Schizophrenia
Thomas S. Stroup, M.D.
- B Dopamine and Glutamate Interactions in the Pathology of Schizophrenia: Insights From New Imaging
Marc Laruelle, M.D.
- C A Review of the Genetics of Schizophrenia
Patrick F. Sullivan, M.D.
- D Evaluation and Treatment of a First Psychotic Episode
Diana O. Perkins, M.D.
- E Recent Advance in Understanding the Neurobiology of Cognitive Dysfunction in Schizophrenia
David A. Lewis, M.D.

LECTURE 26

LECTURE 26
2:00 p.m.-3:30 p.m.
Room 108, Level 100
Toronto Convention Centre North
Bankole Johnson, M.D.
Medications That Act as Ion Channels as Treatment for Alcohol Dependence
Collaborative Session With the National Institute of Alcohol Abuse and Alcoholism
Chp.: Thomas R. Kosten, M.D.

Bankole Johnson, M.D., became Professor and Chairman of the Department of Psychiatric Medicine and Professor of Neuroscience at the University of Virginia on September 1, 2004. He graduated in Medicine from Glasgow University in 1982, trained in Psychiatry at the Royal London and Maudsley and Bethlem Royal Hospitals, trained in research at the Institute of Psychiatry (University of London), and conducted studies in psychopharmacology for his doctoral thesis (degree from Glasgow University) on the Medical Research Council Unit at Oxford University. In 2004, he earned his Doctor of Science degree in Medicine from Glasgow University. His primary area of research expertise is the psychopharmacology of addictive medications, with clinical expertise in addiction, biological, and forensic psychiatry. A licensed physician and board-certified psychiatrist in the U.S. and Europe, he is Principal Investigator on NIH-funded research studies utilizing neuroimaging and molecular genetic techniques. Honors include service on numerous NIH review and other committees/special panels. In 2001 he received the Dan Anderson Research Award for his distinguished contribution to the scientific knowledge of addiction recovery. He received the Distinguished Senior Scholar of Distinction Award from the National Medical Association in 2002 and was inducted into the Texas Hall of Fame in 2003. Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE D.

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3
2:00 p.m.-5:00 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

COLLABORATION IN CRISIS: ACADEMIC MEDICAL CENTERS' RESPONSE TO HURRICANES KATRINA AND RITA

Chp.: Joseph D. Hamilton, M.D.

- A The Acute Clinical Response
Kimberly A. Arlinghaus, M.D.
- B Be Nice to Your Neighbors: How Tulane University Adult Psychiatry and Baylor College of Medicine Worked Together to Rescue a Residency Program and Provide Continued Psychiatry Education in the Aftermath of Hurricane Katrina
Leslie E. Lawrence, M.D.

Discussant: Stuart C. Yudofsky, M.D.

PRESIDENTIAL SYMPOSIUM 4

2:00 p.m.-5:00 p.m.

Ballroom A, Lower Level, Intercontinental Hotel

PSYCHIATRIC PARTICIPATION IN
INTERROGATION OF DETAINEES: ETHICAL
CONSIDERATIONS

Chp.: Steven S. Sharfstein, M.D.

Presenters: Howard V. Zonana, M.D., Kevin C. Kiley, M.D.,
Alan A. Stone, M.D., Steven S. Sharfstein, M.D.

SYMPOSIA 66-99

SYMPOSIUM 66

2:00 p.m.-5:00 p.m.

Room 104 A, Level 100, Toronto Convention Centre North

RISK FACTORS, PERSONALITY VARIABLES, AND
ADDICTIVE DISORDERS*Collaborative Session With the National Institute on Alcohol Abuse and
Alcoholism*

Chp.: Maurice Corcos, Ph.D.

Co-Chp.: Gwenole Loas, M.D.

A Risk Factors for Addictive Disorders

Maurice Corcos, Ph.D., Martine Flament, M.D., Fernando
Perez-Diaz, M.D., Olivier Halfon, M.D., François
Lang, M.D., Paul Bizouard, Ph.D., Jean-Luc Venisse, M.D.,
Philippe Jeammet, Ph.D.

B Dependency and Suicidality in Addictive Disorders

Gwenole Loas, M.D.

C Depressive Psychopathology in Addictive Disorders

Mario Speranza, M.D., Maurice Corcos, Ph.D., Frederic
Atger, M.Eng., Gwenolé Loas, M.D., Philippe Jeammet, M.D.

D Sensation Seeking and Addictive Disorders

Alexandra Pham-Scottet, Fernando Perez-Diaz, M.D.,
Solange Carton, M.D., Julien-Daniel Guelfi, Ph.D., Philippe
Jeammet, Ph.D., Maurice Corcos, Ph.D.E Addictive Disorder: Goodman's Concept of Addiction,
A Study of 692 Addictive SubjectsLudovic A. Gicquel, Ph.D., Fernando Perez-Diaz M.Eng.,
Gwenolé Loas, M.D., Maurice Corcos, Ph.D., Aviel
Goodman, Ph.D., Julien-Daniel Guelfi, Ph.D., Philippe
Jeammet, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67

2:00 p.m.-5:00 p.m.

Room 104 B, Level 100, Toronto Convention Centre North

REDUCTIONISM IN PSYCHIATRY: IMPLICATIONS
AND LIMITS*Association for the Advancement of Philosophy and Psychiatry*

Chp.: Christian D. Perring, Ph.D.

A Is Modern Biological Psychiatry Reductionistic or
Integrative?

G. Scott Waterman, M.D.

B Dr. Chekhov and the Multiplicity of Psychiatric
Experience

Bradley E. Lewis

C Reduction in Psychiatry

Ian Gold, Ph.D.

D Reducing Reductionism: Reclaiming Psychiatry

Wesley E. Sowers, M.D.

Discussant: Peter D. Kramer

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68

2:00 p.m.-5:00 p.m.

Room 104 C, Level 100, Toronto Convention Centre North

COMPLEX PTSD ACROSS THE LIFESPAN:
IMPLICATIONS FOR *DSM-V*

Chp.: David B. Albert, Ph.D.

A Disorders of Extreme Stress: Results From the *DSM-
IV* Field Trial

Bessel A. Van Der Kolk, M.D.

B Self-Regulation as a Framework for Conceptualizing
and Treating Complex PTSD

Julian Ford, Ph.D.

C Early Childhood Trauma, Insecure Attachment, and
Complex PTSD

Marylene Cloitre, Ph.D., Chase Stovall-McClough, Ph.D.

Discussant: Judith L. Herman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69

2:00 p.m.-5:00 p.m.

Room 104 D, Level 100, Toronto Convention Centre North

PHARMACEUTICAL INDUSTRY INFLUENCE IN
PSYCHIATRY

Chp.: Daniel J. Carlat, M.D.

A Physicians and Industry: A Review of Commercial
Influence on Medical Decision-Making

Jerome P. Kassirer, M.D.

B How to Evaluate for the Presence of Commercial Bias
in CME Programs

Daniel J. Carlat, M.D.

C The ADHD/Psychostimulant Epidemic: The Role of
the Pharmaceutical Industry

Lawrence H. Diller, M.D.

(Continued next page)

WEDNESDAY

D Relationship Between Drug Company Funding and Outcomes of Clinical Psychiatric Research
Robert E. Kelly, Jr., M.D., Lisa J. Cohen, Ph.D., Philip Bialer, M.D., Adam Lau, M.D., Alison Bodenheimer, B.A., Elana Neustadter, B.A., Arkady Barenboim, M.D., Igor I. Galynker, M.D.

E Psychiatric Research as Marketing: Common Distortions of Research Design in Industry-Sponsored Clinical Trials
Daniel J. Safer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

NEW DIRECTIONS IN COMMUNITY PSYCHIATRY

Chp.: John S. Strauss, M.D.

A Poverty Reduction Strategies: An Important Focus for Early Intervention Programs
Terry Krupa, Ph.D.

B Aiming for the Star(s): Refining Recovery in Practice
Helen M. Glover, B.S.W.

C You Can Do It. We Can Help.
Larry Davidson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

HOW TO PRACTICE EVIDENCE-BASED MEDICINE

Chp.: Maju Mathews

A Introduction to Evidence-Based Medicine
Kumaraswamy Budur, M.D.

B Review of Basic Statistical Concepts
Maju Mathews

C Critical Appraisal of Systematic Reviews and Meta-Analysis
Babatunde A. Adetunji

D Critical Appraisal of Randomized-Controlled Studies
Adedapo B. Williams

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

THE PROBLEM OF OUTCOMES WITH THE DIFFICULT-TO-TREAT PATIENT

Chp.: Richard L. Munich, M.D.

Co-Chp.: Throstur Bjorgvinsson, Ph.D.

A Framing the Problem of Outcome With the Difficult-to-Treat Patient
Richard L. Munich, M.D.

B Rethinking Outcomes in Mentalization-Based Treatment
Jon G. Allen, Ph.D.

C Cognitive-Behavioral Therapy for Treatment Refractory OCD and Other Anxiety Disorders: Outcome Data From a Specialized Hospital Program
Throstur Bjorgvinsson, Ph.D., Joyce E. Davidson, M.D., Melinda Stanley, Ph.D.

D The Problem of Outcomes With the Difficult-to-Treat Patient
Norma V. Clarke, M.D.

E Future Direction of Specialized Treatment Programs: Mentalizing, Brain Imaging Studies, and Preliminary Outcomes
Efrain Bleiberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

THE ART AND SCIENCE OF BRIEF PSYCHOTHERAPIES

Chp.: Mantosh J. Dewan, M.D.

A Brief Cognitive Therapy
Judith S. Beck, Ph.D.

B Interpersonal Psychotherapy
Scott P. Stuart, M.D.

C Solution-Focused Brief Therapy
Brett Steenbarger

D Common Factors: Essential Ingredients for Successful Psychotherapy
Roger P. Greenberg

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

NEUROPSYCHIATRIC RESPONSES TO BURNS: MODELING THE DEVELOPMENTAL NEUROBIOLOGY OF TRAUMA

Chp.: Frederick J. Stoddard, Jr., M.D.

A Neurobiological Responses to Burn Trauma
John B. Levine, M.D.

B The Psychology and Physiology of Burn Stress in Very Early Childhood
Jennifer E. Drake, M.A.

C **Determinants of Traumatic Stress in Older Children**
Glenn Saxe

D **Pharmacological and Psychological Prevention of PTSD**
Rohini Luthra, Ph.D.

E **Psychopharmacological Interventions for Stress in Children**
Frederick J. Stoddard, Jr., M.D., John B. Levine, M.D.,
Glenn N. Saxe, M.D., Robert L. Sheridan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75 2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

ACUTE BRIEF PSYCHOSES: NOSOLOGY AND BOUNDARIES

Chp.: Ezra S. Susser, M.D.
Co-Chp.: Ramin Mojtabai, M.D.

A **Acute and Transient Psychotic Disorders**
Andreas Marneros, M.D.

B **The Relationship Between Acute and Transient Psychotic Syndromes and Psychotic Symptoms in the General Population: Implications for Causes and Treatment**
Peter B. Jones, Med. Sc., Fiona McDougall, M.P.H.

C **Panic Attacks With Psychotic Features: A Variant of Nonaffective Acute Remitting Psychoses?**
Igor I. Galynker, M.D., Liliya Malaya, Ph.D., Daniel Eisenberg, M.D., James Prosser, M.D., Lisa Cohen, Ph.D.

D **The Place of Nonaffective Acute Remitting Psychoses in *DSM-IV* and ICD-10**
Ramin Mojtabai, M.D., Ezra S. Susser, M.D., Vijoy Varma, M.D.

Discussant: Michael B. First, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

ENHANCING THE WELL-BEING OF OLDER PERSONS WITH SCHIZOPHRENIA

APA Council on Aging

Chp.: Carl I. Cohen, M.D.
Co-Chp.: Paul Ramirez, Ph.D.

A **Assessing Medical Comorbidity and Optimizing Medical Care in Older Patients With Schizophrenia**
Ipsit Vahia, M.D.

B **Enhancing Quality of Life in Older Persons With Schizophrenia**
Azziza O. Bankole, M.D.

C **Diminishing Depression in Older Adults With Schizophrenia: Targets for Intervention**
Shilpa P. Diwan, M.D.

D **Adaptive Functioning in Older Persons With Schizophrenia**
Carl I. Cohen, M.D., Azziza O. Bankole, M.D., Shilpa P. Diwan, M.D., Paul M. Ramirez, Ph.D., Ipsit Vahia, M.D.

Discussant: Dilip V. Jeste, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

DEMORALIZATION AND PSYCHOTHERAPY: A TRIBUTE TO JEROME D. FRANK, M.D.

Chp.: John M. de Figueiredo, M.D.

A **The Demoralization Hypothesis: Conceptualization, Epidemiology, and Clinical Relevance**
John M. de Figueiredo, M.D.

B **Demoralization in the Experience of Being Ill**
David Clarke

C **Brief Psychotherapy at the Bedside: Countering Demoralization From Medical Illness**
James L. Griffith, M.D., Lynne M. Gaby, M.D.

Discussant: Julia Frank, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

USE OF QUANTITATIVE INSTRUMENTS FOR MONITORING DEPRESSION SEVERITY: CLINICAL APPLICATIONS

Chp.: Darrel A. Regier, M.D.
Co-Chp.: Farifteh F. Duffy, Ph.D.

A **National Depression Management Leadership Initiative: Improving Depression Care**
Henry Chung, M.D., David J. Katzelnick, M.D., Farifteh F. Duffy, Ph.D., Donald S. Rae, M.S., Darrel A. Regier, M.D.

B **Depression Management Experience in Private Versus Public Psychiatric Practices**
Rodrigo A. Munoz, M.D.

C **Depression Management Experience in Primary Care**
Jack S. McIntyre, M.D.

D **Depression Screening and Management in New York City**
Lloyd I. Sederer, M.D.

E **Optimizing the Treatment of Depression: Using Treatment Algorithms in Conjunction With Standardized Instruments in Clinical Care Settings**
Madhukar H. Trivedi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WEDNESDAY

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

WOMEN'S LIFE CYCLE AND MENTAL HEALTH

Chp.: Samuel O. Okpaku, M.D.

Co-Chp.: Ponjola Coney

- A **The Female Life Cycle: From Childhood to Old Age**
G. William Bates, M.D.
- B **Menopausal Management**
Esther Eisenberg, M.D.
- C **Sociological Aspects of Family Planning**
Patricia Matthews-Juarez, Ph.D.
- D **Psychosocial Aspects of Infertility**
Samuel O. Okpaku, M.D.

Discussant: William Lawson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

STALKING OFFENDERS AND VICTIMS

Chp.: Gail E. Robinson, M.D.

- A **Stalking: An Overview of the Problem**
Gail E. Robinson, M.D.
- B **Stalking Victims: A Comprehensive Treatment Approach**
Karen M. Abrams, Gail E. Robinson, M.D.
- C **Stalking: A Treatment Concept for Offenders**
Werner Tschan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South

NICOTINE DEPENDENCE AND SCHIZOPHRENIA:
NEUROBEHAVIORAL PATHWAYS

National Institute on Drug Abuse

Chp.: Ivan D. Montoya, M.D.

Co-Chp.: Frank Vocci, Ph.D.

- A **Nicotine Intake and Blood Levels in Smokers With Schizophrenia**
Jill Williams
- B **Effects of Biological and Environmental Challenges on Smoking in Schizophrenic Versus Non-Psychiatric Heavy Smokers**
Jennifer W. Tidey, Ph.D., Damaris J. Rohsenow, Ph.D., Gary B. Kaplan, M.D., Robert M. Swift, M.D.
- C **Nicotine Abuse and the Neurobiology of Schizophrenia**
Robert Freedman, M.D.

- D **Pharmacological Treatment of Nicotine Dependence in Schizophrenia: Modulation of Outcomes by Atypical Antipsychotic Drugs, Cognitive Function, and Genetic Polymorphisms**
Tony P. George

- E **Integrating Tobacco Dependence Treatment Into Mental Health Treatment**
Douglas M. Ziedonis, M.D.

Discussant: Douglas M. Ziedonis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

ADOLESCENT ALCOHOL USE DISORDERS AND PSYCHIATRIC COMORBIDITY

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Howard B. Moss, M.D.

- A **Trauma and Alcohol Use Disorders in Adolescents: Psychiatric Comorbidity and Adult Outcomes**
Duncan B. Clark, M.D.
- B **Assessing Alcohol Problems in Adolescents With Psychiatric Comorbidity**
Deborah Deas, M.D.
- C **Treatment of Adolescents With Alcohol Problems and Major Depression**
Jack R. Cornelius, M.D.
- D **When ADHD and Substance Use Disorders Collide**
Timothy E. Wilens, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

EDUCATING A NEW GENERATION OF PHYSICIANS IN PSYCHIATRY: FOCUS ON MEDICAL STUDENT EDUCATION

Chp.: Michelle B. Riba, M.D.

Co-Chp.: Theodore Feldman, M.D.

- A **Medical Student Education in Psychiatry: Where We Are and Where We Can Go**
Myrl R.S. Manley
- B **Medical Student Education in Psychiatry: A Model That Works**
Lowell D. Tong, M.D.
- C **Medical Student Education in Psychiatry: Impacting Career Choice and Practice**
Brian A. Palmer, M.D.
- D **Medical Student Education in Psychiatry: What We Can Learn From Other Disciplines**
Deborah Danoff, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84 2:00 p.m.-5:00 p.m.

Room 717 A, Level 700, Toronto Convention Centre South

PATIENT SAFETY: TO ERR IS HUMAN, TO BE SAFE IS DIVINE*APA Committee on Patient Safety*Chp.: Geetha Jayaram, M.D.
Co-Chp.: Alfred Herzog, M.D.

- A **Length of Stay in the Psychiatric Emergency Room of an Urban Teaching Hospital**
Patrick T. Triplett, M.D.
- B **A Primer for Prescribing: How to Prevent Medication Errors**
Kathryn J. Ednie, M.D.
- C **Educating Faculty and Residents on Patient Safety**
Carl B. Greiner, M.D.
- D **Suicide and Patient Safety**
Geetha Jayaram, M.D.
- E **Your Role and All of Our Roles in Making Patient Safety a Bigger Reality**
Alfred Herzog, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.

Room 717 B, Level 700, Toronto Convention Centre South

RELATIONSHIPS BETWEEN AXIS I AND AXIS II*Association for Research in Personality Disorders*

Chp.: James H. Reich, M.D.

- A **State and Trait in Personality Disorders**
James H. Reich, M.D.
- B **Spectra of Pathology Across Axis I and Axis II Disorders**
David P. Bernstein, Ph.D., David Watson, Ph.D., Lee Anna Clark, Ph.D., Arnoud Arntz, Ph.D.
- C **Etiological Relationships Among Dimensions of Personality Disorder and Axis I Syndromes**
John Livesley, Ph.D.
- D **A Comparison of Mu-Opioid Receptor Activity in Depressed Subjects and in Subjects With BPD**
Kenneth R. Silk, M.D., Susan E. Kennedy, B.S., Sujata Guduri, M.A., Jon-Kar Zubieta, M.D.
- E **A Neurobiologic Perspective on the Relationship Between Axis I and Axis II Disorders**
Larry J. Siever

Discussant: Donald W. Black, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.

Room 801 A, Level 800, Toronto Convention Centre South

SCIENCE TO POLICY: ADVANCING WOMEN'S MENTAL HEALTH*Association of Women Psychiatrists*

Chp.: Altha J. Stewart, M.D.

- A **Science to Policy: Psychiatric Aspects of Reproductive Health**
Nada L. Stotland, M.D.
- B **PTSD in Women Veterans: From Science to Policy**
Marian I. Butterfield, M.D.
- C **Premenstrual Dysphoric Disorder: Treatment Update**
Tana A. Grady-Weliky, M.D.
- D **Neuroactive Steroids in Men and Women: Investigations in Schizophrenia, Bipolar Disorder, and Alzheimer's Disease**
Christine E. Marx, M.D.
- E **Ethnic and Racial Disparities in Women's Mental Health**
Annelle B. Primm, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87 2:00 p.m.-5:00 p.m.

Room 801 B, Level 800, Toronto Convention Centre South

ALCOHOL, DRUGS, AND PSYCHIATRIC DISORDERS IN THE U.S.*Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism*Chp.: Bridget F. Grant, Ph.D.
Co-Chp.: Deborah Hasin, Ph.D.

- A **Comorbidity of Pain and Substance Use Disorders in the U.S.**
Wilson M. Compton, M.D.
- B **Antisocial Personality Disorder and Lifetime Course of Alcohol Use Disorders in the U.S. General Population**
Rise B. Goldstein, Ph.D., Bridget F. Grant, Ph.D., Wilson M. Compton III, M.D.
- C **Prevalence, Correlates, and Comorbidity of Alcohol Use Disorders in the U.S.**
Frederick S. Stinson, Ph.D.
- D **Prevalence, Correlates, and Comorbidity of Nonmedical Sedative, Tranquilizer, Opioid, and Amphetamine Use, Abuse, and Dependence in the U.S.**
Bridget F. Grant, Ph.D.
- E **Cannabis Withdrawal Syndrome in 2613 Lifetime Heavy Cannabis Users From a National Survey: Symptom Prevalence, Factor Structure, and Correlates**
Deborah S. Hasin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

SOBERING FACTS: ALCOHOL DEPENDENCE AND TREATMENT INTERVENTIONS

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Kathleen T. Brady, M.D.

- A The Impact of Alcohol Use Disorders**
Richard J. Frances, M.D.
- B Alcohol Dependence: Difficulties in Diagnosis**
Kathleen T. Brady, M.D.
- C Integrating Pharmacotherapy and Psychosocial Support in Treating the Alcohol-Dependent Patient**
Roger D. Weiss, M.D.
- D Pharmacotherapy for the Treatment of Alcohol Dependence: Review of Outcome Data**
Robert M. Swift, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.
Imperial Room, Main Floor, Royal York

PHARMACOTHERAPY FOR SINGLE- AND DUAL-DIAGNOSED SUBSTANCE ABUSERS

American Academy of Addiction Psychiatry

Chp.: Marc Galanter, M.D.

- A Comorbidity With Opioid Dependence**
Edward V. Nunes, M.D.
- B Pharmacotherapy of Comorbid Substance Abuse and Schizophrenia**
Steven L. Batki, M.D.
- C Comorbidity of General Psychiatric Disorders and Cocaine Abuse**
Thomas R. Kosten, M.D.
- D The Comorbidity of Bipolar Spectrum Disorders and Substance Use Disorders**
Stephen Ross

Discussant: Elinore F. McCance-Katz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine Floor, Royal York

SCIENCE AND REGULATION AFFECTING PRIVATE PRACTICE

Chp.: Roger Peele, M.D.
Co-Chp.: Maryam Razavi, M.D.

- A Evidence-Based Medicine in Child and Adolescent Psychiatry: What Is Your Best Guess?**
Jeffrey A. Naser, M.D.
- B Evidence-Based Medicine in Solo Private Practice: What If the Patient Doesn't Fit?**
Ronald D. Abramson
- C Missing Resources: Comprehensive Psychiatry for People With Medical Illnesses**
John C. Urbaitis, M.D.
- D Comprehensive Psychiatry in 2006: Confidentiality and Access to Care in Private Practice and in Military Practice**
Brian Crowley
- E Affecting Care and Treatment of Children and Adults**
Harold I. Eist, M.D.

Discussant: Donna M. Norris, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine Floor, Royal York

RECENT ADVANCES IN ETHNOPSYCHOPHARMACOLOGICAL, ETHNIC, AND CULTURAL ASPECTS OF MOOD AND ANXIETY DISORDERS

Chp.: Rajesh M. Parikh, M.D.
Co-Chp.: Shamsah B. Sonawalla, M.D.

- A Ethnopsychopharmacology**
David C. Henderson, M.D.
- B Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology**
David Mischoulon, M.D.
- C Impact of Cultural Beliefs on the Treatment of Depressed Chinese Americans**
Albert Yeung, M.D.
- D Challenges in the Diagnosis and Treatment of Mood and Anxiety Disorders in the Asian-Indian Population: Cross-Cultural Factors and Psychopharmacological Considerations**
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.

Discussant: Gregory L. Fricchione
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

ANXIETY AND EMOTIONAL DYSFUNCTION IN
ENDOPHENOTYPE OF SCHIZOPHRENIA

Chp.: Joseph Zohar, M.D.

Co-Chp.: Stefano Pallanti

- A **Schizophrenia and OCD: The Role of Serotonergic and Dopaminergic Systems**
Joseph Zohar
- B **Anxiety Comorbidities and Role of Emotion in Endophenotype of Schizophrenia**
Stefano Pallanti
- C **Investigating the Cognitive and Emotional Neuropsychology of Schizophrenia Comorbid With Anxiety Disorders**
Naomi A. Fineberg, M.A., Sam R. Chamberlain, B.A., Barbara Sahakian, Ph.D., Trevor W. Robbins, Ph.D.
- D **Psychophysiological Investigation of Pathological Anxiety and Emotional Dysfunction in Patients With Schizophrenia**
Werner Strik, MD., Thomas Müller, MD., Dominik Bach, MD.

Discussant: Lorrin M. Koran, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.

Manitoba Room, Mezzanine Floor, Royal York

TEACHING PSYCHIATRY RESIDENTS ABOUT
INFORMED CONSENT

Chp.: Bret R. Rutherford, M.D.

Co-Chp.: Paul S. Appelbaum, M.D.

- A **Informed Consent in Psychiatry: An Overview**
Thomas G. Gutheil, M.D.
- B **Initiation of Psychotherapeutic and Psychopharmacologic Treatment by Psychiatry Residents**
Bret R. Rutherford, M.D., Thomas G. Gutheil, M.D.
- C **Informed Consent for Psychotherapy**
Thomas G. Gutheil, M.D.
- D **Complications of the Informed Consent Process in Psychotherapy**
Glen O. Gabbard, M.D.
- E **Informed Consent in Psychopharmacology**
Steven K. Hoge, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.

Quebec Room, Mezzanine Floor, Royal York

SUSTAINED RECOVERY AND HEALTHY
FUNCTIONING: THE LONG AND SHORT OF IT

Chp.: John C. Perry, M.D.

- A **Evidence for Recovery in the Psychotherapy of Personality Disorders**
John C. Perry, M.D., Martin Drapeau, Ph.D., Trent Semeniuk, M.D.
- B **Change in Psychological Risk and Recovery in Recurrent Depression**
Elisabeth Banon, John C. Perry, MD., Trent Semeniuk, M.D., Ruta Westreich, M.Psy., Philip R. Beck, M.D., Serge Lecours, Ph.D.
- C **Dynamic Recovery in Patients With Treatment-Refractory Disorders**
Christopher Fowler, John C. Perry, M.D., Stefanie Speanburg, M.S.W.
- D **Examining the Sequence of Recovery in Long-Term Dynamic Psychotherapy**
Michael P. Bond, John C. Perry, M.D.
- E **A Review of Treatment Evidence on Sustained Recovery and Healthy Functioning**
Daniel Frank, M.D., John C. Perry, M.D., Brian M. Robertson, M.D., Paul Crits-Christoph, Ph.D.

Discussant: Brian M. Robertson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.

Territories Room, Mezzanine Floor, Royal York

MENTAL HEALTH DISPARITIES: CONCEPTS,
ASSESSMENT, EVIDENCE-BASED PRACTICE, AND
ADVOCACY*APA Council on Minority Mental Health and Health Disparities*

Chp.: Francis G. Lu, M.D.

Co-Chp.: Margarita Alegria, Ph.D.

- A **Estimating Mental Health Disparities for Latinos and Asians Using the National Latino and Asian American Study**
Margarita Alegria, Ph.D.
- B **Strategies for Assessing Mental Health Disparities Using Health Care for Communities**
Thomas McGuire, Ph.D.
- C **Addressing Mental Health Disparities in Evidence-Based Mental Health Practices**
Steve Leff
- D **Reducing Mental Health Disparities for Racial and Ethnic Minorities: The APA Plan of Action**
Francis G. Lu, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WEDNESDAY

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.

Tudor 8 Room, Mezzanine Floor, Royal York

FEARFUL SLEEP AROUSALS

Chp.: Thomas W. Uhde, M.D.

Co-Chp.: Thomas Roth

- A Does Movement Suppression Index Central Fear System Involvement in PTSD Nightmares?
Steve H. Woodward, Ph.D.
- B Sleep Terrors and Sleepwalking in Children and Adults
Rosalind D. Cartwright, Ph.D.
- C Nocturnal Panic Attack: An Underrecognized Fearful Arousal
Ravi K. Singareddy, M.D.
- D Sleep Paralysis: Overlooked Fearful Arousal
Thomas W. Uhde, M.D., Orlena Merrit-Davis, M.D., Yury Yaroslavsky, M.D., Deborah Glitz, M.D., Ravi K. Singareddy, M.D., Bernadette M. Cortese, M.D.

Discussant: Mark Mahowald, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.

Ballroom, Convention Floor, Royal York

TRANSLATING THE NEUROBIOLOGY OF ALCOHOLISM INTO CLINICAL TREATMENTS

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Markus Heilig, M.D.

Co-Chp.: Barbara Mason, Ph.D.

- A Lost in Translation: Preclinical Studies of Genetic Susceptibility and Neuroadaptations Point to a Growing List of Novel Candidate Targets for Treatment of Alcoholism
Markus Heilig, M.D.
- B Medications for Treating Alcoholism: From Animal Models to Clinical Usefulness
Charles P. O'Brien, M.D.
- C Animal Models for Novel Medications for Alcoholism: View From the Dark Side
George F. Koob
- D Alcohol Relapse-Like Behavior in Laboratory Animals: The Nociceptin/Orphanin Fq System: A Potential Target for the Development of New Pharmacotreatments.
Roberto Ciccocioppo, Ph.D.
- E Development of a Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Implications for Predicting Medication Efficacy in Clinical Trials
Barbara J. Mason, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98 2:00 p.m.-5:00 p.m.

Ontario Room, Convention Floor, Royal York

SAME SEX CIVIL MARRIAGE: HISTORICAL AND MENTAL HEALTH RESEARCH PERSPECTIVES

Chp.: Gene A. Nakajima, M.D.

Co-Chp.: Mary Read, M.D.

- A Gay Marriage in History: New Manifestations of Old Traditions
Robert P. Cabaj, M.D.
- B Gay Marriage in the Netherlands: The First Five Years
Nicolaas F. Hettinga, M.D.
- C Leading the Way: Canadian Same Sex Marriage
Laura M. Chapman, M.D., Gene A. Nakajima, M.D.
- D Six Weeks of Marriage Vows in San Francisco: Personal Perspectives
Ellen Haller, M.D., Mary E. Read, M.D.
- E Same-Sex Marriage From a Mental Health Research Perspective
Robert M. Kertzner, M.D.

Discussant: Renee L. Binder, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.

Salon B, Convention Floor, Royal York

PSYCHIATRY IN AMSTERDAM: ACUTE PSYCHIATRIC SERVICES IN A METROPOLITAN AREA

Chp.: Cecilia M.T. Gijsbers Van Wijk, Ph.D.

Co-Chp.: Robert Schoevers, Ph.D.

- A The Amsterdam Model: Past, Present, and Future
Hans Sanders, M.D.
 - B Urbanization as a Risk Indicator for Psychiatric Disturbances
Jack J. Dekker, Ph.D., Jaap Peen, Sr., Ph.D.
 - C A One-Year Prospective Study of the Temporary Transitional Unit
Wijnand Mulder, M.D., Cecilia M.T. Gijsbers van Wijk, Ph.D.
 - D Controversies and Dilemmas Regarding the Amsterdam Model: Case Histories
Hans Nusselder, M.D.
 - E Community Admission Units in Amsterdam: A Benchmark Study
Cecilia M.T. Gijsbers Van Wijk, Ph.D., Wijnand Mulder, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9

3:00 p.m.-5:00 p.m.

Exhibit Hall B, Level 300, Toronto Convention Centre North

SUBSTANCE ABUSE, SLEEP, AND OTHER TOPICS

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-46

INDUSTRY-SUPPORTED SYMPOSIUM 43

7:00 p.m.-10:00 p.m.

Canadian Room, Convention Floor, Royal York

WHAT IS THE ROLE OF SOMATIC AND PHYSICAL SYMPTOMS IN DEPRESSION?

Supported by Wyeth Pharmaceuticals

Chp.: Maurizio Fava, M.D.

- A **The Neurobiology of Somatic and Physical Symptoms in Depression**
Pedro L. Delgado, M.D.
- B **Pain and Other Somatic Symptoms and Their Relationship to Antidepressant Treatment Outcome**
George I. Papakostas, M.D.
- C **Diagnostic Challenges in Medically Ill Patients With Depression**
Donna E. Stewart, M.D.
- D **Management Issues in the Treatment of Depression With Comorbid Medical Disorders**
Jonathan E. Alpert, M.D.
- E **Are All Antidepressants Equally Effective in the Treatment of Somatic and Physical Symptoms in Depression?**
Maurizio Fava, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 44

7:00 p.m.-10:00 p.m.

Concert Hall, Convention Floor, Royal York

DIAGNOSING AND TREATING ALCOHOL DEPENDENCE IN THE OFFICE

Supported by Alkermes Inc. and Cephalon Inc.

Chp.: Kathleen T. Brady, M.D.

- A **Alcoholism as a Chronic Disease: Implications for Office-Based Treatment**
A. Thomas McLellan, Ph.D.
- B **Screening, Diagnosis, and Early Intervention**
Kathleen T. Brady, M.D.
- C **Current and Emerging Treatment Options in Alcoholism**
Richard N. Rosenthal, M.D.
- D **Office-Based Treatment of Co-Occurring Psychiatric Disorders**
Shelly F. Greenfield, M.D.
- E **Behavioral Therapies for Alcohol Dependence**
Grace Hennessy, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45

7:00 p.m.-10:00 p.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

MANAGING UNMET NEEDS IN PSYCHIATRIC ILLNESSES: A CRITICAL LOOK AT DISORDERS AND PUBLIC POLICY

Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

- A **Managing the Unmet Needs in Depression**
A. John Rush, M.D.
- B **Managing the Unmet Needs in Bipolar Disorder**
Roger S. McIntyre, M.D.
- C **Managing the Unmet Needs in Schizophrenia**
Marvin S. Swartz, M.D.
- D **Managing the Unmet Needs in Dementia**
K. Ranga R. Krishnan, M.D.
- E **Managing the Unmet Needs: A Public Health Dilemma**
Junius J. Gonzales, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46

7:00 p.m.- 10:00 p.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

REMISSION AND RECOVERY IN SCHIZOPHRENIA:
ADVOCATING FOR OUR PATIENTS

Supported by Pfizer Inc.

Chp.: Nancy C. Andreasen, M.D.

- A Defining Remission and Recovery in Schizophrenia
Nancy C. Andreasen, M.D.
- B Should Functional Outcomes Be a Defining Feature of
Remission and Recovery in Schizophrenia?
Stephen R. Marder, M.D.
- C An Evidence-Based Approach to Achieving Remission
and Recovery in Schizophrenia
John M. Kane, M.D.
- D Barriers to Achieving Remission and Recovery in
Schizophrenia
Meera Narasimhan, M.D.



THURSDAY, MAY 25, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 39-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 2

7:00 a.m.-8:30 a.m.

Room 106, Level 100, Toronto Convention Centre North

EMERGING EVIDENCE IN THE TREATMENT OF BIPOLAR DEPRESSION

Supported by AstraZeneca Pharmaceuticals

Chp.: Joseph R. Calabrese, M.D.

A Neurobiology of Bipolar Patients: What Does It Tell Us?

Sophia Frangou, M.D.

B Future Treatments: Repetitive Transcranial Magnetic Stimulation and Vagus Nerve Stimulation in Bipolar Depression

Guohua Xia, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2

7:00 a.m.-8:30 a.m.

Canadian Room, Convention Floor, Royal York

BIPOLAR ILLNESS: THE ROAD TO REMISSION

*Supported by Bristol-Myers Squibb Company and Otsuka America
Pharmaceutical, Inc.*

Chp.: Prakash S. Masand, M.D.

A An Evidence-Based Approach to Achieving Remission in Bipolar Illness

Roger S. McIntyre, M.D.

B The Role of Nonpharmacologic Therapies in Achieving Remission

Eduard Vieta, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom, Lower Concourse, Sheraton Centre

NEW FRONTIERS IN DEPRESSION: PROVIDING SOLUTIONS TO UNMET NEED

Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Stephen M. Stahl, M.D.

A Unipolar Versus Bipolar Depression: Diagnostic and Therapeutic Challenges

James M. Martinez, M.D.

B Current and Novel Treatment Options for Treatment- Resistant Depression

Lauren B. Marangell, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2

7:00 a.m.-8:30 a.m.

Metro Grand Ballroom, Second Level, Westin Harbour Castle

WHAT THE PSYCHIATRIST NEEDS TO KNOW ABOUT SLEEP-RELATED MOVEMENT DISORDERS

Supported by GlaxoSmithKline

Chp.: John W. Winkelman, M.D.

A Restless Legs Syndrome and Psychiatric Disorders: Demonstrating a Relationship

John W. Winkelman, M.D.

B Video of Patient Case: Diagnosis, QOL, and Sleep

John W. Winkelman, M.D.

C Current Therapeutic and Management Strategies in Restless Legs Syndrome

Clete A. Kushida, M.D.

8:00 a.m. Sessions



COURSES 98-101

Course descriptions are available in the *CME
Course Brochure* included in your registration
packet. Admission by ticket only.

COURSE 98

8:00 a.m.-12 noon

Conference Room D/E, Mezzanine, Sheraton Centre

VAGUS NERVE STIMULATION

Director: Ziad H. Nahas, M.D.

Faculty: Linda L. Carpenter, M.D., Mitchel A. Kling, M.D.,
Robert H. Howland, M.D., Mustafa Hussain

COURSE 99

8:00 a.m.-12 noon

Conference Room F, Mezzanine, Sheraton Centre

SPIRITUALITY AND WORLDVIEW IN CLINICAL PRACTICE

Director: Allan M. Josephson, M.D.

Faculty: John R. Peteet, M.D., James L. Griffith, M.D.

COURSE 100

8:00 a.m.-12 noon

Windsor Room West, Mezzanine, Sheraton Centre

THE EVALUATION AND TREATMENT OF PHYSICIANS INVOLVED IN SEXUAL MISCONDUCT AND SEXUAL HARASSMENT

Director: Gene G. Abel, M.D.

Faculty: Tracey I. Marks, M.D., Richard B. Krueger, M.D.

THURSDAY

COURSE 101 8:00 a.m.-12 noon
Essex Room, Mezzanine, Sheraton Centre

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 5
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

CONSULT-LIAISON CASEBOOK CHALLENGE: STRATEGIES AND LIMITATIONS IN ESTABLISHING COMPETENCY

Moderator: Dimitri D. Markov, M.D.
Presenters: Kenneth M. Certa, M.D., John Paul Gomez, M.D., David Lynn, M.D., Jacob Widroff, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

ISSUES 76-94

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.
Room 104 A, Level 100, Toronto Convention Centre North

DIRECT TO CONSUMER MARKETING: JUST WHO IS THE CONSUMER?

Co-Chps.: Nadeem H. Bhanji, M.D., David A. Baron, D.O.
Participants: Lawrence S. Gross, M.D., Calvin R. Sumner, M.D., Marcia K. Goin, M.D., Andrew E. Slaby, M.D., Bernard A. Fischer IV, M.D.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

CAN I CHANGE? A JOURNEY THROUGH EX-GAY MINISTRIES AND BEYOND

Association of Gay and Lesbian Psychiatrists

Co-Chps.: Mary E. Barber, M.D., David L. Scasta, M.D.
Participants: Jack Drescher, M.D., Alicia J. Salzer, M.D., Anat Salomon, Roy Harker

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

A MODEL FOR IMPROVED PSYCHIATRIC SERVICES IN DEVELOPING COUNTRIES: SOUTH ASIAN FORUM

International South Asian Forum

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Russell F. D'Souza, M.D., Arun V. Ravindran, M.D., Parameshvara P. Deva, M.D., Afzal Javed, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

USE OF A STANDARDIZED COMPREHENSIVE PSYCHIATRIC ASSESSMENT TOOL TO FACILITATE EVIDENCE-BASED DECISIONS: THE INTERRAI MENTAL HEALTH

Co-Chps.: John P. Hirdes, Ph.D., Trevor F. Smith, Ph.D.
Participants: Terrie Tucker, Brent Diverty, Edgardo L. Perez, M.D., Terry Rabinowitz, M.D.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

GOING TO THE HEART OF THE MATTER IN PATIENT INTERVIEWS

Chp.: Harold J. Bursztajn, M.D.
Participants: Thomas G. Gutheil, M.D., Max Day, M.D., Robindra K. Paul, M.D., Beata A. Zolovska, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS

Co-Chps.: Alan Z.A. Manevitz, M.D., James P. Halper, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

TRAUMATIZED CHILDREN IN IRAQ

Chp.: Sadiq H. Al-Samarrai, M.D.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

INTERNATIONAL MEDICAL GRADUATES IN TRAINING AND PRACTICE: PROFESSIONAL AND PERSONAL TRIALS

Co-Chps.: Michael F. Myers, M.D., Nyapati R. Rao, M.D.
Participants: Milton Kramer, M.D., Brunhild Kring, M.D., Stuart W. Twemlow, M.D., Jeffrey Goldberg, D.O.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

RACE AND COUNTERTRANSFERENCE IN THE CLINICAL SETTING

Co-Chps.: Sherri M. Simpson, M.D., Sandra C. Walker, M.D.
Participants: Glen O. Gabbard, M.D., Kimberlyn Leary, Ph.D.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

DIALECTICAL BEHAVIORAL THERAPY WITH ADOLESCENTS

Chp.: Syed S.A. Naqvi, M.D.
Participant: Viet Q. Bui, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.
Room 701 A, Level 700, Toronto Convention Centre South

MENTAL HEALTH ISSUES IN THE AFTERMATH OF HURRICANE KATRINA

Co-Chps.: Philip T. Merideth, M.D., Grayson Norquist, M.D.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

SIZE MATTERS: TEACHING MEDICAL STUDENTS IN SMALL GROUPS

Co-Chps.: Lana M. Benedek, M.D., Bruce C. Ballon, M.D.
Participants: Kien T. Dang, M.D., Andrea E. Waddell, M.D.

ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

SO YOU WANT TO BE A CLINICAL INVESTIGATOR

Chp.: Arthur Lazarus, M.D.

ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m.
Room 707, Level 700, Toronto Convention Centre South

COLLABORATIVE MENTAL HEALTH CARE IN CANADA

Chp.: Nick Kates, M.B.
Participants: Scott Dudgeon, M.B.A., Francine L. Lemire, M.D., Phil Upshall

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

PSYCHIATRY IN THE PRIMARY CARE SETTING: MAKING IT WORK FOR DOCTORS AND PATIENTS

Chp.: John C. Urbaitis, M.D.
Participants: Jonathan S. Davine, M.D., Shauna P. Reinblatt, M.D., Joseph M. Schwartz, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.
Room 711, Level 700, Toronto Convention Centre South

COMPUTER TOOLS FOR COGNITIVE-BEHAVIOR THERAPY: INTEGRATING TECHNOLOGY INTO CLINICAL PRACTICE

Chp.: Jesse H. Wright III, M.D.
Participant: Douglas Turkington, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

CULTURAL DIVERSITY AND PSYCHIATRY: CLINICAL CARE, RESEARCH, AND EDUCATION

Chp.: Niranjan S. Karnik, M.D.
Participants: Nisha Dogra, M.D., Claire P. Rivlin, M.A., Hans Steiner, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.
Room 716 A, Level 700, Toronto Convention Centre South

CARDIOVASCULAR COMPLICATIONS OF SECOND GENERATION ANTIPSYCHOTIC DRUGS

Co-Chps.: Peter Manu, M.D., Raymond E. Suarez, M.D.

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.
Room 716 B, Level 700, Toronto Convention Centre South

CHILDREN OF PSYCHIATRISTS

Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.
Participants: Judith S. Beck, Ph.D., Sami Meyerson-Bernstein, Molly R. Kaufman, Matthew Muskin, Sam Raskin, Shoshana L. Shear, M.D., Alexandra Robinson

MEDIA WORKSHOP 7

9:00 a.m.-12 noon
Quebec Room, Mezzanine Floor, Royal York

BAD EDUCATION: PORTRAYING TRANSSEXUALISM, PEDOPHILIA, AND ADDICTION
American Academy of Child and Adolescent Psychiatry

Chp.: Jose P. Vito, M.D.
Participant: Richard R. Pleak, M.D.

11:00 a.m. Sessions

MEDICAL UPDATE 4

11:00 a.m.-12:30 p.m.

Room 716 A, Level 700, Toronto Convention Centre South

LIVER TRANSPLANT UPDATE: CURRENT OUTCOMES AND CHALLENGES IN 2006

Presenters: Philip Wong, M.D.

Chp.: Silvia Hafliger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 34-44

SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.-12:30 p.m.

Room 104 B, Level 100, Toronto Convention Centre North

CURRENT RESEARCH IN DEPRESSION AND ANXIETY

Chp.: Adel A. Gabriel, M.D.

Co-Chp.: Robert B. Shulman, M.D.

11:00 a.m.

100 Desvenlafaxine: Preclinical Evidence for 5HT and Norepinephrine Reuptake Inhibition, Antidepressant, and Antinociceptive Activity

Terrance H. Andree, Ph.D., Darlene Deecher, Ph.D., Lee Dawson, Ph.D., Liza Leventhal, Ph.D., Paul Mitchell, Ph.D., Sharon Rosenzweig-Lipson, Ph.D., Chad E. Beyer, Ph.D.

11:30 a.m.

101 Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of MDD

Nicholas Demartinis, Ph.D., Paul Yeung, M.D., Richard Entsuah, Ph.D.

12 noon

102 Panic Disorder Associated With Severe Dizziness: Demographic and Clinical Features and Treatment With Clonazepam

Antonio E. Nardi, M.D., Marco A.U. Mezzasalma, Alexandre M. Valenca, M.D., Isabella Nascimento, M.D., Fabiana L. Lopes, M.D., Rafael C Freire, M.D., Flavia S. Franco, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.-12:30 p.m.

Room 104 D, Level 100, Toronto Convention Centre North

PANIC DISORDERS

Chp.: Zubin Bhagwagar, M.D.

Co-Chp.: Guillaume Barbes-Morin, M.D.

11:00 a.m.

103 A 40-Year Follow-Up Study of Patients With Panic Disorder

Gabriel Rubio, M.D., Juan J. López-Ibor, Jr., M.D.

11:30 a.m.

104 Resilience in Anxiety Disorders

Catherine Mancini, M.D., Michael Van Ameringen, M.D., Beth Patterson, B.S.N., Mark Bennett, B.A., Jonathan Oakman, Ph.D.

12 noon

105 The Naturalistic Treatment of Panic Disorder in a Real World Clinical Setting

Eric D. Peselow, M.D., Lydia O. Fazzino, M.D., Caroline B. Williams, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 36

11:00 a.m.-12:30 p.m.

Room 201 D, Level 200, Toronto Convention Centre North

FAMILY CONTRIBUTIONS/PERSPECTIVES

Chp.: Tanya R. Anderson, M.D.

Co-Chp.: Rubaba Ansari, M.A.

11:00 a.m.

106 Family Background and Genius: Nobel Laureates in Science

Albert Rothenberg, M.D.

11:30 a.m.

107 Familial Psychiatric Disorders and Sudden Infant Death Syndrome: Is There a Significant Relationship?

Jeffrey Sverd, M.D.

12 noon

108 The Parent's Perspective on Gender Variant Children and Adolescents: Concerns, Hopes, and Joys

Darryl B. Hill, Ph.D., Edgardo J. Menvielle, M.D., Kristin Sica, Alisa Johnson

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 37

11:00 a.m.-12:30 p.m.

Room 205 A, Level 200, Toronto Convention Centre North

MATCHING TREATMENT TO APPROPRIATE POPULATIONS

Chp.: Kenneth Silk, M.D.

Co-Chp.: Paul Fedoroff, M.D.

11:00 a.m.

109 Patterns of Symptom Response in the Treatment for Adolescents With Depression Study (TADS): Do Some Symptoms Respond Better to Certain Treatments?

Jessica L. Murakami M.S., Anne Simons, Ph.D., Lou Moses, Ph.D., Susan Silva, Ph.D., John S. March, M.D.

(Continued next page)

11:30 a.m.

- 110 **Antipsychotics in the Treatment of Delirium: A Review of Prospective Trials**
Dallas P. Seitz, M.D., Sudeep S. Gill, M.D., Louis T. van Zyl, M.D.

12 noon

- 111 **Treatment Matching in the Post-Hospital Care of Patients With Depression**
Gabor I. Keitner, M.D., Ivan W. Miller, Ph.D., Christine E. Ryan, Ph.D., David A. Solomon, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 38

11:00 a.m.-12:30 p.m.

Room 206 A/B, Level 200, Toronto Convention Centre North

SUICIDE

Chp.: Paul S. Links, M.D.
Co-Chp.: Ian C. Dawe, M.D.

11:00 a.m.

- 112 **Distinguishing Patients Who Attempt Suicide From Patients With Ideation Only**
Stephen B. Woolley, M.P.H., John W. Goethe, M.D., Alexis M. May, B.A., Deborah Piez, M.S.

11:30 a.m.

- 113 **Hopelessness and Suicidality Three Months Post-Hospital Discharge**
John W. Goethe, M.D., Stephen B. Woolley, M.P.H., Deborah Piez, M.S.

12 noon

- 114 **Parent's Socioeconomic Status, Psychiatric Disorders, and Suicidality as Risk Factors of Subsequent Suicide of Offspring: The Northern Finland 1966 Birth Cohort Study**
Antti S. Alaräisänen, M.B., Jouko Miettunen, Ph.D., Pirkko Räsänen, M.D., Matti K. Isohanni, M.D., Pirjo H. Maki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39

11:00 a.m.-12:30 p.m.

Room 206 E/F, Level 200, Toronto Convention Centre North

CURRENT TRENDS AND CONTROVERSIES IN PSYCHIATRY

Chp.: Laura Hirshbein, M.D.
Co-Chp.: Daniel Mayman, M.D.

11:00 a.m.

- 115 **A Review of Chemical Castration and Its Use in the U.S. Penal System**
Sara G. West, M.D.

11:30 a.m.

- 116 **Acupuncture and Cognitive-Behavior Therapy for PTSD**
Michael Hollifield, M.D., Nityamo Lian, Teddy Warner, Ph.D., Richard Hammerschlag, Ph.D.

12 noon

- 117 **Pseudoseizures: Interaction of Past Traumatic Stress and Current Suppression of Negative Affects**
Robin Berlin, M.D., James L. Griffith, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40

11:00 a.m.-12:30 p.m.

Algonquin Room, Mezzanine Floor, Royal York

CULTURAL VARIATIONS IN PSYCHIATRIC ILLNESS

Chp.: Nitin Gupta, M.D.

Co-Chp.: Virginia A. Wesson, M.D.

11:00 a.m.

- 118 **BPD and Cultures**
Bernadette M. Grosjean, M.D.

11:30 a.m.

- 118 **Patterns of Antidepressant Prescribing and Suicide in Israel**
Dov Aizenberg, M.D., Yoram Barak, M.D.

12 noon

- 120 **Prevalence of PMDD Among Women in a Primary Care Outpatient Setting in the United Arab Emirates**
Ossama T. Osman, M.D., Dina Rizq, M.D., Sufyan Sabri
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 41

11:00 a.m.-12:30 p.m.

Confederation 3 Room, Mezzanine Floor, Royal York

LIFESTYLE ISSUES IN MENTAL HEALTH

Chp.: Leslie A. Horton, M.D.
Co-Chp.: Matti K. Isohanni, M.D.

11:00 a.m.

- 121 **Lifestyle Issues in Mental Health: Social Support, Diet, Fitness, and Recreation**
Henry T. Chuang, M.D., Scott B. Patten, M.D.

11:30 a.m.

- 122 **Alcoholism in Schizophrenia: Systematic Review 2000-2004**
Johanna Koskinen, M.B., Jouko Miettunen, Ph.D., Erika Lauronen, M.D., Pekka Laine, M.D. Hannu J. Koponen, M.D., Matti K. Isohanni, M.D.

12 noon

- 123 **Cigarette Smoking Among Psychiatric Outpatients: A Matched Case-Control Study in Bucaramanga, Colombia**
Adalberto Campo-Arias, M.D., Luis A. Díaz-Martínez, M.S., German E. Rueda-Jaimes, M.D., Mauricio Rueda-Sánchez, M.D., Daniel Farelo, M.S., Francisco J. Diaz, Ph.D., Jose de Leon, M.D.

THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 42

11:00 a.m.-12:30 p.m.

Confederation 5 Room, Mezzanine Floor, Royal York

STUDIES IN ADDICTION

Chp.: Pinhas N. Dannon, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

124 Substance Abuse in Bipolar Disorder

E. Sherwood Brown, M.D.

11:30 a.m.

125 Substance-Related Disorders Dual Diagnosis in a Random Nationwide Sample of 998 Prisoners: Prevalences and Risk Factors

Michael Lukasiewicz, M.D., Isabelle Gasquet, Ph.D., Michel Reynaud, Bruno Falissard

12 noon

126 Stroop Performance in Pathological Gamblers

Pinhas N. Dannon, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 43

11:00 a.m.-12:30 p.m.

Library, Mezzanine Floor, Royal York

COMPLICATION OF TREATMENTS IN PSYCHIATRIC DISORDERS

Chp.: Geetha Jayaram, M.D.

Co-Chp.: Norman C. Moore, M.D.

11:00 a.m.

127 Armodafinil Improves Fatigue in Patients With Excessive Sleepiness Due to Obstructive Sleep Apnea/Hypopnea Syndrome

Steven Hull, M.D., Alan Lankford, Ph.D., Bradley D. Vince, D.O., Gwendolyn E. Niebler, D.O., Sanjay Arora, Ph.D.

11:30 a.m.

128 Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

Susan Shur-Fen Gau, M.D., Yu-Shu Huang, M.D., Wei-Tsuen Soong, M.D., Miao-Chun Chou, M.D., Phil Lee, M.D., Albert J. Allen

12 noon

129 Medication Nonadherence in Bipolar Disorder: The Role of Patients Treatment Perceptions

Rob Horne, Jane Clatworthy, Rhian Parham, Tim Rank, Richard Bowskill

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 44

11:00 a.m.-12:30 p.m.

Toronto Room, Convention Floor, Royal York

THERAPEUTIC SOLUTIONS FOR CAREGIVING FAMILIES

Chp.: Haldun Soygur, M.D.

Co-Chp.: Bulent Coskun, M.D.

11:00 a.m.

130 Spirituality and Recovery From Depression

Caroline B. Williams, M.D., Eric D. Peselow, M.D., Barbara Ortowski, Ph.D.

11:30 a.m.

131 Depression and Caregiver Burden in Families of People With Schizophrenia

Lawrence Haber, Ph.D., Julie Robison, Ph.D., Kathy Kellett, M.A., Cynthia Gruman, Ph.D.

12 noon

132 Psychodrama Groups for Psychiatric Intervention to Family Members of Patients With Schizophrenia

Derya Iren Akbiyik, M.D., Tulin Kusgozoglu, Bahar Gokler, M.D., Haldun Soygur, Selvet Kurdoglu

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 95-109

ISSUE WORKSHOP 95

11:00 a.m.-12:30 p.m.

Room 104 A, Level 100, Toronto Convention Centre North

GROUP PSYCHOTHERAPY OF SUBSTANCE ABUSE

American Group Psychotherapy Association

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 96

11:00 a.m.-12:30 p.m.

Room 205 B, Level 200, Toronto Convention Centre North

PROVIDING BEHAVIORAL HEALTH TREATMENT SERVICES FOR VERY YOUNG SPECIAL NEEDS CHILDREN AND THEIR FAMILIES

Chp.: Peter D. Ganime, M.D.

Participants: Joanne Dunnigan, M.S.W., Aura R.

Seidler, M.S.W., Vanessa Moss, L.C.S.W.

ISSUE WORKSHOP 97 11:00 a.m.-12:30 p.m.
Room 205 C, Level 200, Toronto Convention Centre North

THE IMPACT OF RACE AND GENDER ON THE INTERACTIONS BETWEEN FEMALE PSYCHIATRY RESIDENTS AND THEIR PATIENTS: AN INTERACTIVE GROUP WORKSHOP

Co-Chps.: Nancy M. Bivens, M.D., Christina V. Mangurian, M.D.
Participants: Stephanie LeMelle, M.D., Maria A. Oquendo, M.D., Juliana I. Ekong, M.D.

ISSUE WORKSHOP 98 11:00 a.m.-12:30 p.m.
Room 205 D, Level 200, Toronto Convention Centre North

IDENTIFYING AND MANAGING PATIENTS WITH SCHIZOPHRENIA AND A GENETIC SYNDROME

Chp.: Anne S. Bassett, M.D.
Participant: Eva W.C. Chow, M.D.

ISSUE WORKSHOP 99 11:00 a.m.-12:30 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

DISASTERS, PUBLIC POLICY, AND ADDICTION PSYCHIATRY

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Richard J. Frances, M.D.
Participants: Avram H. Mack, M.D., Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Frances R. Levin, M.D., Robert B. Millman, M.D., Marc Galanter, M.D.

ISSUE WORKSHOP 100 11:00 a.m.-12:30 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

PERFORMANCE ENHANCEMENT PSYCHOLOGICAL TECHNIQUES IN GOLF

International Society for Sport Psychiatry

Co-Chps.: Syed S.A. Naqvi, M.D., Salvador R. del Rosario, Jr., M.D.

ISSUE WORKSHOP 101 11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South

ANOREXIA AND MALNUTRITION IN THE ELDERLY PATIENT

Chp.: Jonathan T. Stewart, M.D.
Participants: Ellen M. Notz, Linda J. O'Keefe-Wood, M.S.

ISSUE WORKSHOP 102 11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South

MEDICAL COMORBIDITY IN DUAL DIAGNOSIS PATIENTS

Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Vasant P. Dhopes, M.D.
Participant: Rosalinda Dirienzo, M.D.

ISSUE WORKSHOP 103 11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South

DETECTING BIPOLAR DISORDER

Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, M.D.

ISSUE WORKSHOP 104 11:00 a.m.-12:30 p.m.
Room 709, Level 700, Toronto Convention Centre South

SIMULATIONS AND PSYCHIATRIC EDUCATION: WORKSHOP FOR STANDARDIZED PATIENT TRAINING

Co-Chps.: Nancy L. McNaughton, M.Ed., Kerry J. Knickle, B.A.
Participant: Bruce C. Ballon, M.D.

ISSUE WORKSHOP 105 11:00 a.m.-12:30 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

MAKING IT HAPPEN: IMPLEMENTING THE APA PRACTICE GUIDELINE FOR MDD IN EVERYDAY PRACTICE

Chp.: Jack S. McIntyre, M.D.
Participants: Joel Yager, M.D., Rory P. Houghtalen, M.D.

ISSUE WORKSHOP 106 11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

DESPERATE HOUSE WIVES SURVIVE THE WAR OF THE WORLDS: THERAPEUTIC PERSPECTIVES ON WOMEN'S HEALTH

Chp.: Richard K. Harding, M.D.
Participants: Nioaka N. Campbell, M.D., Meera Narasimhan, M.D., Craig A. Stuck, M.D., Leslie E. Frinks, M.D.

ISSUE WORKSHOP 107 11:00 a.m.-12:30 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South

PSYCHIATRISTS WHO HAVE FACED MENTAL ILLNESS IN THEMSELVES: THERE IS A SILVER LINING

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Melanie E. Spritz, D.O., Raymond M. Reyes, M.D., Elizabeth A. Baxter, M.D., Michael Pare, M.D., Francine Cournos, M.D.

ISSUE WORKSHOP 108 11:00 a.m.-12:30 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

TEACHING HUMAN SEXUALITY TO HEALTH SCIENCE STUDENTS USING THE SEXUAL EVENTS CLASSIFICATION SYSTEM

Association for Academic Psychiatry

Co-Chps.: Donald C. Fidler, M.D., Gregg Dwyer, M.D.

THURSDAY

ISSUE WORKSHOP 109 11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

IMPROVING ACCESS TO HEALTHCARE FOR HOMELESS PERSONS LIVING WITH HIV/AIDS

Co-Chps.: Keith R. Stowell, M.D., Antoine B. Douaihy, M.D.
Participant: Ann L. Hackman, M.D.

12 noon Sessions

FORUM 16
12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

MANY FACES OF TRAUMA: A MULTISYSTEMIC VIEW OF THE AFTERMATH OF KATRINA

Chp.: Howard J. Osofsky, M.D.
Co-Chp.: Joy D. Osofsky, M.D.
Participant: Patricia M. Morse, Ph.D., Robert Ursano, M.D.

NEW RESEARCH POSTER SESSION 10
12 noon-2:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

COGNITION AND OTHER TOPICS

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 100-119

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

IDENTIFYING SUBTYPES IN OCD

Chp.: Jane L. Eisen, M.D.

- A **OCD Subtypes and Drug Treatment Response**
Wayne K. Goodman, M.D.
- B **Subtypes of OCD From a Familial Perspective**
Gerald Nestadt, M.D.
- C **OCD Subtypes Based on Course of Illness and Clinical Features**
Jane L. Eisen, M.D.
- D **Neurobiological Heterogeneity in OCD**
Sanjaya Saxena, M.D.

Discussant: James F. Leckman
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

VIRTUAL ENVIRONMENTS AND CONVERGENT MEDIA TECHNOLOGY

Chp.: Henry J. Moller, M.D.
Co-Chp.: Pierre Boulanger, M.D.

- A **Virtual Reality Assets for Assessment, Therapy, and Rehabilitation**
Albert A. Rizzo, Ph.D.
 - B **Why Simulate? The Cognitive Neuroergonomics of Virtual Environments**
Henry J. Moller, M.D.
 - C **Can Virtual Reality Be Useful for the Study of Brain Functions?**
Pierre Boulanger, Ph.D.
 - D **Music Triggered Avatars: A New Way to Express Emotion in the Virtual World**
Robyn Taylor, B.S.C., Pierre Boulanger, Ph.D.
 - E **The Evolution of Clinical VR Simulation Over the Past Ten Years**
Ken Graap, M.Ed.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

A RESEARCH AGENDA FOR *DSM-V* CONCERNING RELIGIOUS AND SPIRITUAL ISSUES IN THE DIAGNOSTIC PROCESS

APA Corresponding Committee on Religion, Spirituality, and Psychiatry

Chp.: John R. Peteet, M.D.
Co-Chp.: Francis Lu, M.D.

- A **Religious and Spiritual Aspects in the Diagnosis of Depression**
Dan G. Blazer II, M.D.
- B **Religious and Spiritual Aspects of the Diagnosis of Anxiety Disorders and Adjustment Disorders**
Samuel B. Thielman, M.D., Gerrit Glas, M.D.
- C **Substance, Dependence, and Spirituality**
Marc Galanter, M.D.
- D **Religious and Spiritual Aspects of Personality Traits and Disorders**
C. Robert Cloninger, M.D.
- E **Religious and Spiritual Aspects of Child and Adolescent Psychiatric Disorders**
Mary Lynn Dell, M.D., Allan M. Josephson, M.D.

Discussant: William E. Narrow, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.
 Room 206 C/D, Level 200, Toronto Convention Centre North

GLOBAL MENTAL HEALTH DISPARITIES: A CULTURAL PERSPECTIVE AND THE POTENTIAL FOR FORMAL AND INFORMAL INTERNATIONAL EXCHANGES

APA Council on Global Psychiatry

Chp.: Samuel O. Okpaku, M.D.

- A The Global Treatment Gap in Mental Health Care**
Robert Kohn, M.D.
- B International Cooperation in Regional Psychiatric Programs**
Rodrigo A. Munoz, M.D.
- C Trauma Treatment at the Child Rescue Center at Bo, Sierra Leone**
Michael A. Hollifield, M.D., John D. Ogram, M.D.
- D Socio-Economical and Environmental Realities and Cultural Factors Affecting Children's Mental Health and Treatment in Africa**
Dolores Garcia-Moreno, M.D.
- E An International Perspective on Disability**
Samuel O. Okpaku, M.D.

Discussant: William B. Lawson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.
 Room 206 E/F, Level 200, Toronto Convention Centre North

PSYCHIATRY ON THE SILVER SCREEN

Chp.: Rudolf A. Feijen, M.D.
Co-Chp.: Bastiaan A. Oele, M.D.

- A The Movies, the Mind, and Hollywood Stereotypes**
Rudolf A. Feijen, M.D.
 - B Teaching Psychiatry by Movie Clips: How to Overcome Stereotypes**
Bastiaan L. Oele, M.D.
 - C Cinema in the Consulting Room: The Silver Screen as a Projection Screen**
Josephine M. Caubel, M.D.
 - D The Use of Film in a Psychodynamic Treatment**
Willem C. Tuinebreijer, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.
 Room 701 A, Level 700, Toronto Convention Centre South

TREATMENT OF PERSONALITY DISORDERS: PREVIEW OF TPD IV

Chp.: John G. Gunderson, M.D.

- A Treatment of the Narcissistic Personality**
Elsa F. Ronningstam, Ph.D., John T. Maltsberger, M.D.
- B Treatment of Histrionic Personality Disorder**
Glen O. Gabbard, M.D.
- C Psychotherapy With Cluster "A" Personality Disorders**
Michael H. Stone, M.D.
- D Treatment of BPD**
John G. Gunderson, M.D.
- E Treatment of Cluster "C" Personality Disorders and Its Empirical Support**
John C. Perry, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m.-5:00 p.m.
 Room 701 B, Level 700, Toronto Convention Centre South

POST-DEPLOYMENT MENTAL HEALTH: TRANSLATING RESEARCH INTO CLINICAL PRACTICE

Chp.: Gregory McCarthy

- A The VA/DOD Response to OIF/OEF Mental Health Challenges**
Harold S. Kudler
- B Traumatic Brain Injury in OEF/OIF Veterans: Implications for Health Care**
Robin A. Hurley, M.D., Katherine H. Taber, Ph.D.
- C Neuroactive Steroids and Stress in Psychiatric Disorders**
Christine E. Marx, M.D.
- D Multi-Modal Imaging Assessment of PTSD**
Rajendra A. Morey, M.D.
- E The Amygdala, Stress, and Substance Abuse**
Scott D. Moore

Discussant: Marian I. Butterfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 107 2:00 p.m.-5:00 p.m.
 Room 705, Level 700, Toronto Convention Centre South

IMPROVING CROSS-CULTURAL COMPETENCY IN PSYCHIATRIC TRAINING

Chp.: Maria A. Velazquez, M.D.
Co-Chp.: Ruksana Iftekhar

- A Preparing Psychiatrists of the Future to Treat an Increasingly Diverse Population**
Annelle B. Primm, M.D.

(Continued next page)

THURSDAY

B ASIA and Psychiatry: Understanding Their Perspectives

Consuelo C. Cagande, M.D.

C Mental Disorders: Hispanics as Patients and Clinicians

Humberto Marin, M.D.

D South Asian Immigrant Physician: American Patient, Cross-Cultural Treatment

R. Rao Gogineni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 108 2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

BEREAVEMENT AND THE *DSM-V*

Chp.: M. Katherine Shear, M.D.

Co-Chp.: Sidney Zisook, M.D.

A Should Bereavement Remain an Exclusion for Major Depression?

Sidney Zisook, M.D., Kenneth S. Kendler, M.D.

B Complicated Grief and *DSM-V*

Holly G. Prigerson, Ph.D.

C Complicated Grief Treatment: Implications for the *DSM-V*

M. Katherine Shear, M.D.

D Treatment of Bereavement Related Depression: Implications for *DSM-V*

Paula Hensley, M.D.

Discussant: Charles F. Reynolds III, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

NAMI DOCTORS SOUND OFF

National Alliance for the Mentally Ill

Chp.: Suzanne E. Vogel-Scibilia, M.D.

A Recovery Programs and Mental Illness

Edward F. Foulks, M.D.

B Formulary Roulette: Getting Better Odds With Access to Treatment

Kenneth Duckworth, M.D.

C Medication Adherence: Partnering With Your Patients

Stephen M. Goldfinger, M.D.

D The Changing Role of Families in Psychiatry

Anand Pandya, M.D.

E Recovering Psychiatrists

Elizabeth A. Baxter, M.D.

Discussant: Frederick J. Frese, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

INFECTIOUS DISEASES AND PSYCHIATRIC SYMPTOMATOLOGY

Chp.: Annette M. Matthews, M.D.

Co-Chp.: Rima Styra, M.D.

A SARS: Psychological Consequences for the Patient, the Healthcare Worker, and the General Population

Rima Styra, M.D., Wayne L. Gold, M.D., Marie Louie, M.D., Laura Hawryluck, M.D., Allison McGeer, M.D., Mark Loeb, M.D.

B Psychiatric Aspects of HIV/AIDS

Stephen J. Ferrando

C Hepatitis C Disease Management Patterns in High-Risk Populations: Testing, Infection, and Treatment Rates Among Patients With Serious Mental Illness and Substance Use Disorders

Peter Hauser, M.D.

D Delusional Parasitosis: An Infectious Disease Created Within Our Own Minds and Spread as Folie-A-Deux by Primitive Biological Mechanisms

Annette M. Matthews, M.D.

Discussant: Glenn J. Treisman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

USING TECHNOLOGY TO IMPROVE PATIENT CARE

American Association for Technology in Psychiatry

Chp.: Carlyle H. Chan, M.D.

A Personal Digital Assistants in Psychiatric Care

John Luo, M.D.

B Quality and Cost Impact of PDA Use in Psychiatry in Florida Medicaid

Naakesh A Dewan, M.D.

C Internet Resources to Assist in Clinical Decision Making

Robert S. Kennedy, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 112 2:00 p.m.-5:00 p.m.
 Room 715 A/B, Level 700, Toronto Convention Centre South

NEUROFEEDBACK ADVANCES IN ADHD: DOES THE RESEARCH VALIDATE CLINICAL USE?

Chp.: Thomas M. Brod, M.D.
 Co-Chp.: Roger deBeus, Ph.D.

- A **Progress in Efficacy Studies of EEG Biofeedback for ADHD**
 Roger J. deBeus, Ph.D.
 - B **The Scientific Foundation of EEG Biofeedback as an Intervention for ADHD**
 Laurence M. Hirshberg, Ph.D.
 - C **The Interaction Between Neurofeedback Training and Medication in the Treatment of ADHD: Four Case Illustrations**
 David A. Mitnick, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 113 2:00 p.m.-5:00 p.m.
 Room 716 A, Level 700, Toronto Convention Centre South

SLEEP DEPRIVATION: THEORETICAL AND PRACTICAL IMPLICATIONS

Chp.: Thomas W. Uhde, M.D.
 Co-Chp.: Andrew D. Krystal, M.D.

- A **Sleep Deprivation: Overview of Implications for Mental Health Professionals**
 Thomas W. Uhde, M.D.
- B **The Effects of Sleep Deprivation on Stress and Immune Systems**
 Alexandros Vgontzas, M.D.
- C **Antidepressant Effects of Sleep Deprivation**
 Robert M. Post, M.D.
- D **Sleep Deprivation and PTSD**
 Bernadette M. Cortese, M.D.

Discussants: Antonio Vela-Bueno, M.D., Timothy A. Roehrs
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 114 2:00 p.m.-5:00 p.m.
 Room 716 B, Level 700, Toronto Convention Centre South

INTERNATIONAL PERSPECTIVE ON QUALITY IMPROVEMENT INITIATIVES

World Psychiatric Association

Chp.: Jack S. McIntyre, M.D.
 Co-Chp.: Wolfgang Gaebel, M.D.

- A **International Issues of Quality Assurance in Mental Health**
 Julio E. Arboleda-Florez, M.D.
- B **Quality Management in Psychiatry: A Task for the Future**
 Wolfgang Gaebel, M.D.
- C **Recent Advances in the Development and Implementation of Practice Guidelines**
 Jack S. McIntyre, M.D.
- D **Malpractice Litigation and Practice Guidelines**
 J. Richard Ciccone, M.D.
- E **Suicide Prevention in Iceland: Outcome Parameters**
 Hogni Oskarsson, M.D., S.P. Palsson, O. Gudmundson, W. Nordfjord, A. Inghorsdottir, S. Bjarnadottir, S. Gudmundsson

Discussant: Rodrigo A. Munoz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 115 2:00 p.m.-5:00 p.m.
 Room 717 A, Level 700, Toronto Convention Centre South

ARMED AND DANGEROUS: IS YOUR PATIENT SAFE TO RETURN TO WORK?

APA Corresponding Committee on Psychiatry in the Workplace

Chp.: Marie-Claude Rigaud, M.D.

- A **Workplace Safety Overview**
 Marie-Claude Rigaud, M.D.
- B **Physician Heal Yourself: The Impaired Physician**
 Marilyn Price, M.D.
- C **The Police Problem, Problem Police**
 Marcia Scott, M.D.
- D **Vulnerable Positions/Defining Roles**
 Andrea G. Stolar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 116 2:00 p.m.-5:00 p.m.
 Room 717 B, Level 700, Toronto Convention Centre South

ONE PATIENT/FOUR MINDS: INTEGRATED TREATMENT FOR MDD

Chp.: Gerard A. Leblanc, M.D.

- A **Mind One: Neurobiological Perspective**
 Guylain Bouchard, M.D.
- B **Mind Two: Interpersonal Psychotherapy for Depression**
 Simon Patry, M.D.

THURSDAY

C Mind Three: Afraid to Take Medicine? Targeting the Rational Thinking
Nicole Thibodeau, M.D.

D Integrated Treatment for MDD
Marie-Josée Filteau, M.D.

E Integrated Treatment Approach for MDD
Gerard Leblanc, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 117 2:00 p.m.-5:00 p.m.

Room 801 A, Level 800, Toronto Convention Centre South

U.S. MILITARY PSYCHIATRY AND THE OPERATION IRAQI FREEDOM: AN UPDATE

Chp.: Theodore S. Nam, M.D.

A Mental Health Impact of Combat Operations in Iraq and Afghanistan: Update and Lessons Learned
Charles W. Hoge, Carl A. Castro, Ph.D.

B The Evolution of Operational Mental Health Care in the U.S. Navy and Marine Corps From WWI to Operation Iraqi Freedom
James J. Reeves, M.D.

C Operation Iraqi Freedom: Walter Reed Army Medical Center Inpatient Psychiatry: An Update
Theodore S. Nam, M.D.

D Psychiatric Intervention With Wounded Soldiers: A Consultation Liaison Approach
Harold J. Wain, Ph.D.

E The Challenges to Psychiatric Leadership at a Military Medical Center During Wartime
Stephen J. Cozza, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 118 2:00 p.m.-5:00 p.m.

Room 801 B, Level 800, Toronto Convention Centre South

COMPLEMENTARY, ALTERNATIVE, AND INTEGRATIVE APPROACHES IN MENTAL HEALTH CARE

Chp.: James H. Lake, M.D.
Co-Chp.: Sudha Prathikanti, M.D.

A Classical Homeopathy: An Overview for Psychiatrists
Pamela A. Pappas, M.D.

B Ayurveda: Ancient Wisdom for Modern Psychiatry
Sudha Prathikanti, M.D.

C No Effect of Anonymous Distant Healing on Survival Time for Patients With Glioblastoma Multiforme
Andrew J. Freinkel, M.D., Cheryl Koopman, Ph.D.

D Select Integrative Medicine Treatments for Depression in Women
Priti Sinha

E Meditation for Psychiatric Disorders: A Review of the Evidence
Jeffrey D. Rediger, M.D.

Discussant: Andrew J. Freinkel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 119 2:00 p.m.-5:00 p.m.

Room 803 A/B, Level 800, Toronto Convention Centre South

SUICIDE ON COLLEGE CAMPUSES: PRACTICAL AND ETHICAL ISSUES

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Barbara H. Stanley

A The Epidemiology of College Student Suicide
Morton M. Silverman, M.D.

B Screening College Students for Suicide Risk
Ann P. Haas, Ph.D.

C The University Response to Suicide Prevention and Treatment
Paul J. Barreira, M.D.

D Ethical Dilemmas of College Student Suicide
Paul S. Appelbaum, M.D.

E Balancing Privacy and Protection Concerns in Suicidal College Students
Barbara H. Stanley, Ruth Fischbach, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

2006 ANNUAL MEETING

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Premenstrual Dysphoric Disorder
12. Schizophrenia and Other Psychotic Disorders
13. Sexual and Gender Identity Disorders
14. Sleep Disorders
15. Somatoform Disorders

PRACTICE AREAS/SETTINGS

16. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

17. Addiction Psychiatry
18. Biological Psychiatry and Neuroscience
19. Brain Imaging
20. Child and Adolescent Psychiatry and Disorders
21. Consultation-Liaison and Emergency Psychiatry
22. Cross-Cultural and Minority Issues
23. Diagnostic Issues
24. Emergency Psychiatry
25. Epidemiology
26. Ethics and Human Right
27. Forensic Psychiatry
28. Geriatric Psychiatry
29. Neuropsychiatry
30. Pain Management
31. Psychiatric Education
32. Psychiatric Rehabilitation

33. Psychoimmunology
34. Research Issues
35. Social and Community Psychiatry
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS

38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Other Somatic Therapies
44. Psychopharmacology
45. Treatment Techniques and Outcome Studies

OTHER ISSUES

46. Computers
47. Creativity and the Arts
48. Electronic Medical Records
49. Gender Issues
50. Health Services Research
51. Historical Questions
52. Information Technology
53. Internet
54. Lesbian/Gay/Bisexual/Transgender Issues
55. Managed Care and Health Care Funding
56. Men's Issues
57. National Institute of Alcohol Abuse and Alcoholism
58. Patient Safety
59. Personal Digital Assistants (PDAs)
60. Political Questions
61. Presidential Theme: "From Science to Public Policy: Advocacy for Patients & the Profession"
62. Professional and Personal Issues
63. Religion, Spirituality, and Psychiatry
64. Resident and Medical Student Concerns
65. Stigma/Advocacy
66. Virtual Reality
67. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

	Page#		Page #
DISORDERS			
TOPIC 1: AIDS AND HIV-RELATED DISORDERS			
LECTURE			
7 The Discourse on Human Sexuality in the Time of AIDS	24		
SYMPOSIA			
1 HIV Prevention Interventions With Psychiatric Patients From Around the World: Turning Research Into Practice	32		
56 HIV Update for Psychiatric Care	62		
COMPONENT WORKSHOP			
13 Sexuality and Its Impact on the HIV Pandemic	28		
ISSUE WORKSHOP			
109 Improving Access to Healthcare for Homeless Persons Living With HIV/AIDS	98		
TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS			
COURSES			
7 Teaching Addiction Medicine Using Films	1		
39 Street Drugs and Mental Disorders: Overview and Treatment	17		
DISCUSSION GROUPS			
8 Alcohol Dependence: What Clinicians Need to Know	23		
18 Substance Abuse: Network Therapy for Promoting Outpatient Compliance With Psychosocial and Pharmacologic Treatment	69		
INDUSTRY-SUPPORTED SYMPOSIUM			
44 Diagnosing and Treating Alcohol Dependence in the Office	89		
LECTURES			
19 An Evidence-Based Clinician's Guide to the New Pharmacotherapies for Alcoholism	57		
23 High on Neurosteroids: Mechanisms and Therapeutic Relevance	73		
SYMPOSIA			
16 Adolescent Brain Development: Implications for Psychiatric Treatment	36		
54 The Methamphetamine Epidemic in the U.S.	62		
61 Pharmacogenetics and Drug Abuse Research	64		
89 Pharmacotherapy for Single- and Dual-Diagnosed Substance Abusers	86		
COMPONENT WORKSHOP			
27 Buprenorphine: Clinical Issues and Managing More Complicated Patients	47		
TOPIC 3: ANXIETY DISORDERS			
INDUSTRY-SUPPORTED SYMPOSIA			
12 The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing Stigma	6		
27 Evidence, Outcomes, and Advocacy: Shaping the Management of GAD, Part 1	17		
27 Evidence, Outcomes, and Advocacy: Shaping the Management of GAD, Part 2	43		
SCIENTIFIC AND CLINICAL REPORTS			
102 Panic Disorder Associated With Severe Dizziness: Demographic and Clinical Features and Treatment With Clonazepam	94		
103 A 40-Year Follow-Up Study of Patients With Panic Disorder	94		
104 Resilience in Anxiety Disorders	94		
105 The Naturalistic Treatment of Panic Disorder in a Real World Clinical Setting	94		
SYMPOSIA			
17 Ethnicity, Age, and Gender as Factors in the Management of Anxiety and Depression	36		
68 Complex PTSD Across the Lifespan: Implications for <i>DSM-V</i>	81		
100 Identifying Subtypes in OCD	98		
ISSUE WORKSHOP			
36 Compulsive Hoarding: Conceptualization and Treatment	48		
TOPIC 4: ATTENTION SPECTRUM DISORDERS			
COURSES			
15 ADD in Children and Adolescents	5		
63 ADD in Adults	44		
101 Advanced Assessment and Treatment of ADD	92		
INDUSTRY-SUPPORTED SYMPOSIA			
11 Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice	6		
23 Advances in the Neurobiology and Therapeutics of ADHD	11		
31 Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder	42		
37 Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD	66		
MEDICAL UPDATE			
2 ADD Kids Get Smart Naturally	50		
SCIENTIFIC AND CLINICAL REPORTS			
7 Transdermal Methylphenidate Versus Placebo in Pediatric ADHD	26		
8 Effects of Transdermal Methylphenidate in a Laboratory Classroom Study	26		
9 Modafinil-ADHD: Long-Term Efficacy and Safety in Children and Adolescents With ADHD	26		
SYMPOSIA			
35 Impulsivity in Axis I and Axis II: Common Substrates, Different Presentations?	58		
112 Neurofeedback Advances in ADHD: Does the Research Validate Clinical Use?	101		
TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)			
COURSE			
13 The Evaluation and Identification of the Major Dementias	3		
INDUSTRY-SUPPORTED SYMPOSIA			
19 Advances in the Understanding of the Dementia Spectrum	9		
20 Alzheimer's Disease: Challenging the Practice Paradigm	10		
SCIENTIFIC AND CLINICAL REPORT			
110 Antipsychotics in the Treatment of Delirium: A Review of Prospective Trials	95		

	Page#		Page #
SYMPOSIA			
29 Dementia in Patients With Down Syndrome: Risk Factors, Biomarkers, Diagnosis, and Treatment	39	17 The Long-Term Clinical Course and Treatment of Recurrent Depression in 2006: New Data and Future Directions	9
49 The Use of Atypical Antipsychotics in Elderly Patients With Dementia: What Next?	61	18 Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar Disorder	9
TOPIC 6: DISSOCIATIVE DISORDERS			
ADVANCES IN SESSION			
1 Advances in Psychopharmacology	31	24 Atypical Depression: Merging Evidence and Public Policy	11
TOPIC 7: EATING DISORDERS			
COURSE			
8 Therapeutic Interventions in Eating Disorders: Basic Principles	1	28 Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety, Part 1	17
FOCUS LIVE SESSION			
2 Eating Disorders and Sexual Disorders	23	28 Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety, Part 2	43
SYMPOSIA			
34 Predictors of Outcome and Treatment Response in Eating Disorders: Results From New Research on Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder	57	30 Helping Depressed Patients Achieve Remission: Advocacy for Improvement	42
62 Eating Disorders 2006: From Science to Practice	64	35 Multiple and Complex Presentations of Bipolar Disorder	65
ISSUE WORKSHOPS			
24 Does Beauty Equal Happiness?	29	39 Emerging Evidence in the Treatment of Bipolar Depression, Part 1	67
33 The Difficult-to-Treat Bulimia Nervosa	48	39 Emerging Evidence in the Treatment of Bipolar Depression, Part 2	91
MEDIA WORKSHOP			
2 <i>Do I Look Fat?</i> Eating Disorder Pathology in Gay Men	23	40 Bipolar Illness: The Road to Remission, Part 1	67
TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)			
COMPONENT WORKSHOP			
25 It Takes a Village: Assessing Behavioral and Psychiatric Disorders in Mentally Retarded Individuals	47	40 Bipolar Illness: The Road to Remission, Part 2	91
TOPIC 9: MOOD DISORDERS			
ADVANCES IN SESSION			
4 Advances in Mood Disorders	68	41 New Frontiers in Depression: Providing Solutions to Unmet Needs, Part 1	67
COURSE			
94 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders	79	41 New Frontiers in Depression: Providing Solutions to Unmet Needs, Part 2	91
INDUSTRY-SUPPORTED SYMPOSIA			
1 New Augmentation Strategies in Depression for Better Outcomes	1	43 What Is the Role of Somatic and Physical Symptoms in Depression?	89
2 Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness	2	LECTURE	
5 Mania in Special Populations	3	5 Gene-Environment Interactions and Risk of Major Depression: Implications for Community-Based Prevention Strategies	24
7 Bipolar Disorder: Creating a Consensus From Science to Public Policy	3	MASTER EDUCATOR CLINICAL CONSULTATION	
8 Treatment-Resistant Depression: New Data, New Approaches	4	3 Refractory Depression: Diagnostic and Treatment Implications	20
13 New Vistas in Treatment-Resistant Depression	6	SCIENTIFIC AND CLINICAL REPORTS	
16 Interrupting the Cycle of Vascular Disease and Depression	9	13 Duloxetine Versus Escitalopram and Placebo in the Long-Term Treatment of Patients With MDD	26
		14 Conditional Probability of Response to Placebo in MDD	26
		15 Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study	26
		16 Management of Side Effects Associated With New Treatments for Bipolar Depression	26
		17 Treatment-Resistant Depression: Changes in Symptoms and Functioning in a Clinical Sample	26
		18 Specificity of Effect of Quetiapine in Bipolar Depression	26
		46 Galantamine-CR for Cognitive Dysfunction in Bipolar Disorder: Efficacy And Biological Correlates	51
		47 Rate of Improvement with Quetiapine Across Different Symptoms and Symptom Clusters in Bipolar Disorder	51
		48 Efficacy of the Antipsychotics in Anxiety Symptoms With or Without Bipolar Disorder	51
		49 Prescription Patterns for Latin Americans Treated for MDD in Naturalistic Clinical Practice Settings	51
		50 Nonadherence in Bipolar Disorder: A Qualitative Study Exploring Perceptual and Practical Barriers to Taking Medication	51
		51 Patient Dissatisfaction With Information Received About Medicines Prescribed for Bipolar Disorder	51
		52 Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic Distinction	52
		53 Treatment of SAD With a Carbohydrate-Rich Nutrient Mixture	52
		54 Impaired Mood and Social Functioning Among Adult Children of Parents With Depression	52
		62 Frequency of EEG Abnormalities and Results of Antiepileptic Drug Therapy in Unstable Mood Disorders	52
		82 Early Symptomatic Worsening During Treatment With Fluoxetine in MDD: A Replication Study	76
		88 PDE5I Sildenafil Treatment of Serotonergic Antidepressant Associated Sexual Dysfunction (SRI-AASD) in Women With MDD in Remission: An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial With Eight-Week Open-Label Continuation	76
		124 Substance Abuse in Bipolar Disorder	96
		129 Medication Nonadherence in Bipolar Disorder: The Role of Patients Treatment Perceptions	96

TOPIC INDEX

	Page#		Page #
SYMPOSIA		TOPIC 11: PREMENSTRUAL DYSPHORIC DISORDER	
11	35		
28	39		
32	40		
39	59		
45	60		
63	64		
77	83		
COMPONENT WORKSHOP		SCIENTIFIC AND CLINICAL REPORT	
9	21	120	95
ISSUE WORKSHOPS			
11	22		
103	97		
TOPIC 10: PERSONALITY DISORDERS		TOPIC 12: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS	
ADVANCES IN SESSION		ADVANCES IN SESSION	
2	44	5	80
COURSES		COURSE	
45	18	73	55
53	31	DEBATE	
DISCUSSION GROUPS		1	19
11	45	FORUM	
19	69	5	30
20	69	INDUSTRY-SUPPORTED SYMPOSIA	
FOCUS LIVE SESSION		6	3
1	19	9	5
LECTURE		14	8
12	45	21	10
MASTER EDUCATOR CLINICAL CONSULTATION		33	42
11	50	34	65
SCIENTIFIC AND CLINICAL REPORTS		36	65
45	51	46	90
91	76	LECTURE	
92	76	6	24
93	76	SCIENTIFIC AND CLINICAL REPORTS	
118	95	10	26
SYMPOSIA		11	26
18	36	12	26
33	40	43	51
40	59	57	52
65	65	58	52
85	85	60	52
105	99	73	75
ISSUE WORKSHOP		74	75
64	72	75	75

	Page#
76 Altered Developmental Trajectories in Schizophrenia	75
77 Characteristics of the Interpersonal Distance of Patients With Schizophrenia in the Virtual Environment	75
78 Familial Risk of Psychosis and Prodromal Features of Psychosis at the Age of 15-16 Years	75
80 Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of First-Episode Psychosis: A Randomized, Double-Blind, 52-Week Comparison	75
122 Alcoholism in Schizophrenia: Systematic Review 2000-2004	95
123 Cigarette Smoking Among Psychiatric Outpatients: A Matched Case-Control Study in Bucaramanga, Colombia	95
131 Depression and Caregiver Burden in Families of People with Schizophrenia	96

SYMPOSIA

8 Treatment Issues in Schizophrenia With Comorbid Disorders	34
12 When Usual Treatments Fail: Augmentation Strategies for Refractory Schizophrenia	35
15 First-Episode Schizophrenia: How Can We Improve Treatment Outcome?	36
27 Not Just Dopamine Any More: Emerging Glutamatergic Therapies for Schizophrenia	39
55 Preventing Schizophrenia: Opportunities and Challenges	62
58 Not Your Parent's EEG: Clinical Applications of Auditory and Visual Event-Related Potentials	63
75 Acute Brief Psychoses: Nosology and Boundaries	83
92 Anxiety and Emotional Dysfunction in Endophenotype of Schizophrenia	87

ISSUE WORKSHOP

32 Metabolic Screening of Patients on Antipsychotic Medications: Development of a Quality Improvement Program in an Urban Training Clinic	48
---	----

TOPIC 13: SEXUAL AND GENDER IDENTITY DISORDERS

COURSE

26 The Management of the Sexual Abuse Phenomenon: A Global Perspective: A Belgian Approach	7
--	---

DISCUSSION GROUP

5 The Psychology of the Closet	23
--------------------------------	----

SCIENTIFIC AND CLINICAL REPORT

42 Effectiveness of Group Interventions for Parents of Gender-Variant Children	51
--	----

COMPONENT WORKSHOP

31 Can We Talk? A Model for Constructive Conversation Between Opponents and Advocates of Same Sex Relationships	53
---	----

ISSUE WORKSHOP

52 Sexual History: The Art and the Science	54
--	----

TOPIC 14: SLEEP DISORDERS

INDUSTRY-SUPPORTED SYMPOSIA

4 Bridging Sleep, Science, and Public Policy	2
15 Vital Signs in Psychiatry: A Perspective on Sleep Across the Life Cycle	8
25 Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy	11
42 What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders, Part 1	67
42 What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders, Part 2	91

SCIENTIFIC AND CLINICAL REPORTS

67 Effect of Armodafinil on Reducing Fatigue in Patients With Narcolepsy	74
68 Effect of Armodafinil on Attention in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder	74
69 Armodafinil Improves Wakefulness in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder	74
127 Armodafinil Improves Fatigue in Patients With Excessive Sleepiness Due to Obstructive Sleep Apnea/Hypopnea Syndrome	96

SYMPOSIUM

96 Fearful Sleep Arousals	88
---------------------------	----

TOPIC 15: SOMATOFORM DISORDERS

COURSE

76 Psychogenic Symptoms: A Challenge for All Specialties	56
--	----

FORUM

15 Environmental Psychiatry: From Sick Buildings to the Gulf War	79
--	----

SCIENTIFIC AND CLINICAL REPORT

117 Pseudoepilepsies: Interaction of Past Traumatic Stress and Current Suppression of Negative Affects	95
--	----

ISSUE WORKSHOP

81 Fibromyalgia: Current Understanding and Future Directions	92
--	----

PRACTICE AREAS/SETTINGS

TOPIC 16: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

COURSES

6 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management	1
17 Home Treatment for Acute Mental Disorders: An Alternative to Hospitalization	5
28 Basic Concepts in Administrative Psychiatry II: Care Management, Law, and Ethics	7
50 Managed Care Contracting for Psychiatrists	19
51 Contemporary Malpractice Liability 2006: A Practical Guide	30
69 Personnel Management for Clinician-Administrators	45

DISCUSSION GROUP

4 Leadership Opportunities: Where and How to Look	19
---	----

FORUM

8 Improving the Quality of Health Care for Mental and Substance Use Conditions	55
--	----

INDUSTRY-SUPPORTED SYMPOSIUM

45 Managing Unmet Needs in Psychiatric Illnesses: A Critical Look at Disorders and Public Policy	89
--	----

LECTURE

14 History of and Corrective Proposals for Disparities in Mental Health Care	49
--	----

TOPIC INDEX

	Page#		Page #
PRESIDENTIAL SYMPOSIA		TOPIC 18: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE	
1 The Public Mental Health System: Critical Issues	32	COURSE	
3 Collaboration in Crisis: Academic Medical Center's Response to Hurricanes Katrina and Rita	80	90 Neuroanatomy of Emotions: From Brain to Clinical Practice	69
4 Psychiatric Participation in Interrogation of Detainees: Ethical Considerations	81	INDUSTRY-SUPPORTED SYMPOSIUM	
SYMPOSIA		32 The Cognition, Neurocircuitry, and Disability Interface: Bringing Evidence to Practice	42
46 APA/APAL: Addressing Psychiatric Patients' Needs in Latin America	60	LECTURE	
47 Helping Returning Veterans: VA Community Collaborations	60	2 Heart Rate Variability and Psychiatry: Beyond Heart-Mind Link	19
99 Psychiatry in Amsterdam: Acute Psychiatric Services in a Metropolitan Area	88	SCIENTIFIC AND CLINICAL REPORTS	
114 International Perspective on Quality Improvement Initiatives	101	28 From Synapse to Psychotherapy: The Fascinating Evolution of Neuroscience	27
117 U.S. Military Psychiatry and the Operation Iraqi Freedom: An Update	102	29 Can Neurological Soft Signs Discriminate Between Four Axis-I Diagnostic Categories in the Prison Population?	27
COMPONENT WORKSHOPS		30 An Association Study of a Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Zotepine Response of Inpatients With Acute Schizophrenia	27
6 Closing a Practice: What Every Psychiatrist's Office and Their Family Should Know	21	SYMPOSIA	
20 The End of Hospitalization? Trends in Intensive Mental Health Services for Children and Adolescents	46	44 Neurobiological Basis for Co-Occurring Substance Abuse and Other Psychiatric Disorders	60
24 Doing It in Public: Opportunities in Public Sector Psychiatry	47	64 Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders	64
39 Doing More With Less: Challenges and Rewards of Becoming a Psychiatrist Executive	71	67 Reductionism in Psychiatry: Implications and Limits	81
ISSUE WORKSHOPS		113 Sleep Deprivation: Theoretical and Practical Implications	101
46 Career Advancement in Academic Psychiatry for Early Career Psychiatrists	54	ISSUE WORKSHOP	
73 Approaches to Chronic Disease Management : Opportunities for Psychiatry	78	56 Psychiatric Aspects of Deep Brain Stimulation for Parkinson's Disease	72
90 Psychiatry in the Primary Care Setting: Making It Work for Doctors and Patients	93	SUBSPECIALTY AREAS OR SPECIAL INTERESTS	
105 Making It Happen: Implementing the APA Practice Guideline for Major Depressive Disorder in Everyday Practice	97	TOPIC 17: ADDICTION PSYCHIATRY	
COURSE		CLINICAL CASE CONFERENCE	
44 Office-Based Buprenorphine Treatment of Opioid-Dependent Patients	18	1 Honorable Discharge: Severe Brain Injury and Psychological Symptoms in a Female Veteran	18
FORUM		COURSE	
7 Who Prescribes What to Whom and Why? Understanding and Assessing the Complex Issue of Addiction to Prescription Medications	55	77 Neurocircuits in Psychotherapy	56
MASTER EDUCATOR CLINICAL CONSULTATION		MASTER EDUCATOR CLINICAL CONSULTATION	
9 Internet Addiction	46	12 Neuropsychiatric Aspects of Traumatic Brain Injury	50
SCIENTIFIC AND CLINICAL REPORT		SCIENTIFIC AND CLINICAL REPORTS	
126 Stroop Performance in Pathological Gamblers	96	55 fMRI of the Brain Reward System: Manipulation of Risk and Reward Value	52
SYMPOSIA		56 Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort	52
52 Choosing the Right Treatment for Substance Abuse	61	TOPIC 19: BRAIN IMAGING	
81 Nicotine Dependence and Schizophrenia: Neurobehavioral Pathways	84	CLINICAL CASE CONFERENCE	
MEDIA WORKSHOPS		1 Honorable Discharge: Severe Brain Injury and Psychological Symptoms in a Female Veteran	18
1 Go: A Triple-Take in the World of Drugs	23	COURSE	
4 I Used. I Am Sorry. Can I Come Back? <i>Sister Helen</i> Says: <i>Piss Off</i>	72	77 Neurocircuits in Psychotherapy	56
		MASTER EDUCATOR CLINICAL CONSULTATION	
		12 Neuropsychiatric Aspects of Traumatic Brain Injury	50
		SCIENTIFIC AND CLINICAL REPORTS	
		55 fMRI of the Brain Reward System: Manipulation of Risk and Reward Value	52
		56 Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort	52
		TOPIC 20: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS	
		DISCUSSION GROUP	
		16 Killer Adolescents: Drugs, School, and the Courts	49
		FORUM	
		1 Harry Potter and the Half-Blood Prince: Harry Grows Up	30
		LECTURE	
		22 Psychiatry and Education: When the Twain Meet	70

	Page#		Page #
ROUND TABLE DISCUSSION			
Child and Adolescent Bipolar Disorder: Out of a Diagnostic Quandry	71		
SCIENTIFIC AND CLINICAL REPORTS		SCIENTIFIC AND CLINICAL REPORTS	
34 Prediction of Suicidality and Violence in Hospitalized Adolescents: Comparisons by Gender	50	22 Teaching of Psychiatry in Primary Care Residencies: Do Training Directors of Primary Care and Psychiatry See Eye to Eye?	27
35 Daily Cigarette Smoking Among Colombian High School Students: Gender Related Factors	50	23 Unrecognized Post-Traumatic Symptoms Triggered by Routine Hospital Care in Patients With Previous Trauma Histories	27
36 Subtypes of Aggression: Incidence and Gender Differences in Adolescents	50	24 Is Asthma Severity Related to Current Major Depressive Episode and Generalized Anxiety Disorder? A Case-Control Study	27
40 The Role of Subjective Emotional Reactivity to Affective Pictures in Predicting Emotional-Behavior Disorders Over a One-Year Period in an Unselected Community Sample of Children Between the Ages of 7 to 11	51	SYMPOSIA	
41 Life Satisfaction in Young Urban Adolescents	51	4 Psychosocial Intervention and Cancer Survival	33
63 How to FACE* Juvenile Epilepsy and Bipolar Disorder: Clinical Challenges	52	41 Sleep, Fatigue, and Depression in Medically-Ill Patients	59
107 Familial Psychiatric Disorders and Sudden Infant Death Syndrome: Is There a Significant Relationship?	94	COMPONENT WORKSHOP	
SYMPOSIA		10 The Gift of Life: A Psychiatric Perspective on Living Hepatic Organ Donation	28
19 Towards a Developmental Trauma Disorder	37	ISSUE WORKSHOPS	
74 Neuropsychiatric Responses to Burns: Modeling the Developmental Neurobiology of Trauma	82	35 Legal Issues in Consultation-Liaison Psychiatry	48
COMPONENT WORKSHOPS		65 Psychiatry Training for Primary Care Physicians: An Ongoing Challenge	78
5 Crime and Cruel Not Unusual Punishment: The Need for Juvenile Justice Mental Health Care Reform	21	TOPIC 22: CROSS-CULTURAL AND MINORITY ISSUES	
32 From Diagnosis to Treatment of Infants and Young Children	53	COURSE	
45 School-Based Suicide Prevention: Evidence-Based Strategies and New Approaches	77	80 <i>DSM-IV-TR</i> Cultural Formulations: Diagnosis and Therapy	67
ISSUE WORKSHOPS		DISCUSSION GROUP	
69 The Nature of Nurture: The Long-Lasting Impacts of Early Adverse Life Events	78	6 Culturally Appropriate Diagnosis and Treatment	23
82 Traumatized Children in Iraq	92	MASTER EDUCATOR CLINICAL CONSULTATION	
96 Providing Behavioral Health Treatment Services for Very Young Special Needs Children and Their Families	96	1 Clinical Dimensions of Cultural Psychiatry	20
MEDIA WORKSHOP		SCIENTIFIC AND CLINICAL REPORTS	
5 The Movie <i>Fun</i> as a Framework for Exploring Conduct Disorder in Adolescent Girls	72	98 Stories About Mental Health: A Cross-Cultural Relapse Prevention Study in Northern Territory Aboriginal Communities	77
TOPIC 21: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY		99 Recognizing and Engaging Depressed Chinese Americans in Treatment in a Primary Care Setting	77
CLINICAL CASE CONFERENCE		SYMPOSIA	
5 Consult-Liaison Casebook Challenge: Strategies and Limitations in Establishing Competency	92	3 Migration and Mental Illness Around the World	33
COURSES		7 The African Diaspora: Identifying and Eliminating Barriers to Mental Health	34
1 Dynamic Psychotherapy for Cancer Patients and Their Spouses	1	91 Recent Advances In Ethnopsychopharmacological, Ethnic, and Cultural Aspects of Mood and Anxiety Disorders	86
14 Collaboration Between Mental Health and Primary Care Providers: What Works and How to Do It	3	95 Mental Health Disparities: Concepts, Assessment, Evidence-Based Practice, and Advocacy	87
74 Overcoming Challenges in the Treatment of Hepatitis C Patients With Psychiatric Illness	55	103 Global Mental Health Disparities: A Cultural Perspective and the Potential for Formal and Informal International Exchanges	99
DISCUSSION GROUP		107 Improving Cross-Cultural Competency in Psychiatric Training	99
21 The Role of the Psychiatrist in End of Life Care	73	COMPONENT WORKSHOPS	
INDUSTRY-SUPPORTED SYMPOSIUM		7 Conquering the Shame, Secrecy, and Stigma of Suicide in Young Asian-American Adults	21
10 Fibromyalgia: Scientific Advances to Reduce the Burden of Illness	6	11 Towards a Better Understanding of Cultural Issues in Clinical Practice: Residents Perspective of a Model Curriculum for Residency Training Programs	28
MASTER EDUCATOR CLINICAL CONSULTATION		26 Media Outreach to Latinos: Enhancing Access and Reducing Stigma	47
16 Performance Enhancing Drug Use in Adolescent Athletes: A Sports Psychiatry Perspective	74	35 From Fantasy to Reality: Recruitment of Minorities in Clinical Research	53
		44 Global Psychiatry: Establishing Formal and Informal Mental Health Exchanges	77
		48 Trauma of Hearts and Minds: Racism and Psychiatry in the 21 st Century	77

TOPIC INDEX

	Page#		Page #
ISSUE WORKSHOPS		SYMPOSIUM	
45	54	50	61
An Integrative Approach to Cultural Competence Training for Resident and Staff Psychiatrists		Prevention of Common Mental Disorders: Is It Time to Start?	
59	72	COMPONENT WORKSHOPS	
The Mirror Has a Reflection: Teaching and Modeling Cultural Competency to General Psychiatry Residents		14	28
92	93	Psychiatric Ethics in the United States and Throughout the World	
Cultural Diversity and Psychiatry: Clinical Care, Research, and Education		28	47
		Ten Ways to Stay Out of Trouble: Ethics and Etiquette	
MEDIA WORKSHOP		TOPIC 26: ETHICS AND HUMAN RIGHTS	
3	48	COURSE	
3 <i>Crash</i> : A Portrait of Multicultural America at the Flashpoint		33	8
		Bioethics Update 2006	
TOPIC 23: DIAGNOSTIC ISSUES		SCIENTIFIC AND CLINICAL REPORTS	
SCIENTIFIC AND CLINICAL REPORTS		4	25
19	27	Ethics and Psychobiological Research	
Screening for History of Physical, Emotional, and Sexual Abuse: How Do We Ask About Abuse?		5	25
20	27	Terrorism and Medical Ethics: Conflicting Loyalties for American Psychiatrists	
Kennedy Axis V: The Next Step for Axis V?		6	25
21	27	A New Mental Health Act: An Australian Experience	
Dimensional Approaches to <i>DSM</i> and the Impact on Diagnostic Instruments		SYMPOSIUM	
		2	33
SYMPOSIUM		Therapeutic Misconception in Clinical Research	
6	34	57	63
Insomnia: What Is It?		Voting by Persons With Cognitive Impairment	
23	38	69	81
Science, Diagnoses, and the Clinician		Pharmaceutical Industry Influence in Psychiatry	
102	98	ISSUE WORKSHOP	
A Research Agenda for <i>DSM-V</i> Concerning Religious and Spiritual Issues in the Diagnostic Process		51	54
108	100	Are There Limits to Boundary Limits?	
Bereavement and the <i>DSM-V</i>		TOPIC 27: FORENSIC PSYCHIATRY	
		CLINICAL CASE CONFERENCE	
ISSUE WORKSHOP		4	68
16	29	Crossing the Line: Determining Your Patient is Too Dangerous to Drive	
Assessment of Capacity: Developments, DVDs, and Defense Organizations		COURSES	
		42	18
TOPIC 24: EMERGENCY PSYCHIATRY		The Psychiatrist as Expert Witness	
FORUM		62	44
14	79	The Detection of Malingered Mental Illness	
Addressing Psychiatric Needs in Asia		83	68
		Insanity Defense Evaluations	
SCIENTIFIC AND CLINICAL REPORT		FORUM	
87	76	12	55
Associations Between Psychiatric Disorder and Commitment Criteria in Acute Involuntarily Admitted Patients in the Netherlands		Correctional Mental Health Issues: An International Perspective.	
		LECTURE	
COMPONENT WORKSHOP		1	10
1	21	The Challenge of Employment-Related Psychiatric Evaluations	
Disaster Psychiatry: Practical Skills to Help District Branches Develop Disaster Plans for Their Communities		SCIENTIFIC AND CLINICAL REPORT	
		115	95
TOPIC 25: EPIDEMIOLOGY		A Review of Chemical Castration and Its Use in the U.S. Penal System	
SCIENTIFIC AND CLINICAL REPORTS		SYMPOSIUM	
64	53	21	37
Mental Health in Iranian Medical Students and Doctors		Criminalization of Mental Illness: Getting In and Out In New York	
65	53	93	87
Three-Year, Follow-Up Study of the Psychosocial Predictors of Delayed and Unresolved Post-Traumatic Stress Symptoms of Geriatric Earthquake Survivors in Yu-Chi, Taiwan		Teaching Psychiatry Residents About Informed Consent	
66	53	115	101
Three-Year, Follow-Up Study of the Relationship Between Post-Traumatic Stress Symptoms and Quality of Life Among Geriatric Earthquake Survivors in Yu-Chi, Taiwan		Armed and Dangerous: Is Your Patient Safe to Return to Work?	
85	76	COMPONENT WORKSHOPS	
Death by Unnatural Causes During Childhood and Early Adulthood in Offspring of Psychiatric Inpatients		4	21
86	76	Severely Mentally Ill Persons in Jails and Prisons: Who Should Stay?	
The Incidence and Prevalence of Diabetes Mellitus Among Inpatients in State-Operated Psychiatric Hospitals in New York State 1997-2004		49	78
125	76	Current Issues in Psychiatry and Law	
Substance-Related Disorders and Dual Diagnosis in a Random Nation-Wide Sample of 998 Prisoners: Prevalence and Risk Factors		ISSUE WORKSHOPS	
		55	71
		Psycho-Killers: Mental Illness and Homicide	
		62	72
		Detection of Malingering	
		98	97
		Identifying and Managing Patients With Schizophrenia and a Genetic Syndrome	

	Page#
TOPIC 28: GERIATRIC PSYCHIATRY	
COURSES	
32 How to Practice Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method	8
41 Psychiatric Consultation in Long-Term Care: Basic Course	18
56 Mood Disorders in Later Life	31
60 Psychiatric Consultation in Long-Term Care: Advanced Course	43
88 Essentials of Geriatric Psychopharmacology	69
INDUSTRY-SUPPORTED SYMPOSIUM	
38 The Maze of Mood and Anxiety in the Elderly Patient: A Case Series	66
LECTURE	
20 Psychiatry and Aging: Contributions of the International Medical Graduates	69
SCIENTIFIC AND CLINICAL REPORTS	
31 The Influence of Dementia on the Treatment of Depression in Geriatric Inpatients	28
32 Overall Efficacy and Time to Response for Duloxetine 60mg Once Daily Versus Placebo in Elderly Patients With MDD	28
33 Safety and Efficacy of Intra-Muscular Ziprasidone Treatment of Acute Psychotic Agitation in Elderly Patients With Schizophrenia	28
SYMPOSIA	
30 Geriatric Psychiatry: New Ideas and New Practices for the 21 st Century	40
76 Enhancing the Well-Being of Older Persons With Schizophrenia	83
COMPONENT WORKSHOPS	
12 Ethnicity and Caregiving Across the Psychiatric Spectrum	28
16 Scales in the Clinical Practice of Geriatric Psychiatry	28
ISSUE WORKSHOP	
101 Anorexia and Malnutrition in the Elderly Patient	97
TOPIC 29: NEUROPSYCHIATRY	
COURSES	
37 Computer-Assisted Diagnostic Interview	8
46 Traumatic Brain Injury: Neuropsychiatric Assessment	18
47 Advances in Neuropsychiatry	18
59 Psychiatric Genomics: Applications for Clinical Practice	43
INDUSTRY-SUPPORTED SYMPOSIUM	
22 Pseudobulbar Affect: A Common Syndrome That Is Underrecognized, Misdiagnosed, and Undertreated	11
SCIENTIFIC AND CLINICAL REPORT	
61 Psychosocial Treatment of Depression in Parkinson's Disease	52
TOPIC 30: PAIN MANAGEMENT	
ISSUE WORKSHOP	
50 Multidisciplinary Treatment of Chronic Pain	54

	Page #
TOPIC 31: PSYCHIATRIC EDUCATION	
COURSES	
5 A Practical Approach to Risk Assessment	1
11 Clinician Administered Rating Scales for Mood and Anxiety Disorders	2
40 Teaching Psychiatry? Let Hollywood Help	18
67 Money Matters: Using Theory in Clinical Practice	45
70 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation	45
75 How to Give a More Effective Lecture: Punch, Passion, and Polish	55
91 Seeing the Forest and the Trees: A Biopsychosocial Approach to the Oral Board Examination	69
DISCUSSION GROUP	
13 Directing a Residency Program: All You Ever Wanted to Know But Were Afraid to Ask	45
MASTER EDUCATOR CLINICAL CONSULTATION	
15 Doing Residency Training in Psychiatry in the U.S. and Returning Home to Practice	70
SCIENTIFIC AND CLINICAL REPORTS	
25 Psychiatric CMEs and Commercial Bias: Are New ACCME Standards Effective?	27
26 Relationships Between Self-Assessment Skills, Test Performance, and Other Variables in Psychiatry Residents	27
27 Coaching Communication Using Standardized Patient Encounters: An Educational Research Study	27
SYMPOSIA	
24 The Effective Psychotherapist: The Role of Common and Specific Factors	38
71 How to Practice Evidence-Based Medicine	82
COMPONENT WORKSHOP	
41 How To Be a More Creative Teacher: Winning Strategies for Residents and Faculty	71
ISSUE WORKSHOPS	
1 A Dimension of Mind: Simulations/Emulations of Psychiatric Symptoms Using the Performing Art of Magic	22
2 What Do You Do With a Patient Who Has Access to a Gun?	22
20 Treating First and Second Generation Immigrants With Psychotherapy During Residency Training	29
22 Psychotherapy Training and International Medical Graduates: The Influence of Cultural Factors	29
29 Pharmaceutical Bias in Presentations: Do's and Don'ts for Educators	47
39 Murder Mysteries, Games, and Psychiatric Education: How and Why to Do a "Who Done It?"	48
42 Teaching Cognitive Behavior Therapy to Residents	54
43 Teaching on the Fly: Practical Tips for Teaching Medical Students One-to-One	54
54 Supervising the Supervisors: See One, Do One, Teach One Model Shattered! An Innovative Group to Train Faculty to Teach Medical Students.	71
87 Size Matters: Teaching Medical Students in Small Groups	93
104 Simulations and Psychiatric Education: Workshop for Standardized Patient Training	97
108 Teaching Human Sexuality to Health Science Students Using the Sexual Events Classification System	97
TOPIC 32: PSYCHIATRIC REHABILITATION	
COURSE	
18 Recovery and Supported Employment: Evidence-Based Integration for Psychiatry	5

TOPIC INDEX

	Page#		Page #
TOPIC 33: PSYCHOIMMUNOLOGY		FORUMS	
		10 Worldwide Interpersonal and Group Terrorism Toward Women	55
		16 Many Faces of Trauma: A Multisystemic View of the Aftermath of Katrina	98
SCIENTIFIC AND CLINICAL REPORT		LECTURE	
44 Potential Role of Interleukin-6 and HPA Axis in Breast Cancer Patients With MDD	51	16 Psychiatric Implications of Displacement: The Emotional Costs of Losing Human Habitat	49
TOPIC 34: RESEARCH ISSUES		SYMPOSIA	
ADVANCES IN RESEARCH		9 Rehabilitation in France, Canada, and the U.S.: From Science to Recovery: Vive la Difference	34
An Update for the Clinician	23	42 Scaling Up Against HIV/AIDS: A Culturally Sensitive and Comprehensive Approach	59
COURSE		70 New Directions in Community Psychiatry	82
2 Research on a Shoestring Budget	1	ISSUE WORKSHOPS	
FORUM		75 The Evolution of Grandfamilies: The Psychological, Social, and Financial Impact of Grandparents Raising Grandchildren	79
2 Research Planning for <i>DSM-V</i>	30	78 A Model for Improved Psychiatric Services in Developing Countries: South Asian Forum	92
INDUSTRY-SUPPORTED SYMPOSIUM		21 Physician Heal Thyself: Workplace Burnout Among Psychiatrists	29
3 Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric Research	2	TOPIC 36: SUICIDE	
LECTURE		RESEARCH CONSULTATION WITH	
3 Rediscovering our Place in the World	20	2 Clinical Research Into Suicide	50
MASTER EDUCATOR CLINICAL CONSULTATION		SCIENTIFIC AND CLINICAL REPORTS	
7 Building a Research Career in Psychiatry	46	112 Distinguishing Patients Who Attempt Suicide From Patients With Ideation Only	95
MEDICAL UPDATE		113 Hopelessness and Suicidality Three Months Post-Hospital Discharge	95
1 Congestive Heart Failure	25	114 Parents Socioeconomic Status, Psychiatric Disorders, and Suicidality as Risk Factors of Subsequent Suicide of Offspring: The Northern Finland 1966 Birth Cohort Study	95
NEW RESEARCH SESSIONS		119 Patterns of Antidepressant Prescribing and Suicide in Israel	95
1 New Research Young Investigators' Poster Session	21	SYMPOSIA	
2 New Research Young Investigators' Oral/Slide Session	31	43 Suicide Research in Canada	60
3 New Research Young Investigators' Oral/Slide Session	31	119 Suicide on College Campuses: Practical and Ethical Issues	102
4 New Research Young Investigators' Oral/Slide Session	31	COMPONENT WORKSHOP	
5 New Research Poster Session	40	21 Bridge Suicide: The Prince Edward Viaduct in Toronto and the Golden Gate Bridge in San Francisco	47
6 New Research Poster Session	55	ISSUE WORKSHOP	
7 New Research Poster Session	65	71 Responding to the Impact of Suicide on Clinicians	78
8 New Research Poster Session	79	TOPIC 37 : VIOLENCE, TRAUMA, AND VICTIMIZATION	
9 New Research Poster Session	89	COURSES	
10 New Research Poster Session	98	21 Risk Assessment for Violence	5
RESEARCH ADVANCES IN MEDICINE		35 Psychiatric Interventions in Disasters and Public Health Emergencies: Theory to Practice	8
Aging, Longevity and Neurological Disorders	46	55 Child Murder by Parents	31
SYMPOSIA		61 Disaster Psychiatry: Terrorism, Trauma, and Things to Do	43
31 Nancy C. Andreasen, M.D.: Festschrift for Her 13 Years as Journal Editor	40	65 Personality and Political Behavior	44
36 Diagnostic Criteria in Alzheimer's Disease and Dementia: Research Challenges and Implications for <i>DSM-V</i>	58	78 Assessing the Risk of Violence in Forensic and Sex Offender Settings	56
53 Stress-Induced and Fear Circuitry Disorders: Planning the Research Agenda for <i>DSM-V</i>	62	FORUM	
ISSUE WORKSHOP		13 Katrina: Psychiatric Responses and Care for Individuals and Communities	79
88 So You Want to Be a Clinical Investigator	93	TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY	
COURSE		COURSE	
57 Overview of Correctional Psychiatry	31		

	Page#
SCIENTIFIC AND CLINICAL REPORTS	
37 Terrorism: A Phenomenon at the Interface Between Individual and Group Psychology	50
38 The Role of the Psychiatrist in Hospital Emergency Planning	50
39 Psychopathological Effects of Work Place Harassment	51
SYMPOSIA	
22 Psychocultural Foundations of Political Terrorism	38
37 Bullying in the Workplace: Psychiatric and Public Health Perspectives	58
80 Stalking Offenders and Victims	84
106 Post-Deployment Mental Health: Translating Research Into Clinical Practice	99
COMPONENT WORKSHOPS	
18 Culture as a Rationalization for Violence Against Women	28
29 Advances in the Treatment of Intimate Partner Violence	53
38 Disasters, Disparities, and Cultural Psychiatry	71
ISSUE WORKSHOP	
72 Non-Governmental Organizations: Response to Mental Health Consequences of Asian Tsunami	78

TREATMENTS

TOPIC 38 : BEHAVIOR AND COGNITIVE THERAPIES

COURSES

3 Cognitive Therapy for Schizophrenia	1
25 Introduction to Cognitive-Behavioral Therapy	7
36 Cognitive Therapy for Severe Mental Disorders	8
43 Engaging Resistant and Difficult-to-Treat Patients Into Collaborative Treatment	18
48 Cognitive Therapy on the Fly	18
64 Cognitive Behavioral Therapy Boot Camp for Psychiatrists: Emphasizing the Practical	44

DISCUSSION GROUP

3 Learning From Cognitive-Behavior Therapy: What Are the Most Powerful Methods for Everyday Clinical Use?	19
---	----

LECTURE

9 New Advances in Cognitive Therapy	32
-------------------------------------	----

ISSUE WORKSHOPS

8 But Can We Do It Here? Challenges of Implementing Cognitive-Behavior Therapy for Schizophrenia Programs in the U.S.	22
23 Cognitive-Behavior Therapy for Psychosis: Basic Techniques for Psychiatrists	29
37 Cognitive Therapy for Personality Disorders	48
58 Training Psychiatric Residents in the Cognitive Therapy of Schizophrenia	72
85 Dialectical Behavior Therapy With Adolescents	93
100 Performance Enhancement Psychological Techniques in Golf	97

TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

COURSES

66 A Psychodynamic Approach to Treatment Refractory Mood Disorders	44
92 Treating Comorbid Adult ADHD by Combining Medication and Cognitive Therapy: Practical Solutions to Common Clinical Problems	79

INDUSTRY-SUPPORTED SYMPOSIUM

29 Pharmacotherapy of Psychotic and Mood Disorders With Co-Existing Medical Illness	41
---	----

SCIENTIFIC AND CLINICAL REPORTS

109 Patterns of Symptom Response in the Treatment for Adolescents With Depression Study: Do Some Symptoms Respond Better to Certain Treatments?	94
111 Treatment Matching in the Post-Hospital Care of Patients With Depression	95

SYMPOSIUM

116 One Patient/Four Minds: Integrated Treatment for MDD	101
--	-----

ISSUE WORKSHOPS

5 Neurocybernetics: Novel Approach in the Treatment of Psychiatric Disorders	22
10 Early Detection and Treatment of Bipolar Illness	22
28 Multidisciplinary Treatment of Adults With Asperger's Syndrome and Related Disorders: Lessons From the University of Pennsylvania Social Learning Disorders Program	30

TOPIC 40: COUPLE AND FAMILY THERAPIES

COURSES

38 Family Skills for a General Psychiatrist	17
52 Families Coping With Medical Illness: A Treatment Approach for Psychiatry	30
95 Emotion Focused Therapy for Couples: Introduction to Theory and Clinical Skills	79

ISSUE WORKSHOPS

26 Secrets in Family Therapy: To Tell or Not to Tell	29
34 Initiating Couples Therapy Today	48

TOPIC 41: GROUP THERAPY

COURSE

29 Treating BPD With the Systems Training for Emotional Predictability and Problem Solving (STEPPS) Model	7
---	---

SCIENTIFIC AND CLINICAL REPORT

132 Psychodrama Groups for Psychiatric Intervention to Family Members of Patients With Schizophrenia	96
--	----

ISSUE WORKSHOP

95 Group Psychotherapy of Substance Abuse	96
---	----

TOPIC 42: INDIVIDUAL PSYCHOTHERAPIES

ADVANCES IN SESSION

3 Advances in Psychodynamic Psychotherapy: The State of the Art	56
---	----

CLINICAL CASE CONFERENCE

2 Sealed With a Kiss: Using the Sexual History in Psychodynamic Psychotherapy	18
---	----

CONTINUOUS CLINICAL CASE CONFERENCES

1 Twenty Therapies Later: Addressing Transference, Part 1	44
2 Twenty Therapies Later: Addressing Transference, Part 2	68

TOPIC INDEX

	Page#		Page #
COURSES		INDUSTRY-SUPPORTED SYMPOSIA	
9	1	26	17
10	2	Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths, Part 1	
20	5	26	43
23	6	Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths, Part 2	
27	7	MASTER EDUCATOR CLINICAL CONSULTATION	
30	7	10	50
34	8	Atypical Antipsychotics: 2006 and Beyond	
49	18	SCIENTIFIC AND CLINICAL REPORTS	
54	31	83	76
68	45	Meta-Analysis of Efficacy of Paroxetine Versus Placebo Utilizing the GlaxoSmithKline Clinical Trials Registry	
87	69	84	76
Love, Desire, Intimacy, and Infidelity: Useful Concepts for the Psychotherapist		Resolution of Sleepiness and Fatigue in the Treatment of MDD: A Comparison of Bupropion and SSRIs	
FOCUS LIVE SESSION		89	76
3	31	Theoretical Implications of Improved Depression Severity by PDE5I Sildenafil Treatment of Erectile Dysfunction Associated With Treated or Untreated MDD for Endothelial Dysfunction Mediation	
SYMPOSIUM		100	94
73	82	Desvenlafaxine: Preclinical Evidence for 5HT ₁ and Norepinephrine Reuptake Inhibition, Antidepressant, and Antinociceptive Activity	
The Art and Science of Brief Psychotherapies		101	94
COMPONENT WORKSHOP		Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of MDD	
15	28	128	96
Teaching the Working Alliance as a Core Process Across the Psychotherapies		Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD	
ISSUE WORKSHOPS		SYMPOSIUM	
57	72	60	63
80	92	The Meanings of Medication: Issues in Patients Compliance With Psychotropic Drugs	
84	93	ISSUE WORKSHOPS	
Race and Countertransference in the Clinical Setting		4	22
TOPIC 43: OTHER SOMATIC THERAPIES		14	23
COURSES		New Research Advances in Ethnopsychopharmacology	
12	3	38	48
24	7	Evidence-Supported, Risk-Minimizing, and Cost-Conscious Approaches in Psychopharmacology	
72	55	93	93
85	68	Cardiovascular Complications of Second Generation Antipsychotic Drugs	
96	80	TOPIC 45: TREATMENT TECHNIQUES AND OUTCOME STUDIES	
98	91	COURSES	
Yoga in Psychiatry: Theory, Clinical Applications, and Beginning Practice		22	5
SCIENTIFIC AND CLINICAL REPORTS		86	68
70	75	Using Boundary Crossings as Creative Therapy Instead of Slippery Slopes	
71	75	89	69
ECT Stimulus Dose as Physiological Volume of Seizure Foci		An Introduction to Complicated Grief Treatment	
ISSUE WORKSHOP		The Assessment and Treatment of Child Sexual Abusers	
66	78	MASTER EDUCATOR CLINICAL CONSULTATION	
When Therapeutic Lifestyle Changes Fail: Pharmacologic Management of Metabolic Syndrome in Psychiatry		6	25
TOPIC 44: PSYCHOPHARMACOLOGY		Clinical Research Across Geographic Borders: Challenges and Opportunities	
COURSES		MEDICAL UPDATE	
4	5	4	94
31	7	Liver Transplant Update: Current Outcomes and Challenges in 2006	
Drug Treatment of Schizophrenia		SCIENTIFIC AND CLINICAL REPORTS	
DISCUSSION GROUP		59	52
10	45	The Swedish Study of Metabolic Risks in Psychiatry	
New Developments in Impulse-Control Disorders and Autism		72	75
FORUM		The Efficacy and Outcome of Combining ECT and Atypical Antipsychotics for Treatment-Resistant Depression	
9	55	81	75
Hot Topics in Psychiatric Drug Safety		Quetiapine for Bipolar Disorder and Schizophrenia: Appropriate Dose for Optimal Response	
		90	76
		Efficacy of Sildenafil for the Treatment of Erectile Dysfunction in Men Taking Antidepressant Medication: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies	
		116	95
		Acupuncture and Cognitive-Behavior Therapy for PTSD	

	Page#
SYMPOSIA	
25 Developing Strategies in Psychotherapy Research	38
72 The Problem of Outcomes With the Difficult-to-Treat Patient	82
78 Use of Quantitative Instruments for Monitoring Depression Severity: Clinical Applications	83
94 Sustained Recovery and Healthy Functioning: The Long and Short of It	87

OTHER ISSUES

TOPIC 46: COMPUTERS

ISSUE WORKSHOP

91 Computer Tools for Cognitive-Behavior Therapy: Integrating Technology Into Clinical Practice	93
---	----

TOPIC 47: CREATIVITY AND THE ARTS

COURSE

93 Reel Psychiatry	79
--------------------	----

FORUM

3 Mozart at 250: The Mind and Music of a Genius	30
---	----

SCIENTIFIC AND CLINICAL REPORT

106 Family Background and Genius: Nobel Laureates in Science	94
--	----

SYMPOSIA

14 The Mid-Life Crisis as Interpreted in Film and Television	36
104 Psychiatry on the Silver Screen	99

TOPIC 48: ELECTRONIC MEDICAL RECORDS

COMPONENT WORKSHOP

42 The National Health Information Network and Psychiatry: How Will the Coming National Electronic Health Record Impact Our Patients and Our Practice?	71
--	----

ISSUE WORKSHOP

79 Use of a Standardized Comprehensive Psychiatric Assessment Tool to Facilitate Evidence-Based Decisions: The InterRAI Mental Health	92
---	----

TOPIC 49: GENDER ISSUES

LECTURE

17 Changing the Landscape of American Psychiatry: An African-American Perspective on Expansive Personality in Women	56
---	----

MASTER EDUCATOR CLINICAL CONSULTATION

5 Late Life Aging Processes and Mental Illness	25
--	----

SCIENTIFIC AND CLINICAL REPORT

94 Gender Differences in Schizophrenia and Other Psychotic Disorders: A 20-Year Follow-up Study	77
---	----

	Page #
ISSUE WORKSHOPS	
19 The Other Desperate Housewives: Hidden Violence in the Home	29
97 The Impact of Race and Gender on the Interactions Between Female Psychiatry Residents and Their Patients: An Interactive Group Workshop	97

TOPIC 50: HEALTH SERVICES RESEARCH

LECTURE

4 The Search for Quality and Equity in Care for Psychiatric Disorders: A Story of Opportunity, Evidence, and Partners	20
---	----

RESEARCH CONSULTATION WITH

3 Mental Health Policy Research	74
---------------------------------	----

SCIENTIFIC AND CLINICAL REPORTS

3 The System for Classification of Inpatient Psychiatry: A New Case-Mix Methodology for Mental Health	25
79 An Effectiveness Trial of a Brief Cognitive Behavioral Intervention by Mental Health Nurses in Schizophrenia: Clinically Important Outcomes in the Medium Term	75
97 All Equal? Advocating Equity in Mental Health Services in France to Ethnic-Minority Disadvantaged Youth and their Families through the Evidence-Based FACE* Protocol	77
121 Lifestyle Issues in Mental Health: Social Support, Diet, Fitness, and Recreation	95

ISSUE WORKSHOPS

63 The Quality Information System: A New System for Measuring Progress in the Doctor-Patient Relationship	72
89 Collaborative Mental Health Care in Canada	93

TOPIC 51: HISTORICAL QUESTIONS

COMPONENT WORKSHOP

40 Teaching the History of Psychiatry to Students and Residents: A Workshop Discussion on Content, Methods, and Ideals	71
--	----

TOPIC 52: INFORMATION TECHNOLOGY

DISCUSSION GROUP

14 The Clinical Use of Buprenorphine	49
--------------------------------------	----

SYMPOSIUM

111 Using Technology to Improve Patient Care	100
--	-----

TOPIC 53: INTERNET

COURSE

97 Psychiatry and the Internet	80
--------------------------------	----

ISSUE WORKSHOP

15 Online Peer Support Groups and Support Group Members	23
---	----

TOPIC INDEX

	Page#		Page #
TOPIC 54: LESBIAN/GAY/BISEXUAL/ TRANSGENDER ISSUES		LECTURES	
DISCUSSION GROUP		13 What Have We Learned About Alcoholism From Animal Models?	46
12 Gay Men and Crystal Meth Abuse	45	18 Pharmacogenetics of Alcohol: Are We There Yet?	56
MASTER EDUCATOR CLINICAL CONSULTATIONS		21 Combining Neuroimaging and Pharmacology to Better Treat Alcoholism?	70
14 Sexual Orientation and Gender Identity in Clinical Care	70	24 A University President's Perspective on Alcohol Related Research	73
17 Working with Lesbian, Gay, Bisexual, and Transgendered Patients: What do you need to know?	74	25 Beyond Dopamine: Neuroadaptations, Negative Affect, and Clinically Relevant Treatment Targets in Alcoholism	80
SCIENTIFIC AND CLINICAL REPORT		26 Medications That Act as Ion Channels as Treatment for Alcohol Dependence	80
108 The Parent's Perspective on Gender Variant Children and Adolescents: Concerns, Hopes, and Joys	94	RESEARCH CONSULTATION WITH	
SYMPOSIA		1 Clinical Research on Alcohol Use Disorders	25
5 Sexual Orientation and Sports	33	SYMPOSIA	
98 Same Sex Civil Marriage: Historical and Mental Health Research Perspectives	88	13 Substance Use Disorders in the U.S.	35
COMPONENT WORKSHOP		26 Taking Science to Policy: Efforts to Reduce Harms Related to Alcohol Misuse	39
46 A Research Agenda for <i>DSM-V</i> : Mental Health in the Gay, Lesbian, and Bisexual Populations	98	38 Screening, Diagnosis, and Management of Alcohol Use Disorders in Psychiatric Practice	58
ISSUE WORKSHOP		48 Substance Use Disorders: Planning a Research Agenda for <i>DSM-V</i>	61
77 Can I Change? A Journey Through Ex-Gay Ministries and Beyond	92	59 Genetic Findings Related to Alcohol Dependence and Related Conditions	63
MEDIA WORKSHOP		66 Risk Factors, Personality Variables, and Addictive Disorders	81
7 <i>Bad Education</i> : Portraying Transsexualism, Pedophilia, and Addiction	93	82 Adolescent Alcohol Use Disorders and Psychiatric Comorbidity	84
TOPIC 55: MANAGED CARE AND HEALTH CARE FUNDING		87 Alcohol, Drugs, and Psychiatric Disorders in the U.S.	85
COURSE		88 Sobering Facts: Alcohol Dependence and Treatment Interventions	86
82 Current CPT Coding and Documentation Requirements	68	97 Translating the Neurobiology of Alcoholism Into Clinical Treatments	88
COMPONENT WORKSHOPS		ISSUE WORKSHOPS	
2 Pay for Performance: Linking Incentives to Provider Performance on Quality Measures	21	3 Managing Complex Comorbid Psychiatric and Alcohol Use Disorders in Psychiatric Practice	22
8 CPT Coding and Documentation Update	21	40 Practical Pharmacotherapy for the Treatment of Alcohol Dependence	48
23 Managed Pharmacy and Pay for Performance: The New Managed Care	47	68 Applying for National Institute of Alcohol Abuse and Alcoholism Research Money: Some Things You Didn't Learn in Graduate School	78
TOPIC 56: MEN'S HEALTH ISSUES		99 Disasters, Public Policy, and Addiction Psychiatry	97
MEDICAL UPDATE		102 Medical Comorbidity in Dual Diagnosis Patients	97
3 Testosterone Replacement Therapy in the Aging Male: Implications for Psychiatry and Other Disciplines	74	MEDIA WORKSHOP	
TOPIC 57: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM		6 <i>Carter's Addiction</i> : Substance Use Disorders in Physicians	72
FORUMS		TOPIC 58: PATIENT SAFETY	
4 Women and Alcohol Use Disorders	30	MASTER EDUCATOR CLINICAL CONSULTATION	
11 The Future of Alcohol Research: NIAAA Resident Travel Award Winners With Discussion by a Panel of Senior Researchers	55	6 Clinical Research Across Geographic Borders: Challenges and Opportunities	25
		SYMPOSIUM	
		84 Patient Safety: To Err Is Human, To Be Safe Is Divine	85
		TOPIC 59: PERSONAL DIGITAL ASSISTANTS (PDA)	
		COURSES	
		58 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Introductory Course	43
		71 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Advanced Course	55
		81 How to Use Your Pocket PC Personal Digital Assistant in Psychiatric Practice	68

	Page#		Page #
TOPIC 60: POLITICAL QUESTIONS			
COMPONENT WORKSHOP			
34 European Psychiatry: Health and Mental Health Policy After the Helsinki Summit	53		
TOPIC 61: PRESIDENTIAL THEME: FROM SCIENCE TO PUBLIC POLICY: ADVOCACY FOR PATIENTS AND THE PROFESSION			
DISCUSSION GROUP			
15 Getting the Psychiatric Message to the Public: You Can Do It	49		
PRESIDENTIAL SYMPOSIUM			
2 International Advocacy Towards a Psychiatry for the Person	57		
SCIENTIFIC AND CLINICAL REPORT			
2 Health Policies and the Diagnostic and Statistical Manual	25		
SYMPOSIA			
90 Science and Regulation Affecting Private Practice	86		
110 Infectious Diseases and Psychiatric Symptomatology	100		
COMPONENT WORKSHOPS			
17 Winning the Fight for Mental Health Benefits: Partnering With Employers	28		
33 Moving the Psychiatric Agenda in the House of Medicine	53		
36 Integrating Evidence-Based Psychiatry With Clinical Intelligence	53		
37 Data Coupled With Advocacy Shaping Public Policy	71		
ISSUE WORKSHOPS			
31 The Creation and Function of a Mental Health Court	48		
60 Assisted Outpatient Treatment and Its Role in the Fabric of the Mental Health System	72		
76 Direct to Consumer Marketing: Just Who Is the Consumer?	92		
TOPIC 62: PROFESSIONAL AND PERSONAL ISSUES			
COURSES			
16 Improving Your Presentation Skills: A Coaching Approach	5		
79 Cover Your Assets: Improved Patient Care through Malpractice Protection	67		
84 Treating Medical Students and Physicians	68		
100 The Evaluation and Treatment of Physicians Involved in Sexual Misconduct and Sexual Harassment	91		
DISCUSSION GROUP			
1 The New Handbook on Professional Development for Academic Psychiatrists	19		
FORUM			
6 The Theory and Practice of Apology	30		
MASTER EDUCATOR CLINICAL CONSULTATION			
8 Treating Physicians and Their Families: Clinical Dilemmas	46		
ISSUE WORKSHOPS			
9 Teaching Boundaries to Practicing Clinicians	54		
SYMPOSIUM			
51 How to Launch a Successful Private Practice: Part 3	61		
		COMPONENT WORKSHOPS	
		19 Facilitating Minority to Excel in Academic Psychiatry	29
		22 You Can Be Leaders Too: A Workshop for IMGs and Minorities	47
		43 Novel Careers in Psychiatry: Women Who Have Made Their Own Way	71
		ISSUE WORKSHOPS	
		7 Risk Management Issues in Psychiatric Practice	22
		12 Reinventing Careers: Transitions and Later-Life Strategies for Psychiatrists	22
		13 American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification in Psychiatry and Its Subspecialties	23
		17 Biopsychosocial and Spiritual Aspects of Treating our Physician Colleagues	29
		30 When Psychiatrists Get Cancer	47
		41 How to Launch a Successful Private Practice: Part 1	48
		47 How to Launch a Successful Private Practice: Part 2	54
		61 Psychiatrists in the Dean's Office: Career Opportunities and Career Development	72
		70 Maintenance of Certification for Diplomats of the American Board of Psychiatry and Neurology	78
		74 The Key to Success, Mentorship Matters: A Practical Guide for Trainees and Educators	78
		83 International Medical Graduates in Training and Practice: Professional and Personal Trials	92
		94 Children of Psychiatrists	93
		107 Psychiatrists Who Have Faced Mental Illness in Themselves: There Is a Silver Lining	97
		TOPIC 63: RELIGION, SPIRITUALITY, AND PSYCHIATRY	
COURSE			
		99 Spirituality and Worldview in Clinical Practice	91
LECTURE			
		8 Culture, Spirituality and Psychiatry: A Psycho-Historical Study of King Saul	31
MASTER EDUCATOR CLINICAL CONSULTATION			
		13 The Role of Spirituality in the Care of Patients	70
SCIENTIFIC AND CLINICAL REPORT			
		130 Spirituality and Recovery From Depression	96
SYMPOSIA			
		10 Model Curricula on Religion and Spirituality for Psychiatry Residency Training Programs	35
		118 Complementary, Alternative, and Integrative Approaches in Mental Health Care	102
ISSUE WORKSHOP			
		9 Religious and Spiritual Assessment in Clinical Practice	22
		TOPIC 64: RESIDENT AND MEDICAL STUDENT CONCERNS	
DISCUSSION GROUPS			
		9 Your Resident Career: Getting Started, Getting Funded	23
		17 Trauma in the Modern World: The Role of the Psychiatrist	49
		22 The Future of Psychiatry: What the Resident Should Know.	73
RESIDENT'S SESSION			
		Meet the Experts: Sunny-Side Up	17

TOPIC INDEX

	Page#		Page #
SYMPOSIUM		TOPIC 67: WOMEN'S HEALTH ISSUES	
83 Educating a New Generation of Physicians in Psychiatry: Focus on Medical Student Education	84		
COMPONENT WORKSHOPS		CLINICAL CASE CONFERENCE	
3 Career Choices in Psychiatry: Exploring Fellowship Training	21	3 Rocking the Cradle: A Case of Postpartum Infanticide	44
30 Employment in the Post-Residency Years: Getting What You Want	53	COURSE	
47 Welcome to the Jungle: The Dynamics Between Residents and Industry	77	19 Management of Psychiatric Disorders in Pregnant and Postpartum Mothers	5
ISSUE WORKSHOPS		DEBATE	
18 Oral Boards Boot Camp: 2006	29	2 Medications in Pregnancy and Lactation: What Have We Learned?	45
67 Countertransference and Boundary Issues of Residents Treating Medical Students, Fellow Residents, and Attendings	78	DISCUSSION GROUPS	
TOPIC 65: STIGMA/ ADVOCACY		2 Why Women's Mental Health?	19
		7 Psychotherapy with Women with Breast Cancer	23
LECTURE		LECTURE	
11 Prevention, Early Intervention, and Elimination	45	15 Priorities, Initiatives, and Women's Health Research	49
SCIENTIFIC AND CLINICAL REPORT		MASTER EDUCATOR CLINICAL CONSULTATIONS	
1 The Impact of an Integrated Community Arts Studio on Stigmatizing Beliefs and Experiences	25	2 Psychiatric Disorders Across the Female Reproductive Cycle	20
SYMPOSIUM		4 Perinatal Psychiatric Disorders	25
109 NAMI Doctors Sound Off	100	SCIENTIFIC AND CLINICAL REPORTS	
ISSUE WORKSHOPS		95 Severe Personality Disorders in the Offspring of Antenatally-Depressed Mothers: A 31-Year Follow-Up of the Northern Finland 1966 Birth Cohort	77
48 Grassroots Advocacy for Patients and for the Psychiatric Profession: How Medical Students, Residents, and Early Career Psychiatrists Can Affect the Legislative, Regulatory, and Political Process	54	96 Outcome of Prenatal Anxiety, Stress, and Depression	77
53 The Psychiatry Resident as Advocate: Practical Steps From the Clinic to the Capitol	54	SYMPOSIA	
TOPIC 66: VIRTUAL REALITY		20 Borderline Mothers and Infant Interactions: Chaotic Contingency	37
		79 Women's Life Cycle and Mental Health	84
SYMPOSIUM		86 Science to Policy: Advancing Women's Mental Health	85
101 Virtual Environments and Convergent Media Technology	98	ISSUE WORKSHOPS	
ISSUE WORKSHOP		6 Treatment of Pregnancy-Related Mood Disorders: From Psychiatry to Pediatrics	22
27 Virtual Reality and Video Games in the Treatment of Mental Health Disorders and Addictions: An Evidence-Based Analysis	30	25 Establishing a Women's Mental Health Program in an Academic or Private Setting	29
		44 Infertility: From Patient Care to Advocacy and Public Policy	54
		106 Desperate Housewives Survive the War of the Worlds: Therapeutic Perspectives on Women's Health	97



Join APA Today and Qualify for a Rebate

You may qualify if you are a psychiatrist in the U.S. or Canada and:

- 1 Have paid the full-time registration fee for the Annual Meeting (\$785 advance, \$860 on-site) and
- 2 Have never been a member of APA.

- 1 Stop by one of the Membership booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Halls D & G, South Levels 800) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.
- 2 Additional documentation (proof of ACGME-, AOA-, or RCPS(C)-approved psychiatry residency training and a current, valid medical license) must be received by APA no later than June 30, 2006.

- 1 The local psychiatric society must approve the application no later than September 30, 2006.
- 2 The difference in the non-member vs. member Annual Meeting registration fee (\$565) will be credited towards your pro-rated 2006 national and local dues with the remaining balance of the rebate amount sent directly to you, or if you choose we can apply the remaining balance to your 2007 dues. It's up to you!.

Please stop by one of the Membership booths to learn more about APA member benefits and privileges.



Healthy Minds. Healthy Lives.

PARTICIPANT INDEX

APA 159TH ANNUAL MEETING

A

Aaronson, Scott T.....	26
Abbey, Susan.....	48
Abel, Kathryn M.....	76
Abi-Dargham, Anissa.....	5, 43
Abikoff, Howard.....	26
Abrams, Karen M.....	84
Abramson, Ronald D.....	86
Adams, Margo S.....	21
Addington, Jean.....	62
Adetunji, Babatunde A.....	82
Adityanjee, A.....	58
Adler, Lawrence W.....	76
Adler, Lenard A.....	26
Adson, David E.....	36
Ahmed, Iqbal.....	28, 35
Aisen, Paul.....	39
Aizenberg, Dov.....	95
Aizenstein, Howard J.....	64
Akaka, Jeffrey.....	53
Akarsu, Eyup.....	51
Akiskal, Hagop S.....	9, 52
Alaraisänen, Antti S.....	95
Alarcon, Renato D.....	20, 72
Albert, David B.....	81
Aledjem, Asher.....	27
Alegria, Margarita.....	87
Alexopoulos, George S.....	64
Alger, Ian E.....	22, 48
Alicata, Daniel A.....	62
Allen, Albert J.....	96
Allen, Jon G.....	82
Allison, Kelly.....	64
Almasy, Laura.....	63
Almeida, Goretti.....	75
Alpert, Jonathan E.....	1, 2, 26, 76, 89
Al-Samarrai, Sadiq H.....	92
Altermus, Margaret.....	29
Alter, Carol L.....	47
Alves-Bradford, Jean-Marie E.....	77
Amaya-Naranjo, Walter.....	50
Ambidge, Chris.....	53
Amiri, Shahrad R.....	54
Amsterdam, Jay D.....	26
Ancoli-Israel, Sonia.....	59
Andermann, Lisa F.....	54
Andersen, Susan L.....	37
Anderson, Allan A.....	21, 28
Anderson, Tanya R.....	53, 94
Andrade, Naleen N.....	23, 78
Andreasen, Nancy C.....	40, 90
Andree, Terrance H.....	94
Ansari, Rubaba.....	76, 94
Antia, Diana.....	48
Anzia, Joan M.....	54, 71
Aoyama, Naoko.....	52
Appelbaum, Paul S.....	33, 63, 78, 87, 102
Appleby, Louis.....	76
Appleton, Darryl.....	74
Apter-Danon, Gisèle.....	37, 77
Araujo, Katie.....	50
Arboleda-Florez, Julio E.....	28, 101
Arciniegas, David B.....	11
Arlinghaus, Kimberly A.....	80
Arnold, Lesley M.....	6, 26
Arnsten, Amy.....	6
Arntz, Arnold.....	85
Arora, Sanjay.....	74, 96
Arroyo, William.....	21, 32, 47

Assadi, Seyed Mohammad.....	27
Atger, Frederic.....	81
Atre-Vaidya, Nutan.....	29
Artia, Evelyn.....	57
Auger, R. Robert.....	2, 67
Aviv, Alex.....	28
Awad, George.....	36
Ayhan, Ismail Hakki.....	51

B

Bach, Dominik.....	87
Bagby, R. Michael.....	37, 65
Bailer, Ursula.....	64
Bain, Jerald.....	74
Baker, F.M.....	79
Baldassano, Claudia F.....	2
Baldessarini, Ross J.....	9
Ballon, Bruce C.....	22, 48, 93, 97
Bankole, Azziza O.....	83
Banon, Elisabeth.....	87
Barak, Yoram.....	28, 52, 95
Barber, Jacques.....	38
Barber, Mary E.....	92
Barbes-Morin, Guillaume.....	94
Barenboim, Arkady.....	82
Bark, Nigel.....	33
Baron, David A.....	92
Baroni, Stefano.....	51
Barreira, Paul J.....	102
Baruch, Yehuda.....	28
Bassett, Anne S.....	97
Bates, Dorothy.....	30
Bates, G. William.....	84
Batki, Steven L.....	86
Baum, Antonia L.....	33
Baxter, Elizabeth A.....	97, 100
Beck, Aaron T.....	32
Beck, Judith S.....	48, 54, 82, 93
Beck, Philip R.....	87
Becker, Daniel F.....	50
Becker, Philip M.....	67
Beekman, Aartjan T.F.....	61
Beezhold, Julian.....	29
Begleiter, Henri.....	63
Beitel, Jeffrey D.....	52
Beitman, Bernard D.....	28, 56
Belenky, Gregory.....	2
Belfort, Edgard.....	60
Bell, Carl C.....	29, 53
Bellack, Alan S.....	34
Benedek, David.....	49
Benedek, Elissa P.....	54, 76
Benedek, Lana M.....	48, 54, 93
Bennett, David A.....	9
Bennett, Mark.....	94
Benowitz, Neal.....	64
Berger, Joseph.....	51
Berger, Ralph.....	60
Berkman, Alan.....	32
Berlin, Jon S.....	12, 21
Berlin, Robin.....	95
Bernstein, David P.....	27, 85
Berrettini, Wade H.....	64
Berthaud, Vladimir.....	59
Beyer, Chad E.....	94
Beyer, John L.....	17, 67
Bhagwagar, Zubin.....	76, 94
Bhanji, Nadeem H.....	92
Bialer, Philip.....	82

Biederman, Joseph.....	11, 71
Bierut, Laura J.....	63
Bilder, Robert M.....	8
Binder, Renee L.....	88
Birmingham, Sarah.....	27
Birndorf, Catherine A.....	29
Bisaga, Adam M.....	61
Bivens, Nancy M.....	97
Bixler, Edward.....	34
Bizamcer, Aurelia.....	48
Bizouard, Paul.....	81
Bjarnadottir, S.....	101
Bjorgvinsson, Throstur.....	82
Black, Donald W.....	7, 58, 85
Blanch, Vincent J.....	21, 45
Blanco-Jerez, Carlos.....	35, 58
Blank, Karen.....	28
Blaustein, Mel.....	47
Blazer II, Dan G.....	98
Bleiberg, Efrain.....	82
Bloch, Sidney.....	33
Bloom, Floyd E.....	40
Blume, Sheila B.....	97
Bodenheimer, Alison.....	82
Boellner, Samuel W.....	26
Bogan, Richard.....	74
Bohus, Martin.....	40, 44
Bokarius, Vladimir.....	54
Boland, Robert J.....	36, 68
Bond, Michael P.....	87
Bonnie, Richard.....	63
Boonyanaruthee, Vudhichai.....	52
Boronow, John J.....	71
Borson, Soo.....	61
Borus, Jonathan F.....	53
Bostic, Jeff Q.....	2
Bouchard, Guylain.....	101
Boulanger, Christophe.....	34
Boulanger, Pierre.....	98
Bowden, Charles L.....	65
Bowskill, Richard.....	51, 96
Bradford, Dianne.....	36
Brady, Kathleen T.....	67, 86, 89
Braff, David L.....	63
Braus, Dieter F.....	52
Briester, Stephanie J.....	46
Brnabic, Alan J.....	51
Brod, Thomas M.....	68, 101
Brodkin, Edward S.....	30
Brook, David W.....	96
Brooks, Beth Ann.....	23
Brown, E. Sherwood.....	96
Brown, Richard P.....	35, 50, 55, 80
Brunette, Mary F.....	39
Buchin, Jacqueline.....	52
Bucholz, Kathleen K.....	63
Buckley, Peter F.....	3, 26, 35
Budur, Kumaraswamy.....	82
Buechel, Christian.....	52
Bui, Viet Q.....	93
Bulik, Cynthia M.....	64
Bullmore, Edward.....	75
Bulmash, Eric.....	37
Burd, Ronald M.....	21
Burkholder, Page.....	22, 72
Bursztajn, Harold J.....	92
Burt, Vivien K.....	22
Busch, Kenneth G.....	71
Bush, George.....	11, 42
Butler, Lisa D.....	33
Butterfield, Marian I.....	10, 37, 47, 60, 85, 99

Buwalda, Victor J.A.72
 Buysse, Daniel J.2, 11

C

Cabaj, Robert P.45, 70, 77, 88
 Cagande, Consuelo C.100
 Cahill, Shawn62
 Caivano, Norana I.29
 Calabrese, Joseph R.3, 26, 39, 51, 67, 91
 Caldas de Almeida, Jose M.60
 Callahan, Jr., William E.48, 54, 61
 Campanini, Paolo58
 Campbell, Nioaka N.35, 97
 Campillo, Horacio A.50
 Campo, Ana E.24, 47
 Campo-Arias, Adalberto27, 50, 95
 Cankurtaran, Eylem51
 Cappelleri, Joseph C.76
 Caraballo, Angel A.28
 Cardasis, William25
 Cardoni, Alex A.26
 Carey, Michael P.32
 Carlat, Daniel J.27, 81
 Carlson, Robert W.33
 Carpenter, Jr., William T.19
 Carpenter, Linda L.4, 6, 91
 Carter, Jacqueline57
 Carton, Solange81
 Cartwright, Rosalind D.88
 Case, Brady G.46
 Casey, Daniel E.22
 Casiano, Delane E.47
 Castellanos, Daniel77
 Castro, Carl A.102
 Catapano, Lisa A.21, 77
 Catena, Mario51
 Caubel, Josephine M.99
 Celestin, Leon-Patrice52, 77
 Celestin-Westreich, Smadar52, 77
 Celis-Perdomo, Antonio51
 Cerro, Lorri76
 Chamberlain, Sam R.87
 Chambers, Robert A.60
 Chan, Carlyle H.43, 80, 100
 Chandra, Prabha S.32
 Chang, Grace30
 Chang, Kiki D.2, 65
 Chang, Linda62
 Chapman, Daniel P.27, 50, 76
 Chapman, Laura M.88
 Charney, Dennis S.30, 62
 Charnsilp, Chawanant52
 Chatoor, Irene53
 Chaudhry, Haroon R.33, 79
 Chen, Andrew C.H.55
 Chen, Ming-Chao27
 Cheong, Josepha A.36, 69
 Cheung, Angela M.46
 Childress, Anna R.61
 Choi-Kain, Lois W.21, 28
 Choong Kam Chong, Steve29
 Chou, Frank H.53
 Chou, Li-Shiu27
 Chou, Miao-Chun96
 Chow, Eva W.C.97
 Christodoulou, George28, 33
 Chuang, Henry T.95
 Chung, Henry83
 Ciccocioppo, Roberto88
 Ciccone, J. Richard101
 Ciechanowski, Paul S.59
 Ciraulo, Domenic56
 Citrome, Leslie L.34, 76
 Clark, Duncan B.84

Clark, Lee Anna85
 Clarke, David33, 83
 Clarke, Norma V.82
 Clarkin, John F.7, 40, 45
 Classen, Catherine33
 Clatworthy, Jane51, 96
 Clayton, Anita H.2
 Clemens, Norman A.28
 Cloitre, Marylene37, 81
 Cloninger, C. Robert98
 Cochran, Susan D.77
 Cogan, Jeanine C.64
 Cohen, Carl I.28, 83
 Cohen, Lisa82, 83
 Colemon, Yolonda R.28
 Collins, Gary R.37
 Collins, Pamela Y.32
 Collison, Joan M.35
 Colliver, James D.62
 Comas-Diaz, Lilliam48
 Combrinck-Graham, Lee47
 Comella, Cynthia L.67
 Comer, James P.70
 Compton III, Wilson M.35, 85
 Compton, Wilson M.30, 35, 61, 85
 Coney, Ponjola84
 Conley, Robert R.19, 34
 Connor, Kathryn M.23
 Constable, Robert T.36
 Conway, Kevin35
 Cora-Locatelli, Gabriella47
 Corcoran, Cheryl66
 Corcos, Maurice65, 81
 Cornblatt, Barbara A.62
 Cornelius, Jack R.8, 78
 Correll, Christoph U.8, 84
 Cortese, Bernadette M.88, 101
 Coryell, William H.65
 Coskun, Bulent96
 Cottler, Linda B.61
 Cournos, Francine24, 32, 97
 Covino, Jennifer26
 Cox, John L.57
 Coyle, Jr., Joseph T.39
 Cozza, Stephen J.102
 Creal, Margaret48
 Crits-Christoph, Paul87
 Crofford, Leslie J.6
 Croft, Harry A.76
 Cronkite, Ruth C.52
 Crosby, Ross D.64
 Crowley, Brian86
 Crowley, Thomas J.61
 Crustolo, Anne Marie78
 Cuijpers, Pim61
 Cummings, Jeffrey L.9, 10, 18
 Cusin, Cristina76

D

Dahl, Ronald E.36
 D'Alli, Richard E.19, 71
 Dalton, Arthur39
 Daly, Patricia A.72
 Dang, Kien T.54, 93
 Dannon, Pinhas N.96
 Danoff, Deborah84
 Danovitch, Itai77
 Davidson, Joyce E.82
 Davidson, Larry82
 Davidson, Leah63
 Davine, Jonathan S.3, 93
 Dawe, Ian C.95
 Dawson, Lee94
 Day, Max92

De Figueiredo, John M.39, 61, 83
 De Leon, Jose95
 Deas, Deborah73, 84
 Debatista, Charles2
 Debeus, Roger J.101
 Debipersad, Prashaant72
 Deckersbach, Thilo51
 Deecher, Darlene94
 Deeg, Dorly61
 Dekker, Jack36, 37, 88
 Del Rosario, Jr., Salvador R.97
 Delbello, Melissa P.36
 Delgado, Pedro L.24, 40, 89
 Dell, Mary Lynn98
 Dell'osso, Bernardo51
 Demartinis, Nicholas94
 Demas, Michael25, 52, 75
 Demidovich, Mark A.46
 Demitrack, Mark3, 59
 Densmore, Maria52
 Derauf, D. Christopher62
 Deva, Parameshvara P.57, 92
 Devlin, Michael J.1, 57, 58, 64, 75
 Devouche, Emmanuel37, 77
 Dewan, Mantosh J.1, 38, 82
 Dhopes, Vasant P.97
 Diaz, Francisco J.95
 Diaz-Martinez, Luis A.27, 50, 95
 Dick, Danielle M.63
 Dickstein, Leah J.23, 30, 47, 49, 55, 68, 93, 97
 Diller, Lawrence H.81
 Dimiceli, Sue33
 Dirienzo, Rosalinda97
 Diverty, Brent92
 Diwadkar, Vaibhav76
 Diwan, Shilpa P.83
 Dogramji, Karl74
 Dogra, Nisha93
 Donahue, Rafe M.76
 Doraiswamy, P. Murali55, 65
 Dossenbach, Martin26
 Douaihy, Antoine B.62, 98
 Dove, Henry W.25
 Downey, Jennifer I.18
 Dragatsi, Dianna75
 Drake, Jennifer E.82
 Drake, Robert22, 39
 Drapeau, Martin87
 Drescher, Jack23, 53, 77, 92
 Dresner, Nehama29
 Drost, Dick J.52
 Drury, Stacy S.78
 Druss, Benjamin G.55
 Dryden-Edwards, Roxanne47, 54
 D'Souza, Russell F.79, 92
 Duane, Drake52
 Dube, Sanjay14, 47, 53, 69
 Duckworth, Kenneth100
 Dudgeon, Scott93
 Duenas, Hector J.51
 Duffy, Farifteh F.83
 Dunlop, Boadie W.42
 Dunn, Laura B.33
 Dunner, David L.4, 26
 Dunnigan, Joanne96
 Durruthy, Stephanie S.71
 Duvall, Loretta E.45
 Dwyer, Gregg97
 Dyachkova, Yulia26

E

Earl, Craig Q.26
 Ebeling, Hanna75
 Edenberg, Howard J.63

PARTICIPANT INDEX

Ednie, Kathryn J.	51, 85
Edwards, Christopher	53
Ehrhardt, Anke A.	24
Eisen, Jane L.	98
Eisenberg, Daniel	83
Eisenberg, Esther	84
Eisenberg, Leon	40
Eist, Harold I.	86
Ekong, Juliana I.	97
Elbaz, Zeinab S.	26
Engel, Scott	64
England, Mary Jane	55
Entsuaah, Richard	94
Ereshefsky, Larry	40
Erman, Milton	74
Ernst, Thomas	62
Escobar, Javier I.	40
Espinoza, Randall T.	75
Eth, Spencer	28, 47
Etu, Sarah	57

F

Faison, Warachal E.	28, 65
Falissard, Bruno	96
Fan, Alexander H.	3
Farabaugh, Amy H.	2, 52
Faraone, Stephen V.	1, 11, 42
Farchione, Tiffany R.	54
Farelo, Daniel	95
Farvolden, Peter	37
Faulkner, Larry R.	23, 72
Faull, Robert	26, 77
Fava, Maurizio	42, 52, 76, 77, 89
Fawzy, Fawzy I.	33
Fazzio, Lydia O.	94
Fearon, Paul	33
Fedoroff, Paul	26, 52, 94
Feheley, Paul	53
Feijen, Rudolf A.	99
Feldman, Howard	9
Feldman, Theodore B.	71
Fennell, Leah A.	71
Ferguson, Yvonne B.	32
Fernandez, Antony	77
Fernandez-Mendoza, Julio	34
Ferrando, Stephen J.	100
Fichera, Giuseppe P.	58
Fidler, Donald C.	97
Filteau, Marie-Josée	102
Findling, Robert L.	26
Fineberg, Naomi A.	87
Finkel, Sanford I.	8
First, Michael B.	18, 59, 77, 83
Fischbach, Ruth	102
Fischbein, Ellen R.	22
Fischer IV, Bernard A.	92
Fitz-Gerald, Mary Jo	21
Flament, Martine	81
Fleischhacker, Wolfgang W.	36
Fleming, Alison	78
Flynn, Julianne	71, 78
Foa, Edna B.	6, 38, 62
Fobair, Pat	33
Fochtmann, Laura J.	21
Fogg-Waberski, Joanna H.	75
Fonagy, Peter	56
Ford, Julian	37, 81
Forde, David R.	27
Forester, Brent P.	3, 31
Foroud, Tatiana	63
Forster, Marshall	28, 62
Foulks, Edward F.	100
Fowler, Christopher	87
Frances, Richard J.	37, 86, 97

Franco, Flavia S.	94
Frangou, Sophia	91
Frank, Daniel	87
Frank, Ellen	3, 11
Frank, Guido K. W.	64
Frank, Julia	50, 83
Frankenburg, Frances R.	40
Frankle, W. Gordon	5
Franko, Debra L.	64
Freedman, Robert	40, 84
Freeman, Marlene P.	43
Freinkel, Andrew J.	102
Freire, Rafael C.	94
Frese, Frederick J.	100
Fricchione, Gregory L.	86
Fried, Ronna	11
Friedman, Joseph	35
Friedman, Richard C.	18
Friebs, Gerhard	64
Fries, Brant	25
Friis, Svein	62
Frinks, Leslie E.	97
Frommann, Nicole	36
Fromson, John A.	21
Frye, Mark A.	60
Fulford, K. W. M.	57
Fuller-Thomson, Esme	79
Fung, Freddy	77
Fung, Kenneth P.	54
Fyer, Abby	62

G

Gabbard, Glen O.	12, 19, 44, 56, 87, 93, 99
Gabriel, Adel A.	26, 51, 94
Gaby, Lynne M.	27, 83
Gaebel, Wolfgang	36, 101
Gagne, Pierre W.	50
Gahunia, Harvina	48
Galanter, Marc	56, 69, 86, 97, 98
Gallagher, Dymphna	57
Gallofin, Leo L.	29
Galynker, Igor I.	82, 83
Ganime, Peter D.	96
Gao, Keming	51
Garbely, Joseph M.	71
Garcia-Moreno, Dolores	99
Garrett, Michael	29, 72
Garza, Daniel	23, 72
Gasquet, Isabelle	96
Gau, Susan Shur-Fen	96
Gaw, Albert C.	31, 47
Gelenberg, Alan J.	21
Geller, Barbara	3, 71
Geller, Jeffrey L.	30
Gennaro, Karen G.	47, 53
Genser, Sander G.	48
Gentilello, Larry	39
George, Lindsey	3, 78
George, Mark S.	18, 68
George, Tony P.	60, 84
Gerbag, Patricia L.	50, 55, 80
Gerber, Andrew J.	38
Germain, Christine	34
Ghadiali, Nafisa Y.	77
Ghaemi, S. Nassir	6, 9, 22
Ghalib, Kareem	25
Ghodse, Hamid	33
Giannaccini, Gino	51
Gianoli-Valente, Marina	37
Gicquel, Ludovic A.	81
Giese-Davis, Janine	33
Giggie, Marisa A.	71
Gignac, Martin	21
Gijsbers van Wijk, Cecilia	37, 88

Gilioli, Renato	58
Gill, Sudeep S.	95
Glaescher, Jan	52
Glas, Gerrit	98
Glaser, Deborah	57
Glick, Rachel	75
Glitz, Deborah	88
Glover, Helen M.	82
Goethe, John W.	26, 28, 75, 95
Goff, Donald C.	39
Gogineni, R. Rao	44, 68, 100
Goin, Marcia K.	69, 92
Gokler, Bahar	96
Gold, Ian	81
Gold, Liza H.	7, 10
Gold, Wayne L.	100
Goldberg, Jeffrey	92
Goldberg, Joseph F.	26
Goldfein, Juli A.	58
Goldfinger, Stephen M.	29, 100
Goldman, Marina	54
Goldstein, Benjamin I.	60
Goldstein, Marion Zucker	47
Goldstein, Rachel	29
Goldstein, Rise B.	85
Gomez, John-Paul	54
Gonzales, Junius J.	89
Gonzalez de Rivera, Jose L.	51, 64
Goodman, Aviel	81
Goodman, Wayne K.	98
Goodwin, Frederick K.	9, 22, 67
Gordon, Edward	21
Gordon, Susan M.	30
Gordy, Tracy R.	21, 54, 68
Gottlieb, Diane B.	48
Gottlieb, Gary L.	55
Gouch, Peter	62
Graap, Ken	98
Grabovac, Andrea D.	35
Grabsch, Brenda	33
Grady-Weliky, Tana A.	72, 85
Graignic-Philippe, Rozenn	37
Grant, Bridget F.	35, 85
Grant, Jon E.	58
Gratier, Maya	37
Graves, Michael C.	11
Gray, Sheila H.	53
Greden, John F.	12, 23, 26
Green, Melva I.	56, 71
Green, Michael	17
Greenberg, Benjamin D.	64, 65
Greenberg, Roger P.	82
Greenfield, Shelly F.	30, 74, 89
Greenlee, Brian A.	21
Greiner, Carl B.	68, 85
Griffin, Dauda A.	28
Griffith, James L.	22, 54, 70, 83, 91, 95
Grilo, Carlos M.	50
Groleger, Urban	26
Grosjean, Bernadette M.	27, 51, 76, 95
Gross, Lawrence S.	92
Grossman, Linda S.	25, 26, 77
Growdon, John	52
Grube, Beth A.	28
Gruber, Staci A.	36
Gruenberg, Peter B.	50
Gruman, Cynthia	96
Gudmundson, O.	101
Gudmundsson, S.	101
Guduri, Sujata	85
Guelfi, Julien-Daniel	81
Gunderson, John G.	40, 99
Gupta, Nitin	95
Gur, Raquel E.	24
Gureje, Oye	34

Gutheil, Thomas G. 22, 44, 87, 92

H

Haahr, Ulrik 62
 Haas, Ann P. 102
 Haber, Lawrence 96
 Hackman, Ann L. 98
 Hafez, Mohammad 38
 Hafliger, Silvia 28, 94
 Hakko, Helinä 75
 Hales, Deborah J. 19, 23, 31
 Hales, Robert E. 17, 43
 Halfon, Olivier 81
 Halkitis, Perry N. 62
 Hall, Heather M. 48
 Hall, Lacresha L. 77
 Hall, Molly J. 71
 Haller, Ellen 74, 88
 Halliday, Basil D. 53
 Halmi, Katherine A. 1, 64
 Halper, James P. 92
 Halpern, Abraham L. 37
 Hamarman, Stephanie 47
 Hamid, Hamada 27
 Hamilton, Joseph D. 80
 Hamilton, Tom 21
 Hammerness, Paul G. 6
 Hammerschlag, Richard 95
 Hanin, Edward 22
 Haning III, William F. 21, 62
 Hanley, Tyrone 51
 Hansen, Thomas E. 22
 Harding, Kelli J.R. 47
 Harding, Richard K. 97
 Hardy, Daniel W. 71
 Harker, Roy 92
 Harris, Gregory G. 47
 Harrow, Martin 26, 77
 Hart, Dionne A. 72
 Hartman, David E. 72
 Hartmann, Lawrence 47
 Harvey, Philip D. 5, 34, 42
 Hasin, Deborah S. 35, 61, 85
 Hassan, Nael 33
 Hatters-Friedman, Susan J. 29, 71
 Hauser, Peter 55, 100
 Hawryluck, Laura 100
 Heilig, Markus 55, 74, 88
 Heiman, Gary 35
 Heiman, Julia R. 76
 Helfand, Stacia 75
 Hellerstein, David J. 75
 Helzer, John E. 38
 Hen, Rene 62
 Henderson, David C. 67, 86
 Henderson, Gail 33
 Hendriksen, Mariëlle 8
 Hennessy, Grace 89
 Henning, Sass 53
 Henry, Joseph 51
 Hensley, Paula L. 76, 100
 Hepburn, Brian M. 71
 Herman, Judith L. 81
 Hermann, Richard C. 21, 72
 Herrman, Helen 57
 Heru, Alison M. 17, 53
 Herzog, Alfred 85
 Herzog, David B. 64
 Hesselbrock, Victor M. 63
 Hettinga, Nicolaas F. 88
 Heymsfield, Steven B. 57
 Hickling, Frederick W. 34
 Higgins, Jr., Napoleon B. 21, 77
 Hill, Darryl B. 51, 94
 Hilty, Donald M. 47

Hines, John K. 47
 Hingson, Ralph 39
 Hirdes, John P. 92
 Hirsch, Alan R. 72
 Hirschfeld, Robert M.A. 3, 26, 51, 67
 Hirshbein, Laura D. 71, 95
 Hirshberg, Laurence M. 68, 101
 Hoffman, Ellen J. 55
 Hogan, Michael F. 61
 Hoge, Charles W. 102
 Hoge, Steven K. 78, 87
 Hollander, Eric 45, 65
 Hollar, Milton C. 49
 Hollifield, Michael A. 77, 95, 99
 Hollingshead, Suzanne 29
 Hollins, Sheila 15, 53
 Hollon, Steven D. 38
 Hoos, David 32
 Home, Rob 51, 96
 Horton, Leslie 77
 Hostetter, Abram M. 22, 53
 Houghtalen, Rory P. 97
 Howells, Valerie L. 25
 Hsiung, Robert C. 23
 Huang, Suenia W. 54
 Huang, William 30
 Huang, Yu-Shu 96
 Hudziak, James J. 38, 66
 Huebner, Robert 78
 Hughes, Michael 29
 Hull, Steven 96
 Huppert, Jonathan D. 62
 Huremovic, Damir 29
 Hurford, Matthew O. 47
 Hurley, Robin A. 50, 99
 Husain, Nisba F. 71
 Husain, Syed A. 78
 Hwang, Michael Y. 34
 Hyman, Steven E. 62

I

Iftekhar, Ruksana 99
 Inderbitzin, Lawrence B. 54
 Ingenhoven, Theo 37
 Ingthorsdottir, A. 101
 Ioannou, Constantine 72
 Iosifescu, Dan V. 48, 51
 Iren Akbiyik, Derya 76, 96
 Isbey, Joanne M. 70
 Ishak, Waguih W. 48, 54
 Ismail, M. Saleem 10
 Isohanni, Matti K. 52, 75, 77, 95
 Israel, Joshua A. 1

J

Jackson, Juanita 75
 Jacob, Suma 71
 Jacobsen, Frederick M. 48
 Jacobsen, Leslie K. 36
 Jacobson, Sandra A. 40
 Jaffe, Ari B. 76
 Jain, Shaily 17
 Jang, Hee-Jeong 75
 Jang, Kerry L. 59
 Janicak, Philip G. 7, 59
 Janofsky, Jeffrey 25
 Januszewski, Andrea 40
 Javed, Afzal 79, 92
 Javitt, Daniel C. 39, 63, 66
 Jayaram, Geetha 19, 25, 55, 85, 96
 Jeammet, Philippe 81
 Jeste, Dilip V. 33, 58, 65, 69, 83
 Jha, Aruna 21

Jhee, Stanford 40
 Jiang, John G. 26
 Jicha, Gregory A. 9
 Jobe, Thomas H. 26
 Johannesen, Jan O. 62
 Johnson, Alisa 94
 Johnson, Bankole 80
 Jokelainen, Jari 77
 Jones, Kevin A. 63
 Jones, Peter B. 83
 Jorge, Ricardo E. 64
 Jorgenson, Linda M. 5, 54
 Josephson, Allan M. 35, 53, 91, 98
 Joukamaa, Matti 77
 Joy, Javed A. 71
 Judge, Sheila 44, 68
 Juthani, Nalini V. 71

K

Kahn, René S. 36
 Kajdasz, Daniel K. 28
 Kalin, Ned H. 6, 8
 Kane, John M. 8, 12, 90
 Kantajarvi, Liisa 77
 Kantor, Edward M. 21
 Kaplan, Allan S. 57
 Kaplan, Gabriel 40
 Kaplan, Gary B. 84
 Kaplan, Kalman J. 26
 Kapur, Shitij 8
 Karam, Elie G. 62
 Karlan, Pamela 63
 Karlawish, Jason 63
 Karnik, Niranjan S. 21, 50, 71, 93
 Kassirer, Jerome P. 81
 Kates, Nick 3, 78, 93
 Katon, Wayne J. 17, 59
 Katona, Cornelius 2
 Katz, Ira R. 28
 Katzelnick, David J. 83
 Kaufman, Joan 78
 Kaufman, Molly R. 93
 Kay, Jerald 29, 31
 Kaye, Walter H. 64
 Keashly, Loraleigh 58
 Keck, Jr., Paul E. 31
 Keefe, Richard S.E. 10, 30
 Keehan, Monique 33
 Keitner, Gabor I. 95
 Keller, Martin B. 9, 11
 Kellett, Kathy 96
 Kelly, Jr., Robert E. 82
 Kendler, Kenneth S. 100
 Kennedy, James A. 27
 Kennedy, Robert S. 80, 100
 Kennedy, Sidney H. 39, 65
 Kennedy, Susan E. 85
 Kent, Justine M. 11
 Kerr-Correa, Florence 51
 Kertzner, Robert M. 24, 88
 Kessler, Ronald 79
 Kestenbaum, Clarice J. 22
 Ketter, Terence A. 9, 43, 51
 Keyssar, Alexander 63
 Khan, Arif 55
 Khan, Yasir 51
 Kibour, Yeshashwork 34
 Kiley, Kevin C. 81
 Kiluvia, Moddy H. 72
 Kim, Chan-Hyung 75
 Kim, In-Young 75
 Kim, Jae-Jin 75
 Kim, Jin-Hun 75
 Kim, Kathy 27

PARTICIPANT INDEX

- Kim, Scott Y.....47
 Kim, Sun I.....75
 Kimaryo, Scholastica59
 King, Jean60
 King, Julie75
 Kingdon, David G.1, 22, 29, 75
 King-Hele, Sarah A.76
 Kingstone, Edward26, 51
 Kirch, Darrell G.....13, 72
 Kirsch, Debra F.47
 Kisely, Stephen R.....33
 Kishore, Anita R.....78
 Kissane, David W.....33
 Kleber, Herbert D.47, 61, 62
 Klein, Marcia34
 Klein, Tara29
 Kling, Mitchel A.91
 Kluft, Richard P.....44, 68
 Knickle, Kerry J.....97
 Knutson, James A.....26
 Kocsis, James H.....38
 Kogan, Richard30
 Kohn, Robert77, 99
 Kolla, Nathan J.....40
 Kollins, Scott66
 Kolodner, George47
 Koob, George F.88
 Kool, Simone8, 36, 37
 Koopman, Cheryl33, 102
 Koponen, Hannu J.....75, 95
 Koran, Lorin M.M.....87
 Kornstein, Susan G.....24
 Koskinen, Johanna95
 Kosten, Thomas R.....18, 80, 86
 Kowatch, Robert A.....71
 Koyanagi, Chad Y.....21
 Krack, Paul72
 Kraemer, Helena C.....2, 33
 Kramer, John63
 Kramer, Milton2, 92
 Kramer, Peter D.36, 81
 Kranzler, Henry R.....56
 Krasner, Ronald F.....27
 Kratochvil, Christopher J.66
 Kraus, Louis J.21
 Kring, Brunhild92
 Krishnan, K. Ranga R.....9, 89
 Krupa, Terry82
 Kryger, Meir8
 Krystal, Andrew D.....101
 Krystal, John H.42
 Ku, Jeonghun75
 Kubu, Cynthia64
 Kudler, Harold60, 99
 Kuechler, Thomas33
 Kunkel, Elisabeth J.S.54
 Kuo, Jack30
 Kuperman, Samuel63
 Kupfer, David J.2, 11, 23, 68
 Kurdoglu, Selvet96
 Kurien, Mary71
 Kusgozoglu, Tulin96
 Kushida, Clete A.....91
 Kussin, Dennis74
 Kyomen, Helen H.....35
- L**
- Laine, Pekka95
 Lake, James H.....102
 Lamb, H. Richard21
 Lamdan, Ruth M.....71
 Lammers, Jeffrey M.....78
 Lancee, William27
 Lancon, Christophe34
- Landa, Yulia22
 Lang, Anthony E.....72
 Lang, François81
 Langlieb, Alan28
 Lankford, Alan96
 Larsen, Tor K.62
 Laruelle, Marc80
 Lau, Adam82
 Lauronen, Erika52, 75, 95
 Lauterbach, Edward C.....11
 Lauterbach, Margo D.....71
 Law, David P.34
 Lawrence, Leslie E.....80
 Lawson, William3, 23, 74, 84, 99
 Lazare, Aaron30
 Lazarus, Arthur1, 7, 71, 75, 93
 Lazarus, Jeremy A.....54
 Le Nestour, Annick37, 77
 Leary, Kimberlyn93
 Leblanc, Gerard101, 102
 Leckman, James F.....98
 Lecours, Serge87
 Lederer, Benjamin D.....78
 Lee, Jr., James E.....79
 Lee, Kibeom59
 Lee, Matthias K.8
 Lee, Phil96
 Leeman, Eve63
 Leff, Steve87
 Lehmann, Laurent S.....60
 Leibenluft, Ellen71
 Leigh, Hoyle27, 78
 Lemelle, Stephanie97
 Lemire, Francine L.....93
 Lenze, Eric J.....2, 66, 69
 Lenzenweger, Mark F.....40
 Leonard, Sherry60
 Lerman, Caryn64
 Lerro, Marc64
 Lesage, Alain D.34, 60
 Leszcz, Molynd27, 33, 45
 Levenson, Alan I.22
 Leventhal, Liza94
 Levin, Frances R.....62, 97
 Levine, Jerome M.....76
 Levine, John B.82, 83
 Levine, Stephen B.....23, 69
 Levounis, Petros1, 23, 72
 Levy, Kenneth M.....56
 Lewis, Bradley E.....81
 Lewis, David A.....80
 Li, Eric C.21
 Li, T-K46
 Lian, Nityamo95
 Liberman, Robert P.....34
 Lidz, Charles W.....33
 Lieberman, Jeffrey A.....10, 30, 66, 80
 Light, Gregory A.....63
 Likhitsathian, Surinporn52
 Lin, Chieh-Hsin27
 Lin, Ching-Hua27
 Lin, Elizabeth H.B.....59
 Lindeman, Sari75
 Lindenmayer, Jean-Pierre35
 Links, Paul S.....40, 50, 60, 95
 Lipsitt, Don R.....78
 Lisanby, Sarah H.....40
 Liu, Linxu58
 Livesley, John18, 50, 59, 85
 Lo, Ted54
 Loas, Gwenolé81
 Loeb, Mark100
 Lofchy, Jodi S.....54
 Lopes, Fabiana L.....94
 Lopez, Frank A.....26
- Lopez, Lina M.29
 López-Ibor, Jr., Juan J.....53, 94
 Louie, Marie100
 Love, Anthony33
 Lowry, Amanda J.....26
 Loza, Nasser F.....33
 Lozano, Andres M.....72
 Lu, Francis G.....22, 28, 35, 48, 67, 87
 Luby, Joan L.....53
 Lugo, Raquel27, 71
 Lukasiewicz, Michael96
 Luna, Beatriz36
 Luo, John43, 55, 100
 Lusskin, Shari5, 22
 Luthra, Rohini83
 Lyketsos, Constantine10
 Lynch, Minda R.....36
 Lynn, David J.....27, 54, 71
- M**
- Mach, Michele3, 78
 Machado, Andre64
 Machado-Romero, Carlos A.....27
 Mack, Avram H.....28, 49, 71, 97
 MacQueen, Glenda M.....65
 Madianos, Michael G.....33
 Madras, Bertha K.....6
 Mahowald, Mark88
 Maki, Pirjo H.....75, 77, 95
 Malaspina, Dolores65
 Malaya, Liliya83
 Malhotra, Anil K.....3
 Mallinckrodt, Craig H.....26
 Mallios, Ronna27
 Malloy, Edward A.....73
 Malmquist, Carl P.....54
 Malone, Jr., Donald A.....64, 65
 Maltzberger, John T.....99
 Manchanda, Rahul52
 Mancho, Claudia27
 Mancini, Catherine94
 Manevitz, Alan Z.A.....92
 Mangurian, Christina V.....21, 97
 Manley, Myrl R.S.....84
 Mann, Karl F.....70
 Manring, John38
 Manschreck, Theo C.....48
 Manu, Peter78, 93
 Marangell, Lauren B.....91
 Marazziti, Donatella51
 March, John S.....94
 Marcus, Eric R.....22, 63
 Marder, Stephen R.....7, 17, 36, 90
 Marin, Humberto40, 100
 Markov, Dimitri D.....54, 92
 Marneros, Andreas83
 Martello, David76
 Martin, Janet A.....22
 Martínez, Adriana M.....27
 Martínez, James M.....91
 Martínez-Mantilla, Jorge A.....50
 Marx, Christine E.....23, 73, 85, 99
 Masand, Prakash S.....50, 66, 67, 75, 91
 Masi, Gabriele52
 Mason, Barbara J.....57, 88
 Mathalon, Daniel H.....63
 Matharu, Yogi54
 Mathew, Sanjay9
 Mathews, Maju82
 Mathews, Travis D.....23
 Matorin, Anu A.....29
 Matthews, Annette57, 100
 Mattos, Paulo E.....32
 Maunder, Robert27

- May, Alexis M.95
 May, J. Christopher.....64
 Mayer, Laurel57
 Mayman, Daniel95
 McBride, Carolina65
 McBride, Margaret51
 McCance-Katz, Elinore F.....86
 McCarthy, Gregory99
 McCartney, Cheryl F.....72
 McCommon, Benjamin H.....77
 McCutchen, Aila J.....52
 McDonald, William M.....31
 McDougall, Fiona83
 McDowell, David M.....49, 61, 62
 McElroy, Susan L.....60
 McEvoy, Joseph P.....10, 19, 22, 30, 75
 McFall, Miles60
 McGeer, Allison100
 McGlashan, Thomas H62, 63
 McGlinchey, Joseph76
 McGough, James J.....26
 McGrath, Patrick J.....76
 McGuire, Thomas87
 McHugo, Gregory J.....39
 McIntyre, Jack S.....10, 21, 53, 83, 97, 101
 McIntyre, Roger S.....89, 91
 McKinnon, Karen32
 McLain, Jennifer L.....48
 McLean, Andy45
 McLean, Diane E.....18
 McLellan, A. Thomas39, 89
 McMair, Shelley40
 McMullin, Melissa50
 McNaughton, Nancy L.....27, 45, 97
 Meaney, Michael78
 Melendez, Karen L.....48
 Melle, Ingrid62
 Melonas, Jacqueline M.....22, 30
 Meltzer, Carolyn C.....64
 Meltzer, Herbert Y.....19
 Meltzer-Brody, Samantha E.....37
 Mencl, W. Einar36
 Mendelsohn, Nathaniel75
 Meneses, Claudia27
 Menfi, Anita48
 Menvielle, Edgardo J.....51, 94
 Menza, Matthew A.....18, 76
 Merideth, Philip T.....28, 93
 Merrit-Davis, Orlena88
 Mestry, Kezziah32
 Mexal, Sharon60
 Meyers, Nicholas21
 Meyerson-Bernstein, Sami93
 Mezzasalma, Marco A.U.94
 Mezzich, Juan E.....15, 57
 Mian, Ayesha I.....29
 Michaeli, Danni Z.....54
 Michels, Robert44, 56, 68
 Michelson, David26
 Mick, Eric11
 Miettunen, Jouko52, 75, 95
 Millepiedi, Stefania52
 Miller, Claudia S.....20, 79
 Miller, Franklin G.....33
 Miller, Gary E.....97
 Miller, Ivan W.....95
 Miller, Michael M.....58
 Miller, Sheldon I.....97
 Miller, Tandy J.....63
 Millman, Robert B.....97
 Milone, Richard D.....47
 Milrod, Barbara L.....38
 Mindell, Jodi A.....8
 Mintzer, Jacobo E.....40
 Miranda, Raquel75
 Mischoulon, David26, 52, 86
 Mitchell III, James E.....64
 Mitchell, Paul94
 Mitnick, David A.....68, 101
 Miyasaki, Janis46
 Moeller, Hans-Juergen11, 36, 42
 Moilanen, Irma75
 Mojtabai, Ramin83
 Moller, Henry J.....98
 Molnar, Miklos Z.....59
 Montoya, Ivan D.....84
 Moon, Eliot26
 Moore, Constance51
 Moore, Norman C.....52, 96
 Moore, Scott D.....99
 Moos, Rudolf H.....52
 Moreno, Francisco A.....4
 Morey, Leslie C.....44
 Morey, Rajendra A.....99
 Morgan, Jessica C.....72
 Moro, Elena72
 Morrow, A. Leslie73
 Morrow, Joseph75
 Morse, Eric D.....33
 Mortensen, Preben B.....76
 Moses, Lou94
 Mosley, Habibah E.....48
 Moss, Howard B.....84
 Moss, Quinton E.....42
 Moss, Vanessa96
 Moyzis, Robert K.....64
 Mucci, Maria52
 Mucsi, Istvan59
 Mueser, Kim T.....39
 Mufti, Khalid A.....14, 33
 Mulder, Cornelis76
 Mulder, Wijnand88
 Müller, Thomas87
 Munich, Richard L.....82
 Munir, Farah73
 Munoz, Alicia A.....77
 Munoz, Rodrigo A.....38, 47, 53, 77, 79, 83, 99, 101
 Munro, Kali23
 Murakami, Jessica L.....94
 Murck, Harald26
 Murphy, Patricia E.....35
 Murray, Graham75
 Muskin, Matthew28, 93
 Muskin, Philip R.....17, 28, 47
 Musselman, Dominique L.....9
 Myers, Michael F.....21, 29, 54, 68, 92, 97
 Myers, Wade C.....28, 47
 Myrick, Hugh58
- N**
- Nace, David K.....21, 47, 68
 Nadal-Vicens, Mireya78
 Nadelson, Carol C.....22, 37
 Nagel, Tricia M.....77
 Nair, Vasavan N.....76
 Nakajima, Gene A.....88
 Nakama, Helenna62
 Nakhaei, Mohammad Reza27
 Nam, Junghyun75
 Nam, Theodore S.....102
 Nand, Surinder S.....21
 Napoli, Joseph C.....21, 43
 Naqvi, Syed S.A.....22, 29, 93, 97
 Narasimhan, Meera3, 20, 90, 97
 Nardi, Antonio E.....94
 Narrow, William E.....98
 Nascimento, Isabella94
 Naser, Jeffrey A.....86
 Nasrallah, Henry A.....41
 Nelson, J. Craig9
 Nemat, Ali54
 Nemeroff, Charles B.....6, 11
 Nestadt, Gerald98
 Neubauer, David N.....2
 Neuman, Joel H.....58
 Neustadter, Elana82
 Newcomer, John W.....5
 Newkirk, Cassandra F.....21, 47
 Newman, Alan W.....11
 Neziroglu, Fugen48
 Ng Ying Kin, Mien-Kwong76
 Ng, Anthony T.....8, 21, 79
 Nichols III, Alphonso28
 Niebler, Gwendolyn E.....74, 96
 Nierenberg, Andrew A.....26, 42, 48, 51, 76
 Nipper, Darlene53
 Njengy, Frank G.....33
 Noel, Richard L.....97
 Nofzinger, Eric A.....8
 Noordsy, Douglas34
 Nordfjord, W.....101
 Norko, Michael10
 Noroozian, Maryam53
 Norquist, Grayson93
 Norris, Donna M.....22, 86
 North, Carol S.....79
 Northcott, Colleen J.....28
 Notman, Malkah T.....54
 Notz, Ellen M.....97
 Novak, Marta59
 Nunes, Edward V.....62, 86
 Numberg, H. George76
 Numberger, Jr., John I.....63
 Nusselder, Hans88
 Nutche, Jeffrey76
 Nutt, David J.....43, 76
- O**
- Oakman, Jonathan94
 O'Brien, Charles P.....46, 55, 88
 O'Connor, Christopher M.....9
 O'Donovan, Claire M.....39
 Oele, Bastiaan L.....99
 Ogram, John D.....99
 Okasha, Tarek A.....23
 O'keefe-Wood, Linda J.....97
 Okorochoa, Gloria N.....55
 Okpaku, Joseph59
 Okpaku, Samuel O.....34, 59, 77, 84, 99
 Olarte, Silvia49
 Oldham, John M.....21, 44, 69
 Olmsted, Marion57
 Olympia, Josie L.....47
 O'Neal, Erica L.....72
 O'Neill, Patrick T.....27
 Ong, Elizabeth Q.....64
 Onyike, Chiadi34
 Opjordsmoen, Stein62
 Opler, Lewis A.....22, 34, 55
 Oquendo, Maria A.....40, 97
 O'Reardon, John P.....3, 59
 Ormston, Edward F.....48
 Orlowski, Barbara96
 Osby, Urban P.....52
 Oskarsson, Hogni101
 Oslin, David W.....64
 Osman, Ossama T.....95
 Ososky, Howard J.....79, 98
 Osser, David N.....48
 Ostermeyer, Britta71
 Otto-Salaj, Laura32
 Owens, Judith66
 Ozalp, Elvan51

PARTICIPANT INDEX

P

Page, Ann E.K.55
 Palaoglug, Ozden51
 Pallandi, Derek48
 Pallanti, Stefano87
 Palmer, Barton W.33
 Palmer, Brian A.84
 Palsson, S.P.101
 Pandya, Anand46, 100
 Pang, Deborah39
 Papakostas, George I.76, 89
 Pappas, Pamela A.102
 Pardo, Jose V.4
 Pare, Michael97
 Parham, Rhian51, 96
 Parides, Michael57
 Parikh, Rajesh M.86
 Parikh, Sagar V.2, 39
 Paris, Joel45, 60, 76
 Park, Sung-Hyounk75
 Patri, Mallika48
 Patel, Bindu N.39
 Patel, Malini71
 Patel, Shirish V.71
 Patry, Simon101
 Patten, Scott B.95
 Patterson, Beth94
 Patterson, Ellen54
 Paul, Robindra K.92
 Pava, Joel A.52
 Pecenak, Jan26
 Pedersen, Cort A.37
 Peele, Roger25, 48, 86
 Peen, Sr., Jaap88
 Pender, Jennifer D.28
 Pender, Maribeth51
 Perez, Edgardo L.25, 92
 Perez-Diaz, Fernando81
 Perkins, Diana O.36, 42, 80
 Perlis, Roy H.42, 76
 Perring, Christian D.81
 Perry, John C.87, 99
 Perugi, Giulio52
 Peselow, Eric D.29, 75, 94, 96
 Peteet, John R.35, 53, 91, 98
 Peterkin, Allan D.27, 45
 Petitjean, Francois34
 Petkova, Eva58
 Pham-Scottex, Alexandra81
 Pi, Edmond H.23
 Pickles, Andrew R.76
 Pierre, Joseph M.42
 Pierson, Jr., Richard N.57
 Piez, Deborah26, 95
 Pigott, Teresa A.26
 Pike, Kathleen M.57
 Pinals, Stephen35
 Pincus, Harold Alan46, 78
 Pinn, Vivian W.49
 Pinninti, Narisimha R.22
 Pittman, Mary72
 Plakun, Eric M.28, 44, 72, 78
 Pleak, Richard R.93
 Plopsky, Igor52
 Plovnick, Robert M.71
 Polcari, Ann M.37
 Pollock, Bruce G.61
 Poortinga, Earnest51
 Popma, Arne50
 Porjesz, Bernice63
 Posner, Kelly26
 Post, Jerrold M.38, 44
 Post, Robert M.101
 Potkin, Steven G.42

Powers, Pauline64
 Powsner, Seth M.78
 Prakash, Apurva26
 Prathikanti, Sudha102
 Pratt, Sarah35
 Pray, Jason54
 Price, Julie C.64
 Price, Marilyn22, 53, 101
 Prigerson, Holly G.100
 Primm, Annelie B.34, 47, 53, 72, 85, 99
 Prosser, James83
 Puchalski, Christina M.22, 35
 Pugh, Kenneth R.36
 Pulier, Myron L.40
 Pumariega, Andres J.29, 47
 Punzi, Silvia58
 Pynoos, Robert S.37

Q

Quanbeck, Cameron D.60
 Quitkin, Frederick M.76

R

Rabinowitz, Terry92
 Raboch, Jiri13, 53
 Rado, Jeffrey T.59
 Rae, Donald S.83
 Raichle, Marcus40
 Raja, Rekha54
 Ramirez, Paul M.55, 83
 Ramos, Gamaliel47
 Ramsay, J. Russell30, 79
 Randall, Carrie L.30
 Rank, Tim51, 96
 Rantakallio, Paula77
 Rao, Aruna S.77
 Rao, Nyapati R.29, 92
 Rapaport, Mark H.3, 19, 23, 31, 43
 Räsänen, Pirkko95
 Rasgon, Natalie L.3
 Raskin, Joel28
 Raskin, Sam93
 Rasmussen, Steven A.64
 Rataemane, Solomon34
 Rathod, Shanaya29, 75
 Ravindran, Arun V.92
 Ravitz, Paula1, 27, 45
 Rawson, Richard62
 Razavi, Maryam25, 86
 Read, Mary E.88
 Rebeck, Timothy64
 Rector, Neil A.72
 Recuperero, Patricia R.14, 53, 61
 Redelmeier, Donald46
 Rediger, Jeffrey D.102
 Reeves, James J.102
 Regent, Nicole29
 Regier, Darrel A.30, 38, 59, 83
 Reich, D. Bradford40
 Reich, James H.85
 Reich, Wendy63
 Reid, William H.7, 22
 Reifler, Burton V.23, 78
 Reimherr, Frederick W.26
 Reinblatt, Shauna P.93
 Reisberg, Barry58
 Renaud, Suzanne26
 Renner, Jr., John A.47
 Renshaw, Perry F.51
 Resendez, Cynthia I.28
 Reus, Victor I.78
 Reyes, Raymond M.97
 Reynaud, Michel96

Reynolds III, Charles F.64, 66, 100
 Rezaei, Ali R.64
 Rho, Yanni C.28
 Riba, Michelle B.19, 41, 47, 54, 72, 73, 84, 93
 Richards, Lawrence K.48
 Richardson, Don75
 Richeimer, Steven H.54
 Richelson, Elliott59
 Richman, Judith A.58
 Ridler, Khanum75
 Rigaud, Marie-Claude101
 Ring, Huijun Z.64
 Rinne, Thomas37
 Ritvo, Eva C.29
 Rivlin, Claire P.93
 Rizq, Diaa95
 Rizzo, Albert A.98
 Robbins, Trevor42, 87
 Roberto, Christina57
 Roberts, Esther P.71
 Roberts, Laura W.27, 47, 68
 Robertson, Brian M.87
 Robinowitz, Carolyn B.7, 22, 53, 72
 Robins, Lee N.38
 Robinson, Alexandra93
 Robinson, Delbert G.66
 Robinson, Gail E.5, 28, 54, 55, 84
 Robinson, Michael J.26
 Robinson, Rebecca L.52
 Robinson, Robert G.64
 Robison, Julie96
 Roca, Robert P.53
 Rodriguez-Abuin, Manuel J.51
 Rodriguez-Muñoz, Alfredo34
 Roehrs, Timothy A.101
 Roffman, Joshua25
 Rogoff, Jerome71
 Rohsenow, Damaris J.84
 Romine, Ann58
 Rondon, Marta B.55, 57
 Ronningstam, Elsa F.99
 Roose, Steven P.9, 38, 64
 Roozgar, Mozhddeh25
 Rosen, Cherise25, 77
 Rosenbaum, Jerrold F.26
 Rosenberg, Russell74
 Rosenbluth, Michael B.65
 Rosenfield, Paul J.64
 Rosenheck, Robert A.5, 11, 30
 Rosenthal, Richard N.70, 89
 Rosenzweig-Lipson, Sharon94
 Roskes, Erik J.21
 Ross, Heather25
 Ross, Stephen86
 Rosso, Isabelle M.36
 Rostain, Anthony L.30, 79
 Roth, Thomas34, 88
 Rothe, Eugenio M.77
 Rothenberg, Albert94
 Rothstein, David A.25, 38, 50
 Rowland, Melisa D.46
 Roy-Byrne, Peter P.17
 Rubin, Jeffrey64
 Rubio, Gabriel94
 Rubio-Stipec, Maritza27
 Rueda-Jaimes, German E.95
 Rueda-Sánchez, Mauricio95
 Ruelaz, Alicia R.4, 29
 Ruiz, Pedro10, 17, 23, 29, 41, 60, 79
 Rundell, James Ray R.79
 Rush, A. John42, 68, 89
 Rutherford, Bret R.38, 87
 Rutter, Joni L.64
 Ryan, Christine E.95

S

Saari, Kaisa	75
Saathoff, Gregory B.....	38
Sabri, Sufyan	95
Sachs, Gary S.....	2, 51
Sadee, Wolfgang	64
Saeed, Sy A.....	1, 71
Safer, Daniel J.....	82
Sahakian, Barbara	87
Sailasuta, Napapon	62
Sakinofsky, Isaac	60
Salary, Cheryl Y.....	71
Salomon, Anat	92
Salzer, Alicia J.....	92
Salzman, Carl	65
Sanchez, Francis M.....	47
Sanchez, Manuel O.....	51
Sanders, Hans.....	88
Sandfort, Theodorus G.M.....	77
Sano, Mary	39, 58
Satcher, David	6
Saxe, Glenn N.....	83
Saxena, Sanjaya	98
Scasta, David L.....	92
Schatzberg, Alan F.....	9, 15, 20, 26, 31, 59, 67
Scheiber, Stephen C.....	23, 78
Scher, Christine D.....	27
Schiffer, Randolph B.....	3, 11
Schlesinger, Abigail B.....	47
Schmidt, Jr., Chester W.....	21, 54, 68
Schneider, Lon S.....	65
Schneider, Richard D.....	48
Schoevers, Robert A.....	8, 37, 61
Schroeder, Katrin	52
Schuckit, Marc A.....	61, 63
Schulz, S. Charles	36, 58
Schupf, Nicole	39
Schwab-Stone, Mary	70
Schwartz, Bruce J.....	21
Schwartz, George	76
Schwartz, Joseph M.....	93
Schwarzkopf, Steven B.....	63
Scott, Marcia	101
Scott, Naksia G.....	53, 71
Scully, Jr., James H.....	7, 23
Sederer, Lloyd I.....	83
Seeman, Mary V.....	75
Seidler, Aura R.....	96
Seidman, Larry J.....	6
Seitz, Dallas P.....	95
Seligman, Roslyn	45
Semeniuk, Trent	87
Sermons-Ward, Lydia	47
Shack, Jonathan G.....	71
Shaffer, David	55
Shapiro, Colin M.....	59
Shapiro, Edward R.....	44, 72, 78
Shapiro, Colin M.....	59
Sharfstein, Steven S.....	7, 10, 17, 32, 41, 57, 81
Sharfiat, Sayed Vahid.....	53
Sharkey, John	29
Sharp, Carla	51
Shaw, Jon A.....	29
Shear, M. Katherine	38, 68, 100
Shear, Shoshana L.....	93
Sheehan, David V.....	17, 31, 43, 76
Sheridan, Robert L.....	83
Shields, Peter	64
Shihabuddin, Lina S.....	28
Shiner, Rebecca L.....	59
Shinfuku, Naotaka	79
Shivers, Tony B.....	54
Shrikhande, Aditi M.....	72
Shulman, Robert B.....	26, 52, 94
Shurtleff, David	64
Sica, Kristin	94
Siegel, Glenn N.....	72
Siegel, Richard L.....	76
Siever, Larry J.....	85
Silk, Kenneth	40, 76, 94
Silva, Susan	94
Silver, Ivan	22
Silveri, Marisa M.....	36
Silverman, Joel J.....	54
Silverman, Morton M.....	102
Silverman, Wayne	39
Simon, Gregory E.....	59
Simons, Anne	94
Simonsen, Erik	62
Simpson, Sherri M.....	20, 93
Singareddy, Ravi K.....	34, 88
Singh, Bruce	78, 79
Sinha, Prii	102
Skodol II, Andrew E.....	44
Slaby, Andrew E.....	92
Small, Gary W.....	58
Smit, Filip	61
Smith, Graeme C.....	33
Smith, Mary K.....	77
Smith, Trevor F.....	92
Sneed, Joel R.....	64
Snihurowych, Roman	19
Soloff, Paul H.....	76
Solomon, David A.....	95
Sommer, Tobias	52
Sonawalla, Shamsah B.....	86
Sood, Aradhana B.....	29
Soong, Wei-Tsuen	96
Sorel, Eliot	53
Sorrentino, Renee M.....	29, 48, 71
Sowers, Wesley E.....	81
Soygur, Haldun	51, 96
Speanburg, Stefanie	87
Spencer, Thomas J.....	6
Speranza, Mario	81
Spiegel, David	1, 30, 33
Spindler, Evangeline J.....	77
Spitz, Deborah	71
Spitz, Henry I.....	96
Spritz, Melanie E.....	97
Srabstein, Jorge C.....	58
Srinivasan, Krishnamachari	19
Srinivasaraghavan, Jagannathan	29, 47, 71, 78, 92
Srisurapanont, Manit	52
Stahl, Stephen M.....	6, 67, 91
Stanford, Laurence R.....	36
Stanford, Sharon B.....	6
Stankowski, Joy E.....	29, 71
Stanley, Barbara H.....	102
Stanley, Melinda	82
Steenbarger, Brett	82
Steenfeldt-Foss, Otto	57
Stefanek, Michael	33
Steffens, David C.....	9, 64
Steiger, Howard	76
Stein, Bradley D.....	46
Stein, Dan J.....	58, 68
Stein, Murray B.....	6, 21, 27
Steiner, Hans	50, 93
Stenger, V. Andrew	62
Stern, Harriet C.....	47
Stewart, Altha J.....	33, 56, 85
Stewart, Deborah C.....	27
Stewart, Donna E.....	19, 25, 41, 45, 89
Stewart, Jonathan T.....	97
Stewart, Jonathan W.....	76
Stewart, Stephanie M.....	22, 29, 54
Stinson, Frederick S.....	35, 85
Stoddard, Jr., Frederick J.....	82, 83
Stolar, Andrea G.....	101
Stone, Alan A.....	81
Stone, Michael H.....	99
Stotland, Nada L.....	49, 85
Stovall-Mcclough, Chase	81
Stowell, Keith R.....	98
Strain, Eric C.....	18, 47, 55
Straus, Joshua	68
Strauss, Jennifer L.....	37, 60
Strauss, John S.....	82
Streltzer, Jon M.....	78
Strik, Werner	87
Stroup, Thomas S.....	10, 80
Stuart, Scott P.....	1, 38, 82
Stubbe, Dorothy E.....	78
Stuck, Craig A.....	35, 97
Stunkard, Albert J.....	64
Styra, Rima	100
Suarez, Raymond E.....	78, 93
Suchinsky, Richard T.....	46
Sudak, Donna M.....	54
Sugden, Steve	47
Sullivan, Patrick F.....	80
Summers, Alan L.....	22
Summer, Calvin R.....	92
Sunderland, Trey	30, 40, 58
Surman, Craig B.H.....	42
Susser, Ezra S.....	33, 83
Suzuki, David T.....	20
Sverd, Jeffrey	94
Swartz, Conrad M.....	75
Swartz, Holly A.....	2
Swartz, Mamina	52
Swartz, Marvin S.....	89
Swift, Robert M.....	48, 84, 86
Swindle, Ralph W.....	52
Sysko, Robyn	58
Szarek, Bonnie L.....	28, 75
Szarfman, Ana	55
Szigethy, Eva M.....	30, 78
Szulc, Agata	26

T

Taanila, Anja	75
Taber, Katherine H.....	99
Tahilani, Kavita K.....	64
Taintor, Zebulon C.....	12, 22, 37, 46, 71
Talbott, John A.....	34
Tamminga, Carol A.....	3
Tan, Adrienne O.....	52
Tandon, Rajiv	7, 26
Tariot, Pierre N.....	10
Taylor, Robyn	98
Taylor, Warren D.....	66
Teicher, Martin H.....	37
Tekell, Janet L.....	51
Tellier, Claude	76
Temple, Scott	22
Tesar, George E.....	64
Thase, Michael E.....	8, 11, 38, 42
Théberge, Jean	52
Thibodeau, Nicole	102
Thielman, Samuel B.....	98
Thombs, Brett D.....	27
Thompson Fullilove, Mindy	49
Thompson, Ann	34
Thompson, Carolyn	77
Thompson, Sarah J.....	52
Thongdy, Tavi	76
Thornhill IV, Joshua T.....	71
Tidey, Jennifer W.....	84
Tillman, Jane G.....	78
Titus-Villedrouin, Mary	34
Tomoda, Akemi	37

PARTICIPANT INDEX

Toneatto, Tony	37
Tong, Lowell D.	71, 84
Toni, Cristina	52
Tracy, Martin G.	22, 48
Treisman, Glenn J.	42, 100
Trinh, Nhi-Hà T.	28
Trinidad, Anton C.	27, 36, 44
Triplett, Patrick T.	85
Trivedi, Harsh K.	54
Trivedi, Madhukar H.	9, 17, 43, 83
Tsai, Guochuan E.	35
Tsai, Kuan-Yi	53
Tschan, Werner	54, 84
Tseng, Li-Jung	76
Tucker, Terrie	92
Tuerk, Catherine	51
Tuinebreijer, Willem C.	99
Tulving, Endel	40
Turecki, Gustavo	60
Turhan, Levent	51
Turkel, Ann R.	63
Turkington, Douglas	1, 29, 72, 75, 93
Turnbow, John M.	26
Twemlow, Stuart W.	92
Tyndale, Rachel	64
Tyrka, Audrey R.	9

U

Uhde, Thomas W.	34, 88, 101
Upshall, Phil	93
Urbaitis, John C.	86, 93
Ursano, Amy	24
Ursano, Robert J.	79, 98

V

Vaglum, Per	62
Vahia, Ipsit	83
Valenca, Alexandre M.	94
Valente, Elizabeth	37
Valmaggia, Angel	60
Van Ameringen, Michael	94
Van Den Berg, Henk	72
Van der Kolk, Bessel A.	37, 81
Van Tilburg, Willem	14, 61
Van Zyl, Louis T.	95
Van, Henricus L.	8, 37
Vanderpool, Donna	48
Vangel, Mark	52
Varma, Vijoy	83
Vasa, Monisha R.	29, 54, 72
Vaswani, Meera	53, 75, 96
Veijola, Juha M.	52, 75, 77
Vela-Bueno, Antonio	34, 101
Velazquez, Maria A.	99
Velligan, Dawn I.	42
Venisse, Jean-Luc	81
Vergare, Michael J.	54
Vgontzas, Alexandros	34, 101
Victor, Lisa	54
Victoroff, Jeff	38
Vieta, Eduard	22, 91
Vijayakumar, Lakshmi	78
Vince, Bradley D.	96
Vito, Jose P.	23, 54, 93
Vocci, Frank	62, 84
Vogel-Scibilia, Suzanne E.	100
Volkow, Nora D.	6, 14, 62
Volman, Susan F.	60
Volpp, Serena Y.	77
Von Korff, Michael	59
Voon, Valerie	72
Vorono, Sienna	77

W

Waddell, Andrea E.	48, 54, 93
Waggoner, William	53
Wagner, Angela	64
Wagner, Karen D.	3
Wahlstrom, Jr., Carl M.	72
Wain, Harold J.	102
Wainberg, Milton L.	28, 32, 62
Wainscott, Cynthia	55
Waldbaum, Marjorie E.	72
Waldman, Amy	38
Walick, David J.	78
Walker, Edward A.	27
Walker, Sandra C.	49, 79, 93
Walsh, B. Timothy	57, 58
Walsh, Elizabeth	60
Wang, Jack	57
Wapenyi, Khakasa H.	28
Warner, Teddy	95
Warnock, Julia K.	76
Warshaw, Carole	32
Washam, Terry C.	61
Washington, LaShondra T.	77
Waterman, G. Scott	38, 81
Watson, Darryl P.	25
Watson, David	85
Webb, Roger T.	76
Weerasekera, Priyanthy	38
Wei, Gwo-Jen	27
Weiden, Peter J.	22, 42
Weinberger, Daniel R.	42, 67
Weine, Stevan M.	38
Weiner, Elyse D.	29
Weinstein, Henry C.	21, 37
Weisberg, Risa B.	6
Weiss, Roger D.	48, 86
Weisser, Lydia E.	71
Wells, Kenneth B.	20
Welsh, Christopher J.	1, 72
Wernert III, John J.	53
Wesnes, Keith	74
Wesson, Virginia A.	95
West, Sara G.	95
Westen, Drew	44, 56
Westerveld, Michael	36
Westreich, Ruta	87
White III, O.C.	79
Wick, Paul H.	47
Widiger, Thomas A.	59
Wiegand, Ryan	63
Wigal, Sharon B.	26, 42
Wilens, Timothy E.	42, 66, 84
Wilkins, Jeffery N.	30
Wilkinson, David	9
Willenbring, Mark L.	22, 25, 39, 55, 58, 78
Williams, Adedapo B.	82
Williams, Caroline B.	96
Williams, Eric R.	77
Williams, Jill	84
Williamson, Kathryn E.	52
Williamson, Peter C.	52
Winkelman, John W.	67, 91
Winstead, Daniel K.	23
Wise, M.E. Jan	29
Wisner, Katherine L.	23
Woelwer, Wolfgang	36
Wohreich, Madelaine M.	26, 47
Wolf, Mary K.	54
Wonderlich, Stephen A.	64
Wong, Jiahui	27
Wong, Philip	94
Wonodi, Ikwunga	34
Wood, William C.	7, 53
Woods, Scott W.	39, 62, 63

Woodside, Blake	57
Woodward, Steve H.	88
Woolley, Stephen B.	26, 95
Wright III, Jesse H.	1, 8, 19, 32, 54, 93
Wright, Harry H.	53, 79
Wright, Tara	55
Wurtman, Judith	52
Wurtman, Richard	52

X

Xia, Guohua	91
Xu, Jimmy Y.	28

Y

Yacubian, Juliana	52
Yager, Joel	1, 22, 23, 64, 97
Yamada, David	58
Yang, Ronguha	26
Yap, Liang	52
Yaroslavsky, Yury	88
Yaryura-Tobias, Jose A.	48
Yatham, Lakshmi N.	39
Yehuda, Rachel	62
Yeung, Albert	77, 86
Yeung, Paul	94
Yim, Seonjin	75
Yonkers, Kimberly A.	50
Young, Alveth J.	28
Young, Keith W.	48, 54, 61
Young, Robert C.	35
Yudofsky, Stuart C.	17, 43, 80
Yue, Kenneth	62
Yum, Sun Young	34
Yurgelun-Todd, Deborah A.	36

Z

Zajacka, John M.	26
Zammit, Gary	74
Zanarini, Mary C.	40
Zaretsky, Ari E.	18, 54
Zdanowicz, Mary	72
Zeanah, Jr., Charles H.	78
Zee, Phyllis C.	2, 11
Zelnik, Thomas C.	25
Zepp, Henri	76
Zerbe, Kathryn J.	64
Ziedonis, Douglas M.	58, 70, 84
Ziegelstein, Roy C.	27
Zigman, Warren B.	39
Zimmerman, Mark	76
Zisook, Sidney	100
Zohar, Joseph	87
Zolovska, Beata A.	92
Zonana, Howard V.	78, 81
Zubieta, Jon-Kar	85
Zweben, Allen	48
Zweig-Frank, Hallie	76




Institute on
Psychiatric
Services

APA's Leading Educational
Conference on Public and
Community Psychiatry

Start Spreading The News...

October 5-8, 2006 • New York, NY


TRAUMA AND VIOLENCE IN OUR COMMUNITIES



Save the date now to attend the American Psychiatric Association's 58th Institute on Psychiatric Services, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness.

This four-day event will feature more than 100 exhibits that complement the educational program, popular networking events, and over 200 expertly-led educational sessions on topics including:

Violence, Trauma, and Victimization; Social and Community Psychiatry; Psychopharmacology; Resident and Medical Student Concerns; Substance Abuse; Child and Adolescent Issues; AIDS and HIV Related Disorders; Cross-Cultural and Minority Issues; Psychiatric Administration and Services; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia and Other Psychotic Disorders; and much more.....



Who Should Attend?

- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector including state and Veterans Affairs hospitals, community clinics, and jails and prisons
- Psychiatric Administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents (only \$60 for advance registration)
- Nonmember Residents and Advocacy Group Members (only \$85 for advance registration)
- Medical Students (free registration); and
- Consumers interested in recovery issues

Why Should You Attend?

- Earn up to 40 hours of category 1 CME credit
- Receive a 40% discount on APA member registration fees
- Network with colleagues at receptions and other events
- Industry-supported lunch and dinner symposia
- Valuable exhibit hall prizes drawn each day
- Visit New York City's fabulous restaurants, theaters, museums, and shopping!

How Will You Benefit?

- Learn about the latest updates and acquire new skills in clinical psychiatry, that can be utilized to improve patient care;
- Acquire a deeper understanding of how the current health care system affects patient care;
- Demonstrate and apply new skills useful in clinical and public psychiatry settings;
- Recognize and improve mental health disparities in the community;
- Understand all aspects of recovery and how this affects families and the community; and
- Learn to diagnose and treat victims of trauma and violence in the community.

The Preliminary Program, which includes registration, housing, and travel information will be available in May at www.psych.org/2006IPS or call 1-888-35-PSYCH and request a copy.

Online registration will begin on June 1.

For more information, please contact:

American Psychiatric Association

1000 Wilson Blvd., Suite 1825

Arlington, VA 22209-3901

Phone: 1-888- 35-PSYCH or (703) 907-7300

Fax: (703) 907-1090

E-mail: apa@psych.org

Web: www.psych.org/2006IPS

THE FIRST AND LAST

APPI BOOKSTORE AT THE 2006 APA ANNUAL MEETING IN TORONTO!

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online—including PsychiatryOnline.com.

The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss Author Book Signings or discounts for APA Members—see you there!

APPI Bookstore Hours during the 2006 APA Annual Meeting

Saturday, May 20	10:00 am-5:00 pm
Sunday, May 21	10:00 am-4:30 pm
Monday, May 22	10:00 am-5:30 pm
Tuesday, May 23	10:00 am-6:00 pm
Wednesday, May 24	10:00 am-3:00 pm



The American Psychiatric Publishing Textbook of Mood Disorders

Edited by Dan J. Stein, M.D., Ph.D., David J. Kupfer, M.D., and Alan F. Schatzberg, M.D.

2006 • 792 pages • ISBN 1-58562-151-X • Hardcover
\$119.00 • Item #62151



Learning Cognitive-Behavior Therapy An Illustrated Guide Core Competencies in Psychotherapy

Jesse H. Wright, M.D., Ph.D., Monica R. Basco, Ph.D., and Michael E. Thase, M.D.
Glen O. Gabbard, M.D., Series Editor


2006 • 316 pages • ISBN 1-58562-153-6 • Paperback
\$49.00 • Item #62153



Infant and Early Childhood Mental Health A Comprehensive Developmental Approach to Assessment and Intervention

Stanley I. Greenspan, M.D., and Serena Wieder, Ph.D.

2006 • 398 pages • ISBN 1-58562-164-1 • Paperback
\$43.95 • Item #62164



Essentials of Clinical Psychopharmacology, Second Edition

Edited by Alan F. Schatzberg, M.D., and Charles B. Nemeroff, M.D., Ph.D.

2006 • 848 pages • ISBN 1-58562-243-5 • Paperback
\$99.00 • Item #62243



The American Psychiatric Publishing Textbook of Schizophrenia

Edited by Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H., and Diana O. Perkins, M.D., M.P.H.


2006 • 464 pages • ISBN 1-58562-191-9 • Hardcover
\$95.00 • Item #62191



Essentials of Child and Adolescent Psychiatry

Edited by Mina K. Dulcan, M.D., and Jerry M. Wiener, M.D.

2006 • 720 pages • ISBN 1-58562-217-6 • Paperback
\$85.00 • Item #62217



The American Psychiatric Publishing Textbook of Suicide Assessment and Management

Edited by Robert I. Simon, M.D., and Robert E. Hales, M.D., M.B.A.

2006 • 688 pages • ISBN 1-58562-213-3 • Hardcover
\$85.00 • Item #62213

American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2006

American Psychiatric Association

2006 • 1,700 pages • ISBN 0-89042-383-0 • Hardcover • \$89.00 • Item #2383
2006 • 1,700 pages • ISBN 0-89042-385-7 • Paperback • \$72.00 • Item #2385

Quick Reference to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2006

American Psychiatric Association

2006 • 275 pages • ISBN 0-89042-382-2 • Paperback
\$36.95 • Item #2382

American
Psychiatric
Publishing, Inc.

The *First and Last Word* in Psychiatry
American Psychiatric Publishing, Inc.
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901

Phone: 703-907-7322 or 1-800-368-5777 • Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1091 Email: appi@psych.org Web: www.appi.org

Please reference priority code AP631 when ordering

WORD IN PSYCHIATRY

JANUARY

Coping With Depression From Catch-22 to Hope

Jon G. Allen, Ph.D.

2006 • 341 pages • ISBN 1-58562-211-7 • Paperback
\$29.95 • Item #62211

Psychotherapy for Borderline Personality

Focusing on Object Relations

John F. Clarkin, Ph.D., Frank E. Yeomans, M.D., Ph.D., and Otto F. Kernberg, M.D.

2006 • 411 pages • ISBN 1-58562-210-9 • Hardcover
\$55.00 • Item #62210

Personality-Disordered Patients Treatable and Untreatable

Michael H. Stone, M.D.

2006 • 277 pages • ISBN 1-58562-172-2 • Paperback
\$42.00 • Item #62172

FEBRUARY

Pocket Guideline for the Assessment and Treatment of Major Depressive Disorder

American Psychiatric Association

2006 • ISBN 0-89042-384-9 • Pamphlet
\$14.95 • Item #2384
SET of 5: \$49.95 • Item #5095

Handbook of Medicine in Psychiatry

Edited by Peter Manu, M.D., Raymond E. Suarez, M.D., and Barbara J. Barnett, M.D.

2006 • 640 pages • ISBN 1-58562-182-X • Paperback
\$69.00 • Item #62182

MARCH

Homicide

A Psychiatric Perspective, Second Edition

Carl P. Malmquist, M.D., M.S.

2006 • 432 pages • ISBN 1-58562-204-4 • Paperback
\$49.00 • Item #62204

Concise Guide to Psychopharmacology, Second Edition

Lauren B. Marangell, M.D., and

James M. Martinez, M.D.

2006 • 304 pages • ISBN 1-58562-255-9 • Paperback
\$37.95 • Item #62255

APRIL

Study Guide to Geriatric Psychiatry

A Companion to the American Psychiatric Publishing Textbook of Geriatric Psychiatry, Third Edition

Lloyd Benjamin, M.D., James A. Bourgeois, O.D., M.D., Narriman C. Shahrokh, and Dan G. Blazer, M.D., Ph.D.

2006 • 178 pages • ISBN 1-58562-263-X • Paperback
\$29.95 • Item #62263

Study Guide to Neuropsychiatry and Clinical Neurosciences

A Companion to The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences, Fourth Edition

James A. Bourgeois, O.D., M.D., Narriman C. Shahrokh, Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.

2006 • 200 pages • ISBN 1-58562-259-1 • Paperback
\$29.95 • Item #62259

Contemporary Psychoanalysis in America

Leading Analysts Present Their Work

Edited by Arnold M. Cooper, M.D.

2006 • 768 pages • ISBN 1-58562-232-X • Hardcover
\$65.00 • Item #62232

Study Guide to Child and Adolescent Psychiatry

A Companion to The American Psychiatric Publishing Textbook of Child and Adolescent Psychiatry, Third Edition

Stephen J. Cozza, M.D., Robert E. Hales, M.D., M.B.A., and Narriman C. Shahrokh

2006 • 223 pages • ISBN 1-58562-261-3 • Paperback
\$29.95 • Item #62261

Study Guide to Clinical Psychiatry

A Companion to The American Psychiatric Publishing Textbook of Clinical Psychiatry, Fourth Edition

Donald M. Hilty, M.D., James A. Bourgeois, O.D., M.D., and Robert E. Hales, M.D., M.B.A.

2006 • 155 pages • ISBN 1-58562-260-5 • Paperback
\$29.95 • Item #62260

Clinical Manual of Cultural Psychiatry

Edited by Russell F. Lim, M.D.

2006 • 368 pages • ISBN 1-58562-256-7 • Paperback
\$46.00 • Item #62256

Study Guide to Substance Abuse Treatment

A Companion to The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Third Edition

Stephen Ross, M.D., and Francis Hayden, M.D.

2006 • 233 pages • ISBN 1-58562-262-1 • Paperback
\$29.95 • Item #62262

Study Guide to Forensic Psychiatry

A Companion to The American Psychiatric Publishing Textbook of Forensic Psychiatry

Robert I. Simon, M.D., and Liza H. Gold, M.D.

2006 • 132 pages • ISBN 1-58562-264-8 • Paperback
\$29.95 • Item #62264

MAY

Understanding and Treating Adults With Attention Deficit Hyperactivity Disorder

Brian B. Doyle, M.D.

2006 • 400 pages • ISBN 1-58562-221-4 • Paperback
\$47.00 • Item #62221

Bipolar Depression

A Comprehensive Guide

Edited by Rif S. El-Mallakh, M.D., and S. Nassir Ghaemi, M.D.

2006 • 304 pages • ISBN 1-58562-171-4 • Paperback
\$46.00 • Item #62171

Clinical Manual of Geriatric Psychiatry

James E. Spar, M.D., and Asenath La Rue, Ph.D.

2006 • 464 pages • ISBN 1-58562-195-1 • Paperback
\$48.00 • Item #62195

PsychiatryOnline.com—a state-of-the-art website offering access to the most trusted and reliable psychiatric references for patient diagnosis, treatment, research, and professional development and lifelong learning, including DSM-IV-TR® and *American Journal of Psychiatry*. Featuring search, navigation, and cross-referencing tools custom-designed for psychiatrists. Subscribe now at www.psychiatryonline.com. See demo at APPI Bookstore.



American Psychiatric Foundation
Advancing public understanding of mental illnesses

EDUCATION. ENTERTAINMENT. PHILANTHROPY.

**Join the American Psychiatric Foundation for four special events at the
2006 APA Annual Meeting.**

2006 Annual Benefit "Toronto Tapestry"

Saturday, May 20, 2006
7:00 – 10:00 p.m.
The Royal Ontario Museum
100 Queen's Park
Toronto, Ontario

You are invited to an exciting special evening featuring the Royal Ontario Museum's historic art collections, a menu of eclectic and delicious international cuisine, live music and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation's programs that advance public understanding that mental illnesses are real and treatable.

Tickets:

\$100 USD per person if purchased by April 1 or \$125 USD per person thereafter. To order tickets, please call (703) 907-8512 or visit www.psychfoundation.org.

Supported By:



Abbott Laboratories

Cyberonics, Inc.

Forest Laboratories, Inc.

Otsuka America Pharmaceutical, Inc.

Professional Risk Management Services, Inc.


Takeda Pharmaceuticals North America, Inc.

"Conversations" featuring Mariel Hemingway



Tuesday, May 23, 2006 - 5:30 – 6:30 p.m.
Hall A of the Toronto Convention Center
Open to all annual meeting attendees

Don't miss our 5th annual "Conversations" event, an interactive series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Mariel Hemingway, a successful model, actress, author and mother, will be our guest. Hemingway will discuss her family connection with mental illness and its impact on future generations.

Supported by an unrestricted educational grant from:  AstraZeneca
life inspiring ideas

Take Me Out to the Ball Game

Tuesday, May 23, 2006 – 7:00 p.m. \$22 CAD per ticket (\$7 to the foundation) – Ticket value of \$29
Wednesday May 24, 2006 – 7:00 p.m. \$30 CAD per ticket (\$10 to the foundation) – Ticket value of \$39

Enjoy a spring evening at the ball park (directly across from the convention center) while supporting the philanthropic work of the foundation. First-rate, field level baseline tickets are available for two Toronto Blue Jays vs. the Tampa Bay Devil Rays games through a special discount offer. A portion of each ticket sold is contributed to the foundation. To order tickets, call Harry Einbinder at (888) 654-6529 ext.1666 or harry.einbinder@bluejays.com. For a seating chart and order form, visit www.psychfoundation.org.

Golfers of the APA 2006 Annual Golf Tournament

Monday, May 22, 2006
7:30 a.m. with a shotgun start
Angus Glen Golf Club

Enjoy friendly competition and 18 holes of golf at the north course of Angus Glen, site of the 2007 Canadian Open. \$250 USD includes transportation, greens fees, carts and prizes. All event proceeds will benefit the foundation. For more information on the course, visit www.angusglen.com. To enter the tournament, contact Stan Jennings at mbears@comcast.net or (804) 320-7881.



American Psychiatric Association – 160th Annual Meeting
 May 19-24, 2007
 San Diego, CA

CALL FOR PAPERS

PRESIDENT'S THEME:

Addressing Patient Needs: Access, Parity, and Humane Care

Pedro Ruiz, M.D.
 President

Marian I. Butterfield, M.D., Chairperson
 Scientific Program Committee

THE SUBMISSION SCHEDULE

Format	Deadline
Industry-Supported Symposia	June 2, 2006
Courses	September 10, 2006
Reports	September 10, 2006
Symposia	
Chair deadline:	September 6, 2006 (no new submissions accepted after this date)
Author deadline:	September 10, 2006 (deadline to complete all information)
Workshops	
Issue & Media:	September 10, 2006
Component:	September 24, 2006
New Research	December 11, 2006

***Submissions can only be made and accepted online by visiting www.psych.org.
 Click on the Annual Meeting logo, then click on the submission box.
 Feel free to contact the APA toll free at 1-888-357-7924
 to speak directly with an Answer Center Coordinator.***

Paper submissions, as well as incomplete submissions, will not be accepted or considered.

If you would like to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

INDUSTRY-SUPPORTED SYMPOSIUM 1
 Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
 Toronto Convention Centre, North Level 100, Room 102


TO BE HELD AT THE
 APA 2006 ANNUAL MEETING

NEW AUGMENTATION STRATEGIES IN DEPRESSION FOR BETTER OUTCOMES

SATURDAY, MAY 20

12-12:30 PM LUNCH • 12:30-3:30 PM CLINICAL PROGRAM
 TORONTO CONVENTION CENTRE • JOHN BASSETT THEATRE, NORTH BUILDING, LEVEL 100

A FIVE-MINUTE Q&A IS INCLUDED AT THE END OF EACH PRESENTATION.



EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, the participant should be able to: discuss polypharmacy in the treatment of depression, recruit up-to-date approaches to manage common antidepressant side effects, address residual symptoms; construct a treatment plan for resistant depression, and incorporate evolving knowledge on adding psychotherapy to pharmacotherapy to optimize treatment outcome.

Introduction Jonathan E. Alpert, MD, PhD Symposium Chair & Speaker	12:30 PM	Pharmacological Antidotes for Antidepressant-Induced Side Effects Anita H. Clayton, MD University of Virginia Health System	2:40 PM
Polypharmacy for Depression: How Often Is It Used and Why? Joshua A. Israel, MD University of California San Francisco	12:40 PM	Question & Answer Session	3:10 PM
"How To" Augmentation Strategies in Resistant Depression Charles DeBattista, DMH, MD Stanford University School of Medicine	1:10 PM	Program Concludes	3:30 PM
When Does Polypharmacy Lead to Higher Remission Rates? Jonathan E. Alpert, MD, PhD Harvard Medical School	1:40 PM		
Adding Psychotherapy: Pearls for Improved Outcomes Amy H. Farabaugh, PhD Massachusetts General Hospital	2:10 PM		



Sponsored by the American Psychiatric Association.
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Supported by an educational grant from GlaxoSmithKline

INDUSTRY-SUPPORTED SYMPOSIUM 2
 Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
 Royal York, Convention Floor, Canadian Room

MAINTAINING WELLNESS IN PATIENTS WITH BIPOLAR DISORDER MOVING BEYOND EFFICACY TO EFFECTIVENESS

DATE: SATURDAY, MAY 20TH TIME: 12:30 PM - 3:30 PM ACTIVITY CHAIRPERSON: GARY SACHS, MD
 THE FAIRMONT ROYAL YORK - CANADIAN ROOM - TORONTO, CANADA

PROGRAM OVERVIEW

Bipolar disorder is commonly misdiagnosed as unipolar depression because patients more often present with depressive rather than manic symptoms. Furthermore, comorbidities such as general anxiety and substance abuse are frequently present in this patient population and further contribute to misdiagnosis. Proper diagnosis is the first, but certainly not the only, obstacle to achieving desired outcomes in patients with bipolar disorder. Because the chronicity of the disease often necessitates long-term therapy, patient satisfaction with pharmacologic and nonpharmacologic treatments is key to maintaining wellness. This symposium will discuss effective strategies for the management of bipolar disorder and will review the most recent clinical trials evaluating various treatment interventions. The potential implications of genetic and brain imaging studies on the future management of bipolar disorder will also be presented.

LEARNING OBJECTIVES

After attending this symposium, participants should be better able to:

- Discuss basic neurobiologic and genetic factors underlying the pathophysiology of bipolar disorder
- Differentiate the clinical manifestations of bipolar disorder and unipolar depression by examining clinical presentation and other factors
- Evaluate the most recent clinical trial data that assess the efficacy of behavioral and pharmacologic treatments for bipolar disorder

ACCREDITATION STATEMENT

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AGENDA


SATURDAY, MAY 20, 2006

12:00 PM - 12:30 PM	LUNCH	1:35 PM - 2:05 PM	EVALUATION OF CLINICAL TRIALS IN BIPOLAR DISEASE Gary Sachs, MD
12:30 PM - 12:35 PM	WELCOME AND INTRODUCTION Gary Sachs, MD	2:05 PM - 2:35 PM	IMPACT OF PATIENT SATISFACTION ON TREATMENT OUTCOMES Holly A. Swartz, MD
12:35 PM - 1:05 PM	IMPACT OF MISDIAGNOSIS OF BIPOLAR DISORDER ON PATIENT OUTCOMES Claudia F. Bellassano, MD	2:35 PM - 3:25 PM	PANEL DISCUSSION Moderator: Gary Sachs, MD
1:05 PM - 1:35 PM	BRAINS AND GENES: IMPLICATIONS FOR THE TREATMENT OF BIPOLAR DISORDER Xihui Qieng, MD	3:25 PM - 3:30 PM	CLOSING REMARKS Gary Sachs, MD

Attendees must be registered for the 2006 APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7300.

Sponsored by The American Psychiatric Association

Supported by an educational grant from Bristol-Myers Squibb Company and TEVA USA PHARMACEUTICAL, INC.



INDUSTRY-SUPPORTED SYMPOSIUM 3
 Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
 Royal York, Convention Floor, Concert Hall

APA 2006 ANNUAL MEETING | SATURDAY, MAY 20, 2006

Navigating the Maze: Understanding Methods, Results and Risk in Psychiatric Research

Saturday, May 20, 2006

Lunch: 12:00 pm - 12:30 pm
 12:30 pm - 3:30 pm
 Royal York, Convention Floor, Concert Hall
 Toronto, Ontario

APA 2006 SYMPOSIUM AGENDA

12:30 - 12:40 PM

Welcome and Introduction

DAVID J. KUPFER, MD, SYMPOSIUM CHAIRPERSON
 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
 WESTERN PSYCHIATRIC INSTITUTE AND CLINIC

12:40 - 1:05 PM

Assessing Statistical and Clinical Significance in Medical Research

DAVID J. KUPFER, MD
 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
 WESTERN PSYCHIATRIC INSTITUTE AND CLINIC

1:05 - 1:10 PM

Questions

1:10 - 1:35 PM

All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care

HELENA CHMURA KRAEMER, PHD
 STANFORD UNIVERSITY

1:35 - 1:40 PM

Questions

1:40 - 2:05 PM

Determining Efficacy: Sound Clinical Trial Design and Interpretation

CORNELIUS KATONA, MD, FRCP
 KENT INSTITUTE OF MEDICINE AND HEALTH SCIENCES
 UNIVERSITY OF KENT

2:05 - 2:10 PM

Questions

2:10 - 2:35 PM

Treating Depression in Children and Adolescents: What's a Clinician to Do?

JEFF Q. BOSTIC MD, EDD
 MASSACHUSETTS GENERAL HOSPITAL

2:35 - 2:40 PM

Questions

2:40 - 3:05 PM

How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly

ERIC J. LENZE, MD
 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
 WESTERN PSYCHIATRIC INSTITUTE AND CLINIC

3:05 - 3:30 PM

Questions

At the conclusion of the symposium, participants should be able to:

- discuss statistical and clinical significance in the design of clinical trials and how to analyze the results of clinical studies in terms of medical decision making; compare the different methods used to determine the clinical significance of medical research;
- evaluate risk factors in medical research; understand the differences between risk factors and causation; differentiate between mediators and moderators and the role they play in risk research;
- examine the current issues and complexities involved in interpreting the results of clinical trials of psychotropic drugs;
- evaluate the reported risk of suicidality associated with antidepressant treatment in children and adolescents; recognize the risks of untreated depression; gain a better understanding of the pharmacological and psychosocial treatment options for depression in this population;
- develop strategies for effective medical decision making in cases where the scientific literature lacks sufficient evidence to support any particular medication or treatment; gain an understanding of treatment options for geriatric patients with anxiety disorders where little data exist regarding effective treatments.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium.

Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This program is sponsored by the American Psychiatric Association



Supported by an educational grant from Forest Pharmaceuticals, Inc.

Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 4
 Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

APA 2006 ANNUAL MEETING | Sponsored by the American Psychiatric Association

BRIDGING
 Sleep Science & Public Policy

**SATURDAY,
 MAY 20, 2006**

Lunch: 12:00 noon - 12:30 pm
 Symposium: 12:30 pm - 3:30 pm

Sheraton Centre
 Lower Concourse
 Grand Ballroom
 Toronto, Canada

3.0 CME Credits
 are designated for
 participation in this
 Educational Symposium.

Learning Objectives:

At the conclusion of this symposium, the participants should be able to:

- Recognize the manifestations of sleep deprivation and chronic insomnia
- Understand the risks associated with special populations
- Appreciate the role of public policy and regulatory guidelines in addressing these clinical problems

Program Chair:



David N. Neubauer, MD
 Assistant Professor of Psychiatry
 Johns Hopkins University School of Medicine
 Associate Director
 Johns Hopkins Sleep Disorders Center
 Medical Director
 Psychiatry Mobile Treatment Program
 Johns Hopkins Bayview Medical Center
 Baltimore, MD

Agenda:

12:00 noon - 12:30 pm

Complimentary Lunch

12:30 pm - 12:35 pm

Welcome and Introduction

David N. Neubauer, MD
 Johns Hopkins University School of Medicine

12:35 pm - 1:00 pm

The Science of Sleep

David N. Neubauer, MD

1:00 pm - 1:25 pm

Adolescents and School Start Times:

The Intersection of Research and Public Policy

R. Robert Auger, MD

Mayo Clinic College of Medicine

1:25 pm - 1:50 pm

Shiftwork, Sleep, and Performance

Gregory Belenky, MD

Washington State University - Spokane

1:50 pm - 2:15 pm

Medical Education and Resident Duty Hours

Phyllis C. Zee, MD, PhD

Northwestern University

2:15 pm - 2:40 pm

Insomnia and Public Policy

Daniel J. Buysse, MD

University of Pittsburgh School of Medicine

2:40 pm - 3:20 pm

Question-and-Answer Session

Faculty Panel

3:20 pm - 3:30 pm

Summary and Conclusions

David N. Neubauer, MD

Accreditation:

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 5
 Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
 Toronto Convention Centre, North Level 100, Room 102

Mania in Special Populations

**A-CME INDUSTRY-SUPPORTED SYMPOSIUM
 AT THE 2006 AMERICAN PSYCHIATRIC
 ASSOCIATION ANNUAL MEETING**

**Saturday, May 20, 2006
 6:00 pm - 9:00 pm Dinner
 9:00 pm - 9:30 pm Scientific Program**

**Metro Toronto Convention Centre
 North Level 100
 Room 102
 John Bassett Theatre**

Speakers and Faculty

6:00 pm - 6:30 pm **Director**
 Robert M.A. Hirschfeld, MD, University of Texas
 The University of Texas Medical Branch

6:30 pm - 6:45 pm **Recent Developments in the Treatment of Mania**
 Robert M.A. Hirschfeld, MD

6:45 pm - 8:00 pm **Prevalence and Management of Child and Adolescent Bipolar Disorder**
 Karen D. Wagner, MD, PhD
 The University of Texas Medical Branch

8:00 pm - 8:30 pm **Bipolar Disorder in Women: Clinical and Metabolic Correlates**
 Marlene L. Mangin, MD, PhD
 Stanford University School of Medicine

8:30 pm - 9:00 pm **Bipolar Disorder in the Elderly Patient**
 Brent P. Poole, MD
 McLean Hospital

9:00 pm - 9:30 pm **Prevalence of Bipolar Disorder in African Americans**
 William B. Lawson, MD, PhD, FAHA
 Harvard University School of Medicine

9:30 pm - 9:45 pm **C. S. A. / Chairpersons**
 All Faculty

9:45 pm - 10:00 pm **Closing Remarks**
 Robert M.A. Hirschfeld, MD

Educational Objectives

At the conclusion of this symposium, the participant should be able to:

- 1. Discuss prevalence and how this information can help the clinician manage the patient with mania.
- 2. Describe the clinical presentation of bipolar disorder in children and adolescents, as well as address special treatment issues in this population.
- 3. Evaluate special issues regarding mania in women, clinical management during pregnancy and breastfeeding, and management of adverse event issues, such as metabolic and hormonal abnormalities.
- 4. Identify special concerns in older adults, including differential diagnosis with neurologic disorders, and address special treatment considerations.
- 5. Evaluate knowledge about bipolar disorder in African Americans, including diagnosis as comorbidities, and appropriate differing patterns of care in this population.

The American Psychiatric Association (APA) is committed to the highest quality of continuing medical education for its members. The APA designates this educational activity for a maximum of 3 AHA PBA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 888-357-7324 (within the U.S. or Canada) or 703-907-7300.

Designated conference participants and selected quantitative attenders are eligible for a complimentary membership in the APA.

Sponsored by an educational grant from **Shire**

INDUSTRY-SUPPORTED SYMPOSIUM 6
 Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
 Royal York, Convention Floor, Canadian Room

VERGING ON REALITY

2006 APA ANNUAL MEETING
EMERGENT THERAPEUTIC APPROACHES FOR SCHIZOPHRENIA
 DATE SATURDAY, MAY 20th, 2006 TIME 6:00 PM - 9:00 PM | ACTIVITY CHAIRPERSON PETER F. BUCKLEY, MD
 THE FAIRMONT ROYAL YORK = CANADIAN ROOM = TORONTO, CANADA

AGENDA		
SATURDAY, MAY 20, 2006		
5:30 PM - 6:00 PM	DINNER	7:05 PM - 7:35 PM
6:00 PM - 6:05 PM	WELCOME AND INTRODUCTION Peter F. Buckley, MD	7:35 PM - 8:05 PM
6:05 PM - 6:35 PM	FUNCTIONAL GENOMICS AND THERAPEUTIC EFFECTS OF ANTIPSYCHOTICS Anil Malhotra, MD	8:05 PM - 8:50 PM
6:35 PM - 7:05 PM	INSIGHTS FROM NEUROIMAGING TO GUIDE DRUG CHOICE AND DEVELOPMENT Carol A. Tamminga, MD	8:50 PM - 9:00 PM
		THE SCIENCE OF SUBJECTIVE TOLERABILITY: "WELLNESS" AS A TREATMENT OUTCOME Meera Marasimhan, MD
		RECOVERY AND REMISSION: DEFINITIONS, DILEMMAS, AND THE EMERGENT ROLE OF PEER SUPPORT Peter F. Buckley, MD
		PANEL DISCUSSION Moderator: Peter F. Buckley, MD
		CLOSING REMARKS Peter F. Buckley, MD

Attendees must be registered for the 2006 APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact APA toll free at 1-888-357-7324 (within the US or Canada) or 1-703-907-7300.

PROGRAM OVERVIEW

Rapidly expanding knowledge in neuroscience, new developments in technology, and broadening domains of outcome collectively create new opportunities for developing more effective treatments for schizophrenia. These seemingly disparate paths of innovation in psychopharmacology, psychiatry, and recovery are represented in the broad scope of the President's New Freedom Commission, which calls for a more rapid translation of basic science and clinical research findings into service delivery.

Specific genetic changes that can modify brain structure and physiology are being studied to evaluate how they alter response to pharmacologic treatments in schizophrenia. In addition, neuroimaging is now being incorporated as a critical tool to elucidate neural systems and drug effects and to guide drug development.

A critical component influencing outcomes with atypical antipsychotics is the subjective tolerability of these agents. Recent data describing the subjective tolerability of atypical antipsychotics go beyond the traditional adverse effect burden to focus on quality of life, sexual functioning, and the role of "wellness" behavior in treating schizophrenia. The clinical impact of these innovations in terms of the current realities of drug selection and switching of antipsychotic medications will be discussed. Beyond neuroscience, the growth of consumerism and patient advocacy has launched the recovery approach, including emergent Peer Support Specialist services. Emerging information on remission and recovery from schizophrenia will be presented, evaluating the impact of the recovery approach and how this innovation has advanced alongside optimum pharmacologic treatment for schizophrenia.

LEARNING OBJECTIVES

After attending this symposium, participants should be better able to:

- Identify the role of genetic effects on brain physiology and treatment response in schizophrenia.
- Recognize insights from neuroimaging on the physiology of pharmacotherapy and the implications for drug development.
- Discuss the differential adverse event profiles and subjective tolerability of atypical antipsychotics with regard to patient-centered treatment outcomes.

ACCREDITATION STATEMENT

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AHA PBA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by The American Psychiatric Association

Sponsored by Bristol-Myers Squibb Company and OTSUKA AMERICA PHARMACEUTICAL, INC.

INDUSTRY-SUPPORTED SYMPOSIUM 7
 Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
 Royal York, Convention Floor, Concert Hall



Sponsored by the American Psychiatric Association
 Take Advantage of this Invaluable Educational Opportunity at **APA 2006!**

**Bipolar Disorder: Creating a Consensus
 from Science to Public Policy**

3.0 CME Credits are designated for participation in this Educational Symposium.

SATURDAY, MAY 20, 2006

5:30 - 6:00 pm DINNER
 6:00 - 9:00 pm PROGRAM
 Royal York Convention Center
 Concert Hall Room
 Fairmont Royal York Hotel
 Toronto, Canada

PROGRAM CHAIR:



Mark H. Rapaport, MD
 Chairman, Department of Psychiatry
 The Poller Endowed Chair in Schizophrenia
 and Related Disorders
 Cedars-Sinai Medical Center
 Vice Chair, Psychiatry
 UCLA School of Medicine
 Los Angeles, California

LEARNING OBJECTIVES:

At the end of this symposium the participants should be able to:

- Discuss the onset and course of bipolar disorder in children and adolescents
- Outline the severity of dysfunction associated with bipolar disorder and its individual and societal impact on the legal system
- Examine the relative benefits and limitations of our current knowledge about longer term pharmacotherapy and psychotherapy for bipolar disorder
- Relate the strengths and limitations of existing data about alternative traditional and nontraditional pharmacotherapies for bipolar disorder

AGENDA

5:30 - 6:00 pm Complimentary Dinner
 6:00 - 6:10 pm Introduction and Welcome
 6:10 - 6:35 pm The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder
 6:35 - 7:00 pm A Rational Approach for the Longitudinal Pharmacologic Management of Patients with Bipolar Disorder: An Argument
 7:00 - 7:25 pm Alternative Pharmacologic Approaches to the Care of Bipolar Patients
 7:25 - 7:50 pm Treatment Considerations for Mania in Young Children
 7:50 - 8:15 pm Treatment of Bipolar Disorder in U.S. Jails and Prisons
 8:15 - 9:00 pm Question-and-Answer Session

Mark H. Rapaport, MD
 Cedars-Sinai Medical Center

Ellen Frank, PhD
 University of Pittsburgh School of Medicine

Mark H. Rapaport, MD

Alexander H. Fan, MD
 Cedars - Sinai Medical Center

Barbara Geller, MD
 Washington University
 in St. Louis

Joseph R. Calabrese, MD
 University Hospital Cleveland

Entire Panel

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

ACCREDITATION



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from:
 Solvay Pharmaceuticals and Wyeth Pharmaceuticals.

Solvay
 Pharmaceuticals



Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 8
 Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

Treatment-Resistant Depression: New Data, New Approaches

Saturday, May 20, 2006 ■ Dinner: 5:30-6:00 PM ■ Scientific Program: 6:00-9:00 PM
 Sheraton Centre Toronto Hotel ■ Lower Concourse Grand Ballroom ■ Toronto, Ontario, Canada

Agenda

6:00 PM **Introduction**
 David L. Dunner, MD—Chairman • University of Washington School of Medicine

6:05 **Definitions and Clinical Characteristics of Treatment-Resistant Depression**
 David L. Dunner, MD

6:30 **Treatment Resistance and Genes: The Biology vs. Pharmacology Enigma**
 Francisco A. Moreno, MD • University of Arizona College of Medicine

6:55 **Positron Emission Tomography of Chronic Vagus Nerve Stimulation for Severe Treatment-Resistant Depression**
 Jose V. Pardo, MD • University of Minnesota Medical School

7:20 **Augmentation Strategies for Patients With Difficult-to-Treat Major Depressive Disorder**
 Alicia Ruelaz, MD • Cedars-Sinai Health System

7:45 **Brain Stimulation Therapies for Treatment-Resistant Depression**
 Linda L. Carpenter, MD • Brown Medical School

8:10 **Panel Discussion and Q&A Session**

9:00 **Conclusion**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Statement of Need

This symposium will present new findings regarding treatment-resistant depression (TRD). About half of all patients who are treated for depression either do not respond to therapy or do not achieve a full remission of symptoms. Persistence of depression in these patients results in continued impairment in psychosocial function and increases the likelihood of medical morbidity and suicide mortality. In this symposium, there will be a discussion of the definition of TRD, its clinical, neurobiological, and familial characteristics, psychotherapeutic and psychopharmacologic treatment strategies, and the use of physical therapies to enhance response. Novel treatments undergoing research in this population will be presented. Patients with TRD pose considerable problems for clinicians involved in their care. Presentations from this symposium will be aimed at providing rational and systematic approaches for clinicians to improve outcomes in patients with TRD.

Educational Objectives

At the conclusion of this program, the participants should be better able to

- Assess the therapeutic approach to treating patients with treatment-resistant depression (TRD)
- Identify the complexities of a diagnosis of TRD
- Recognize the "naturalistic" treatment outcome of TRD
- Identify brain metabolic correlates of TRD and describe the effects of chronic vagus nerve stimulation (VNS) on brain metabolism in TRD
- Define the role of genetics in depressive disorders
- Describe genetic and environmental influences in the biology of depression and treatment resistance
- Evaluate the strengths and weaknesses of the existing acute treatment data investigating the efficacy of augmentation treatment for difficult-to-treat major depressive disorder
- Utilize efficacy data for established and investigational central neuromodulatory treatments for TRD, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), magnetic seizure therapy (MST), and vagus nerve stimulation (VNS) therapy

Sponsored by the
 American Psychiatric Association



Supported by an
 educational grant from

Cyberonics

Held at the APA 2006 Annual Meeting

INDUSTRY-SUPPORTED SYMPOSIUM 9
 Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
 Toronto Convention Centre, North Level 100, Room 102

APA 2006 Annual Meeting

**Differentiating Atypical Antipsychotics
 in the Treatment of Schizophrenia:
 From Theory to Practice**

Sunday, May 21, 2006 • 7:30 AM – 8:00 AM Breakfast • 8:00 AM – 11:00 AM Symposium
 Toronto Convention Centre, North Building, Level 100, John Bassett Theater/Room 102, Toronto, Ontario, Canada

- 8:00 AM **Introduction**
 Anissa Abi-Dargham, MD, Program Chairperson
 Columbia University Medical School
 New York, New York
- 8:10 AM – 8:35 AM **Pharmacodynamic Differences Among Antipsychotic Treatments**
 Anissa Abi-Dargham, MD
- 8:35 AM – 9:00 AM **The Antipsychotic Effect: Lessons from Occupancy Studies**
 W. Gordon Frankle, MD
 Columbia University Medical School
 New York, New York
- 9:00 AM – 9:25 AM **Evaluation of Metabolic Outcome During Antipsychotic Treatment: Lessons from CATIE and Other Recent Studies**
 John W. Newcomer, MD
 Washington University School of Medicine
 St. Louis, Missouri
- 9:25 AM – 9:50 AM **Cognitive Responses to Atypical Antipsychotic Medications: Factors Affecting the Potential to Differentiate Treatments**
 Philip D. Harvey, PhD
 Mount Sinai School of Medicine
 New York, New York
- 9:50 AM – 10:15 AM **Clinical Integration in the Care for Patients with Schizophrenia: What Are the Current Best Practices?**
 Robert A. Rosenheck, MD
 Yale Medical School
 New Haven, Connecticut
- 10:15 AM – 11:00 AM **Question and Answer Session**
 11:00 AM **Adjournment**

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Differentiate among atypical antipsychotic pharmacodynamic and pharmacokinetic properties from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
 - Apply the findings of CATIE to choices among a range of atypical antipsychotic medications.

Attendees must be registered for the American Psychiatric Association's 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-257-7924 (within the United States and Canada) or 703-907-7300.

The APA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 CME credits. Physicians should only claim credit commensurate with the participation in the activity.



Featuring
 Latest CATIE Data

INDUSTRY-SUPPORTED SYMPOSIUM 10
 Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
 Royal York, Convention Floor, Canadian Room

Don't Miss This Important Educational Activity!

Fibromyalgia: Scientific Advances to Reduce the Burden of Illness

A Breakfast Symposium Held During the APA 2006 Annual Meeting

Sunday, May 21, 2006

7:30AM-8:00AM Breakfast
 8:00AM-11:00AM Educational Activity

The Fairmont Royal York
 Convention Floor, Canadian Room
 Toronto, Ontario, Canada

7:30AM-8:00AM Breakfast

8:00AM
Welcome and Introduction
 Lesley M. Arnold, MD
 Program Chairperson
 University of Cincinnati College of Medicine

8:15AM
The Socioeconomic Burden of Fibromyalgia
 Sharon B. Stanford, MD
 University of Cincinnati College of Medicine

8:45AM
New Evidence for the Pathophysiological Basis of Fibromyalgia
 Lesley M. Arnold, MD
 Program Chairperson

9:15AM
Current and Emerging Strategies for the Pharmacologic Management of Fibromyalgia
 Leslie J. Crofford, MD
 University of Kentucky

9:45AM
Living With Fibromyalgia: A Patient's Perspective
 Lesley M. Arnold, MD
 Program Chairperson

10:15AM
Question and Answer Session

11:00AM
Program Adjournment

- Learning Objectives**
- Upon completion of the activity, participants should be able to:
1. Recognize the significant morbidity associated with fibromyalgia.
 2. Recognize the impact on social functioning and work-related disability in those suffering from fibromyalgia.
 3. Recognize the psychiatrist's potential role in easing the socioeconomic burden of fibromyalgia.
 4. Recognize the role of stressful life events, trauma, and disturbances in the stress-response system in the pathophysiology of fibromyalgia.
 5. Explain the rationale for selection of therapeutic agents for treatment of fibromyalgia.
 6. Discuss the data from clinical trials of drugs used in the treatment of fibromyalgia.
 7. Develop an algorithm for the treatment of patients with fibromyalgia.
 8. Discuss how physician accessibility, perceptions, and patient experience influence access to care and effective treatment of fibromyalgia and how this can impact a patient's life.

Accreditation Statement
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Faculty Disclosure Statement
 All faculty are required to disclose to the audience any real or apparent conflicts of interest that may have a direct bearing on the subject matter of the educational activity. The faculty disclosure statements will be listed in the course syllabus and at the beginning of each slide presentation.


Sponsored by the American Psychiatric Association



Supported by an educational grant from Eli Lilly and Company

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-257-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 11
 Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
 Royal York, Convention Floor, Concert Hall



Sunday, May 21, 2006
7:30 AM – 8:00 AM Breakfast
8:00 AM – 11:00 AM Program
The Fairmont Royal York Hotel
Convention Floor Concert Hall

Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

APA 2006 ANNUAL MEETING: ISS-11
Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice

Breakfast
 7:30 AM – 8:00 AM

Program
 8:00 AM • **Welcome/Introduction**
 Thomas J. Spencer, MD, Chair
 Massachusetts General Hospital

8:05 AM • **ADHD Neuropsychology and Executive**

Function Deficits
 Larry J. Seidman, PhD
 Harvard Medical School

8:30 AM • **Stimulants: Therapeutic and Reinforcing Effects**
 Nora D. Volkow, MD
 National Institute on Drug Abuse

8:55 AM • **The Relevance of the Trace Amine Phenylethylamine (PEA) to ADHD**
 Bertha K. Madras, PhD
 Harvard Medical School

Learning Objectives:

At the conclusion of this symposium, the participant should be able to:

1. Describe neuropsychological dysfunctions in ADHD
2. Explain the mechanism of action of the various psychostimulants used for ADHD
3. Describe the involvement of the dopaminergic and adrenergic systems in the pathophysiology of ADHD
4. Evaluate available pharmacotherapeutic options for ADHD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association.



9:15 AM • **New Insights Into the Noradrenergic System in ADHD**

Amy F.T. Arnsten, PhD
 Yale University School of Medicine

9:40 AM • **Advances in the Therapeutics of ADHD**

Paul G. Hammerness, MD
 Massachusetts General Hospital

10:05 AM • **Discussant**

Thomas J. Spencer, MD
 Massachusetts General Hospital

10:15 AM • **Question and Answer Session**
 Faculty

11:00 AM • **Adjournment**

Supported by an educational grant from Shire.



INDUSTRY-SUPPORTED SYMPOSIUM 12
 Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

THE IMPACT OF ANXIETY DISORDERS: A CASE-BASED APPROACH TO IMPROVING OUTCOMES AND REMOVING STIGMA

Sunday, May 21, 2006
7:30 AM – 8:00 AM Breakfast
8:00 AM – 11:00 AM Scientific Session
Sheraton Centre • Lower Concourse, Grand Ballroom
123 Queens St. West, Toronto, Ontario, Canada M5H 2M6



Supported by an unrestricted educational grant from Cephalon, Inc.



Sponsored by the American Psychiatric Association.

LEARNING OBJECTIVES

At the conclusion of this symposium the participant should be able to:

- Assess the public and individual health consequences of anxiety disorders.
- Discuss the neurobiological underpinnings of anxiety disorders.
- Implement a treatment plan that incorporates non-pharmacologic and pharmacologic strategies to enhance patient outcomes.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.

Symposium to be held at the APA 2006 Annual Meeting

SCIENTIFIC PROGRAM AGENDA

8:00 AM – 8:10 AM
 Welcome and Introduction
 Ned H. Kalin, MD (Symposium Chair)

8:10 AM – 8:35 AM
 Public Health Consequences of Anxiety: A Surgeon General's Perspective
 David Satcher, MD, PhD
 Morehouse School of Medicine

8:35 AM – 9:00 AM
 Individual Consequences of Anxiety
 Rhea B. Weisberg, PhD
 Brown University

9:00 AM – 9:25 AM
 Anxiety Disorders: A Glimpse Inside the Brain
 Ned H. Kalin, MD
 University of Wisconsin

9:25 AM – 9:50 AM
 Linking Symptoms to Treatment Selection in Anxiety Disorders
 Murray B. Stein, MD, FRCPC, MPH
 University of California, San Diego

9:50 AM – 10:15 AM
 Non-Pharmacologic Approach to the Treatment of Anxiety Disorders
 Edna B. Foa, PhD
 University of Pennsylvania

10:15 AM – 11:00 AM
 Panel Discussion/Question-and-Answer Session

INDUSTRY-SUPPORTED SYMPOSIUM 13
 Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

**New Vistas in
 Treatment-Resistant Depression**

Sunday, May 21, 2006 • 7:30 AM – 8:00 AM Breakfast • 8:00 AM – 11:00 AM Symposium
 Metropolitan Ballroom, Convention Level, Westin Harbour Castle • Toronto, Ontario, Canada

8:00 AM – 8:15 AM

Welcome and Introduction

Charles B. Nemeroff, MD, PhD
 Reunette W. Harris Professor and Chairman
 Department of Psychiatry and
 Behavioral Sciences
 Emory University School of Medicine
 Atlanta, GA

8:15 AM – 8:45 AM

**Evolving Concepts in
 Treatment-Resistant Depression**

Charles B. Nemeroff, MD, PhD

8:45 AM – 9:15 AM

**Neuropharmacological Basis
 for Treatment Strategies in the
 Management of Refractory Depression**

Stephen Stahl, MD, PhD
 Adjunct Professor
 University of California, San Diego,
 School of Medicine
 La Jolla, CA
 Chairman
 Neuroscience Education Institute
 Carlsbad, CA

9:15 AM – 9:45 AM

**New Strategies for
 Treatment-Resistant Depression**

Linda L. Carpenter, MD
 Associate Professor
 Department of Psychiatry and
 Human Behavior
 Brown Medical School
 Providence, RI

9:45 AM – 10:15 AM

**Re-evaluating Concepts
 of Depression: Bipolar Spectrum**

S. Nassir Chaemi, MD, MPH
 Associate Professor of Psychiatry
 and Public Health
 Emory University School of Medicine
 Atlanta, GA

10:15 AM – 11:00 AM

Question-and-Answer Session

Faculty Panel

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Understand the evolving definitions of treatment-resistant depression.
- Understand the evolving concepts and clinical approaches to treatment-resistant depression.
- Discuss the impact of mood disorders on public health and public policy.
- Discuss the predictors of antidepressant response.


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is an affiliate of the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. PRA Category 3 Credit™ is a trademark of the AMA.



INDUSTRY-SUPPORTED SYMPOSIUM 14

Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Toronto Convention Centre, North Level 100, Room 102



Sponsored by the American Psychiatric Association
 Take Advantage of this Invaluable Educational Opportunity at **APA 2006!**

**New Developments in Schizophrenia:
 From Neurobiology to Public Health**

3.0 CME Credits are designated for participation in this Educational Symposium.

SUNDAY, MAY 21, 2006

1:00 – 1:30 PM LUNCH
 1:30 – 4:30 PM PROGRAM
 Toronto Convention Centre
 North Level 100, Room 102
 Toronto, Canada

PROGRAM CHAIR:



John M. Kane, MD
 Professor of Psychiatry, Neurology and Neuroscience
 The Albert Einstein College of Medicine
 Bronx, New York
 Chairman, Department of Psychiatry
 The Zucker Hillside Hospital
 Glen Oaks, New York

LEARNING OBJECTIVES:

- At the end of this symposium the participants should be able to:
- Discuss recent developments in the pharmacologic treatment of schizophrenia
 - Describe the current thinking as to the assessment and management of cognitive dysfunction in schizophrenia
 - Describe the current understanding of the neurobiology of psychosis
 - List the metabolic adverse effects of antipsychotic medication and how to manage them
 - Discuss the public health implications of treatment decisions and disease management in schizophrenia

AGENDA

- | | |
|----------------|--|
| 1:00 – 1:30 pm | Complimentary Lunch |
| 1:30 – 1:40 pm | Introduction and Welcome |
| 1:40 – 2:10 pm | Pharmacologic Treatment of Schizophrenia: The State-of-the-Art |
| 2:10 – 2:40 pm | From Dopamine to Delusions: Understanding Psychosis from the Bench to the Bedside |
| 2:40 – 3:10 pm | Cognitive Functioning in Schizophrenia: Cognitive Impairments as Clues for Treatment Development |
| 3:10 – 3:40 pm | Metabolic Risks of Second-Generation Antipsychotic Medications |
| 3:40 – 4:30 pm | Question-and-Answer Session |

- John M. Kane, MD
 Albert Einstein College of Medicine
- John M. Kane, MD
- Shilpi Kapur, MD
 University of Toronto
- Robert M. Bilder, PhD
 David Geffen School of Medicine at UCLA
- Christoph U. Correll, MD
 Albert Einstein College of Medicine
- Entire Panel

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

ACCREDITATION



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The APA designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Solvay Pharmaceuticals and Wyeth Pharmaceuticals.

Solvay Pharmaceuticals



Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 15
 Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Royal York, Convention Floor, Canadian Room

VITAL SIGNS IN PSYCHIATRY:
 A PERSPECTIVE ON SLEEP ACROSS THE LIFE CYCLE
 A CME Symposium to be held during the 2006
 American Psychiatric Association (APA) Annual Meeting

Sunday, May 21, 2006
 1:00 PM - 1:30 PM Lunch
 1:30 PM - 4:30 PM CME Symposium



The Fairmont Royal York
 Canadian Room, Convention Floor
 Toronto, Ontario, Canada

Interactive debate-style format!

TARGET AUDIENCE

This activity has been designed to meet the educational needs of psychiatrists involved in the management of sleep dysfunction and insomnia.

LEARNING OBJECTIVES

At the conclusion of the symposium, the participant should be able to:

- Understand normal sleep patterns, sleep architecture, and sleep behaviors as they develop and change from infancy through adolescence
- Discuss the epidemiology, impact, evaluation, and general approaches to treatment of insomnia in the adult population
- Review medical and psychiatric comorbidities associated with insomnia and discuss the importance of addressing underlying conditions when managing sleep dysfunction
- Describe gender-related differences in sleep architecture and the development of sleep-related disorders
- Identify changes in the pattern of normal sleep that occur with advancing age

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Supported by an educational grant from Sepracor Inc.
 Sponsored by the American Psychiatric Association

AGENDA

- 1:00 PM-1:30 PM Lunch
- 1:30 PM-1:40 PM Introduction and Overview
 Eric A. Nofzinger, MD (Chair)
 University of Pittsburgh School of Medicine
 Pittsburgh, Pennsylvania
- 1:40 PM-2:05 PM Sleep in Infancy, Childhood, and Adolescence: Normal Sleep Patterns, Developmental Issues, and Sleep Problems
 Joel A. Mindall, PhD
 Saint Joseph's University
 Philadelphia, Pennsylvania
- 2:05 PM-2:30 PM Insomnia in Adulthood: Causes, Consequences, and Treatment
 Ned H. Kalin, MD
 University of Wisconsin Medical School
 Madison, Wisconsin
- 2:30 PM-2:55 PM Insomnia Secondary to Medical or Psychiatric Comorbidity: Implications for Evaluation and Management
 Matthias K. Lee, MD
 Virginia Mason Sleep Disorders Center
 Seattle, Washington
- 2:55 PM-3:20 PM Sleep in Women Across the Life Cycle: How the Reproductive Cycle Impacts Sleep
 Meir H. Kryger, MD, FRCP
 University of Manitoba
 Winnipeg, Manitoba
- 3:20 PM-3:45 PM Sleep in the Elderly: Is Poor Sleep a Normal Concomitant of Advancing Age?
 Sanford I. Finkel, MD
 University of Chicago Medical School
 Chicago, Illinois
- 3:45 PM-4:30 PM Audience Questions/Panel Discussion
 Eric A. Nofzinger, MD (Chair)
 University of Pittsburgh School of Medicine
 Pittsburgh, Pennsylvania

INDUSTRY-SUPPORTED SYMPOSIUM 16
 Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Royal York, Convention Floor, Concert Hall

Interrupting the Cycle of Vascular Disease and Depression
 Held at the APA 2006 Annual Meeting

Sunday, May 21, 2006 • Lunch: 1:00-1:30 PM • Scientific Program: 1:30-4:30 PM
 Fairmont Royal York Hotel • Convention Floor Concert Hall • Toronto, Canada

- 1:00 PM Lunch
- 1:30 **Welcome and Introduction**
 Steven P. Roose, MD—Chairman
 Columbia University and the New York State Psychiatric Institute
- 1:40 **Vascular Disease: Mechanisms Underlying the Relationship***
 Dominique Musselman, MD • Emory University School of Medicine
- 2:10 **The Bidirectional Relationship Between Diabetes and Depression***
 Sanjay J. Mathew, MD • Mount Sinai School of Medicine
- 2:40 **Post-Stroke Depression and the Vascular Depression Hypothesis***
 David C. Steffens, MD • Duke University Medical Center
- 3:10 **Vascular Disease and Depression: Challenges in Management and Treatment***
 Christopher M. O'Connor, MD • Duke University Medical Center
- 3:40 **Clinical Treatment Perspectives: A Focus on Diagnosis and Safety***
 J. Craig Nelson, MD
 University of California, San Francisco School of Medicine
- 4:10 **Panel Discussion and Q & A Session**
- 4:30 **Conclusion**

*Each presentation will include 5 minutes for audience questions.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Educational Objectives

At the conclusion of this program, participants should be able to

- Identify the mechanisms that underlie the relationship between vascular disease and depression
- Define the relationship between depression and metabolism as it relates to diabetes
- Recognize the impact that stroke has on the development of depression
- Manage and treat patients who present with comorbid depression and vascular disease
- Implement safe and effective treatments for patients with vascular disease and depression



Sponsored by the
 American Psychiatric Association

Supported by an educational grant from Forest Pharmaceuticals, Inc.



Pharmaceuticals • Therapeutics • Healthcare • Ethics • Managed Care • Specialty Sales

INDUSTRY-SUPPORTED SYMPOSIUM 17
 Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

APA 159th Annual Meeting
 Please to join us for a CME Symposium on...

**Update on Insights From and Future Course
 of the Collaborative Depression Study**

Sunday, May 21, 2006
 1:00–1:30 PM Lunch
 1:30–4:30 PM

Learning Objectives

At the conclusion of this symposium, the participant should be able to...

1. Summarize current insights into the naturalistic course of depression, as informed by several long-term naturalistic observational studies
2. Integrate insights from research in neurobiology, neuroimaging, and genomics with new epidemiologic perspectives on the pathophysiology of depression
3. Discuss current treatment strategies and candidates for future treatments as informed by these epidemiologic and other research findings

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or +1-703-907-7300.

Agenda

- 1:00–1:30 PM Lunch
- 1:30–1:40 PM Welcome and Overview
Martin Keller, MD
Brown University
- 1:40–2:05 PM The Pernicious Course of Depression and the Impact of New Insights From Imaging, Genomics, Neurobiology, and Learning
Martin Keller, MD
Brown University
- 2:05–2:30 PM Update on the Clinical Course of Major Depression
Audrey Tyrka, MD
Brown University
- 2:30–2:55 PM Using Pharmacogenetics in Practice
Alan Schatzberg, MD
Stanford University
- 2:55–3:20 PM Biological and Imaging Changes in Depression
K. Ranga R. Krishnan, MD
Duke University Medical Center
- 3:20–3:45 PM Review of the Current State of Evidence-based Treatment of Depression
Madhukar Trivedi, MD
University of Texas Southwestern
- 3:45–4:30 PM Panel Discussion and Q & A
Martin Keller, MD
Brown University



Sponsored by the American Psychiatric Association and supported by an educational grant from

Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 18
 Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Westin Harbour Castle, Street Level, Frontenac Room

MISDIAGNOSIS OF **BIPOLAR**

Methods for Screening Patients at Risk for Bipolar Disorder

Scientific Agenda and Distinguished Faculty
SUNDAY, MAY 21

1:00pm: Lunch

1:30pm: Introduction

1:40pm: Diagnosing Bipolar Disorder and the Role of Screening Instruments
Terence Ketter, MD
 Professor of Psychiatry and Behavioral Sciences
 Stanford University School of Medicine


2:05pm: Major Depression: Clues to Bipolarity
Hagop S. Akiskal
 Professor of Psychiatry and Director of International Mood Center
 University of California at San Diego

2:30pm: Bipolar Depression: Implications for Morbidity, Mortality, and Therapeutics
Ross J. Baldessarini, MD
 Professor of Psychiatry (Neuroscience)
 Harvard Medical School
 Mailman Research Center, McLean Hospital

2:55pm: Antidepressants and the Bipolar Spectrum
S. Nassir Ghaemi, MD, MPH
 Associate Professor of Psychiatry and Public Health
 Emory University

3:20pm: Depression and the Affective Spectrum: The Role of Mood Stabilizers
Frederick K. Goudwin, MD
 Professor of Psychiatry
 Director, Center for Neuroscience, Medical Progress and Society
 George Washington University Medical Center

3:45pm: Question & Answer Session
 4:30pm: Adjourn



2006 APA ANNUAL MEETING
 SUNDAY, MAY 21, 2006



1:00pm Lunch
 1:30pm – 4:30pm Symposium
 Toronto, Canada
 Westin Harbour Castle, Frontenac Room

Intended Audience: Psychiatrists

Educational Objectives: At the conclusion of this session, participants should be able to recognize and describe:

- Depressive features in unipolar patients suggestive of a bipolar diathesis
- Highly recurrent unipolar depression
- Depressive mixed states
- The affective spectrum and how it differs from the bipolar spectrum
- Treatment strategies for depression in the bipolar spectrum

Program Administration and Americans with Disabilities Act: Event staff will be glad to assist you with any special needs (e.g., physical, dietary). Please contact Connie Maslow prior to the live event at 720-748-8800 or e-mail at cmaslow@intellyst.com.

Sponsored by the American Psychiatric Association
 Funded by an educational grant from GlaxoSmithKline

INDUSTRY-SUPPORTED SYMPOSIUM 19
 Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

Advances in the Understanding of the Dementia Spectrum

Sunday, May 21, 2006 • 1:00 PM – 1:30 PM Lunch • 1:30 PM – 4:30 PM Symposium

Metropolitan Grand Ballroom, Second Level, Westin Harbour Castle • Toronto, Ontario, Canada

1:30 PM – 1:35 PM

Welcome and Introduction

Jeffrey L. Cummings, MD, *Program Chairperson*
 UCLA Alzheimer's Disease Center
 Los Angeles, California

1:35 PM – 2:00 PM

The Neurobiology of Alzheimer's Disease

David A. Bennett, MD
 Rush Alzheimer's Disease Center
 Chicago, Illinois

2:00 PM – 2:25 PM

Therapeutic Options in the Management of Vascular Dementia

David Wilkinson, MB, ChB, MRCCP, FRCPsych
 Memory Assessment and Research Centre
 Moorgreen Hospital
 Southampton, United Kingdom

2:25 PM – 2:50 PM

Evolution in the Understanding and Treatment of Mild Cognitive Impairment

Gregory A. Jicha, MD, PhD
 Alzheimer's Disease Center
 Sanders-Brown Center on Aging
 University of Kentucky Medical Center
 Lexington, Kentucky

2:50 PM – 3:15 PM

Improving Outcomes for Patients with Advanced Dementia

Howard Feldman, MD, CM, FRCP(C)
 University of British Columbia (UBC) and
 Vancouver Hospital
 UBC Clinic for Alzheimer's Disease
 and Related Disorders
 Vancouver, British Columbia, Canada

3:15 PM – 3:40 PM

Optimizing Behavioral Outcomes Across the Dementia Spectrum

Jeffrey L. Cummings, MD

3:40 PM – 3:45 PM

Concluding Remarks

Jeffrey L. Cummings, MD

3:45 PM – 4:30 PM

Question and Answer Session

Faculty Panel

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Describe the neurobiological foundations of dementia
 - Discuss strategies for identifying and treating dementia
 - Explain the differences between prodromal and dementia states including mild cognitive impairment (MCI) and advanced Alzheimer's disease
 - Review the treatment strategies for patients with advanced dementia
 - Identify strategies for optimizing behavioral outcomes in patients with dementia

Attendees must be registered for the American Psychiatric Association (APA) Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States and Canada) or at 703-907-7300.

The APA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Sponsored by the American Psychiatric Association



Supported by an educational grant from Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 20
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Toronto Convention Centre, North Level 100, Room 102



Alzheimer's Disease: Challenging the Practice Paradigm

A CME SYMPOSIUM AT THE
 APA 159TH ANNUAL MEETING

Sunday, May 21, 2006
 6:30 PM – 7:00 PM Dinner
 7:00 PM – 10:00 PM Scientific Program

Toronto Convention Centre
 North Level 100 Room 102

Agenda and Faculty

6:30 PM – 7:00 PM	Dinner
7:00 PM – 7:10 PM	Introduction Pierre N. Tariot, MD (Chairperson) University of Arizona School of Medicine
7:10 PM – 7:40 PM	Variability in the Clinical Presentation of Alzheimer's Disease M. Saleem Ismail, MD University of Rochester Medical Center
7:40 PM – 8:10 PM	Treatment Initiation in Alzheimer's Disease Pierre N. Tariot, MD
8:10 PM – 8:40 PM	Individualizing Alzheimer's Disease Therapy Over the Disease Course Constantine Lyketsos, MD, MHS The Johns Hopkins University School of Medicine
8:40 PM – 9:10 PM	Neuropsychiatric Symptoms in Alzheimer's Disease: Preventing Emergence and Decreasing Severity Jeffrey L. Cummings, MD UCLA Department of Neurology
9:10 pm – 9:45 pm	Discussion/Q&A Faculty
9:45 pm – 10:00 pm	Concluding Remarks & Close Pierre N. Tariot, MD

Educational Objectives

- At the conclusion of the symposium, activity participants should be able to:
- Understand variability in the patient population that presents with Alzheimer's disease and formulate appropriate management plans based on individual patient needs and/or medical concerns
 - Comprehend the rationale and critically evaluate clinical safety and efficacy of current therapeutic approaches in treatment-naïve and treatment-experienced patients
 - Discuss the impact of neuropsychiatric symptoms in Alzheimer's disease, outline safety issues associated with the use of psychotropics in the elderly, and delineate efficacy of current Alzheimer's disease therapies in reducing the severity of behavioral symptoms

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This symposium is sponsored by the American Psychiatric Association.




Supported by an educational grant from Forest Pharmaceuticals, Inc.

Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 21
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Canadian Room

A Dinner Symposium Held During the APA 2006 Annual Meeting

Effectiveness of Antipsychotic
 Drugs in Chronic
Schizophrenia:
 Complete Results of the
 CATIE Trial



Sunday, May 21, 2006
 6:30PM-7:00PM Dinner
 7:00PM-10:00PM Educational Activity

The Fairmont Royal York
 Convention Floor, Canadian Room • Toronto, Ontario, Canada

6:30PM-7:00PM Dinner

7:00PM Welcome and Introduction
 Jeffrey A. Lieberman, MD
 Program Chairperson
 Columbia University Medical Center

**7:10PM Comparison of Primary
 Outcome Measures of Efficacy
 and Safety**
 Jeffrey A. Lieberman, MD
 Program Chairperson

**7:35PM Comparison of Clozapine vs
 Other Atypical Drugs in Prospectively
 Defined Unresponsive Patients**
 Joseph P. McEvoy, MD
 Duke University School of Medicine

**8:00PM Comparison of Ziprasidone vs
 Other Atypical Drugs in Prospectively
 Defined Unresponsive Patients**
 T. Scott Stroup, MD, MPH
 University of North Carolina at Chapel Hill

**8:25PM Comparison of Treatment
 Effects on Cognition**
 Richard S.E. Keefe, PhD
 Duke University Medical Center

**8:50PM Comparison of Treatments on
 Health Service Utilization and
 Cost-Effectiveness Measures**
 Robert A. Rosenheck, MD
 Yale School of Medicine

9:15PM Question and Answer Session
10:00PM Program Adjournment

Learning Objectives

- Upon completion of the activity, participants should be able to
1. Identify the primary outcome measures used to measure safety and efficacy in the CATIE Trial.
 2. Evaluate the impact of antipsychotics on cognitive function in schizophrenia.
 3. Compare differences in the efficacy of antipsychotics in defined unresponsive patients.
 4. Differentiate antipsychotics in measures of healthcare utilization and cost-effectiveness measures.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Faculty Disclosure Statement

All faculty are required to disclose to the audience any real or apparent conflicts of interest that may have a direct bearing on the subject matter of the educational activity. The faculty disclosure statements will be listed in the course syllabus and at the beginning of each slide presentation.

Sponsored by the American Psychiatric Association



Supported by an educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.

Don't Miss This Important Educational Activity!

INDUSTRY-SUPPORTED SYMPOSIUM 22
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Concert Hall

Mania in Special Populations

A CME INDUSTRY-SUPPORTED SYMPOSIUM
 AT THE 2006 AMERICAN PSYCHIATRIC
 ASSOCIATION ANNUAL MEETING

Saturday, May 20, 2006
 6:30 PM - 6:00 PM Dinner
 6:00 PM - 9:00 PM Scientific Program
 Metro Toronto Convention Centre
 North Level 100
 Room 102

John Bassett, Toronto

Agenda and Faculty

- 6:30 PM - 6:00 PM** Dinner
- 6:00 PM - 6:30 PM** **Welcome and Introduction**
 Robert M.A. Hirschfeld, MD, University Chair
 The University of Texas Medical Branch
- 6:30 PM - 6:35 PM** **Recent Developments in the Treatment of Mania**
 Robert M.A. Hirschfeld, MD
- 6:35 PM - 6:55 PM** **Prevalence and Management of Child and Adolescent Bipolar Disorder**
 Karen D. Wagner, MD, PhD
 The University of Texas Medical Branch
- 6:55 PM - 7:20 PM** **Bipolar Disorders in Women: Clinical and Molecular Correlates**
 Manjula L. Duggan, PhD, PhD
 Stanford University School of Medicine
- 7:20 PM - 7:45 PM** **Bipolar Disorder in the Chinese Patient**
 Brent P. Forsythe, MD
 McLaughlin Hospital
- 7:45 PM - 8:15 PM** **Prevalence of Bipolar Disorder in African Americans**
 William B. Lawson, MD, PhD, DAPA
 Howard Lykes College of Medicine
- 8:15 PM - 8:35 PM** **Q & A / Discussion**
 All Faculty
- 8:35 PM - 9:00 PM** **Concluding Remarks**
 Robert M.A. Hirschfeld, MD

Educational Objectives

- At the conclusion of this symposium, the participant should be able to:
1. Obtain new data and how this information can help the clinician manage the patient with mania.
 2. Describe the clinical presentation of bipolar disorder in children and adolescents, as well as address special treatment issues in this population.
 3. Evaluate special issues regarding mania in women, such as management during pregnancy and breastfeeding, and management of schizoaffective illness, such as psychotic and behavioral abnormalities.
 4. Identify special concerns in other adults, including differential diagnosis with neurologic disorders, and address special treatment issues in this population.
 5. Enhance knowledge about bipolar disorder in African Americans, including management in emergency and specialty settings, and appropriate diagnosis of care in the community.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA CME Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the U.S. or Canada) or 703.907.7300.

Registered conference participants and registered guests may attend an industry-sponsored symposium at the APA meeting.


Sponsored by an educational grant from Shire



INDUSTRY-SUPPORTED SYMPOSIUM 23
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

<p>ADVANCES IN THE NEUROBIOLOGY AND THERAPEUTICS OF ADHD</p> <p>Sunday, May 21, 2006 6:30 PM – 7:00 PM Dinner 7:00 PM – 10:00 PM Scientific Session Sheraton Centre Toronto • Lower Concourse, Grand Ballroom 123 Queen Street West, Toronto, Ontario, Canada</p>		<p>Symposium to be held at the APA 2006 Annual Meeting</p> <p>SCIENTIFIC PROGRAM AGENDA</p> <p>7:00 PM – 7:10 PM Program Introduction <i>Joseph Biederman MD, (Symposium Chair)</i></p> <p>7:10 PM – 7:40 PM Sleep and ADHD <i>Eric Mick, ScD Massachusetts General Hospital</i></p> <p>7:40 PM – 8:10 PM New Therapeutic Developments in ADHD <i>Joseph Biederman, MD Massachusetts General Hospital</i></p> <p>8:10 PM – 8:40 PM Defining Executive Function Deficits in ADHD <i>Ronna Fried, EdD Massachusetts General Hospital</i></p> <p>8:40 PM – 9:10 PM Advances in f-MRI research in ADHD <i>George Bush, MD Massachusetts General Hospital</i></p> <p>9:10 PM – 9:40 PM New Targets for Pharmacogenetic Research in ADHD <i>Stephen Faraone, PhD SUNY Upstate Medical University</i></p> <p>9:40 PM – 10:00 PM Panel Discussion/Question-and-Answer Session</p>
<p>LEARNING OBJECTIVES</p> <p>At the conclusion of this symposium the participant should be able to:</p> <ul style="list-style-type: none"> describe new horizons in the neurobiology and psychopharmacology of ADHD. associate new findings between ADHD and sleep disorders. review new findings pertaining to neuropsychological impairments in ADHD and their functional consequences. discover new developments in the psychopharmacology of ADHD. 	<p>ACCREDITATION STATEMENT</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>CREDIT DESIGNATION</p> <p>The APA designates this educational activity for a maximum of 3 <i>AMA PRA Category 1 Credits</i>SM. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>REGISTRATION</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.</p>	<p>Supported by an educational grant from Cephalon, Inc.</p> <p>Sponsored by the American Psychiatric Association.</p>

INDUSTRY-SUPPORTED SYMPOSIUM 24
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Westin Harbour Castle, Street Level, Frontenac Room

	<p>Presented at the APA 2006 Annual Meeting</p> <p>Atypical Depression: Merging Evidence and Public Policy</p> <p>Sunday, May 21, 2006 • 7:00 p.m.–10:00 p.m. (Dinner 6:30 p.m.–7:00 p.m.) Westin Harbour Castle, Street Level, Frontenac Room, Toronto, Canada</p>	<p>Bristol-Myers Squibb Company Supported by an educational grant from Bristol-Myers Squibb Company.</p>
	<p>Program Agenda ▼</p> <p>6:30 p.m.–7:00 p.m. Dinner</p> <p>7:00 p.m.–7:10 p.m. Welcome and Introduction <i>Michael E. Thase, MD (Chair) University of Pittsburgh</i></p> <p>7:10 p.m.–7:35 p.m. The Neurobiology of Depression: Bringing the Latest in Science to Clinicians <i>Charles B. Nemeroff, MD, PhD Emory University</i></p> <p>7:35 p.m.–8:00 p.m. Phenomenology of Atypical Depression <i>Hans-Jürgen Möller, MD University of Munich</i></p> <p>8:00 p.m.–8:25 p.m. An Evidence-Based Approach to Managing the Disabilities of Atypical Depression <i>Justine M. Kent, MD Columbia University</i></p> <p>8:25 p.m.–8:50 p.m. Future Directions in the Treatment of Atypical Depression <i>Michael E. Thase, MD University of Pittsburgh</i></p> <p>8:50 p.m.–9:15 p.m. Interactive Patient Cases</p> <p>9:15 p.m.–10:00 p.m. Panel Discussion/Q&A</p>	<p>Learning Objectives</p> <ul style="list-style-type: none"> Identify the clinical features of atypical depression. Examine the neurobiological underpinnings of atypical depression. Implement a treatment plan that incorporates non-pharmacologic and pharmacologic strategies to enhance patient outcomes. <p>Statement of Need ▼</p> <p>Atypical depression is a common subtype of depression that affects 29 to 42 percent of depressed patients. Patients with atypical depression have unique differences in symptom and biological profiles, sleep characteristics, age of onset of disease, and response to drug treatment. A diagnosis of atypical depression must include mood reactivity and at least two of the following symptoms: hyperphagia, hypersomnia, leaden paralysis, or rejection sensitivity. The National Comorbidity Survey found that among patients diagnosed with atypical depression, a higher percentage are women and there is a higher overall rate of comorbidities, including drug dependence, and a higher prevalence of suicide. Atypical depression impacts public health through an increased burden on the health care system and hospital emergency rooms. Patients with atypical depression have significantly more disability days due to mental health than patients with typical depression. A correct diagnosis of atypical depression is critical to appropriate treatment selection and positive patient outcomes. Utilizing a case-based, interactive presentation, the experts will explore the unique presentations of atypical depression to enhance the audience's understanding of atypical depression and improve patient outcomes.</p> <p>References:</p> <ol style="list-style-type: none"> Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey. <i>Arch Gen Psychiatry</i> 2003;60:817-826. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. <i>J Clin Psychiatry</i> 1998;59(suppl 18):5-9. <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.</p> <p>Sponsored by the American Psychiatric Association.</p>

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 *AMA PRA Category 1 Credits*SM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 25
 Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

Insomnia From the Inside-Out

(From Neuroscience to Clinical Experience to Public Policy)

Sunday, May 21, 2006 • 6:30 PM – 7:00 PM Dinner • 7:00 PM – 10:00 PM Symposium
 Metropolitan Ballroom, Convention Level, Westin Harbour Castle • Toronto, Ontario, Canada

7:00 PM–7:15 PM

Welcome and Introduction

Ellen Frank, PhD, *Chair*
 University of Pittsburgh School of Medicine
 Western Psychiatric Institute and Clinic

David Kupfer, MD, *Co-Chair*
 University of Pittsburgh School of Medicine
 Western Psychiatric Institute and Clinic
 Pittsburgh, PA

7:15 PM–7:45 PM

Insomnia: Symptom, Syndrome, or Disorder

Martin Keller, MD
 Brown University
 Providence, RI

7:45 PM–8:15 PM

The Science of Insomnia

Phyllis Zee, MD, PhD
 Northwestern University
 Chicago, IL

8:15 PM–8:45 PM

Putting the Science to Work

Daniel Buysse, MD
 University of Pittsburgh School of
 Medicine
 Pittsburgh, PA

8:45 PM–9:15 PM

Insomnia: Cost of Illness, Public Policy, and Medico-legal Issues

Alan Newman, MD
 Georgetown University Hospital
 Washington, DC

9:15 PM–10:00 PM

Question-and-Answer Session
 Faculty Panel

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Review the science of insomnia from the neurobiology to clinical practice
 - Assess the ways the practitioner can be informed by the clinical research
 - Demonstrate an understanding of the impact of insomnia on the individual, healthcare, and public policy.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7924.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits™ toward the AMA Physician's Recognition Award and the Accreditation Council for Continuing Medical Education (ACCME) Category 1 CME credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. APA (AMA Category 1) credit is available only for physicians.



Sponsored by the American Psychiatric Association



Supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 26
 Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
 Royal York, Convention Floor, Canadian Room

CLINICAL IMPLICATIONS OF CHOICE OF ATYPICAL ANTIPSYCHOTIC REALITIES AND MYTHS

2006 APA ANNUAL MEETING

DATE: MONDAY, MAY 22nd TIME: 7:00 AM – 8:30 AM ACTIVITY CHAIRPERSON: ROBERT E. HALES, MD, MBA
 TUESDAY, MAY 23rd TIME: 7:00 AM – 8:30 AM CO-CHAIR: STUART C. YUDOFSKY, MD
 THE FAIRMONT ROYAL YORK = CANADIAN ROOM = TORONTO, CANADA

AGENDA			
MONDAY, MAY 22, 2006	TUESDAY, MAY 23, 2006		
6:30 AM – 7:00 AM	BREAKFAST	6:30 AM – 7:00 AM	BREAKFAST
7:00 AM – 7:05 AM	WELCOME AND INTRODUCTION Robert E. Hales, MD, MBA Stuart C. Yudofsky, MD	7:00 AM – 7:05 AM	WELCOME AND INTRODUCTION Robert E. Hales, MD, MBA Stuart C. Yudofsky, MD
7:05 AM – 7:30 AM	IMPACT OF SHORT-TERM TREATMENT ON LONG-TERM PATIENT OUTCOMES Stephen R. Marder, MD	7:05 AM – 7:30 AM	BRIDGING PHARMACOLOGY AND CLINICAL EFFECTIVENESS IN SCHIZOPHRENIA Anissa Ali-Bangham, MD
7:30 AM – 7:55 AM	NEUROCOGNITION, FUNCTIONAL OUTCOMES, AND PSYCHOPHARMACOLOGY Michael F. Green, PhD	7:30 AM – 7:55 AM	ADVANCES IN PHARMACOTHERAPY FOR MAINTENANCE TREATMENT IN BIPOLAR DISORDER Torrence A. Ketter, MD
7:55 AM – 8:25 AM	PANEL DISCUSSION Discussion: Claudia F. Baldassano, MD	7:55 AM – 8:25 AM	PANEL DISCUSSION Discussion: Claudia F. Baldassano, MD
8:25 AM – 8:30 AM	CLOSING REMARKS Robert E. Hales, MD, MBA Stuart C. Yudofsky, MD	8:25 AM – 8:30 AM	CLOSING REMARKS Robert E. Hales, MD, MBA Stuart C. Yudofsky, MD

Attendees must be registered for the 2006 APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7900.

PROGRAM OVERVIEW

With an increasing appreciation of the pathophysiologic mechanisms underlying psychotic disorders, such as bipolar disorder and schizophrenia, atypical antipsychotics have been developed that demonstrate greater clinical efficacy and fewer adverse effects compared with conventional antipsychotics. In addition to improved efficacy against negative symptoms, atypical antipsychotics offer advantages in improving cognitive deficits, a core feature of schizophrenia that has drawn considerable interest as a drug target. In choosing an atypical antipsychotic for the treatment of bipolar disorder or schizophrenia, the differential pharmacologic profiles of these agents can be utilized to personalize pharmacotherapy based on patient preferences, prior response, and metabolic and cardiovascular health vulnerabilities. This two-part symposium will review the implications of choice of therapy on neurocognition, functional outcomes, and overall patient health in individuals with bipolar disorder and schizophrenia.

LEARNING OBJECTIVES

- After attending this symposium, participants should be better able to:
- Discuss the differential pharmacology of atypical antipsychotics and the clinical implications in patients with psychotic disorders
 - Differentiate between atypical antipsychotics and mood stabilizers with respect to efficacy, safety, and tolerability
 - Consider the impact of sedation on functionality and cognition in patients with psychotic disorders

ACCREDITATION STATEMENT


The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT



The APA designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by the American Psychiatric Association

Supported by an educational grant from Bristol-Myers Squibb Company and OTSUKA AMERICA PHARMACEUTICAL, INC.



INDUSTRY-SUPPORTED SYMPOSIUM 27
 Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING THE MANAGEMENT OF GAD		Symposium to be held at the APA 2006 Annual Meeting
<p>Monday, May 22, 2006 and Tuesday, May 23, 2006 6:30 AM – 7:00 AM Breakfast 7:00 AM – 8:30 AM Scientific Session Sheraton Centre • Lower Concourse, Grand Ballroom 123 Queens St. West, Toronto, Ontario, Canada M5H 2M6</p>		<p>SCIENTIFIC PROGRAM AGENDA</p> <p>Monday, May 22 7:00 AM – 7:10 AM Welcome and Introduction David V. Sheehan, MD, MBA (Chair)</p> <p>7:10 AM – 7:35 AM Evidence-Based Advocacy: A Data-Driven Look at the Somatic Expression of GAD Philip R. Muskin, MD Columbia University</p> <p>7:35 AM – 8:00 AM Comorbidity in GAD: A Public Health Challenge John L. Beyer, MD Duke University Medical Center</p> <p>8:00 AM – 8:30 AM Panel Discussion/Question-and-Answer Session</p> <p>Tuesday, May 23 7:00 AM – 7:20 AM The Cognitive Expression of GAD David J. Nutt, MD University of Bristol</p> <p>7:20 AM – 7:40 AM Gender Differences in GAD from Menarche to Menopause Marlene P. Freeman, MD University of Arizona</p> <p>7:40 AM – 8:00 AM The Evidence Supporting Targeted Pharmacotherapy in GAD David V. Sheehan, MD, MBA University of South Florida</p> <p>8:00 AM – 8:30 AM Panel Discussion/Question-and-Answer Session</p>
<p> Supported by an unrestricted educational grant from Cephalon, Inc.</p>	<p> Sponsored by the American Psychiatric Association</p>	
<p>LEARNING OBJECTIVES</p> <p>At the conclusion of this symposium the participant should be able to:</p> <ul style="list-style-type: none"> Identify and recognize the myriad presentations of anxiety disorders. Recognize the somatic comorbidities of anxiety disorders. Evaluate targeted non-pharmacologic and pharmacologic strategies for the optimal treatment of generalized anxiety disorder. 	<p>ACCREDITATION STATEMENT</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>CREDIT DESIGNATION</p> <p>The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>REGISTRATION</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.</p>	

INDUSTRY-SUPPORTED SYMPOSIUM 28
 Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 159th Annual Meeting
 Please join us for a two-part CME breakfast symposium on ...

Learning Objectives

At the conclusion of this symposium, the participant should be able to:

Identify and manage comorbid or residual anxiety in patients with depression; address the needs of different patient populations with depression and anxiety with respect to presentation, response to therapy, comorbidities, and psychosocial needs; describe the therapeutic challenge of treating patients with anxiety and depression and the relative efficacy of therapeutic options; describe the prevalence and impact of anxiety in patients with depression; and summarize evidence from randomized controlled trials describing the safety and efficacy of different antidepressant agents used in the management of depression and anxiety

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or +1-703-907-7300.



Sponsored by the American Psychiatric Association and supported by an educational grant from

Wyeth

Part 1	Part 2
Date: Monday, May 22, 2006	Date: Tuesday, May 23, 2006
Time: 6:30-7:00 AM Breakfast	Time: 6:30-7:00 AM Breakfast
7:00-8:30 AM Scientific Program	7:00-8:30 AM Scientific Program
Room: Westin Harbour Castle, Second Level Metro Grand Ballroom	Room: Westin Harbour Castle, Second Level Metro Grand Ballroom
Chairperson: Madhukar H Trivedi, MD	Chairperson: Madhukar H Trivedi, MD
6:30-7:00 AM Breakfast	6:30-7:00 AM Breakfast
7:00-7:05 AM Welcome and Overview Madhukar H Trivedi, MD University of Texas Southwestern	7:00-7:15 AM Welcome, Summary of Day 1 Madhukar H Trivedi, MD University of Texas Southwestern
7:05-7:30 AM Impact of Associated Anxiety Symptoms on Depression Peter P Roy-Byrne, MD University of Washington	7:15-7:30 AM New Strategies to Address Anxiety and Resistant Somatic Symptoms Mark H Kapur, MD Cedars-Sinai Medical Center
7:30-7:55 AM Collaborative Management Strategies for Patients With Comorbid Anxiety With Depression Wayne J Katon, MD University of Washington Medical Center	7:40-8:05 AM How to Monitor Progress of Treatment of Depression With Anxiety Madhukar H Trivedi, MD University of Texas Southwestern
7:55-8:20 AM Strategies to Achieve and Sustain Remission in Patients Shailesh Jain, MD University of Texas Southwestern	8:05-8:30 AM Panel Discussion and Q & A Madhukar H Trivedi, MD University of Texas Southwestern
8:20-8:30 AM Panel Discussion and Q & A Madhukar H Trivedi, MD University of Texas Southwestern	



PHARMACOTHERAPY of PSYCHOTIC and MOOD DISORDERS WITH COEXISTING MEDICAL ILLNESS

Monday, May 22, 2006 • Dinner: 6:30-7:00 PM • Symposium: 7:00-10:00 PM

Toronto Convention Centre North, Level 100 • Room 106 • Toronto, Ontario, Canada

This program will be conducted on May 22, 2006 during the APA 2006 Annual Meeting

AGENDA:

6:30-7:00 PM	Dinner	8:00-8:25 PM	Pharmacotherapy of Psychotic and Mood Disorders in the Context of Thromboembolic Disease QUINTON E. MOSS, MD <i>University of Cincinnati</i>
7:00-7:10 PM	Welcome and Introductions MICHELLE B. RIBA, MD, MS (CHAIRPERSON) <i>University of Michigan</i>	8:25-8:50 PM	When Mental Illness Is Complicated by Respiratory Symptoms: Management Implications PETER J. WEIDEN, MD <i>SUNY Downstate Medical Center</i>
7:10-7:35 PM	Optimal Selection of Pharmacotherapy in Psychotic and Mood Disorders With Coexisting Metabolic Disorders HENRY A. NASRALLAH, MD (CO-CHAIRPERSON) <i>University of Cincinnati Medical Center</i>	8:50-9:15 PM	When HIV Complicates Psychosis or Mood Disorder: Pharmacotherapeutic Considerations and Drug Interactions GLENN J. TREISMAN, MD, PhD <i>Johns Hopkins University</i>
7:35-8:00 PM	Patients With Mental Illness and Cancer DIANA O. PERKINS, MD, MPH <i>University of North Carolina School of Medicine</i>	9:15-10:00 PM	Question and Answer Session ALL FACULTY
		10:00 PM	Adjourn

LEARNING OBJECTIVES:

- After attending this symposium, participants will be able to:
- Identify the method for achieving the optimal pharmacotherapy in patients who have psychotic and mood disorders with coexisting metabolic disorders
 - Discuss the medical management of mental illness in a person who also has a diagnosis of cancer
 - Review the appropriate pharmacotherapy of psychotic and mood disorders in the presence of thromboembolic disease
 - Analyze the management implications when treating a person with mental illness complicated by the presence of respiratory symptoms
 - Discuss the pharmacotherapy of psychiatric problems in the patient with AIDS

CME STATEMENT

This symposium will be conducted on May 22, 2006, during the APA 2006 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US) or 703-907-7300.

If any participant in this educational activity is in need of accommodations, please call 860-434-1650 by May 1, 2006, in order to receive service.



Sponsored by the American Psychiatric Association

Sponsored by an educational grant from AstraZeneca

INDUSTRY-SUPPORTED SYMPOSIUM 30 Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m. Royal York, Convention Floor, Canadian Room



Presented at the APA 2006 Annual Meeting

Helping Depressed Patients Achieve Remission: Advocacy for Improvement

Learning Objectives

- Recognize factors contributing to heterogeneity in response and remission and the implications for treatment outcomes.
- Evaluate strategies for partial or non-responders that include switching, augmentation, and combination treatments.
- Examine the role of pharmacogenetics in treatment selection.
- Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to achieve remission.

Statement of Need

Symptom remission is the goal of treating depression. However, most patients are "treatment resistant" and don't achieve remission with any one treatment, likely reflecting the heterogeneous pathobiology underpinning depression. Current practice recommends a range of "trial and error" sequential treatment steps, including switching, augmentation, or combination treatments. Unfortunately, few prospective randomized controlled trials have compared multiple augmentation or switch treatments. This symposium will present findings from controlled treatment trials—including the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial—that have investigated augmentation/combination treatments at the second and third treatment steps and switch treatments at the second, third, and fourth treatment steps.

References

- Warden D, Rush AJ, Trivedi M, Ritz L, Stegman D, Wisniewski SR: Quality improvement methods as applied to a multicenter effectiveness trial—STAR*D. *Contemp Clin Trials*, 2005 Feb;26(1):95-112. Epub 2005 Jan 27.
- Trivedi MH, Klettner BA: Using treatment algorithms for the effective management of treatment-resistant depression. *J Clin Psychiatry*. 2001;62 (Suppl 18):25-9.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an educational grant from Bristol-Myers Squibb Company.
 Bristol-Myers Squibb Company



Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Program Agenda


6:30 p.m. - 7:00 p.m.	Dinner
7:00 p.m. - 7:10 p.m.	Welcome and Introductions MICHELLE B. RIBA, MD, MS <i>University of Michigan</i>
7:10 p.m. - 7:35 p.m.	Optimal Selection of Pharmacotherapy in Psychotic and Mood Disorders With Coexisting Metabolic Disorders HENRY A. NASRALLAH, MD (CO-CHAIRPERSON) <i>University of Cincinnati Medical Center</i>
7:35 p.m. - 8:00 p.m.	Patients With Mental Illness and Cancer DIANA O. PERKINS, MD, MPH <i>University of North Carolina School of Medicine</i>
8:00 p.m. - 8:25 p.m.	Pharmacotherapy of Psychotic and Mood Disorders in the Context of Thromboembolic Disease QUINTON E. MOSS, MD <i>University of Cincinnati</i>
8:25 p.m. - 8:50 p.m.	When Mental Illness Is Complicated by Respiratory Symptoms: Management Implications PETER J. WEIDEN, MD <i>SUNY Downstate Medical Center</i>
8:50 p.m. - 9:15 p.m.	When HIV Complicates Psychosis or Mood Disorder: Pharmacotherapeutic Considerations and Drug Interactions GLENN J. TREISMAN, MD, PhD <i>Johns Hopkins University</i>
9:15 p.m. - 10:00 p.m.	Question and Answer Session ALL FACULTY
10:00 p.m.	Adjourn

Monday, May 22, 2006

7:00 p.m. - 10:00 p.m.
 (Dinner 6:30 p.m. - 7:00 p.m.)

Royal York Hotel,
 Convention Floor, Canadian
 Room, Toronto, Canada

INDUSTRY-SUPPORTED SYMPOSIUM 31
 Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Concert Hall



Monday, May 22, 2006
6:30 PM – 7:00 PM Dinner
7:00 PM – 10:00 PM Program
The Fairmont Royal York Hotel
Convention Floor Concert Hall

Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

APA 2006 ANNUAL MEETING: ISS-31
Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder

Dinner
 6:30 PM – 7:00 PM

Program
 7:00 PM • **Welcome/Introduction**
 Timothy E. Wilens, MD, Chair
 Massachusetts General Hospital

7:10 PM • **Imaging the Brains of ADHD Adults: New Findings**
 George Bush, MD
 Massachusetts General Hospital

7:35 PM • **ADHD 'Not Otherwise Specified': Conceptual Issues**
 Stephen V. Faraone, PhD
 SUNY Upstate Medical University

8:00 PM • **ADHD Behind the Wheel: Driving With ADHD**
 Craig B. Surman, MD
 Massachusetts General Hospital

8:25 PM • **ADHD Goes to College: Planning, Protecting, and Prospering**
 Sharon B. Wigal, PhD
 University of California, Irvine

8:50 PM • **Emerging Therapies in the Treatment of ADHD**
 Timothy E. Wilens, MD
 Massachusetts General Hospital

9:15 PM • **Question and Answer Session**

10:00 PM • **Adjournment**

Learning Objectives:

At the conclusion of this symposium, the participant should be able to:

1. Understand the clinical presentation of ADHD through young adulthood
2. Appreciate the special considerations in the diagnosis and treatment of young adults with ADHD
3. Discuss new and emerging pharmacological treatments for adolescents and adults with ADHD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association.



Supported by an educational grant from Shire.




INDUSTRY-SUPPORTED SYMPOSIUM 32
 Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

THE COGNITION, NEUROCIRCUITRY,
 AND DISABILITY INTERFACE:

**BRINGING EVIDENCE
 TO PRACTICE**

Symposium to be held at the APA 2006 Annual Meeting

Monday, May 22, 2006
6:30 PM – 7:00 PM Dinner
7:00 PM – 10:00 PM Scientific Session
Sheraton Centre • Lower Concourse, Grand Ballroom
123 Queens St. West, Toronto, Ontario, Canada M5H 2M6

 Supported by an unrestricted educational grant from Cephalon, Inc.

 Sponsored by the American Psychiatric Association

SCIENTIFIC PROGRAM AGENDA

7:00 PM – 7:10 PM
 Welcome and Introduction
 John H. Krystal, MD (Chair)

7:10 PM – 7:35 PM
 The Neurocircuitry of Cognition
 John H. Krystal, MD
 Yale University

7:35 PM – 8:00 PM
 Cognition: What Is the Role of Genetics?
 Daniel R. Weinberger, MD
 The George Washington University

8:00 PM – 8:25 PM
 Cognition, Attention, and Executive Function:
 How Do They Translate in Our Patients?
 Philip D. Harvey, PhD
 Mt. Sinai School of Medicine

8:25 PM – 8:50 PM
 From Brain to Bedside: Understanding the Clinical
 Interface of Cognition and Neurocircuitry of
 Depression
 Boadie W. Dunlop, MD
 Emory University

8:50 PM – 9:15 PM
 Novel Treatments for Cognitive Enhancement:
 Can Drugs Make People Smarter?
 Trevor Robbins, PhD
 University of Cambridge

9:15 PM – 10:00 PM
 Panel Discussion/Question-and-Answer Session

LEARNING OBJECTIVES

At the conclusion of this symposium the participant should be able to:

- Illustrate the impact of genetics on the cognitive process.
- Describe the neurocircuitry of the brain driving executive dysfunction in schizophrenia, depression, and ADHD.
- Evaluate treatments that target neurotransmitters that may enhance executive function.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.

INDUSTRY-SUPPORTED SYMPOSIUM 33
 Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting • Monday, May 22, 2006

Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia

Dinner • 6:30PM – 7:00PM • Symposium • 7:00 PM – 10:00 PM
 Metro Grand Ballroom, Second Level, Westin Harbour Castle • Toronto, Canada

6:30 PM–7:00 PM Dinner

7:00 PM–7:15 PM **Welcome and Introduction**
 Steven G. Potkin, MD, Chairman
 Department of Psychiatry and Human Behavior,
 University of California, Irvine

7:15 PM–7:45 PM **Recognizing Negative Symptoms
 and Their Importance**
 Joseph M. Pierre, MD
 Department of Psychiatry and
 Biobehavioral Sciences
 University of California, Los Angeles

7:45 PM–8:15 PM **Psychosis Circuits, Negative Symptoms
 and Brain Imaging**
 Steven G. Potkin, MD

8:15 PM–8:45 PM **Treatment of Negative Symptoms**
 Hans-Jürgen Möller, MD
 Department of Psychiatry,
 Ludwig-Maximilians-University

8:45 PM–9:15 PM **Positive Outcomes with Negative Symptoms:
 Measuring and Monitoring Your Patients**
 Dawn I. Velligan, PhD
 Department of Psychiatry,
 University of Texas H.S.C.

9:15 PM–10:00 PM **Question-and-Answer Session**
 Faculty Panel

OBJECTIVES

After attending this symposium, the participant will be able to:

- Recognize that patients with schizophrenia can have prominent negative symptoms, which severely limit their functional outcomes.
- Differentiate negative symptoms from cognitive, affective, and other independent symptom domains in schizophrenia.
- Demonstrate understanding of the neuronal circuitry that underlie negative symptoms.
- Understand treatment strategies to reduce negative symptoms in patients with schizophrenia.
- Utilize an informed approach to improve treatment of negative symptoms in patients.
- Measure and monitor negative symptoms in patients to improve outcomes.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (with the US or Canada) or (703) 907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council on Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Sponsored by the American Psychiatric Association
 Supported by an educational grant from Organon USA



INDUSTRY-SUPPORTED SYMPOSIUM 34
 Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
 Toronto Convention Centre, North Level 100, Room 102

Sponsored by the American Psychiatric Association
 Take Advantage of this Invaluable Educational Opportunity at **APA 2006!**

Management of Psychosis in the Elderly: The Science and the Art

3.0 CME Credits are designated for participation in this Educational Symposium.

TUESDAY, MAY 23, 2006

6:30 – 7:00 PM DINNER

7:00 – 10:00 PM PROGRAM

Toronto Convention Centre
 North Level 100, Room 106

PROGRAM CHAIR:



Dilip V. Jeste, MD
 Estelle and Edgar Levi Chair in Aging
 Distinguished Professor of Psychiatry and Neurosciences
 Director, Sam and Rose Stein Institute for Research on Aging
 Chief, Geriatric Psychiatry Division
 University of California, San Diego
 VA San Diego Healthcare System
 San Diego, California

LEARNING OBJECTIVES:

At the end of this symposium, the participants should be able to:

- Develop different diagnoses and differential diagnoses of psychotic disorders in elderly
- Treat psychotic disorders in elderly with appropriate pharmacotherapy
- Recognize adverse effects of medications in older persons
- Choose appropriate psychosocial interventions in older psychotic patients

AGENDA:

6:30 pm – 7:00 pm

7:00 pm – 7:05 pm

7:05 pm – 7:30 pm

7:30 pm – 7:35 pm

7:35 pm – 8:00 pm

8:00 pm – 8:05 pm

8:05 pm – 8:30 pm

8:30 pm – 8:35 pm

8:35 pm – 9:00 pm

9:00 pm – 9:05 pm

9:05 pm – 9:30 pm

9:30 pm – 10:00 pm

Complimentary Dinner
 Welcome and Introduction

Evaluation of Psychosis
 in the Elderly
 Discussion from the Floor
 Efficacy and Effectiveness of
 Antipsychotics in the Elderly

Discussion from the Floor
 Safety of Antipsychotics in
 Elderly Patients
 Discussion from the Floor
 Novel Antipsychotic Strategies:
 Implications for Biology and
 Future Treatment

Discussion from the Floor
 Nonpharmacologic Interventions
 for Psychosis in the Elderly
 Question-and-Answer Session

Dilip V. Jeste, MD
 University of California, San Diego
 Carl Salzman, M.D.
 Harvard Medical School

Lon S. Schneider, MD
 University of Southern California,
 Kock School of Medicine

Dilip V. Jeste, MD

P. Murali Doraiswamy, MD
 Duke University

Warachal E. Faizon, MD
 Medical University of South Carolina
 Entree Panel

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

ACCREDITATION



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Solvay Pharmaceuticals and Wyeth Pharmaceuticals.

Solvay
 Pharmaceuticals



Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 35
 Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Canadian Room



MULTIPLE AND COMPLEX PRESENTATIONS OF
Bipolar Disorder

Charles L. Bowden, MD—Program Chairman

Tuesday, May 23, 2006

The Fairmont Royal York—Convention Floor, Canadian Room

- 6:30–7:00 pm** Dinner
- 7:00–7:10 pm** **Welcome and Introduction**
 Charles L. Bowden, MD—Program Chairman
 University of Texas Health Science Center at San Antonio
- 7:10–7:40 pm** **Presentations of Bipolar Disorder in Children and Adolescents**
 Kiki D. Chang, MD
 Stanford University School of Medicine
- 7:40–8:10 pm** **The Impulsive-Aggression Symptom Domain in Personality Disorders**
 Eric Hollander, MD
 Mount Sinai School of Medicine
- 8:10–8:40 pm** **Bipolar II Disorder and Suicidal Behaviors**
 William H. Coryell, MD
 University of Iowa Carver College of Medicine
- 8:40–9:10 pm** **Predicting Maintenance Response from the Acute Episode**
 Charles L. Bowden, MD
- 9:10–10:00 pm** **Q&A / Panel Discussion**
 All Faculty
- 10:00 pm** **Adjourn**

APA 2006 Annual Meeting

LEARNING OBJECTIVES

- Discern and differentiate between presentations of bipolar disorder.
- Understand the subgroups in the bipolar spectrum, with emphasis on early diagnosis and individualized pharmacotherapy.

ACCREDITATION

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at (888) 357-7924 (within the U.S. or Canada) or (703) 907-7200.




Sponsored by the American Psychiatric Association



Supported by an educational grant from Abbott

INDUSTRY-SUPPORTED SYMPOSIUM 36
 Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Concert Hall



TREATING the EARLY STAGES of SCHIZOPHRENIA

Tuesday, May 23, 2006 • Dinner: 6:30–7:00 PM • Symposium: 7:00–10:00 PM

The Fairmont Royal York • Convention Floor, Concert Hall • Toronto, Ontario, Canada

This program will be conducted on May 23, 2006 during the APA 2006 Annual Meeting

AGENDA:

- | | | | |
|---------------------|--|----------------------|---|
| 6:30–7:00 PM | Dinner | 8:00–8:25 PM | Evaluation of Prodromal Schizophrenia
CHERYL CORCORAN, MD
Columbia University Medical Center
New York State Psychiatric Institute |
| 7:00–7:10 PM | Welcome and Introductions
DOLORES MALASPINA, MD, MSPH (CHAIRPERSON)
Columbia University Medical Center
New York State Psychiatric Institute | 8:25–8:50 PM | Pharmacologic Strategies for the Treatment of Prodromal Schizophrenia
DANIEL C. JAVITT, MD, PhD
New York University School of Medicine |
| 7:10–7:35 PM | Genetic and Clinical Risk Factors for Schizophrenia: Predicting the Onset and Outcomes of the Illness and Treatment Response
DOLORES MALASPINA, MD, MSPH
Columbia University Medical Center
New York State Psychiatric Institute | 8:50–9:15 PM | Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection
JEFFREY A. LIEBERMAN, MD
Columbia University Medical Center |
| 7:35–8:00 PM | Treatment of First Episode Schizophrenia: Tolerability and Adherence
DELBERT G. ROBINSON, MD
Zucker Hillside Hospital | 9:15–10:00 PM | Question and Answer Session
ALL FACULTY |
| | | 10:00 PM | Adjourn |

LEARNING OBJECTIVES:

- After attending this symposium, participants will be able to:
- Describe how genetic and clinical risk factors influence the onset, treatment response, and outcomes for patients with schizophrenia
 - Recognize the impact of tolerability and adherence in treating first episode schizophrenia
 - Discern the prodromal phase for schizophrenia
 - Formulate effective pharmacologic approaches to the treatment of prodromal schizophrenia
 - Interpret the evidence of neuroprotection associated with the treatment of early stage schizophrenia

CME STATEMENT

This symposium will be conducted on May 23, 2006, during the APA 2006 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US) or 703-907-7200.

If any participant in this educational activity is in need of accommodations, please call 860-434-1650 by May 1, 2006, in order to receive service.



Sponsored by the American Psychiatric Association



INDUSTRY-SUPPORTED SYMPOSIUM 37
 Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

ADVOCATING FOR CHANGE THROUGH EVIDENCE-BASED MEDICINE: A FOCUS ON ADHD		Symposium to be held at the APA 2006 Annual Meeting	
Tuesday, May 23, 2006 6:30 PM – 7:00 PM Dinner 7:00 PM – 10:00 PM Scientific Session Sheraton Centre - Lower Concourse, Grand Ballroom 123 Queens St. West, Toronto, Ontario, Canada M5H 2M6		SCIENTIFIC PROGRAM AGENDA 7:00 PM – 7:10 PM Welcome and Introduction Christopher J. Kratochvil, MD (Chair)	
Supported by an unrestricted educational grant from Cephalon, Inc.		Sponsored by the American Psychiatric Association	
LEARNING OBJECTIVES At the conclusion of this symposium the participant should be able to:	ACCREDITATION STATEMENT The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.	7:10 PM – 7:35 PM Neurocircuitry of ADHD James J. Hudziak, MD University of Vermont	
<ul style="list-style-type: none"> Link attentional deficits, impulsivity, and hyperactivity to neural circuitry. Recognize the impact of sleep/wake disturbances on patients with ADHD. Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to improve patient outcomes. 	CREDIT DESIGNATION The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.	7:35 PM – 8:00 PM Phenomenology and Diagnosis of ADHD Christopher J. Kratochvil, MD University of Nebraska	
	REGISTRATION Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.	8:00 PM – 8:25 PM The Impact of Sleep/Wake Disturbances in ADHD Judith Owens, MD, MPH Brown University	
		8:25 PM – 8:50 PM Evidence-Based Pharmacotherapy of ADHD Timothy E. Wilens, MD Massachusetts General Hospital	
		8:50 PM – 9:15 PM Role of Family and Social Support Systems in the Management of ADHD Scott Kollins, PhD Duke University Medical Center	
		9:15 PM – 10:00 PM Panel Discussion/Question-and-Answer Session	

INDUSTRY-SUPPORTED SYMPOSIUM 38
 Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

The Maze of Mood and Anxiety in the Elderly Patient: A Case Series

Presented at the APA 2006 Annual Meeting
 Tuesday, May 23, 2006
 7:00 p.m.–10:00 p.m. (Dinner 6:30 p.m.–7:00 p.m.)
 Westin Harbour Castle, Second Level Metro, Grand Ballroom, Toronto, Canada

Supported by an educational grant from GlaxoSmithKline.

Program Agenda

- 6:30 p.m.–7:00 p.m. Dinner
- 7:00 p.m.–7:10 p.m. **Welcome and Introduction**
 Charles F. Reynolds III, MD (Chair)
 University of Pittsburgh
- 7:10 p.m.–7:35 p.m. **Achieving a Better Understanding of the Neurobiology of Mood and Anxiety Disorders in the Elderly**
 Prakash S. Masand, MD
 Duke University Medical Center
- 7:35 p.m.–8:00 p.m. **The Impact of Medical Comorbidity on Mood and Anxiety Disorders in the Elderly Patient**
 Eric J. Lenze, MD
 University of Pittsburgh
- 8:00 p.m.–8:25 p.m. **An Evidence-Based Approach to the Acute Management of Mood and Anxiety Disorders in the Elderly Population**
 Warren D. Taylor, MD
 Duke University Medical Center
- 8:25 p.m.–8:50 p.m. **Optimizing Long-Term Treatment in Old-Age Depression**
 Charles F. Reynolds III, MD
 University of Pittsburgh
- 8:50 p.m.–9:15 p.m. **Interactive Case Presentation**
- 9:15 p.m.–10:00 p.m. **Panel Discussion/Q&A**

Learning Objectives

- Identify comorbidities that may mimic mood and anxiety disorders.
- Recognize the over-arching relationship between depression and anxiety disorders in the elderly.
- Evaluate targeted non-pharmacologic, psychotherapeutic, and pharmacologic options for the optimal treatment of anxiety and mood disorders in the elderly.

Statement of Need

Many studies report that mood and anxiety disorders are less frequent among the elderly than in younger people. However, other data suggest that these disorders are actually underdiagnosed and undertreated in the elderly because the physiologic symptoms of mood and anxiety disorders overlap with other medical problems associated with advancing age. Multiple physical and neurologic conditions can mimic, exacerbate, or accompany symptoms of anxiety and mood disorders, including cardiovascular disease, cerebrovascular accidents, hyperthyroidism, sensory impairments, and dementia.² "Anxious depression" may be the most common clinical presentation of anxiety in older patients, with an estimated 70% of patients with GAD also suffering from depression.¹ GAD may arise secondarily to a depression, and recovery is closely associated with recovery from depression. Available data suggest that certain psychosocial interventions may be effective for anxiety disorders in older adults, and that clinicians should consider the effects of aging on safety and tolerability to various medications when choosing a medication regimen.³ This interactive, case-based symposium will provide practical diagnostic tools and review current evidence supporting age-appropriate psychotherapeutic and pharmacologic treatment to best accommodate this challenging population.

References:


- Sable JA, Jeste DV. Anxiety disorders in older adults. *Curr Psych Reports* 2001;3:302-7.
- Beekman ATF, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. *Am J Psychiatry* 2000;157:89–95.
- Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. *Drugs Aging* 2005;22:102-14.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association.

INDUSTRY-SUPPORTED SYMPOSIUM 39
 Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
 Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
 Toronto Convention Centre, North Level 100, Room 102

EMERGING EVIDENCE in the
TREATMENT of BIPOLAR DEPRESSION



Wednesday, May 24 & Thursday, May 25, 2006 • Breakfast: 6:30-7:00 AM • Symposium: 7:00-8:30 AM

Toronto Convention Centre North, Level 100 • Room 106 • Toronto, Ontario, Canada

This program will be conducted on May 24 and 25, 2006 during the APA 2006 Annual Meeting


AGENDA:

WEDNESDAY, MAY 24

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
JOSEPH R. CALABRESE, MD (Chairperson)
Case Western Reserve University School of Medicine
- 7:05-7:25 AM The Clinical Management of Bipolar Disorder
FREDERICK K. GOODWIN, MD
George Washington University
- 7:25-7:45 AM How Guidelines Influence Acute and Long Term Treatment of Bipolar Depression
ROBERT M.A. HIRSCHFELD, MD
University of Texas Medical Branch at Galveston
- 7:45-8:05 AM Treatment of Alcohol and Drug Abuse in Bipolar Disorder
KATHLEEN T. BRADY, MD, PhD
Medical University of South Carolina
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn

THURSDAY, MAY 25

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
JOSEPH R. CALABRESE, MD (Chairperson)
Case Western Reserve University School of Medicine
- 7:05-7:35 AM Neurobiology of Bipolar Patients: What Does It Tell Us?
SOPHIA FRANGOU, MD, PhD
Institute of Psychiatry
- 7:35-8:05 AM Future Treatments: Repetitive Transcranial Magnetic Stimulation and Vagus Nerve Stimulation in Bipolar Depression
GUOHUA XIA, MD, PhD
Case Western Reserve University School of Medicine
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn



LEARNING OBJECTIVES:

- After attending this symposium, participants will be able to:
- Review the management of patients with bipolar depression and how emerging evidence may impact the current paradigm
 - Assess current guidelines for the treatment of bipolar depression and how to use these guidelines to achieve therapeutic success
 - Explore strategies for the management of comorbid alcohol and drug abuse in patients with bipolar disorder
 - Examine the neurobiology of bipolar disorder and how it relates to the management of patients with bipolar depression
 - Outline progress related to TMS and VNS in the research field of emerging interventional psychiatry for treatment of bipolar depression

CME STATEMENT

This symposium will be conducted on May 24 and 25, 2006, during the APA 2006 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2006 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US) or 703-907-7303.

If any participant in this educational activity is in need of accommodations, please call 860-434-1430 by May 1, 2006, in order to receive service.



INDUSTRY-SUPPORTED SYMPOSIUM 40
 Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
 Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
 Royal York, Convention Floor, Canadian Room

BIPOLAR ILLNESS 2006 APA ANNUAL MEETING
THE ROAD TO REMISSION

DATE WEDNESDAY, MAY 24TH TIME 7:00 AM - 8:30 AM ACTIVITY CHAIRPERSON PRAKASH S. MASAND, MD
 THURSDAY, MAY 25TH 7:00 AM - 8:30 AM THE FAIRMONT ROYAL YORK - CANADIAN ROOM - TORONTO, CANADA

AGENDA

WEDNESDAY, MAY 24, 2006		THURSDAY, MAY 25, 2006	
6:30 AM - 7:00 AM	BREAKFAST	6:30 AM - 7:00 AM	BREAKFAST
7:00 AM - 7:05 AM	WELCOME AND INTRODUCTION Prakash S. Masand, MD	7:00 AM - 7:05 AM	WELCOME AND INTRODUCTION Prakash S. Masand, MD
7:05 AM - 7:30 AM	IS REMISSION ACHIEVABLE IN BIPOLAR DISORDER? John I. Beyer, MD	7:05 AM - 7:30 AM	AN EVIDENCE-BASED APPROACH TO ACHIEVING REMISSION IN BIPOLAR DISORDER Roger S. McIntyre, MD, FRCP
7:30 AM - 7:55 AM	ROADBLOCKS TO REMISSION IN PATIENTS WITH BIPOLAR DISORDER Prakash S. Masand, MD	7:30 AM - 7:55 AM	THE ROLE OF NONPHARMACOLOGIC THERAPIES IN ACHIEVING REMISSION Edward Vieta, MD, PhD
7:55 AM - 8:25 AM	PANEL DISCUSSION Moderator: Prakash S. Masand, MD	7:55 AM - 8:25 AM	PANEL DISCUSSION Moderator: Prakash S. Masand, MD
8:25 AM - 8:30 AM	CLOSING REMARKS Prakash S. Masand, MD	8:25 AM - 8:30 AM	CLOSING REMARKS Prakash S. Masand, MD

Attendees must be registered for the 2006 APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7300.

PROGRAM OVERVIEW

Remission of symptoms in patients with bipolar disorder is a complex concept to define and a difficult goal to achieve. The American Psychiatric Association guidelines define remission as a virtual lack of symptoms and a complete return to baseline level of functioning. The latter part of this definition may be more useful from a clinical standpoint, because assessing symptoms alone may not accurately reflect a patient's functionality. One of the initial roadblocks to remission is the misdiagnosis of patients with bipolar disorder, because these patients typically report depressive, but not manic, symptoms. Pharmacotherapy should be chosen that will achieve remission and maximize adherence to medication. Many variables contribute to poor adherence to therapy in patients with bipolar disorder, including medication-related adverse effects. Atypical antipsychotics are increasingly being used to manage bipolar disorder. Although often grouped as a class, these agents have distinct pharmacologic profiles that may impact patient adherence to therapy and overall long-term health. In order for optimal outcomes to be realized, pharmacotherapy must be individualized and combined with nonpharmacologic treatments, such as psychosocial education, group therapy, and cognitive-behavioral therapy. This symposium will review pharmacologic and nonpharmacologic strategies for achieving remission of symptoms while maximizing quality of life in patients with bipolar disorder.

LEARNING OBJECTIVES



- After attending this symposium, participants should be better able to:
- Outline a long-term strategy to enhance cognitive function and overall patient outcomes while minimizing the risk of adverse events
 - Discuss the different rates of remission associated with various pharmacotherapeutic regimens
 - Describe the role of psychosocial therapies in maintaining remission in patients with bipolar disorder

ACCREDITATION STATEMENT


The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



INDUSTRY-SUPPORTED SYMPOSIUM 41
 Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
 Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom



Sponsored by the American Psychiatric Association
 Take Advantage of this Invaluable Educational Opportunity at **APA 2006!**

**New Frontiers in Depression:
 Providing Solutions to Unmet Needs, Parts 1 & 2**

3.0 CME Credits are designated for participation in this Educational Symposium.

Weds. - Thurs., May 24-25, 2006
 6:30 - 7:00 AM BREAKFAST
 7:00 - 8:30 AM PROGRAM
 Sheraton Centre
 Lower Concourse - Grand Ballroom
 Toronto, Canada

PROGRAM CHAIR:



Stephen M. Stahl, MD, PhD
 Adjunct Professor of Psychiatry
 University of California,
 San Diego School of Medicine
 La Jolla, California
 Carlsbad, California

LEARNING OBJECTIVES:

At the end of this symposium the participants should be able to:

- Review the unmet needs in the diagnosis of major depressive disorder, by discussing the importance of often neglected painful physical symptoms, and the necessity of distinguishing unipolar depression from bipolar depression, including their treatment implications
- Show how imaging genetics is leading to an understanding of the circuits underlying the symptoms of depression, including the role of the serotonin transporter in regulating the cingulate-amygdala circuit
- Review the current approach to treating resistant depression, and also novel treatments for depression on the horizon

AGENDA (WEDNESDAY, MAY 24):

6:30 - 7:00 am Complimentary Breakfast
 7:00 - 7:10 am Introduction and Welcome

7:10 - 7:40 am Genetic Mechanisms of Mood and Temperament
 7:40 - 8:10 am Chronic Pain and Major Depression

8:10 - 8:30 am Question-and-Answer Session

AGENDA (THURSDAY, MAY 25):

6:30 - 7:00 am Complimentary Breakfast
 7:00 - 7:10 am Welcome and Part 1 Recap

7:10 - 7:35 am Unipolar versus Bipolar Depression: Diagnostic and Therapeutic Challenges
 7:35 - 8:00 am Current and Novel Treatment Options for Treatment-Resistant Depression
 8:00 - 8:30 am Question-and-Answer Session from Day 2

Stephen M. Stahl, MD, PhD
 University of California, San Diego
 School of Medicine
 Daniel R. Weinberger, MD
 National Institute of Mental Health
 Alan F. Schatzberg, MD
 Stanford University
 Drs. Stahl, Weinberger, and Schatzberg

Stephen M. Stahl, MD, PhD
 James M. Martinez, MD
 Baylor College of Medicine
 Lauren B. Marangell, MD
 Baylor College of Medicine
 Drs. Stahl, Marangell, and Martinez

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

ACCREDITATION



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The APA designates this educational activity for a maximum of 3 ABA CME Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Solvay Pharmaceuticals and Wyeth Pharmaceuticals



INDUSTRY-SUPPORTED SYMPOSIUM 42
 Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
 Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

**What the Psychiatrist Needs to Know About
 Sleep-Related Movement Disorders**



Wednesday, May 24, 2006 and Thursday, May 25, 2006 • Breakfast: 6:30 AM - 7:00 AM • Symposium: 7:00 AM - 8:30 AM
 Location: Westin Harbour Castle • Second Level, Metro Grand Ballroom • Toronto, Ontario, Canada

Held during the APA's 159th Annual Meeting

Day 1

- 7:00 AM-7:03 AM **Introduction**
 John W. Winkelman, MD, PhD—Activity Chair
 Brigham and Women's Hospital
 Harvard University Medical School
 Boston, Massachusetts
- 7:03 AM-7:28 AM **Diagnosis, Epidemiology and Natural History of Restless Legs Syndrome and Periodic Limb Movements of Sleep**
 Philip M. Becker, MD
 University of Texas
 Southwestern Medical Center at Dallas
 Dallas, Texas
- 7:28 AM-7:48 AM **Sleep, Health and Quality of Life (QOL) Consequences**
 R. Robert Auger, MD
 Mayo Clinic College of Medicine
 Mayo Sleep Disorders Center
 Rochester, Minnesota
- 7:48 AM-8:08 AM **Diagnostic Challenges and Initial Treatment Strategies**
 Cynthia Comella, MD
 Rush University Medical Center
 Chicago, Illinois
- 8:08 AM-8:30 AM **Q&A Session Faculty Panel**

Day 2

- 7:00 AM-7:03 AM **Introduction**
 John W. Winkelman, MD, PhD—Activity Chair
 Brigham and Women's Hospital
 Harvard University Medical School
 Boston, Massachusetts
- 7:03 AM-7:28 AM **Restless Legs Syndrome and Psychiatric Disorders: Demonstrating a Relationship**
 John W. Winkelman, MD, PhD
- 7:28 AM-7:37 AM **Video of Patient Case: Diagnosis, QOL, and Sleep**
 John W. Winkelman, MD, PhD
- 7:37 AM-8:07 AM **Current Therapeutic and Management Strategies in Restless Legs Syndrome**
 Clete A. Kushida, MD
 Stanford University
 Center of Excellence for Sleep Disorders
 Stanford, California
- 8:07 AM-8:30 AM **Q&A Session Faculty Panel**

This symposium is supported by an educational grant from



Learning Objectives

At the conclusion of the symposium the participants should be able to:

- Assess the burden of restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) on a patient's quality of life through a better understanding of the epidemiology, diagnostic features, and consequences of these disorders.
- Differentiate between RLS and PLMS and other clinical "mimic" disorders, and assess the presence of coexisting sleep disorders, based on an understanding of clinical presentation and risk factors.
- Formulate effective treatment strategies for patients with RLS, with or without PLMS, based on the efficacy and safety of available pharmacologic and nonpharmacologic therapies.
- Tailor treatment strategies that improve outcomes of special populations of patients with RLS, including those with major depression.

CME Information

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Physician Attendance

Attendees must be registered for the APA Institute on Psychiatric Services to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 43
 Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Canadian Room

APA 159th Annual Meeting
 Please to join us for a CME Symposium on...

What Is the Role of Somatic and Physical Symptoms in Depression?

Wednesday, May 24, 2006
 6:30-7:00 PM Dinner
 7:00-10:00 PM

Learning Objectives

- At the conclusion of this symposium, the participant should be able to:
- Describe the somatic and physical symptom presentations of depression and interpret their prognostic value
 - Understand the role played by the neurotransmitter systems in the pathophysiology of these symptoms
 - Describe the diagnostic and management approaches to depressed patients with physical and somatic symptoms, particularly among depressed patients with comorbid medical illnesses
 - Upon completion of this medical education activity, participants should have improved overall knowledge, skills, and attitudes concerning the diagnosis and treatment of depression and comorbid medical conditions

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or +1-703-907-7300.

Agenda

- 6:30-7:00 PM Dinner
- 7:00-7:10 PM Introduction and Overview
Maurizio Fava, MD
Massachusetts General Hospital
- 7:10-7:35 PM The Neurobiology of Somatic and Physical Symptoms in Depression
Pedro Delgado, MD
University of Texas Health Science Center
- 7:35-8:00 PM Pain and Other Somatic Symptoms and Their Relationship to Antidepressant Treatment Outcome
George Papakostas, MD
Massachusetts General Hospital
- 8:00-8:25 PM Diagnostic Challenges in Medically Ill Patients With Depression
Donna E. Stewart, MD
University Health Network, Canada
- 8:25-8:50 PM Management Issues in the Treatment of Depression with Comorbid Medical Disorders
Jonathan E. Alpert, MD
Massachusetts General Hospital
- 8:50-9:15 PM Are All Antidepressants Equally Effective in the Treatment of Somatic and Physical Symptoms in Depression?
Maurizio Fava, MD
Massachusetts General Hospital
- 9:15-10:00 PM Panel Discussion and Q & A
Maurizio Fava, MD
Massachusetts General Hospital



Sponsored by the American Psychiatric Association and supported by an educational grant from




INDUSTRY-SUPPORTED SYMPOSIUM 44
 Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
 Royal York, Convention Floor, Concert Hall

<p>DIAGNOSING AND TREATING ALCOHOL DEPENDENCE IN THE OFFICE</p> <p>Wednesday, May 24, 2006 6:30 PM - 7:00 PM Dinner 7:00 PM - 10:00 PM Scientific Session The Fairmont Royal York - Convention Floor, Concert Hall 100 Front Street W, Toronto, Ontario, Canada M5J 1E3</p>		<p>Symposium to be held at the APA 2006 Annual Meeting</p> <p>SCIENTIFIC PROGRAM AGENDA</p> <p>7:00 PM - 7:10 PM Program Introduction <i>Kathleen Brady, MD, PhD (Symposium Chair)</i></p> <p>7:10 PM - 7:40 PM Alcoholism as a Chronic Disease: Implication for Office-based Treatment <i>Thomas McLellan, PhD</i> <i>Treatment Research Institute</i></p> <p>7:40 PM - 8:10 PM Screening, Diagnosis, and Early Intervention <i>Kathleen Brady, MD, PhD</i> <i>Medical University of South Carolina</i></p> <p>8:10 PM - 8:40 PM Current and Emerging Treatment Options in Alcoholism <i>Richard N. Rosenthal, MD</i> <i>Columbia University College of Physicians & Surgeons</i></p> <p>8:40 PM - 9:10 PM Office-based Treatment of Co-occurring Psychiatric Disorders <i>Shelly Greenfield, MD, MPH</i> <i>Harvard Medical School</i></p> <p>9:10 PM - 9:40 PM Behavioral Therapies for Alcohol Dependence <i>Grace Hennessy, MD</i> <i>New York Veterans Administration Hospital</i></p> <p>9:40 PM - 10:00 PM Panel Discussion/Question-and-Answer Session</p>
<p>Alkermes Supported by an unrestricted educational grant from Cephalon Alkermes, Inc. and Cephalon, Inc.</p>	<p>Sponsored by the American Psychiatric Association</p>	
<p>LEARNING OBJECTIVES</p> <p>At the conclusion of this symposium the participant should be able to:</p> <ul style="list-style-type: none"> • Describe the chronic nature of alcoholism and how it affects treatment in the office setting • Discuss screening, diagnosis, and early intervention for alcohol dependence • Review the rationale, mechanism, and relevant data of current and emerging treatments for alcohol dependence • Identify the most common co-occurring psychiatric disorders seen with alcohol dependence and discuss treatment options • Discuss the various types of behavioral therapies used in office-based practice for the treatment of alcohol-dependent patients. 	<p>ACCREDITATION STATEMENT</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>CREDIT DESIGNATION</p> <p>The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>REGISTRATION</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.</p>	

INDUSTRY-SUPPORTED SYMPOSIUM 45
 Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
 Sheraton Centre, Lower Concourse, Grand Ballroom

PRESENTED AT THE APA 2006 ANNUAL MEETING
 WEDNESDAY, MAY 24, 2006 • 7:00 P.M. - 10:00 P.M. (DINNER 6:30 P.M. - 7:00 P.M.)
 SHERATON CENTRE, LOWER CONCOURSE, GRAND BALLROOM, TORONTO, CANADA



**MANAGING UNMET NEEDS IN PSYCHIATRIC ILLNESS:
 A CRITICAL LOOK AT DISORDERS AND PUBLIC POLICY**

Program Agenda

- 6:30 p.m. - 7:00 p.m. Dinner**
- 7:00 p.m. - 7:10 p.m. Welcome and Introduction**
K. Ranga Krishnan, MD (Chair)
Duke University Medical Center
- 7:10 p.m. - 7:35 p.m. Managing the Unmet Needs in Depression**
A. John Rush, MD
UT Southwestern Medical Center
- 7:35 p.m. - 8:00 p.m. Managing the Unmet Needs in Bipolar Disorder**
Roger S. McIntyre, MD, FRCP
University of Toronto
- 8:00 p.m. - 8:25 p.m. Managing the Unmet Needs in Schizophrenia**
Marvin S. Swartz, MD
Duke University Medical Center
- 8:25 p.m. - 8:50 p.m. Managing the Unmet Needs in Dementia**
K. Ranga Krishnan, MD
Duke University Medical Center
- 8:50 p.m. - 9:15 p.m. Managing the Unmet Needs: A Public Health Dilemma**
Junius J. Gonzales, MD, MDA
The George Washington University
- 9:15 p.m. - 10:00 p.m. Panel Discussion/Q&A**

LEARNING OBJECTIVES

- Describe underserved patient populations in depression, bipolar disorder, schizophrenia, and dementia.
- Enumerate public policy positions to address unmet needs in psychiatric disorders.
- Evaluate management strategies to improve access to care, reduce stigma, and improve outcomes.

Statement of Need

In psychiatry, underserved patient populations exist across multiple disorders and for myriad reasons. A common thread that may explain these unmet needs is not a paucity of treatment modalities, but rather inconsistent or ineffective use of them. Can public policy be crafted and inculcated in the clinical community so as to achieve better access to services, combat social stigma, and enhance adherence to treatment regimens? How do key psychiatric disorders differ and resemble one another in their likelihood to benefit from this approach? Stakeholders at every level of the care continuum must find ways to embrace and refine this new paradigm and lend their efforts to reduce the number of underserved patients. In this evidence-based and forward-looking symposium, the experts will explore the unmet needs in depression, bipolar disorder, schizophrenia, and dementia, addressing treatment strategies and current/potential public policy positions affecting these illnesses.

References:

1. Kessler RC, et al. Prevalence and severity of mental illness in the United States. *Arch Gen Psychiatry*. 2005;62:617-627.
2. Wang PS, et al. Many individuals with mental disorders may be untreated or poorly treated. *Arch Gen Psychiatry*. 2005;62:629-640.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



Supported by an educational grant from Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association.



INDUSTRY-SUPPORTED SYMPOSIUM 46
 Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
 Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

**Remission and Recovery in Schizophrenia:
 Advocating for Our Patients**

Wednesday, May 24, 2006 • 6:30 PM - 7:00 PM Dinner • 7:00 PM - 10:00 PM Symposium
 Grand Ballroom, Second Level Metro, Westin Harbour Castle • Toronto, Canada

- 7:00 PM - 7:15 PM Welcome and Introduction**
 Nancy C. Andreasen, MD, PhD (Chair)
 University of Iowa
 Iowa City, IA
- 7:15 PM - 7:45 PM Defining Remission and Recovery in Schizophrenia**
 Nancy C. Andreasen, MD, PhD
 University of Iowa
 Iowa City, IA
- 7:45 PM - 8:15 PM Should Functional Outcomes Be a Defining Feature of Remission and Recovery in Schizophrenia?**
 Stephen R. Marder, MD
 Semel Institute at UCLA
 Los Angeles, CA
- 8:15 PM - 8:45 PM An Evidence-Based Approach to Achieving Remission and Recovery in Schizophrenia**
 John M. Kane, MD
 Albert Einstein College of Medicine
 Glen Oaks, NY
- 8:45 PM - 9:15 PM Barriers to Achieving Remission and Recovery in Schizophrenia**
 Meera Narasimhan, MD
 University of South Carolina
 Columbia, SC
- 9:15 PM - 10:00 PM Q&A**

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Define remission and recovery in schizophrenia.
 - Identify barriers to remission and recovery in schizophrenia.
 - Implement a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to improve patient outcomes.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.



Sponsored by the American Psychiatric Association.



Supported by an educational grant from Pfizer Inc.



Visit the APA Member Center

Find out how APA helps you in your profession

Whether you are a psychiatrist in patient care, administration, research, teaching, or a resident/medical student, the APA Member Center has relevant information for you.

New this year! Get your questions answered by experts. The APA Member Center provides you the opportunity to discuss clinical, administrative, research or academic questions with experts in the field. Check *The Daily Bulletin*, APA's annual meeting newspaper, for topics, dates and times.

At the APA Member Center you can:

- ◆ Apply for APA membership on-site and find out how you may be eligible for a rebate
- ◆ Pick up the *APA Resource Handbook* and benefit information
- ◆ Find out how to navigate Medicare Part D
- ◆ Get help with payment issues
- ◆ Participate in APA advocacy efforts
- ◆ Search the Job Bank for the latest employment opportunities
- ◆ Activate your online subscriptions to APA journals
- ◆ Learn how "OMNA On Tour" can help your community eliminate mental health disparities
- ◆ Explore APA Fellowship opportunities for residents and medical students
- ◆ Find out how APA's CME Journal FOCUS can help you prepare for recertification
- ◆ Learn how to use the Annual Meeting Online Library for CME credit
- ◆ Pick up information about updates on the APA Practice Guidelines
- ◆ Obtain valuable resources on HIV psychiatry and learn how to schedule onsite training
- ◆ Find out about SSRI updates (ParentsMedGuide.org)
- ◆ Keep up to date on the DSM-V Prelude Project: Research and Outreach
- ◆ Find out about APA's revised "Let's Talk Facts" patient information brochures
- ◆ Learn how the Foundation's public education programs promote awareness of mental illness
- ◆ And more!



While at the exhibit, learn about the key roles of these APA subsidiaries:



Contributing to psychiatry's science base and improving psychiatric care through research, education, health policy analysis and dissemination.



A charitable and educational subsidiary whose mission is to advance public understanding that mental illnesses are real and can be effectively treated.



The leading publisher of books, journals, and other media related to psychiatry and mental health.

The APA Member Center (booth #644) is in the exhibit hall next to the APPI Bookstore

Hours:

Saturday, May 20	10:00-5:00
Sunday, May 21	10:00-4:30
Monday, May 22	10:00-5:30
Tuesday, May 23	10:00-6:00
Wednesday, May 24	10:00-3:00